[{"title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"XE-ODN-GxesJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31710-7/abstract","googleCitationCount":606,"googleAuthor":""},{"title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","googleId":"jbBfhU99zq4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309974","googleCitationCount":427,"googleAuthor":"M Yarchoan","doi":"10.1093/annonc/mdy495","elsevierAuthor":"Chan T.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"295","altmetricAuthors":["T.A. Chan","M. Yarchoan","E. Jaffee","C. Swanton","S.A. Quezada","A. Stenzinger","S. Peters"],"twitterCount":331,"altmetricId":50771120},{"title":"4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4)","googleId":"OovdHxUh4f4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34113-4/abstract","googleCitationCount":639,"googleAuthor":"F Cardoso"},{"title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"9BFapTr-f0EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31287-6/abstract","googleCitationCount":383,"googleAuthor":"F Cardoso"},{"title":"Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 …","googleId":"iH4n8WCRI_gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341055","googleCitationCount":506,"googleAuthor":"","doi":"10.1093/annonc/mdy166","elsevierAuthor":"Haenssle H.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"323","altmetricAuthors":["H.A. Haenssle","C. Fink","R. Schneiderbauer","F. Toberer","T. Buhl","A. Blum","A. Kalloo","A. Ben Hadj Hassen","L. Thomas","A. Enk","L. Uhlmann","Christina Alt","Monika Arenbergerova","Renato Bakos","Anne Baltzer","Ines Bertlich","Andreas Blum","Therezia Bokor-Billmann","Jonathan Bowling","Naira Braghiroli","Ralph Braun","Kristina Buder-Bakhaya","Timo Buhl","Horacio Cabo","Leo Cabrijan","Naciye Cevic","Anna Classen","David Deltgen","Christine Fink","Ivelina Georgieva","Lara-Elena Hakim-Meibodi","Susanne Hanner","Franziska Hartmann","Julia Hartmann","Georg Haus","Elti Hoxha","Raimonds Karls","Hiroshi Koga","Jürgen Kreusch","Aimilios Lallas","Pawel Majenka","Ash Marghoob","Cesare Massone","Lali Mekokishvili","Dominik Mestel","Volker Meyer","Anna Neuberger","Kari Nielsen","Margaret Oliviero","Riccardo Pampena","John Paoli","Erika Pawlik","Barbar Rao","Adriana Rendon","Teresa Russo","Ahmed Sadek","Kinga Samhaber","Roland Schneiderbauer","Anissa Schweizer","Ferdinand Toberer","Lukas Trennheuser","Lyobomira Vlahova","Alexander Wald","Julia Winkler","Priscila Wölbing","Iris Zalaudek"],"twitterCount":744,"altmetricId":42877749},{"title":"Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"E_R-TgfQFuQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31692-8/abstract","googleCitationCount":346,"googleAuthor":""},{"title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"oIQVuQDeP1EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31711-9/abstract","googleCitationCount":237,"googleAuthor":"A Vogel"},{"title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","googleId":"rPeA_3if0MYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348938","googleCitationCount":283,"googleAuthor":"L Derosa","doi":"10.1093/annonc/mdy103","elsevierAuthor":"Derosa L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"214","altmetricAuthors":["L. Derosa","M.D. Hellmann","M. Spaziano","D. Halpenny","M. Fidelle","H. Rizvi","N. Long","A.J. Plodkowski","K.C. Arbour","J.E. Chaft","J.A. Rouche","L. Zitvogel","G. Zalcman","L. Albiges","B. Escudier","B. Routy"],"twitterCount":93,"altmetricId":35016882},{"title":"ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours …","googleId":"hWQqZLH2abIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311627","googleCitationCount":204,"googleAuthor":"N Colombo","doi":"10.1093/annonc/mdz062","elsevierAuthor":"Gupta N.","publicationName":"Oncotarget","elsevierCoverDate":"2021-01-05","elsevierCoverDisplayDate":"5 January 2021","elsevierCitationCount":"0","altmetricAuthors":["N. Colombo","C. Sessa","A. du Bois","J. Ledermann","W.G. McCluggage","I. McNeish","P. Morice","S. Pignata","I. Ray-Coquard","I. Vergote","T. Baert","I. Belaroussi","A. Dashora","S. Olbrecht","F. Planchamp","D. Querleu","T. Baert","S. Banerjee","I. Belaroussi","P. Blecharz","I. Bruchim","D. Cibula","N. Colombo","N. Concin","B. Davidson","A. Dashora","M. Devouassoux-Shisheboran","A. du Bois","A. Ferrero","R. Glasspool","A. González-Martin","V. Heinzelmann-Schwarz","F. Joly","J.W. Kim","F. Kridelka","J. Ledermann","D. Lorusso","S. Mahner","W.G. McCluggage","I. McNeish","M. Mikami","M.R. Mirza","P. Morice","S. Nicum","S. Olbrecht","D.M. O’Donnell","P. Pautier","F. Planchamp","S. Pignata","D. Querleu","I. Ray-Coquard","A. Rodolakis","J. Sehouli","F. Selcukbiricik","C. Sessa","N. Singh","D.S.P. Tan","D. Timmerman","G. Tognon","J. van der Velden","I. Vergote","P.O. Witteveen","A.G. Zeimet"],"twitterCount":18,"altmetricId":59826395},{"title":"Comprehensive analysis of the clinical immuno-oncology landscape","googleId":"JMxuRntBcUIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350203","googleCitationCount":301,"googleAuthor":"J Tang","doi":"10.1093/annonc/mdx755","elsevierAuthor":"Tang J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"212","altmetricAuthors":["J. Tang","A. Shalabi","V.M. Hubbard-Lucey"],"twitterCount":390,"altmetricId":30115438},{"title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","googleId":"-rKOmtHlwLEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931110X","googleCitationCount":214,"googleAuthor":"A Daud","doi":"10.1093/annonc/mdz011","elsevierAuthor":"Krakowski I.","publicationName":"Journal of the European Academy of Dermatology and Venereology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":["O. Hamid","C. Robert","A. Daud","F.S. Hodi","W.J. Hwu","R. Kefford","J.D. Wolchok","P. Hersey","R. Joseph","J.S. Weber","R. Dronca","T.C. Mitchell","A. Patnaik","H.M. Zarour","A.M. Joshua","Q. Zhao","E. Jensen","S. Ahsan","N. Ibrahim","A. Ribas"],"twitterCount":71,"altmetricId":54810010},{"title":"Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes …","googleId":"HVMLQS5nSUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454859","googleCitationCount":229,"googleAuthor":"L Horn","doi":"10.1093/annonc/mdy041","elsevierAuthor":"Vokes E.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"180","altmetricAuthors":["E.E. Vokes","N. Ready","E. Felip","L. Horn","M.A. Burgio","S.J. Antonia","O. Arén Frontera","S. Gettinger","E. Holgado","D. Spigel","D. Waterhouse","M. Domine","M. Garassino","L.Q.M. Chow","G. Blumenschein","F. Barlesi","B. Coudert","J. Gainor","O. Arrieta","J. Brahmer","C. Butts","M. Steins","W.J. Geese","A. Li","D. Healey","L. Crinò"],"twitterCount":55,"altmetricId":32647455},{"title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","googleId":"nuUZaLcYH6QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310750","googleCitationCount":203,"googleAuthor":"","doi":"10.1093/annonc/mdy517","elsevierAuthor":"Adams S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"151","altmetricAuthors":["S. Adams","P. Schmid","H.S. Rugo","E.P. Winer","D. Loirat","A. Awada","D.W. Cescon","H. Iwata","M. Campone","R. Nanda","R. Hui","G. Curigliano","D. Toppmeyer","J. O’Shaughnessy","S. Loi","S. Paluch-Shimon","A.R. Tan","D. Card","J. Zhao","V. Karantza","J. Cortés"],"twitterCount":5,"altmetricId":51802228},{"title":"Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast …","googleId":"wYsU2zHYLYsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609786","googleCitationCount":151,"googleAuthor":"S Loibl","doi":"10.1093/annonc/mdz235","elsevierAuthor":"Burstein H.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"112","altmetricAuthors":["H.J. Burstein","G. Curigliano","S. Loibl","P. Dubsky","M. Gnant","P. Poortmans","M. Colleoni","C. Denkert","M. Piccart-Gebhart","M. Regan","H.-J. Senn","E.P. Winer","B. Thurlimann"],"twitterCount":196,"altmetricId":64491149},{"title":"CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced …","googleId":"9HCRc53DNvAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603893","googleCitationCount":174,"googleAuthor":"T Yau","doi":"10.1093/annonc/mdz394.029","elsevierAuthor":"Pinter M.","publicationName":"JAMA Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"3","altmetricAuthors":["T. Yau","J.W. Park","R.S. Finn","A.-L. Cheng","P. Mathurin","J. Edeline","M. Kudo","K.-H. Han","J.J. Harding","P. Merle","O. Rosmorduc","L. Wyrwicz","E. Schott","S.P. Choo","R.K. Kelley","D. Begic","G. Chen","J. Neely","J. Anderson","B. Sangro"],"twitterCount":6,"altmetricId":68417959},{"title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","googleId":"I8ZTgQgo1xcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312840","googleCitationCount":175,"googleAuthor":"J Mazieres","doi":"10.1093/annonc/mdz167","elsevierAuthor":"Mazieres J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"131","altmetricAuthors":["J. Mazieres","A. Drilon","A. Lusque","L. Mhanna","A.B. Cortot","L. Mezquita","A.A. Thai","C. Mascaux","S. Couraud","R. Veillon","M. Van den Heuvel","J. Neal","N. Peled","M. Früh","T.L. Ng","V. Gounant","S. Popat","J. Diebold","J. Sabari","V.W. Zhu","S.I. Rothschild","P. Bironzo","A. Martinez-Marti","A. Curioni-Fontecedro","R. Rosell","M. Lattuca-Truc","M. Wiesweg","B. Besse","B. Solomon","F. Barlesi","R.D. Schouten","H. Wakelee","D.R. Camidge","G. Zalcman","S. Novello","S.I. Ou","J. Milia","O. Gautschi"],"twitterCount":74,"altmetricId":61025174},{"title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2 …","googleId":"KUsvv8xkoKIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321052","googleCitationCount":240,"googleAuthor":"SM Stemmer","doi":"10.1093/annonc/mdy155","elsevierAuthor":"Ribelles N.","publicationName":"European Journal of Cancer","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["G.N. Hortobagyi","S.M. Stemmer","H.A. Burris","Y.S. Yap","G.S. Sonke","S. Paluch-Shimon","M. Campone","K. Petrakova","K.L. Blackwell","E.P. Winer","W. Janni","S. Verma","P. Conte","C.L. Arteaga","D.A. Cameron","S. Mondal","F. Su","M. Miller","M. Elmeliegy","C. Germa","J. O’Shaughnessy"],"twitterCount":83,"altmetricId":39386777},{"title":"Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro …","googleId":"xgZdBbeTMhwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341936","googleCitationCount":187,"googleAuthor":"KW Lee","doi":"10.1093/annonc/mdy264","elsevierAuthor":"Bang Y.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"138","altmetricAuthors":["Y.-J Bang","E.Yañez Ruiz","E. Van Cutsem","K.-W Lee","L. Wyrwicz","M. Schenker","M. Alsina","M.-H Ryu","H.-C Chung","L. Evesque","S.-E Al-Batran","S.H. Park","M. Lichinitser","N. Boku","M.H. Moehler","J. Hong","H. Xiong","R. Hallwachs","I. Conti","J. Taieb"],"twitterCount":72,"altmetricId":45508230},{"title":"Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"pNNlJJvhfpgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31691-6/abstract","googleCitationCount":220,"googleAuthor":""},{"title":"Novel patterns of response under immunotherapy","googleId":"GAMzWoEnEhoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931083X","googleCitationCount":122,"googleAuthor":"Y Kanjanapan","doi":"10.1093/annonc/mdz003","elsevierAuthor":"Borcoman E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"88","altmetricAuthors":["E. Borcoman","Y. Kanjanapan","S. Champiat","S. Kato","V. Servois","R. Kurzrock","S. Goel","P. Bedard","C. Le Tourneau"],"twitterCount":47,"altmetricId":54123198},{"title":"Correction to:“Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”","googleId":"XRWSwiszWlAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31151-2/abstract","googleCitationCount":156,"googleAuthor":""},{"title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by …","googleId":"n1aDxA3wLe8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350173","googleCitationCount":198,"googleAuthor":"G Pentheroudakis","doi":"10.1093/annonc/mdx738","elsevierAuthor":"Yoshino T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"154","altmetricAuthors":["T. Yoshino","D. Arnold","H. Taniguchi","G. Pentheroudakis","K. Yamazaki","R.-H. Xu","T.W. Kim","F. Ismail","I.B. Tan","K.-H. Yeh","A. Grothey","S. Zhang","J.B. Ahn","M.Y. Mastura","D. Chong","L.-T. Chen","S. Kopetz","T. Eguchi-Nakajima","H. Ebi","A. Ohtsu","A. Cervantes","K. Muro","J. Tabernero","H. Minami","F. Ciardiello","J.-Y. Douillard"],"twitterCount":37,"altmetricId":29047821},{"title":"Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"VWEZuMEIBLoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31712-0/abstract","googleCitationCount":154,"googleAuthor":""},{"title":"Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines","googleId":"GCroUoe4INgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31698-9/abstract","googleCitationCount":220,"googleAuthor":"R Giusti"},{"title":"IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo)+ bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for …","googleId":"Jm2AXK-pY6EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582072","googleCitationCount":132,"googleAuthor":"P Galle","doi":"10.1093/annonc/mdz446.002","elsevierAuthor":"Nault J.C.","publicationName":"Hepatology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"4","altmetricAuthors":["A.-L. Cheng","S. Qin","M. Ikeda","P. Galle","M. Ducreux","A. Zhu","T.-Y. Kim","M. Kudo","V. Breder","P. Merle","A. Kaseb","D. Li","W. Verret","Z. Xu","S. Hernandez","J. Liu","C. Huang","S. Mulla","H.Y. Lim","R. Finn"],"twitterCount":0,"altmetricId":74984888},{"title":"Selective RET kinase inhibition for patients with RET-altered cancers","googleId":"BK7Pn-ZJLqwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341043","googleCitationCount":153,"googleAuthor":"V Subbiah","doi":"10.1093/annonc/mdy137","elsevierAuthor":"Subbiah V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"114","altmetricAuthors":["V. Subbiah","V. Velcheti","B.B. Tuch","K. Ebata","N.L. Busaidy","M.E. Cabanillas","L.J. Wirth","S. Stock","S. Smith","V. Lauriault","S. Corsi-Travali","D. Henry","M. Burkard","R. Hamor","K. Bouhana","S. Winski","R.D. Wallace","D. Hartley","S. Rhodes","M. Reddy","B.J. Brandhuber","S. Andrews","S.M. Rothenberg","A. Drilon"],"twitterCount":158,"altmetricId":37998552},{"title":"A decade of clinical development of PARP inhibitors in perspective","googleId":"y6ldpFWClDAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459851","googleCitationCount":112,"googleAuthor":"J Mateo","doi":"10.1093/annonc/mdz192","elsevierAuthor":"Mateo J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"76","altmetricAuthors":["J. Mateo","C.J. Lord","V. Serra","A. Tutt","J. Balmaña","M. Castroviejo-Bermejo","C. Cruz","A. Oaknin","S.B. Kaye","J.S. de Bono"],"twitterCount":114,"altmetricId":62493598},{"title":"Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy","googleId":"6M7ygNDwgRwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312293","googleCitationCount":132,"googleAuthor":"M Silva","doi":"10.1093/annonc/mdz117","elsevierAuthor":"González Maldonado S.","publicationName":"International Journal of Cancer","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"1 March 2021","elsevierCitationCount":"0","altmetricAuthors":["U. Pastorino","M. Silva","S. Sestini","F. Sabia","M. Boeri","A. Cantarutti","N. Sverzellati","G. Sozzi","G. Corrao","A. Marchianò"],"twitterCount":169,"altmetricId":58420812},{"title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour …","googleId":"OhOda1_-_qUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312694","googleCitationCount":129,"googleAuthor":"C Luchini","doi":"10.1093/annonc/mdz116","elsevierAuthor":"Luchini C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"76","altmetricAuthors":["C. Luchini","F. Bibeau","M.J.L. Ligtenberg","N. Singh","A. Nottegar","T. Bosse","R. Miller","N. Riaz","J.-Y. Douillard","F. Andre","A. Scarpa"],"twitterCount":140,"altmetricId":59973223},{"title":"Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study","googleId":"mCTvC-S32QoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50454-9/abstract","googleCitationCount":145,"googleAuthor":""},{"title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","googleId":"HCWSEYGxVdoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312414","googleCitationCount":121,"googleAuthor":"","doi":"10.1093/annonc/mdz135","elsevierAuthor":"Dong A.","publicationName":"Journal of Gene Medicine","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["U.A. Matulonis","R. Shapira-Frommer","A.D. Santin","A.S. Lisyanskaya","S. Pignata","I. Vergote","F. Raspagliesi","G.S. Sonke","M. Birrer","D.M. Provencher","J. Sehouli","N. Colombo","A. González-Martín","A. Oaknin","P.B. Ottevanger","V. Rudaitis","K. Katchar","H. Wu","S. Keefe","J. Ruman","J.A. Ledermann"],"twitterCount":12,"altmetricId":59967934},{"title":"Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors","googleId":"BtloFdMWIG8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316692","googleCitationCount":161,"googleAuthor":"CM Lovly","doi":"10.1093/annonc/mdx703","elsevierAuthor":"Westover D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"124","altmetricAuthors":[],"twitterCount":0},{"title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"7JMTnEptucgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31690-4/abstract","googleCitationCount":136,"googleAuthor":""},{"title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","googleId":"CWHiydiOzTkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345326","googleCitationCount":153,"googleAuthor":"MK McConechy","doi":"10.1093/annonc/mdy058","elsevierAuthor":"Kommoss S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"103","altmetricAuthors":["S. Kommoss","M.K. McConechy","F. Kommoss","S. Leung","A. Bunz","J. Magrill","H. Britton","F. Kommoss","F. Grevenkamp","A. Karnezis","W. Yang","A. Lum","B. Krämer","F. Taran","A. Staebler","S. Lax","S.Y. Brucker","D.G. Huntsman","C.B. Gilks","J.N. McAlpine","A. Talhouk."],"twitterCount":10,"altmetricId":32815487},{"title":"Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer","googleId":"LrlT1bUzII8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312402","googleCitationCount":129,"googleAuthor":"AB Schrock","doi":"10.1093/annonc/mdz134","elsevierAuthor":"Zhou P.","publicationName":"Aging","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":["A.B. Schrock","C. Ouyang","J. Sandhu","E. Sokol","D. Jin","J.S. Ross","V.A. Miller","D. Lim","I. Amanam","J. Chao","D. Catenacci","M. Cho","F. Braiteh","S.J. Klempner","S.M. Ali","M. Fakih"],"twitterCount":60,"altmetricId":59740488},{"title":"ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up","googleId":"Z5_4ivDLP68J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934133X","googleCitationCount":120,"googleAuthor":"D Berney","doi":"10.1093/annonc/mdy217","elsevierAuthor":"Honecker F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"83","altmetricAuthors":["F. Honecker","J. Aparicio","D. Berney","J. Beyer","C. Bokemeyer","R. Cathomas","N. Clarke","G. Cohn-Cedermark","G. Daugaard","K.-P. Dieckmann","K. Fizazi","S. Fosså","J.R. Germa-Lluch","P. Giannatempo","J.A. Gietema","S. Gillessen","H.S. Haugnes","A. Heidenreich","K. Hemminki","R. Huddart","M.A.S. Jewett","F. Joly","J. Lauritsen","A. Lorch","A. Necchi","N. Nicolai","C. Oing","J. Oldenburg","D. Ondruš","A. Papachristofilou","T. Powles","A. Sohaib","O. Ståhl","T. Tandstad","G. Toner","A. Horwich"],"twitterCount":54,"altmetricId":45994890},{"title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA …","googleId":"NaA7zsiFfF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311111","googleCitationCount":141,"googleAuthor":"ME Robson","doi":"10.1093/annonc/mdz012","elsevierAuthor":"Gupta G.K.","publicationName":"Cancers","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"5","altmetricAuthors":["M.E. Robson","N. Tung","P. Conte","S.-A. Im","E. Senkus","B. Xu","N. Masuda","S. Delaloge","W. Li","A. Armstrong","W. Wu","C. Goessl","S. Runswick","S.M. Domchek"],"twitterCount":34,"altmetricId":54335885},{"title":"Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study","googleId":"Z2g9gYxJEgoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341468","googleCitationCount":131,"googleAuthor":"AR Hansen","doi":"10.1093/annonc/mdy232","elsevierAuthor":"Hansen A.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"92","altmetricAuthors":["A.R. Hansen","C. Massard","P.A. Ott","N.B. Haas","J.S. Lopez","S. Ejadi","J.M. Wallmark","B. Keam","J.-P. Delord","R. Aggarwal","M. Gould","P. Yang","S.M. Keefe","S.A. Piha-Paul"],"twitterCount":42,"altmetricId":44741209},{"title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","googleId":"yIEhPn-jRE8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310762","googleCitationCount":161,"googleAuthor":"S Loi","doi":"10.1093/annonc/mdy518","elsevierAuthor":"Adams S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"123","altmetricAuthors":["S. Adams","S. Loi","D. Toppmeyer","D.W. Cescon","M. De Laurentiis","R. Nanda","E.P. Winer","H. Mukai","K. Tamura","A. Armstrong","M.C. Liu","H. Iwata","L. Ryvo","P. Wimberger","H.S. Rugo","A.R. Tan","L. Jia","Y. Ding","V. Karantza","P. Schmid"],"twitterCount":42,"altmetricId":51780264},{"title":"Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers","googleId":"rxpHSpgEVSQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312025","googleCitationCount":107,"googleAuthor":"NJ Birkbak","doi":"10.1093/annonc/mdz108","elsevierAuthor":"Watson G.A.","publicationName":"British Journal of Clinical Pharmacology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"2","altmetricAuthors":["S. Trebeschi","S.G. Drago","N.J. Birkbak","I. Kurilova","A.M. Cǎlin","A. Delli Pizzi","F. Lalezari","D.M.J. Lambregts","M.W. Rohaan","C. Parmar","E.A. Rozeman","K.J. Hartemink","C. Swanton","J B A G Haanen","C.U. Blank","E.F. Smit","R.G.H. Beets-Tan","H.J.W.L Aerts"],"twitterCount":43,"altmetricId":57474773},{"title":"European cancer mortality predictions for the year 2018 with focus on colorectal cancer","googleId":"9X7u_Z26O6QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341945477X","googleCitationCount":138,"googleAuthor":"M Malvezzi","doi":"10.1093/annonc/mdy033","elsevierAuthor":"Malvezzi M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"90","altmetricAuthors":["M. Malvezzi","G. Carioli","P. Bertuccio","P. Boffetta","F. Levi","C. La Vecchia","E. Negri"],"twitterCount":158,"altmetricId":34495957},{"title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","googleId":"rGRTXs2Y9gIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934997X","googleCitationCount":156,"googleAuthor":"A Betof","doi":"10.1093/annonc/mdx642","elsevierAuthor":"Pollack M.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"130","altmetricAuthors":["M.H. Pollack","A. Betof","H. Dearden","K. Rapazzo","I. Valentine","A.S. Brohl","K.K. Ancell","G.V. Long","A.M. Menzies","Z. Eroglu","D.B. Johnson","A.N. Shoushtari"],"twitterCount":46,"altmetricId":27511607},{"title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"GWGDRocMmTUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32563-1/abstract","googleCitationCount":88,"googleAuthor":"PA Ascierto"},{"title":"Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board","googleId":"whg1ImT-CS8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350720","googleCitationCount":138,"googleAuthor":"","doi":"10.1093/annonc/mdx781","elsevierAuthor":"Somashekhar S.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"89","altmetricAuthors":["S.P. Somashekhar","M.-J. Sepúlveda","S. Puglielli","A.D. Norden","E.H. Shortliffe","C. Rohit Kumar","A. Rauthan","N. Arun Kumar","P. Patil","K. Rhee","Y. Ramya"],"twitterCount":132,"altmetricId":31502934},{"title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage …","googleId":"CKBbpFfqB9MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345417","googleCitationCount":127,"googleAuthor":"MR Sydes","doi":"10.1093/annonc/mdy072","elsevierAuthor":"Sydes M.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"91","altmetricAuthors":["M.R. Sydes","M.R. Spears","M.D. Mason","N.W. Clarke","D.P. Dearnaley","J.S. de Bono","G. Attard","S. Chowdhury","W. Cross","S. Gillessen","Z.I. Malik","R. Jones","C.C. Parker","A.W.S. Ritchie","J.M. Russell","R. Millman","D. Matheson","C. Amos","C. Gilson","A. Birtle","S. Brock","L. Capaldi","P. Chakraborti","A. Choudhury","L. Evans","D. Ford","J. Gale","S. Gibbs","D.C. Gilbert","R. Hughes","D. McLaren","J.F. Lester","A. Nikapota","J. O’Sullivan","O. Parikh","C. Peedell","A. Protheroe","S.M. Rudman","R. Shaffer","D. Sheehan","M. Simms","N. Srihari","R. Strebel","S. Sundar","S. Tolan","D. Tsang","M. Varughese","J. Wagstaff","M.K.B. Parmar","N.D. James"],"twitterCount":138,"altmetricId":33684368},{"title":"KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)","googleId":"8lloK8EpRN8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50436-7/abstract","googleCitationCount":117,"googleAuthor":"R Greil"},{"title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis","googleId":"2orw7pHP3CsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320988","googleCitationCount":115,"googleAuthor":"M Bruzzone","doi":"10.1093/annonc/mdy127","elsevierAuthor":"Poggio F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"81","altmetricAuthors":["F. Poggio","M. Bruzzone","M. Ceppi","N.F. Pondé","G. La Valle","L. Del Mastro","E. de Azambuja","M. Lambertini"],"twitterCount":121,"altmetricId":43356739},{"title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","googleId":"AaDdn2x1JM8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312372","googleCitationCount":110,"googleAuthor":"GJ Riely","doi":"10.1093/annonc/mdz131","elsevierAuthor":"Chen J.A.","publicationName":"Current Treatment Options in Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"1 July 2020","elsevierCitationCount":"0","altmetricAuthors":["A.T. Shaw","G.J. Riely","Y.-J. Bang","D.-W. Kim","D.R. Camidge","B.J. Solomon","M. Varella-Garcia","A.J. Iafrate","G.I. Shapiro","T. Usari","S.C. Wang","K.D. Wilner","J.W. Clark","S.-H.I. Ou"],"twitterCount":93,"altmetricId":58967868},{"title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 …","googleId":"tw8SztNGAmoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459887","googleCitationCount":81,"googleAuthor":"","doi":"10.1093/annonc/mdz197","elsevierAuthor":"Wang F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"54","altmetricAuthors":["F. Wang","X.L. Wei","F.H. Wang","N. Xu","L. Shen","G.H. Dai","X.L. Yuan","Y. Chen","S.J. Yang","J.H. Shi","X.C. Hu","X.Y. Lin","Q.Y. Zhang","J.F. Feng","Y. Ba","Y.P. Liu","W. Li","Y.Q. Shu","Y. Jiang","Q. Li","J.W. Wang","H. Wu","H. Feng","S. Yao","R.H. Xu"],"twitterCount":34,"altmetricId":62672149},{"title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","googleId":"M20N-uY9ucwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345569","googleCitationCount":117,"googleAuthor":"S Gutiérrez-Enríquez","doi":"10.1093/annonc/mdy099","elsevierAuthor":"Cruz C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"84","altmetricAuthors":["C. Cruz","M. Castroviejo-Bermejo","S. Gutiérrez-Enríquez","A. Llop-Guevara","Y.H. Ibrahim","A. Gris-Oliver","S. Bonache","B. Morancho","A. Bruna","O.M. Rueda","Z. Lai","U.M. Polanska","G.N. Jones","P. Kristel","L. de Bustos","M. Guzman","O. Rodríguez","J. Grueso","G. Montalban","G. Caratú","F. Mancuso","R. Fasani","J. Jiménez","W.J. Howat","B. Dougherty","A. Vivancos","P. Nuciforo","X. Serres-Créixams","I.T. Rubio","A. Oaknin","E. Cadogan","J.C. Barrett","C. Caldas","J. Baselga","C. Saura","J. Cortés","J. Arribas","J. Jonkers","O. Díez","M.J. O’Connor","J. Balmaña","V. Serra"],"twitterCount":44,"altmetricId":35366205},{"title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","googleId":"TcW2JC9xwwsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350069","googleCitationCount":137,"googleAuthor":"V Lemaire","doi":"10.1093/annonc/mdx686","elsevierAuthor":"Rotte A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"89","altmetricAuthors":["A. Rotte","J.Y. Jin","V. Lemaire"],"twitterCount":13,"altmetricId":27879820},{"title":"European cancer mortality predictions for the year 2019 with focus on breast cancer","googleId":"JuabRO68Ai0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311561","googleCitationCount":103,"googleAuthor":"M Malvezzi","doi":"10.1093/annonc/mdz051","elsevierAuthor":"AlOmeir O.","publicationName":"Supportive Care in Cancer","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"1 November 2020","elsevierCitationCount":"1","altmetricAuthors":["M. Malvezzi","G. Carioli","P. Bertuccio","P. Boffetta","F. Levi","C. La Vecchia","E. Negri"],"twitterCount":62,"altmetricId":57250371},{"title":"Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer","googleId":"fhrRhhCgghkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310816","googleCitationCount":105,"googleAuthor":"D Dong","doi":"10.1093/annonc/mdz001","elsevierAuthor":"Dong D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"85","altmetricAuthors":["D. Dong","L. Tang","Z -Y Li","M -J Fang","J -B Gao","X -H Shan","X -J Ying","Y -S Sun","J. Fu","X -X Wang","L -M Li","Z -H Li","D -F Zhang","Y. Zhang","Z -M Li","F. Shan","Z -D Bu","J. Tian","J.-F. Ji"],"twitterCount":7,"altmetricId":55091298},{"title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX …","googleId":"jmz885CC1e8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318848","googleCitationCount":105,"googleAuthor":"S Peters","doi":"10.1093/annonc/mdy405","elsevierAuthor":"Gadgeel S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"83","altmetricAuthors":["S. Gadgeel","S. Peters","T. Mok","A.T. Shaw","D.W. Kim","S.I. Ou","M. Pérol","A. Wrona","S. Novello","R. Rosell","A. Zeaiter","T. Liu","E. Nüesch","B. Balas","D.R. Camidge"],"twitterCount":50,"altmetricId":48197357},{"title":"Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program","googleId":"y3PaGTiJQdIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350379","googleCitationCount":129,"googleAuthor":"F Cardoso","doi":"10.1093/annonc/mdx651","elsevierAuthor":"Cardoso F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"91","altmetricAuthors":["F. Cardoso","J.M.S. Bartlett","L. Slaets","C.H.M. van Deurzen","E. van Leeuwen-Stok","P. Porter","B. Linderholm","I. Hedenfalk","C. Schröder","J. Martens","J. Bayani","C. van Asperen","M. Murray","C. Hudis","L. Middleton","J. Vermeij","K. Punie","J. Fraser","M. Nowaczyk","I.T. Rubio","S. Aebi","C. Kelly","K.J. Ruddy","E. Winer","C. Nilsson","L. Dal Lago","L. Korde","K. Benstead","O. Bogler","T. Goulioti","A. Peric","S. Litière","K.C. Aalders","C. Poncet","K. Tryfonidis","S.H. Giordano"],"twitterCount":12,"altmetricId":28052076},{"title":"Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer","googleId":"WqKlO74zAvMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454641","googleCitationCount":123,"googleAuthor":"","doi":"10.1093/annonc/mdy014","elsevierAuthor":"Adam J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"107","altmetricAuthors":["J. Adam","N. Le Stang","I. Rouquette","A. Cazes","C. Badoual","H. Pinot-Roussel","L. Tixier","C. Danel","F. Damiola","D. Damotte","F. Penault-Llorca","S. Lantuéjoul"],"twitterCount":31,"altmetricId":31801996},{"title":"Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer","googleId":"bME61RUdIk4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354985","googleCitationCount":129,"googleAuthor":"","doi":"10.1093/annonc/mdx784","elsevierAuthor":"Condorelli R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"102","altmetricAuthors":["R. Condorelli","L. Spring","J. O’Shaughnessy","L. Lacroix","C. Bailleux","V. Scott","J. Dubois","R.J. Nagy","R.B. Lanman","A.J. Iafrate","F. Andre","A. Bardia"],"twitterCount":27,"altmetricId":30299072},{"title":"Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines","googleId":"Rq1p5-uN4eMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31688-6/abstract","googleCitationCount":99,"googleAuthor":"M Dicato"},{"title":"Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials","googleId":"p_bZDQKIRaAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311597","googleCitationCount":88,"googleAuthor":"DH Lee","doi":"10.1093/annonc/mdz059","elsevierAuthor":"Yeh W.Z.","publicationName":"British Journal of Pharmacology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"1","altmetricAuthors":["N. Keum","D.H. Lee","D.C. Greenwood","J.E. Manson","E. Giovannucci"],"twitterCount":46,"altmetricId":56012753},{"title":"Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the …","googleId":"aJ-Ko0Ibtj4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325527","googleCitationCount":78,"googleAuthor":"","doi":"10.1093/annonc/mdz396","elsevierAuthor":"Clarke N.W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"0","altmetricAuthors":["N.W. Clarke","A. Ali","F.C. Ingleby","A. Hoyle","C.L. Amos","G. Attard","C.D. Brawley","J. Calvert","S. Chowdhury","A. Cook","W. Cross","D.P. Dearnaley","H. Douis","D. Gilbert","S. Gillessen","R.J. Jones","R.E. Langley","A. MacNair","Z. Malik","M.D. Mason","D. Matheson","R. Millman","C.C. Parker","A.W.S. Ritchie","H. Rush","J.M. Russell","J. Brown","S. Beesley","A. Birtle","L. Capaldi","J. Gale","S. Gibbs","A. Lydon","A. Nikapota","A. Omlin","J.M. O'Sullivan","O. Parikh","A. Protheroe","S. Rudman","N.N. Srihari","M. Simms","J.S. Tanguay","S. Tolan","J. Wagstaff","J. Wallace","J. Wylie","A. Zarkar","M.R. Sydes","M.K.B. Parmar","N.D. James"],"twitterCount":179,"altmetricId":67326289},{"title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR …","googleId":"DYKqcjdUTUwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349014","googleCitationCount":116,"googleAuthor":"J Mazières","doi":"10.1093/annonc/mdy121","elsevierAuthor":"Griesinger F.","publicationName":"Oncotarget","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"1 October 2018","elsevierCitationCount":"6","altmetricAuthors":["S. Novello","J. Mazières","I.-J. Oh","J. de Castro","M.R. Migliorino","Å. Helland","R. Dziadziuszko","F. Griesinger","A. Kotb","A. Zeaiter","A. Cardona","B. Balas","H.K. Johannsdottir","A. Das-Gupta","J. Wolf"],"twitterCount":63,"altmetricId":37135325},{"title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic …","googleId":"NR80ytPApcMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341341","googleCitationCount":104,"googleAuthor":"TR Cottrell","doi":"10.1093/annonc/mdy218","elsevierAuthor":"Cottrell T.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"74","altmetricAuthors":["T.R. Cottrell","E.D. Thompson","P.M. Forde","J.E. Stein","A.S. Duffield","V. Anagnostou","N. Rekhtman","R.A. Anders","J.D. Cuda","P.B. Illei","E. Gabrielson","F.B. Askin","N. Niknafs","K.N. Smith","M.J. Velez","J.L. Sauter","J.M. Isbell","D.R. Jones","R.J. Battafarano","S.C. Yang","L. Danilova","J.D. Wolchok","S.L. Topalian","V.E. Velculescu","D.M. Pardoll","J.R. Brahmer","M.D. Hellmann","J.E. Chaft","A. Cimino-Mathews","J.M. Taube"],"twitterCount":88,"altmetricId":44717108},{"title":"Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer","googleId":"q2NPQJHIb-wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312311","googleCitationCount":84,"googleAuthor":"MH Hong","doi":"10.1093/annonc/mdz123","elsevierAuthor":"Kas B.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"13","altmetricAuthors":["C.G. Kim","K.H. Kim","K.-H. Pyo","C.-F. Xin","M.H. Hong","B.-C. Ahn","Y. Kim","S.J. Choi","H.I. Yoon","J.G. Lee","C.Y. Lee","S.Y. Park","S.-H. Park","B.C. Cho","H.S. Shim","E.-C. Shin","H.R. Kim"],"twitterCount":36,"altmetricId":58956835},{"title":"IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) …","googleId":"oiOwkryJ6fMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603595","googleCitationCount":78,"googleAuthor":"","doi":"10.1093/annonc/mdz293","elsevierAuthor":"Landre T.","publicationName":"Drugs and Aging","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"1 October 2020","elsevierCitationCount":"0","altmetricAuthors":["D. Spigel","F. de Marinis","G. Giaccone","N. Reinmuth","A. Vergnenegre","C.H. Barrios","M. Morise","E. Felip","Z.G. Andric","S. Geater","M. Özgüroğlu","S. Mocci","M. McCleland","I. Enquist","K.M. Komatsubara","Y. Deng","H. Kuriki","X. Wen","J. Jassem","R.S. Herbst"],"twitterCount":1,"altmetricId":68179413},{"title":"Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy","googleId":"f1jkyjFeOmsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316795","googleCitationCount":102,"googleAuthor":"","doi":"10.1093/annonc/mdx810","elsevierAuthor":"Baracos V.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"71","altmetricAuthors":["V.E. Baracos","L. Arribas"],"twitterCount":53,"altmetricId":33923037},{"title":"Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed …","googleId":"m1ODQena_u8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310464","googleCitationCount":70,"googleAuthor":"S Lu","doi":"10.1093/annonc/mdy554","elsevierAuthor":"Wu Y.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"52","altmetricAuthors":["Y.-L. Wu","D. Planchard","S. Lu","H. Sun","N. Yamamoto","D.-W. Kim","D.S.W. Tan","J.C.-H. Yang","M. Azrif","T. Mitsudomi","K. Park","R.A. Soo","J.W.C. Chang","A. Alip","S. Peters","J.-Y. Douillard"],"twitterCount":2,"altmetricId":53798853},{"title":"Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results …","googleId":"tPKKWUyHOLoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342462","googleCitationCount":85,"googleAuthor":"S Loibl","doi":"10.1093/annonc/mdy460","elsevierAuthor":"Loibl S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"58","altmetricAuthors":["S. Loibl","K.E. Weber","K.M. Timms","E.P. Elkin","E. Hahnen","P.A. Fasching","B. Lederer","C. Denkert","A. Schneeweiss","S. Braun","C.T. Salat","M. Rezai","J.U. Blohmer","D.M. Zahm","C. Jackisch","B. Gerber","P. Klare","S. Kümmel","C. Schem","S. Paepke","R. Schmutzler","K. Rhiem","S. Penn","J. Reid","V. Nekljudova","A.-R. Hartman","G. von Minckwitz","M. Untch"],"twitterCount":28,"altmetricId":49913934},{"title":"Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression","googleId":"AJ6vBhtPHH8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609841","googleCitationCount":63,"googleAuthor":"JF Gainor","doi":"10.1093/annonc/mdz288","elsevierAuthor":"Aguilar E.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"44","altmetricAuthors":["E.J. Aguilar","B. Ricciuti","J.F. Gainor","K.L. Kehl","S. Kravets","S. Dahlberg","M. Nishino","L.M. Sholl","A. Adeni","S. Subegdjo","S. Khosrowjerdi","R.M. Peterson","S. Digumarthy","C. Liu","J. Sauter","H. Rizvi","K.C. Arbour","B.W. Carter","J.V. Heymach","M. Altan","M.D. Hellmann","M.M. Awad"],"twitterCount":161,"altmetricId":65313926},{"title":"Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC","googleId":"zRwJzoFqamIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32762-0/abstract","googleCitationCount":86,"googleAuthor":"NA Rizvi"},{"title":"Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer","googleId":"kZCcStisSwAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318861","googleCitationCount":80,"googleAuthor":"GV Long","doi":"10.1093/annonc/mdy408","elsevierAuthor":"Long G.V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"58","altmetricAuthors":["G.V. Long","S.S. Tykodi","J.G. Schneider","C. Garbe","G. Gravis","M. Rashford","S. Agrawal","E. Grigoryeva","A. Bello","A. Roy","L. Rollin","X. Zhao"],"twitterCount":62,"altmetricId":48227872},{"title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","googleId":"TfDayX7T_hMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459929","googleCitationCount":84,"googleAuthor":"C Marchiò","doi":"10.1093/annonc/mdz204","elsevierAuthor":"Marchiò C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"67","altmetricAuthors":["C. Marchiò","M. Scaltriti","M. Ladanyi","A.J. Iafrate","F. Bibeau","M. Dietel","J.F. Hechtman","T. Troiani","F. López-Rios","J.-Y. Douillard","F. Andrè","J.S. Reis-Filho"],"twitterCount":92,"altmetricId":63080177},{"title":"Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"roYk1TxvdXIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31689-8/abstract","googleCitationCount":81,"googleAuthor":"I Ray-Coquard"},{"title":"Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial","googleId":"KZvArhuaafoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342413","googleCitationCount":89,"googleAuthor":"TG Kwon","doi":"10.1093/annonc/mdy454","elsevierAuthor":"Gross-Goupil M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"58","altmetricAuthors":["M. Gross-Goupil","T.G. Kwon","M. Eto","D. Ye","H. Miyake","S.I. Seo","S.-S. Byun","J.L. Lee","V. Master","J. Jin","R. DeBenedetto","R. Linke","M. Casey","B. Rosbrook","M. Lechuga","O. Valota","E. Grande","D.I. Quinn"],"twitterCount":38,"altmetricId":49972708},{"title":"Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or …","googleId":"MtuPwyffdCMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310361","googleCitationCount":70,"googleAuthor":"","doi":"10.1093/annonc/mdy540","elsevierAuthor":"Boku N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"55","altmetricAuthors":["N. Boku","M.-H. Ryu","K. Kato","H.C. Chung","K. Minashi","K.-W. Lee","H. Cho","W.K. Kang","Y. Komatsu","M. Tsuda","K. Yamaguchi","H. Hara","S. Fumita","M. Azuma","L.-T. Chen","Y.-K. Kang"],"twitterCount":21,"altmetricId":53767604},{"title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","googleId":"5eX2SfV5OHkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341791","googleCitationCount":110,"googleAuthor":"J Mateo","doi":"10.1093/annonc/mdy263","elsevierAuthor":"Mateo J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"75","altmetricAuthors":["J. Mateo","D. Chakravarty","R. Dienstmann","S. Jezdic","A. Gonzalez-Perez","N. Lopez-Bigas","C.K.Y. Ng","P.L. Bedard","G. Tortora","J.-Y. Douillard","E.M. Van Allen","N. Schultz","C. Swanton","F. André","L. Pusztai"],"twitterCount":248,"altmetricId":46756092},{"title":"PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous …","googleId":"WgptB7ZVt1wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603996","googleCitationCount":70,"googleAuthor":"J Mateo","doi":"10.1093/annonc/mdz394.039","elsevierCitationCount":0,"altmetricAuthors":["M. Hussain","J. Mateo","K. Fizazi","F. Saad","N.D. Shore","S. Sandhu","K.N. Chi","O. Sartor","N. Agarwal","D. Olmos","A. Thiery-Vuillemin","P. Twardowski","N. Mehra","C. Goessl","J. Kang","J. Burgents","W. Wu","A. Kohlmann","C.A. Adelman","J. de Bono"],"twitterCount":0,"altmetricId":68179451},{"title":"PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers","googleId":"ZLv0BPO-6RcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342073","googleCitationCount":84,"googleAuthor":"","doi":"10.1093/annonc/mdy334","elsevierAuthor":"Sabari J.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"60","altmetricAuthors":["J.K. Sabari","G.C. Leonardi","C.A. Shu","R. Umeton","J. Montecalvo","A. Ni","R. Chen","J. Dienstag","C. Mrad","I. Bergagnini","W.V. Lai","M. Offin","K.C. Arbour","A.J. Plodkowski","D.F. Halpenny","P.K. Paik","B.T. Li","G.J. Riely","M.G. Kris","C.M. Rudin","L.M. Sholl","M. Nishino","M.D. Hellmann","N. Rekhtman","M.M. Awad","A. Drilon"],"twitterCount":50,"altmetricId":47331018},{"title":"How liquid biopsies can change clinical practice in oncology","googleId":"TtpBLXHkp8cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609725","googleCitationCount":55,"googleAuthor":"G Siravegna","doi":"10.1093/annonc/mdz227","elsevierAuthor":"Siravegna G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"40","altmetricAuthors":["G. Siravegna","B. Mussolin","T. Venesio","S. Marsoni","J. Seoane","C. Dive","N. Papadopoulos","S. Kopetz","R.B. Corcoran","L.L. Siu","A. Bardelli"],"twitterCount":57,"altmetricId":64515702},{"title":"Correction to:“Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”","googleId":"_3pKC04ni6sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31152-4/abstract","googleCitationCount":72,"googleAuthor":"A Vogel"},{"title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer …","googleId":"f__GGZDtafkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312785","googleCitationCount":102,"googleAuthor":"S Loibl","doi":"10.1093/annonc/mdz158","elsevierAuthor":"Loibl S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"73","altmetricAuthors":["S. Loibl","M. Untch","N. Burchardi","J. Huober","B.V. Sinn","J.-U. Blohmer","E.-M. Grischke","J. Furlanetto","H. Tesch","C. Hanusch","K. Engels","M. Rezai","C. Jackisch","W.D. Schmitt","G. von Minckwitz","J. Thomalla","S. Kümmel","B. Rautenberg","P.A. Fasching","K. Weber","K. Rhiem","C. Denkert","A. Schneeweiss"],"twitterCount":47,"altmetricId":60557668},{"title":"Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study","googleId":"5HT_3DNQlooJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50455-0/abstract","googleCitationCount":84,"googleAuthor":""},{"title":"ClarIDHy: a global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an …","googleId":"jfU-RHVtjGkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960387X","googleCitationCount":68,"googleAuthor":"","doi":"10.1093/annonc/mdz394.027","elsevierAuthor":"Vienot A.","publicationName":"Clinics and Research in Hepatology and Gastroenterology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0","altmetricAuthors":["G.K. Abou-Alfa","T. Macarulla Mercade","M. Javle","R.K. Kelley","S. Lubner","J. Adeva","J.M. Cleary","D.V. Catenacci","M.J. Borad","J.A. Bridgewater","W.P. Harris","A.G. Murphy","D.-Y. Oh","J. Whisenant","B. Wu","L. Jiang","C. Gliser","S.S. Pandya","J.W. Valle","A.X. Zhu"],"twitterCount":0,"altmetricId":69142278},{"title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of> 2 …","googleId":"ubmiQDXRcIgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312104","googleCitationCount":81,"googleAuthor":"Y Fradet","doi":"10.1093/annonc/mdz127","elsevierAuthor":"Lebossé F.","publicationName":"Bulletin du Cancer","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"0","altmetricAuthors":["Y. Fradet","J. Bellmunt","D.J. Vaughn","J.L. Lee","L. Fong","N.J. Vogelzang","M.A. Climent","D.P. Petrylak","T.K. Choueiri","A. Necchi","W. Gerritsen","H. Gurney","D.I. Quinn","S. Culine","C.N. Sternberg","K. Nam","T.L. Frenkl","R.F. Perini","R. de Wit","D.F. Bajorin"],"twitterCount":43,"altmetricId":59897015},{"title":"European Society for Medical Oncology (ESMO) position paper on supportive and palliative care","googleId":"ZRjJkyqwv_8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350215","googleCitationCount":99,"googleAuthor":"F Scotté","doi":"10.1093/annonc/mdx757","elsevierAuthor":"Jordan K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"68","altmetricAuthors":["K. Jordan","M. Aapro","S. Kaasa","C.I. Ripamonti","F. Scotté","F. Strasser","A. Young","E. Bruera","J. Herrstedt","D. Keefe","B. Laird","D. Walsh","J.Y. Douillard","A. Cervantes"],"twitterCount":185,"altmetricId":30460851},{"title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","googleId":"xG-NnAYhDXAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454707","googleCitationCount":102,"googleAuthor":"Y Bareche","doi":"10.1093/annonc/mdy024","elsevierAuthor":"Bareche Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"63","altmetricAuthors":["Y. Bareche","D. Venet","M. Ignatiadis","P. Aftimos","M. Piccart","F. Rothe","C. Sotiriou"],"twitterCount":41,"altmetricId":32072934},{"title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","googleId":"eu1SFmu76QYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35043-4/abstract","googleCitationCount":96,"googleAuthor":"AG Marcelin"},{"title":"Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): results from CheckMate 331","googleId":"U2QG0fxaBlAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32761-9/abstract","googleCitationCount":75,"googleAuthor":""},{"title":"Alpelisib (ALP)+ fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase III SOLAR-1 trial","googleId":"9zOYoaMAvCwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50401-X/abstract","googleCitationCount":79,"googleAuthor":"F André"},{"title":"Updated safety and clinical activity results from a phase Ib study of atezolizumab+ bevacizumab in hepatocellular carcinoma (HCC)","googleId":"vBdmkqm1QqQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50419-7/abstract","googleCitationCount":78,"googleAuthor":""},{"title":"Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma","googleId":"xnFuV0ZuYnkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354900","googleCitationCount":94,"googleAuthor":"","doi":"10.1093/annonc/mdx765","elsevierAuthor":"Krug A.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"67","altmetricAuthors":["A.K. Krug","D. Enderle","C. Karlovich","T. Priewasser","S. Bentink","A. Spiel","K. Brinkmann","J. Emenegger","D.G. Grimm","E. Castellanos-Rizaldos","J.W. Goldman","L.V. Sequist","J.-C. Soria","D.R. Camidge","S.M. Gadgeel","H.A. Wakelee","M. Raponi","M. Noerholm","J. Skog"],"twitterCount":49,"altmetricId":30341671},{"title":"Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced …","googleId":"pO5kBYhk4FkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348926","googleCitationCount":83,"googleAuthor":"","doi":"10.1093/annonc/mdy101","elsevierAuthor":"Abou-Alfa G.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"64","altmetricAuthors":["G.K. Abou-Alfa","S. Qin","B.-Y. Ryoo","S.-N. Lu","C.-J. Yen","Y.-H. Feng","H.Y. Lim","F. Izzo","M. Colombo","D. Sarker","L. Bolondi","G. Vaccaro","W.P. Harris","Z. Chen","R.A. Hubner","T. Meyer","W. Sun","J.J. Harding","E.M. Hollywood","J. Ma","P.J. Wan","M. Ly","J. Bomalaski","A. Johnston","C.-C. Lin","Y. Chao","L.-T. Chen"],"twitterCount":9,"altmetricId":36755011},{"title":"EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer","googleId":"sHKJXYmEJUUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312724","googleCitationCount":66,"googleAuthor":"HA Yu","doi":"10.1093/annonc/mdz141","elsevierAuthor":"Hastings K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"53","altmetricAuthors":["K. Hastings","H.A. Yu","W. Wei","F. Sanchez-Vega","M. DeVeaux","J. Choi","H. Rizvi","A. Lisberg","A. Truini","C.A. Lydon","Z. Liu","B.S. Henick","A. Wurtz","G. Cai","A.J. Plodkowski","N.M. Long","D.F. Halpenny","J. Killam","I. Oliva","N. Schultz","G.J. Riely","M.E. Arcila","M. Ladanyi","D. Zelterman","R.S. Herbst","S.B. Goldberg","M.M. Awad","E.B. Garon","S. Gettinger","M.D. Hellmann","K. Politi"],"twitterCount":138,"altmetricId":60461303},{"title":"Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer","googleId":"nNtHp7zSw7oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349919","googleCitationCount":94,"googleAuthor":"M Ilié","doi":"10.1093/annonc/mdx636","elsevierAuthor":"Ilié M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"65","altmetricAuthors":["M. Ilié","E. Szafer-Glusman","V. Hofman","E. Chamorey","S. Lalvée","E. Selva","S. Leroy","C.-H. Marquette","M. Kowanetz","P. Hedge","E. Punnoose","P. Hofman"],"twitterCount":51,"altmetricId":27232644},{"title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"bcTa42E45d4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32555-2/abstract","googleCitationCount":84,"googleAuthor":"S Filetti"},{"title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","googleId":"SrujySyAX1QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310440","googleCitationCount":72,"googleAuthor":"N Steeghs","doi":"10.1093/annonc/mdy551","elsevierAuthor":"Heinhuis K.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"50","altmetricAuthors":["K.M. Heinhuis","W. Ros","M. Kok","N. Steeghs","J.H. Beijnen","J.H.M. Schellens"],"twitterCount":44,"altmetricId":53511211},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by …","googleId":"fCfp8uuhvtQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310038","googleCitationCount":58,"googleAuthor":"G Pentheroudakis","doi":"10.1093/annonc/mdy502","elsevierAuthor":"Muro K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"50","altmetricAuthors":["K. Muro","E. Van Cutsem","Y. Narita","G. Pentheroudakis","E. Baba","J. Li","M -H Ryu","W I Wan Zamaniah","W -P Yong","K -H Yeh","K. Kato","Z. Lu","B.C. Cho","I.M. Nor","M. Ng","L -T Chen","T.E. Nakajima","K. Shitara","H. Kawakami","T. Tsushima","T. Yoshino","F. Lordick","E. Martinelli","E.C. Smyth","D. Arnold","H. Minami","J. Tabernero","J -Y Douillard"],"twitterCount":15,"altmetricId":51601359},{"title":"Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of …","googleId":"hjfkNGjS19sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454604","googleCitationCount":85,"googleAuthor":"JJ Yang","doi":"10.1093/annonc/mdy009","elsevierAuthor":"Li Y.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"65","altmetricAuthors":["Y.S. Li","B.Y. Jiang","J.J. Yang","X.C. Zhang","Z. Zhang","J.Y. Ye","W.Z. Zhong","H.Y. Tu","H.J. Chen","Z. Wang","C.R. Xu","B.C. Wang","H.J. Du","S. Chuai","H. Han-Zhang","J. Su","Q. Zhou","X.N. Yang","W.B. Guo","H.H. Yan","Y.H. Liu","L.X. Yan","B. Huang","M.M. Zheng","Y.L. Wu"],"twitterCount":3,"altmetricId":31726445},{"title":"Immunological differences between primary and metastatic breast cancer","googleId":"YMCvlmhyiV8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318782","googleCitationCount":73,"googleAuthor":"X Li","doi":"10.1093/annonc/mdy399","elsevierAuthor":"Szekely B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"51","altmetricAuthors":["B. Szekely","V. Bossuyt","X. Li","V.B. Wali","G.A. Patwardhan","C. Frederick","A. Silber","T. Park","M. Harigopal","V. Pelekanou","M. Zhang","Q. Yan","D.L. Rimm","G. Bianchini","C. Hatzis","L. Pusztai"],"twitterCount":138,"altmetricId":48087768},{"title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"GNA4kIAX048J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31693-X/abstract","googleCitationCount":63,"googleAuthor":"PL Zinzani"},{"title":"Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines","googleId":"n-RV3PkMrBYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31697-7/abstract","googleCitationCount":63,"googleAuthor":"NI Cherny"},{"title":"The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?","googleId":"4roaPHV5OkEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609671","googleCitationCount":41,"googleAuthor":"A Elkrief","doi":"10.1093/annonc/mdz206","elsevierAuthor":"Elkrief A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"33","altmetricAuthors":["A. Elkrief","L. Derosa","G. Kroemer","L. Zitvogel","B. Routy"],"twitterCount":56,"altmetricId":63076276},{"title":"Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis","googleId":"iPUKuO-jOJIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604369","googleCitationCount":58,"googleAuthor":"","doi":"10.1093/annonc/mdz394.076","elsevierAuthor":"Vavala T.","publicationName":"Journal of Clinical Pathology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["S.S. Ramalingam","J.E. Gray","Y. Ohe","B.C. Cho","J. Vansteenkiste","C. Zhou","T. Reungwetwattana","Y. Cheng","B. Chewaskulyong","R. Shah","K.H. Lee","P. Cheema","M. Tiseo","T. John","M.C. Lin","F. Imamura","R. Hodge","Y. Rukazenkov","J.-C. Soria","D. Planchard"],"twitterCount":1,"altmetricId":67608254},{"title":"Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients","googleId":"hUIjPQsLEXAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934983X","googleCitationCount":82,"googleAuthor":"V Bernard","doi":"10.1093/annonc/mdx542","elsevierAuthor":"Castillo J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"66","altmetricAuthors":["J. Castillo","V. Bernard","F.A. San Lucas","K Allenson","M. Capello","D.U. Kim","P. Gascoyne","F.C. Mulu","B.M. Stephens","J. Huang","H. Wang","A.A. Momin","R.O. Jacamo","M. Katz","R. Wolff","M. Javle","G. Varadhachary","I.I. Wistuba","S. Hanash","A. Maitra","H. Alvarez"],"twitterCount":28,"altmetricId":26558717},{"title":"IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin+ nab-paclitaxel (CnP) with or without atezolizumab …","googleId":"dpDeks1nvgEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50456-2/abstract","googleCitationCount":69,"googleAuthor":"F Cappuzzo"},{"title":"CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials","googleId":"TMTicSZFpmQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355115","googleCitationCount":112,"googleAuthor":"G Goss","doi":"10.1093/annonc/mdx820","elsevierAuthor":"Goss G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"86","altmetricAuthors":["G. Goss","C.-M. Tsai","F.A. Shepherd","M.-J. Ahn","L. Bazhenova","L. Crinò","F. de Marinis","E. Felip","A. Morabito","R. Hodge","M. Cantarini","M. Johnson","T. Mitsudomi","P.A. Jänne","J.C.-H. Yang"],"twitterCount":21,"altmetricId":30831463},{"title":"Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast …","googleId":"j9n3rYkfiOUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349798","googleCitationCount":84,"googleAuthor":"M Robson","doi":"10.1093/annonc/mdx505","elsevierAuthor":"Han H.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"74","altmetricAuthors":["H.S. Han","V. Diéras","M. Robson","M. Palácová","P.K. Marcom","A. Jager","I. Bondarenko","D. Citrin","M. Campone","M.L. Telli","S.M. Domchek","M. Friedlander","B. Kaufman","J.E. Garber","Y. Shparyk","E. Chmielowska","E.H. Jakobsen","V. Kaklamani","W. Gradishar","C.K. Ratajczak","C. Nickner","Q. Qin","J. Qian","S.P. Shepherd","S.J. Isakoff","S. Puhalla"],"twitterCount":1,"altmetricId":27031791},{"title":"Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer","googleId":"EAJljg9-vMgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345570","googleCitationCount":66,"googleAuthor":"S Siena","doi":"10.1093/annonc/mdy100","elsevierAuthor":"Siena S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"51","altmetricAuthors":["S. Siena","A. Sartore-Bianchi","S. Marsoni","H.I. Hurwitz","S.J. McCall","F. Penault-Llorca","S. Srock","A. Bardelli","L. Trusolino"],"twitterCount":38,"altmetricId":35755731},{"title":"OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer","googleId":"_9FpTDPFRjsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310294","googleCitationCount":68,"googleAuthor":"EA Blair","doi":"10.1093/annonc/mdy522","elsevierAuthor":"Göttgens E.L.","publicationName":"Radiotherapy and Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"1","altmetricAuthors":["T.Y. Seiwert","C.C. Foster","E.A. Blair","T.G. Karrison","N. Agrawal","J.M. Melotek","L. Portugal","R.J. Brisson","A. Dekker","S. Kochanny","Z. Gooi","M.W. Lingen","V.M. Villaflor","D.T. Ginat","D.J. Haraf","E.E. Vokes"],"twitterCount":14,"altmetricId":52180542},{"title":"Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge","googleId":"Y_RnIY7LBNMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310245","googleCitationCount":57,"googleAuthor":"JM Loree","doi":"10.1093/annonc/mdy509","elsevierAuthor":"Parseghian C.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"41","altmetricAuthors":["C.M. Parseghian","J.M. Loree","V.K. Morris","X. Liu","K.K. Clifton","S. Napolitano","J.T. Henry","A.A. Pereira","E. Vilar","B. Johnson","B. Kee","K. Raghav","A. Dasari","J. Wu","N. Garg","V.M. Raymond","K.C. Banks","A.A. Talasaz","R.B. Lanman","J.H. Strickler","D.S. Hong","R.B. Corcoran","M.J. Overman","S. Kopetz"],"twitterCount":11,"altmetricId":51654035},{"title":"RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study","googleId":"z2Eb6009_PUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934534X","googleCitationCount":77,"googleAuthor":"JB Bachet","doi":"10.1093/annonc/mdy061","elsevierAuthor":"Bachet J.B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"56","altmetricAuthors":["J.B. Bachet","O. Bouché","J. Taieb","O. Dubreuil","M.L. Garcia","A. Meurisse","C. Normand","J.M. Gornet","P. Artru","S. Louafi","F. Bonnetain","A. Thirot-Bidault","I. Baumgaertner","R. Coriat","D. Tougeron","T. Lecomte","F. Mary","T. Aparicio","L. Marthey","V. Taly","H. Blons","D. Vernerey","P. Laurent-Puig"],"twitterCount":9,"altmetricId":33197535},{"title":"Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H …","googleId":"9MWA4VyBm4kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50410-0/abstract","googleCitationCount":64,"googleAuthor":"HJJ Lenz"},{"title":"Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer","googleId":"oWfOuyjvNCYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349774","googleCitationCount":81,"googleAuthor":"IG Murillas","doi":"10.1093/annonc/mdx483","elsevierAuthor":"Fribbens C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"53","altmetricAuthors":["C. Fribbens","I. Garcia Murillas","M. Beaney","S. Hrebien","B. O’Leary","L. Kilburn","K. Howarth","M. Epstein","E. Green","N. Rosenfeld","A. Ring","S. Johnston","N. Turner"],"twitterCount":19,"altmetricId":27031736},{"title":"Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158","googleId":"SFv0W1jJUaIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594042","googleCitationCount":51,"googleAuthor":"MG Fakih","doi":"10.1093/annonc/mdz253.018","elsevierCitationCount":0,"altmetricAuthors":["A. Marabelle","M.G. Fakih","J. Lopez","M. Shah","R. Shapira-Frommer","K. Nakagawa","H.C. Chung","H.L. Kindler","J.A. Lopez-Martin","W. Miller","A. Italiano","S. Kao","S.A. Piha-Paul","J.-P. Delord","R.R. McWilliams","D. Aurora-Garg","M. Chen","F. Jin","K. Norwood","Y.-J. Bang"],"twitterCount":0,"altmetricId":86405391},{"title":"HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib","googleId":"6srZZ6G8ZiAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310774","googleCitationCount":56,"googleAuthor":"","doi":"10.1093/annonc/mdy542","elsevierAuthor":"Wang Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"49","altmetricAuthors":["Y. Wang","T. Jiang","Z. Qin","J. Jiang","Q. Wang","S. Yang","C. Rivard","G. Gao","T.L. Ng","M.M. Tu","H. Yu","H. Ji","C. Zhou","S. Ren","J. Zhang","P. Bunn","R.C. Doebele","D.R. Camidge","F.R. Hirsch"],"twitterCount":31,"altmetricId":53596185},{"title":"Severe immune-related adverse events are common with sequential PD-(L) 1 blockade and osimertinib","googleId":"k4fb_JXeXpgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311652","googleCitationCount":69,"googleAuthor":"AJ Schoenfeld","doi":"10.1093/annonc/mdz077","elsevierAuthor":"Zhai X.","publicationName":"Cancer Biology and Medicine","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"1 August 2020","elsevierCitationCount":"0","altmetricAuthors":["A.J. Schoenfeld","K.C. Arbour","H. Rizvi","A.N. Iqbal","S.M. Gadgeel","J. Girshman","M.G. Kris","G.J. Riely","H.A. Yu","M.D. Hellmann"],"twitterCount":54,"altmetricId":56948983},{"title":"FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma","googleId":"HOtsu9gEikcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342036","googleCitationCount":54,"googleAuthor":"L Emmett","doi":"10.1093/annonc/mdy330","elsevierAuthor":"Tan A.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"50","altmetricAuthors":["A.C. Tan","L. Emmett","S. Lo","V. Liu","R. Kapoor","M.S. Carlino","A.D. Guminski","G.V. Long","A.M. Menzies"],"twitterCount":9,"altmetricId":46879649},{"title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206","googleId":"4XrLOEF45I4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350033","googleCitationCount":75,"googleAuthor":"N Adra","doi":"10.1093/annonc/mdx680","elsevierAuthor":"Adra N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"66","altmetricAuthors":["N. Adra","L.H. Einhorn","S.K. Althouse","N.R. Ammakkanavar","D. Musapatika","C. Albany","D. Vaughn","N.H. Hanna"],"twitterCount":12,"altmetricId":27569023},{"title":"Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 …","googleId":"2auh0-fIwtYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595217","googleCitationCount":43,"googleAuthor":"H Gogas","doi":"10.1093/annonc/mdz255","elsevierAuthor":"Kitano S.","publicationName":"Cancer Chemotherapy and Pharmacology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":["J.S. Weber","M. Del Vecchio","M. Mandala","H. Gogas","A.M. Arance","S. Dalle","C.L. Cowey","M. Schenker","J.J. Grob","V. Chiarion-Sileni","I. Marquez-Rodas","M.O. Butler","M. Maio","M.R. Middleton","T. Tang","A. Saci","V. De Pril","M. Lobo","J.M.G. Larkin","P.A. Ascierto"],"twitterCount":0,"altmetricId":68179434},{"title":"Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma","googleId":"zevF3PiDyUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931227X","googleCitationCount":54,"googleAuthor":"YJL Jansen","doi":"10.1093/annonc/mdz110","elsevierAuthor":"Fedorova L.V.","publicationName":"Annals of Hematology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["Y.J.L. Jansen","E.A. Rozeman","R. Mason","S.M. Goldinger","M.H. Geukes Foppen","L. Hoejberg","H. Schmidt","J.V. van Thienen","J.B.A.G. Haanen","L. Tiainen","I.M. Svane","S. Mäkelä","T. Seremet","A. Arance","R. Dummer","L. Bastholt","M. Nyakas","O. Straume","A.M. Menzies","G.V. Long","V. Atkinson","C.U. Blank","B. Neyns"],"twitterCount":86,"altmetricId":58001485},{"title":"Randomised efficacy and safety results for atezolizumab (Atezo)+ bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular …","googleId":"vDaSB3-vMv0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960390X","googleCitationCount":47,"googleAuthor":"","doi":"10.1093/annonc/mdz394.030","elsevierAuthor":"Pinter M.","publicationName":"JAMA Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"3","altmetricAuthors":["M. Lee","B.-Y. Ryoo","C.-H. Hsu","K. Numata","S. Stein","W. Verret","S. Hack","J. Spahn","B. Liu","H. Abdullah","R. He","K.-H. Lee"],"twitterCount":0,"altmetricId":83417949},{"title":"Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study","googleId":"y851gSX83Z0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931035X","googleCitationCount":56,"googleAuthor":"","doi":"10.1093/annonc/mdy539","elsevierAuthor":"Hong D.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"40","altmetricAuthors":["D.S. Hong","T.M. Bauer","J.J. Lee","A. Dowlati","M.S. Brose","A.F. Farago","M. Taylor","A.T. Shaw","S. Montez","F. Meric-Bernstam","S. Smith","B.B. Tuch","K. Ebata","S. Cruickshank","M.C. Cox","H.A. Burris","R.C. Doebele"],"twitterCount":95,"altmetricId":53889240},{"title":"Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer","googleId":"9j0uvrbDQh4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50438-0/abstract","googleCitationCount":59,"googleAuthor":""},{"title":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant …","googleId":"vLCJ9MCArbMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325515","googleCitationCount":50,"googleAuthor":"G Bataillon","doi":"10.1093/annonc/mdz395","elsevierAuthor":"Park J.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"32","altmetricAuthors":["J H Park","S F Jonas","G Bataillon","C Criscitiello","R Salgado","S Loi","G Viale","H J Lee","M V Dieci","S -B Kim","A Vincent-Salomon","G Curigliano","F André","S Michiels"],"twitterCount":46,"altmetricId":67482561},{"title":"Latest clinical evidence and further development of PARP inhibitors in ovarian cancer","googleId":"P6jyX2doe-4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349178","googleCitationCount":59,"googleAuthor":"MR Mirza","doi":"10.1093/annonc/mdy174","elsevierAuthor":"Mirza M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"46","altmetricAuthors":["M.R. Mirza","S. Pignata","J.A. Ledermann"],"twitterCount":1,"altmetricId":58307152},{"title":"Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in …","googleId":"lSKLqWIqryIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311147","googleCitationCount":62,"googleAuthor":"WT Barry","doi":"10.1093/annonc/mdz018","elsevierAuthor":"Neves K.B.","publicationName":"Clinical Science","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"1","altmetricAuthors":["J.F. Liu","W.T. Barry","M. Birrer","J.-M. Lee","R.J. Buckanovich","G.F. Fleming","B.J. Rimel","M.K. Buss","S.R. Nattam","J. Hurteau","W. Luo","J. Curtis","C. Whalen","E.C. Kohn","S.P. Ivy","U.A. Matulonis"],"twitterCount":25,"altmetricId":55112927},{"title":"Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)","googleId":"VH2wnWYIDlAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318964","googleCitationCount":52,"googleAuthor":"","doi":"10.1093/annonc/mdy423","elsevierAuthor":"Marabelle A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"43","altmetricAuthors":["A. Marabelle","R. Andtbacka","K. Harrington","I. Melero","R. Leidner","T. de Baere","C. Robert","P.A. Ascierto","J -F Baurain","M. Imperiale","S. Rahimian","D. Tersago","E. Klumper","M. Hendriks","R. Kumar","M. Stern","K. Öhrling","C. Massacesi","I. Tchakov","A. Tse","J -Y Douillard","J. Tabernero","J. Haanen","J. Brody"],"twitterCount":42,"altmetricId":49381781},{"title":"Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) tumors: pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001","googleId":"2jn2ehTMEpUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50408-2/abstract","googleCitationCount":61,"googleAuthor":""},{"title":"Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"hqTJ9bBmyZUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)60977-4/abstract","googleCitationCount":40,"googleAuthor":"F Carneiro"},{"title":"Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer","googleId":"f9GG1JvXz9wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454586","googleCitationCount":72,"googleAuthor":"N Feeney","doi":"10.1093/annonc/mdy005","elsevierAuthor":"Guibert N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"55","altmetricAuthors":["N. Guibert","Y. Hu","N. Feeney","Y. Kuang","V. Plagnol","G. Jones","K. Howarth","J.F. Beeler","C.P. Paweletz","G.R. Oxnard"],"twitterCount":51,"altmetricId":31455638},{"title":"Safety and dose modification for patients receiving niraparib","googleId":"iqtQSV85LXkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341092","googleCitationCount":64,"googleAuthor":"","doi":"10.1093/annonc/mdy181","elsevierAuthor":"Banerjee S.","publicationName":"ESMO Open","elsevierCoverDate":"2020-12-11","elsevierCoverDisplayDate":"11 December 2020","elsevierCitationCount":"1","altmetricAuthors":["J.S. Berek","U.A. Matulonis","U. Peen","P. Ghatage","S. Mahner","A. Redondo","A. Lesoin","N. Colombo","I. Vergote","O. Rosengarten","J. Ledermann","M. Pineda","S. Ellard","J. Sehouli","A. Gonzalez-Martin","D. Berton-Rigaud","R. Madry","A. Reinthaller","S. Hazard","W. Guo","M.R. Mirza"],"twitterCount":14,"altmetricId":41973859},{"title":"A randomized trial of induction docetaxel–cisplatin–5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma …","googleId":"LqvwrgRiaU0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354936","googleCitationCount":74,"googleAuthor":"","doi":"10.1093/annonc/mdx770","elsevierAuthor":"Frikha M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"51","altmetricAuthors":["M. Frikha","A. Auperin","Y. Tao","F. Elloumi","N. Toumi","P. Blanchard","P. Lang","S. Sun","S. Racadot","J. Thariat","M. Alfonsi","C. Tuchais","A. Cornely","A. Moussa","J. Guigay","J. Daoud","J. Bourhis"],"twitterCount":7,"altmetricId":30375563},{"title":"Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting","googleId":"7RVfRil2YBcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609737","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdz228","elsevierAuthor":"Amant F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"23","altmetricAuthors":["F. Amant","P. Berveiller","I.A. Boere","E. Cardonick","R. Fruscio","M. Fumagalli","M.J. Halaska","A. Hasenburg","A.L.V. Johansson","M. Lambertini","C.A.R. Lok","C. Maggen","P. Morice","F. Peccatori","P. Poortmans","K. Van Calsteren","T. Vandenbroucke","M. van Gerwen","M. van den Heuvel-Eibrink","F. Zagouri","I. Zapardiel"],"twitterCount":31,"altmetricId":65306759},{"title":"FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)","googleId":"tzJq6OAr2FIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603911","googleCitationCount":45,"googleAuthor":"A Hollebecque","doi":"10.1093/annonc/mdz394.031","elsevierAuthor":"Vienot A.","publicationName":"Clinics and Research in Hepatology and Gastroenterology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0","altmetricAuthors":["A. Vogel","V. Sahai","A. Hollebecque","G. Vaccaro","D. Melisi","R. Al-Rajabi","A.S. Paulson","M.J. Borad","D. Gallinson","A.G. Murphy","D.-Y. Oh","E. Dotan","D.V. Catenacci","E. Van Cutsem","C.F. Lihou","H. Zhen","L. Féliz","G.K. Abou-Alfa"],"twitterCount":0,"altmetricId":79022186},{"title":"Delirium in adult cancer patients: ESMO Clinical Practice Guidelines","googleId":"g7JkhZhsFgMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31696-5/abstract","googleCitationCount":53,"googleAuthor":"SH Bush"},{"title":"Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo (radio) therapy: current …","googleId":"vmXWzOuDY_EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345661","googleCitationCount":56,"googleAuthor":"A Laviano","doi":"10.1093/annonc/mdy114","elsevierAuthor":"de van der Schueren M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"49","altmetricAuthors":["M.A.E. de van der Schueren","A. Laviano","H. Blanchard","M. Jourdan","J. Arends","V.E. Baracos"],"twitterCount":40,"altmetricId":38062521},{"title":"Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional …","googleId":"YkOYFko8N-EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345338","googleCitationCount":66,"googleAuthor":"","doi":"10.1093/annonc/mdy060","elsevierAuthor":"Nauta I.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"60","altmetricAuthors":["I.H. Nauta","M.M. Rietbergen","A.A.J.D. van Bokhoven","E. Bloemena","B.I. Lissenberg-Witte","D.A.M. Heideman","R.J. Baatenburg de Jong","R.H. Brakenhoff","C.R. Leemans"],"twitterCount":3,"altmetricId":33162595},{"title":"Molecular correlates differentiate response to atezolizumab (atezo)+ bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated …","googleId":"z6r8M_03wBAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50428-8/abstract","googleCitationCount":59,"googleAuthor":"BI Rini"},{"title":"Identifying patients with NTRK fusion cancer","googleId":"_zVnDmJ_F8wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419551183","googleCitationCount":46,"googleAuthor":"JF Hechtman","doi":"10.1093/annonc/mdz384","elsevierAuthor":"Solomon J.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"1 November 2019","elsevierCitationCount":"34","altmetricAuthors":["J.P. Solomon","R. Benayed","J.F. Hechtman","M. Ladanyi"],"twitterCount":3,"altmetricId":70762978},{"title":"TRK inhibitors in TRK fusion-positive cancers","googleId":"pbNES49JFCwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419551146","googleCitationCount":51,"googleAuthor":"A Drilon","doi":"10.1093/annonc/mdz282","elsevierAuthor":"Drilon A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"1 November 2019","elsevierCitationCount":"40","altmetricAuthors":["A. Drilon"],"twitterCount":2,"altmetricId":70781567},{"title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) …","googleId":"jkx2c8Pi3gsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312906","googleCitationCount":47,"googleAuthor":"T Sato","doi":"10.1093/annonc/mdz176","elsevierAuthor":"Khoja L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"25","altmetricAuthors":["L. Khoja","E.G. Atenafu","S. Suciu","S. Leyvraz","T. Sato","E. Marshall","U. Keilholz","L. Zimmer","S.P. Patel","S. Piperno-Neumann","J. Piulats","T.T. Kivelä","C. Pfoehler","S. Bhatia","P. Huppert","L.B.J. Van Iersel","I.J.M. De Vries","N. Penel","T. Vogl","T. Cheng","G. Fiorentini","F. Mouriaux","A. Tarhini","P.M. Patel","R. Carvajal","A.M. Joshua"],"twitterCount":9,"altmetricId":61478505},{"title":"Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer","googleId":"n3ncIXWoiqsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934904X","googleCitationCount":57,"googleAuthor":"","doi":"10.1093/annonc/mdy126","elsevierAuthor":"Wang H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"43","altmetricAuthors":["H. Wang","J. Agulnik","G. Kasymjanova","A. Wang","P. Jiménez","V. Cohen","D. Small","C. Pepe","L. Sakr","P.O. Fiset","M. Auger","S. Camilleri-Broet","M. Alam El Din","G. Chong","L. van Kempen","A. Spatz"],"twitterCount":33,"altmetricId":37820613},{"title":"Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma","googleId":"7HpsXiZd5nEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350501","googleCitationCount":67,"googleAuthor":"RJ Lee","doi":"10.1093/annonc/mdx717","elsevierAuthor":"Lee R.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"52","altmetricAuthors":["R.J. Lee","G. Gremel","A. Marshall","K.A. Myers","N. Fisher","J.A. Dunn","N. Dhomen","P.G. Corrie","M.R. Middleton","P. Lorigan","R. Marais"],"twitterCount":118,"altmetricId":28480893},{"title":"Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for …","googleId":"Djtj1qIVatgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309858","googleCitationCount":50,"googleAuthor":"YP Chen","doi":"10.1093/annonc/mdy470","elsevierAuthor":"Chen Y.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"32","altmetricAuthors":["Y.-P. Chen","Y.-Q. Wang","J.-W. Lv","Y.-Q. Li","M.L.K. Chua","Q.-T. Le","N. Lee","A. Dimitrios Colevas","T. Seiwert","D.N. Hayes","N. Riaz","J.B. Vermorken","B. O’Sullivan","Q.-M. He","X.-J. Yang","L.-L. Tang","Y.-P. Mao","Y. Sun","N. Liu","J. Ma"],"twitterCount":16,"altmetricId":50993919},{"title":"Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal …","googleId":"oF-X3zRFY_wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603674","googleCitationCount":48,"googleAuthor":"S Chia","doi":"10.1093/annonc/mdz394.007","elsevierCitationCount":0,"altmetricAuthors":["D.J. Slamon","P. Neven","S. Chia","P.A. Fasching","M. De Laurentiis","S.-A. Im","K. Petrakova","G.V. Bianchi","F.J. Esteva","M. Martin","A. Nusch","G.S. Sonke","L. De la Cruz-Merino","J.T. Beck","X. Pivot","M. Sondhi","Y. Wang","A. Chakravartty","K. Rodriguez-Lorenc","G. Jerusalem"],"twitterCount":0,"altmetricId":68179380},{"title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and …","googleId":"nT3V-MJosoEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325539","googleCitationCount":33,"googleAuthor":"U Dafni","doi":"10.1093/annonc/mdz398","elsevierAuthor":"Dafni U.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"23","altmetricAuthors":["U Dafni","O Michielin","S Martin Lluesma","Z Tsourti","V Polydoropoulou","D Karlis","M J Besser","J Haanen","I -M Svane","P S Ohashi","U S Kammula","A Orcurto","S Zimmermann","L Trueb","C A Klebanoff","M T Lotze","L E Kandalaft","G Coukos"],"twitterCount":11,"altmetricId":67509333},{"title":"Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer","googleId":"c4_Mxz0sCQ8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342061","googleCitationCount":57,"googleAuthor":"M Scheffler","doi":"10.1093/annonc/mdy333","elsevierAuthor":"Kron A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"44","altmetricAuthors":["A. Kron","C. Alidousty","M. Scheffler","S. Merkelbach-Bruse","D. Seidel","R. Riedel","M.A. Ihle","S. Michels","L. Nogova","J. Fassunke","C. Heydt","F. Kron","F. Ueckeroth","M. Serke","S. Krüger","C. Grohe","D. Koschel","J. Benedikter","B. Kaminsky","B. Schaaf","J. Braess","M. Sebastian","K -O Kambartel","R. Thomas","T. Zander","A.M. Schultheis","R. Büttner","J. Wolf"],"twitterCount":37,"altmetricId":47182351},{"title":"Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study","googleId":"aH6AkxVOh1AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342310","googleCitationCount":69,"googleAuthor":"AA Brandes","doi":"10.1093/annonc/mdy414","elsevierAuthor":"Conte P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"49","altmetricAuthors":["P. Conte","A. Frassoldati","G. Bisagni","A.A. Brandes","M. Donadio","O. Garrone","F. Piacentini","L. Cavanna","F. Giotta","M. Aieta","V. Gebbia","A. Molino","A. Musolino","A. Ferro","R. Maltoni","S. Danese","C. Zamagni","A. Rimanti","K. Cagossi","A. Russo","P. Pronzato","F. Giovanardi","G. Moretti","L. Lombardo","A. Schirone","A. Beano","L. Amaducci","E.A. Bajardi","R. Vicini","S. Balduzzi","R. D’Amico","V. Guarneri"],"twitterCount":74,"altmetricId":48446077},{"title":"Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after …","googleId":"4AdrvcxzRfAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310427","googleCitationCount":45,"googleAuthor":"SJ Luen","doi":"10.1093/annonc/mdy547","elsevierAuthor":"Luen S.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"33","altmetricAuthors":["S.J. Luen","R. Salgado","M.V. Dieci","A. Vingiani","G. Curigliano","R.E. Gould","C. Castaneda","T. D’Alfonso","J. Sanchez","E. Cheng","E. Andreopoulou","M. Castillo","S. Adams","S. Demaria","W.F. Symmans","S. Michiels","S. Loi"],"twitterCount":27,"altmetricId":53258877},{"title":"First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer","googleId":"VFnIN_ezYA0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341651","googleCitationCount":52,"googleAuthor":"C Massard","doi":"10.1093/annonc/mdy244","elsevierAuthor":"Massard C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"40","altmetricAuthors":["C. Massard","A. Azaro","J.-C. Soria","U. Lassen","C. Le Tourneau","D. Sarker","C. Smith","U. Ohnmacht","G. Oakley","B.K.R. Patel","E.S.M. Yuen","K.A. Benhadji","J. Rodon"],"twitterCount":1,"altmetricId":51241828},{"title":"Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient …","googleId":"8UMUDp2Gh8IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341766","googleCitationCount":56,"googleAuthor":"","doi":"10.1093/annonc/mdy257","elsevierAuthor":"Ettl J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"32","altmetricAuthors":["J. Ettl","R.G.W. Quek","K.-H. Lee","H.S. Rugo","S. Hurvitz","A. Gonçalves","L. Fehrenbacher","R. Yerushalmi","L.A. Mina","M. Martin","H. Roché","Y.-H. Im","D. Markova","H. Bhattacharyya","A.L. Hannah","W. Eiermann","J.L. Blum","J.K. Litton"],"twitterCount":36,"altmetricId":46565446},{"title":"Timing of radiotherapy (RT) after radical prostatectomy (RP): first results from the RADICALS RT randomised controlled trial (RCT)","googleId":"_gO3PTzClp8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604023","googleCitationCount":43,"googleAuthor":"HG Kynaston","doi":"10.1093/annonc/mdz394.042","elsevierAuthor":"Kokorovic A.","publicationName":"Canadian Urological Association Journal","elsevierCoverDate":"2020-04-28","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"3","altmetricAuthors":["C. Parker","N.W. Clarke","A. Cook","H.G. Kynaston","P. Meidahl Petersen","W. Cross","R. Persad","C. Catton","J. Logue","H. Payne","F. Saad","K. Brasso","H. Lindberg","A. Zarkar","R. Raman","M.A. Roder","C. Heath","W.R. Parulekar","M.K.B. Parmar","M.R. Sydes"],"twitterCount":3,"altmetricId":68179449},{"title":"KEYNOTE-522: Phase III study of pembrolizumab (pembro)+ chemotherapy (chemo) vs placebo (pbo)+ chemo as neoadjuvant treatment, followed by pembro …","googleId":"wESk3ByKIIwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603637","googleCitationCount":43,"googleAuthor":"R Dent","doi":"10.1093/annonc/mdz394.003","elsevierAuthor":"Navani V.","publicationName":"British Journal of Clinical Pharmacology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"1","altmetricAuthors":["P. Schmid","J. Cortés","R. Dent","L. Pusztai","H.L. McArthur","S. Kuemmel","J. Bergh","C. Denkert","Y.H. Park","R. Hui","N. Harbeck","M. Takahashi","T. Foukakis","P.A. Fasching","F. Cardoso","L. Jia","V. Karantza","J. Zhao","G. Aktan","J. O’Shaughnessy"],"twitterCount":0,"altmetricId":68179388},{"title":"Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer","googleId":"YgTrH2tOFsIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420326016","googleCitationCount":45,"googleAuthor":"F Saad","doi":"10.1093/annonc/mdz397","elsevierAuthor":"Small E.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"33","altmetricAuthors":["E.J. Small","F. Saad","S. Chowdhury","S. Oudard","B.A. Hadaschik","J.N. Graff","D. Olmos","P.N. Mainwaring","J.Y. Lee","H. Uemura","P. De Porre","A.A. Smith","K. Zhang","A. Lopez-Gitlitz","M.R. Smith"],"twitterCount":37,"altmetricId":67409635},{"title":"Pembrolizumab for advanced biliary adenocarcinoma: results from the multicohort, phase II KEYNOTE-158 study","googleId":"-BvgtB7RN94J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49087-X/abstract","googleCitationCount":52,"googleAuthor":"A Nagrial"},{"title":"Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution","googleId":"hFVONvIPuWwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355152","googleCitationCount":60,"googleAuthor":"S Venkatesan","doi":"10.1093/annonc/mdy003","elsevierAuthor":"Venkatesan S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"41","altmetricAuthors":["S. Venkatesan","R. Rosenthal","N. Kanu","N. McGranahan","J. Bartek","S.A. Quezada","J. Hare","R.S. Harris","C. Swanton"],"twitterCount":31,"altmetricId":31398642},{"title":"Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma","googleId":"ITC6lEts3YAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931004X","googleCitationCount":44,"googleAuthor":"","doi":"10.1093/annonc/mdy507","elsevierAuthor":"Oliva M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"36","altmetricAuthors":["M. Oliva","A. Spreafico","M. Taberna","L. Alemany","B. Coburn","R. Mesia","L.L. Siu"],"twitterCount":60,"altmetricId":51530719},{"title":"Pertuzumab, trastuzumab, and standard anthracycline-and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive …","googleId":"ySGaJ99_7m0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935495X","googleCitationCount":63,"googleAuthor":"SM Swain","doi":"10.1093/annonc/mdx773","elsevierAuthor":"Swain S.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"49","altmetricAuthors":["S.M. Swain","M.S. Ewer","G. Viale","S. Delaloge","J.-M. Ferrero","M. Verrill","R. Colomer","C. Vieira","T.L. Werner","H. Douthwaite","D. Bradley","M. Waldron-Lynch","A. Kiermaier","J. Eng-Wong","C. Dang"],"twitterCount":11,"altmetricId":30501274},{"title":"Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial","googleId":"V0mTyQeYmDsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454513","googleCitationCount":64,"googleAuthor":"B Allard","doi":"10.1093/annonc/mdx730","elsevierAuthor":"Buisseret L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"50","altmetricAuthors":["L. Buisseret","S. Pommey","B. Allard","S. Garaud","M. Bergeron","I. Cousineau","L. Ameye","Y. Bareche","M. Paesmans","J.P.A. Crown","A. Di Leo","S. Loi","M. Piccart-Gebhart","K. Willard-Gallo","C. Sotiriou","J. Stagg"],"twitterCount":22,"altmetricId":29285356},{"title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary …","googleId":"UmMY_-3_bgYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454525","googleCitationCount":61,"googleAuthor":"H Takahashi","doi":"10.1093/annonc/mdx771","elsevierAuthor":"Fushimi C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"49","altmetricAuthors":["C. Fushimi","Y. Tada","H. Takahashi","T. Nagao","H. Ojiri","T. Masubuchi","T. Matsuki","K. Miura","D. Kawakita","H. Hirai","E. Hoshino","S. Kamata","T. Saotome"],"twitterCount":13,"altmetricId":29890796},{"title":"Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium","googleId":"X7U2Z5pwlL0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311275","googleCitationCount":48,"googleAuthor":"R Alden","doi":"10.1093/annonc/mdz046","elsevierAuthor":"Siravegna G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"40","altmetricAuthors":["B.T. Li","F. Janku","B. Jung","C. Hou","K. Madwani","R. Alden","P. Razavi","J.S. Reis-Filho","R. Shen","J.M. Isbell","A.W. Blocker","N. Eattock","S. Gnerre","R.V. Satya","H. Xu","C. Zhao","M.P. Hall","Y. Hu","A.J. Sehnert","D. Brown","M. Ladanyi","C.M. Rudin","N. Hunkapiller","N. Feeney","G.B. Mills","C.P. Paweletz","P.A. Janne","D.B. Solit","G.J. Riely","A. Aravanis","G.R. Oxnard"],"twitterCount":74,"altmetricId":57315344},{"title":"Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer","googleId":"XSoIvimC20kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459917","googleCitationCount":38,"googleAuthor":"B Lee","doi":"10.1093/annonc/mdz200","elsevierAuthor":"Lee B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"27","altmetricAuthors":["B. Lee","L. Lipton","J. Cohen","J. Tie","A.A. Javed","L. Li","D. Goldstein","M. Burge","P. Cooray","A. Nagrial","N.C. Tebbutt","B. Thomson","M. Nikfarjam","M. Harris","A. Haydon","B. Lawrence","D.W.M. Tai","K. Simons","A.M. Lennon","C.L. Wolfgang","C. Tomasetti","N. Papadopoulos","K.W. Kinzler","B. Vogelstein","P. Gibbs"],"twitterCount":8,"altmetricId":62844326},{"title":"Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the …","googleId":"bTEH5zyfKmEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604370","googleCitationCount":37,"googleAuthor":"RS Herbst","doi":"10.1093/annonc/mdz394.077","elsevierAuthor":"Chakraborty A.","publicationName":"Biochemical Society Transactions","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0","altmetricAuthors":["R.S. Herbst","G. Lopes","D.M. Kowalski","M. Nishio","Y.-L. Wu","G. de Castro Junior","P. Baas","D.-W. Kim","M.A. Gubens","R. Cristescu","D. Aurora-Garg","A. Albright","M. Ayers","A. Loboda","J. Lunceford","J. Kobie","G.M. Lubiniecki","M.C. Pietanza","B. Piperdi","T.S.K. Mok"],"twitterCount":0,"altmetricId":69820636},{"title":"Long-course preoperative chemoradiation versus 5× 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results …","googleId":"-ztpBsjY5VQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312967","googleCitationCount":48,"googleAuthor":"W Michalski","doi":"10.1093/annonc/mdz186","elsevierAuthor":"Ciseł B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"30","altmetricAuthors":["B. Ciseł","L. Pietrzak","W. Michalski","L. Wyrwicz","A. Rutkowski","E. Kosakowska","A. Cencelewicz","M. Spałek","W. Polkowski","M. Jankiewicz","R. Styliński","M. Bębenek","B. Kapturkiewicz","A. Maciejczyk","J. Sadowski","J. Zygulska","W. Zegarski","M. Jankowski","M. Las-Jankowska","Z. Toczko","U. Żelazowska-Omiotek","L. Kępka","J. Socha","E. Wasilewska-Tesluk","W. Markiewicz","J. Kładny","A. Majewski","W. Kapuściński","R. Suwiński","K. Bujko"],"twitterCount":33,"altmetricId":62567962},{"title":"Overview of current systemic management of EGFR-mutant NSCLC","googleId":"vFBC2Khe6MkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316680","googleCitationCount":58,"googleAuthor":"HH Loong","doi":"10.1093/annonc/mdx702","elsevierAuthor":"Hsu W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"44","altmetricAuthors":["W.-H. Hsu","J.C.-H. Yang","T.S. Mok","H.H. Loong"],"twitterCount":5,"altmetricId":33367601},{"title":"Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial","googleId":"zr4CoiyuQnAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310403","googleCitationCount":40,"googleAuthor":"RS Herbst","doi":"10.1093/annonc/mdy545","elsevierAuthor":"Herbst R.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"35","altmetricAuthors":["R.S. Herbst","P. Baas","J.L. Perez-Gracia","E. Felip","D.-W. Kim","J.-Y. Han","J.R. Molina","J.-H. Kim","C. Dubos Arvis","M.-J. Ahn","M. Majem","M.J. Fidler","V. Surmont","G. de Castro","M. Garrido","Y. Shentu","K. Emancipator","A. Samkari","E.H. Jensen","G.M. Lubiniecki","E.B. Garon"],"twitterCount":25,"altmetricId":54090333},{"title":"Surgery in reference centers improves survival of sarcoma patients: a nationwide study","googleId":"iWz5eFiC5KIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312323","googleCitationCount":45,"googleAuthor":"JY Blay","doi":"10.1093/annonc/mdz124","elsevierAuthor":"Mesko N.W.","publicationName":"Surgical Oncology Clinics of North America","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"0","altmetricAuthors":["J.-Y. Blay","C. Honoré","E. Stoeckle","P. Meeus","M. Jafari","F. Gouin","P. Anract","G. Ferron","A. Rochwerger","M. Ropars","S. Carrere","F. Marchal","F. Sirveaux","A. Di Marco","L.R. Le Nail","J. Guiramand","G. Vaz","J.-C. Machiavello","O. Marco","S. Causeret","P. Gimbergues","F. Fiorenza","L. Chaigneau","F. Guillemin","J.-M. Guilloit","F. Dujardin","J.-P. Spano","J.-C. Ruzic","A. Michot","P. Soibinet","E. Bompas","C. Chevreau","F. Duffaud","M. Rios","C. Perrin","N. Firmin","F. Bertucci","C. Le Pechoux","F. Le Loarer","O. Collard","M. Karanian-Philippe","M. Brahmi","A. Dufresne","A. Dupré","F. Ducimetière","A. Giraud","D. Pérol","M. Toulmonde","I. Ray-Coquard","A. Italiano","A. Le Cesne","N. Penel","S. Bonvalot"],"twitterCount":41,"altmetricId":60216044},{"title":"Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc …","googleId":"0jR1BCf407QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603698","googleCitationCount":46,"googleAuthor":"S Loi","doi":"10.1093/annonc/mdz394.009","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas …","googleId":"scNCVpsFdAAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325904","googleCitationCount":31,"googleAuthor":"V Makker","doi":"10.1093/annonc/mdz291","elsevierAuthor":"Jhaveri K.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"27","altmetricAuthors":["K.L. Jhaveri","X.V. Wang","V. Makker","S.-W. Luoh","E.P. Mitchell","J.A. Zwiebel","E. Sharon","R.J. Gray","S. Li","L.M. McShane","L.V. Rubinstein","D. Patton","P.M. Williams","S.R. Hamilton","B.A. Conley","C.L. Arteaga","L.N. Harris","P.J. O’Dwyer","A.P. Chen","K.T. Flaherty"],"twitterCount":16,"altmetricId":65889838},{"title":"The European society for medical oncology (ESMO) precision medicine glossary","googleId":"16uKHIZmFr0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350112","googleCitationCount":61,"googleAuthor":"LL Siu","doi":"10.1093/annonc/mdx707","elsevierAuthor":"Yates L.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"35","altmetricAuthors":["L.R. Yates","J. Seoane","C. Le Tourneau","L.L. Siu","R. Marais","S. Michiels","J.C. Soria","P. Campbell","N. Normanno","A. Scarpa","J.S. Reis-Filho","J. Rodon","C. Swanton","F. Andre"],"twitterCount":99,"altmetricId":28839354},{"title":"A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural …","googleId":"haiUYizilZ8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604515","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdz394.091","elsevierCitationCount":0,"altmetricAuthors":["S. Popat","A. Curioni-Fontecedro","V. Polydoropoulou","R. Shah","M. O’Brien","A. Pope","P. Fisher","J. Spicer","A. Roy","D. Gilligan","O. Gautschi","E. Nadal","W.-D. Janthur","R. López Castro","R. García Campelo","H. Roschitzki-Voser","B. Ruepp","S. Rusakiewicz","S. Peters","R.A. Stahel"],"twitterCount":1,"altmetricId":67608243},{"title":"The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular …","googleId":"x5G1gAdb-PgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318885","googleCitationCount":54,"googleAuthor":"CK Lee","doi":"10.1093/annonc/mdy410","elsevierAuthor":"Mooi J.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"37","altmetricAuthors":["J.K. Mooi","P. Wirapati","R. Asher","C.K. Lee","P. Savas","T.J. Price","A. Townsend","J. Hardingham","D. Buchanan","D. Williams","S. Tejpar","J.M. Mariadason","N.C. Tebbutt"],"twitterCount":11,"altmetricId":48780676},{"title":"Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and …","googleId":"odR8Vk1w7u8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604382","googleCitationCount":34,"googleAuthor":"","doi":"10.1093/annonc/mdz394.078","elsevierCitationCount":0,"altmetricAuthors":["L. Paz-Ares","C.J. Langer","S. Novello","B. Halmos","Y. Cheng","S.M. Gadgeel","R. Hui","S. Sugawara","H. Borghaei","R. Cristescu","D. Aurora-Garg","A. Albright","A. Loboda","J. Kobie","J. Lunceford","M. Ayers","G.M. Lubiniecki","M.C. Pietanza","B. Piperdi","M.C. Garassino"],"twitterCount":0,"altmetricId":69820639},{"title":"Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases","googleId":"HuF1PmDnk7EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310397","googleCitationCount":37,"googleAuthor":"A Bardelli","doi":"10.1093/annonc/mdy544","elsevierAuthor":"Seoane J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"24","altmetricAuthors":["J. Seoane","L. De Mattos-Arruda","E. Le Rhun","A. Bardelli","M. Weller"],"twitterCount":23,"altmetricId":53009558},{"title":"Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind …","googleId":"iVoGQe7utRMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354912","googleCitationCount":57,"googleAuthor":"","doi":"10.1093/annonc/mdx767","elsevierAuthor":"Tabernero J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"41","altmetricAuthors":["J. Tabernero","R.R. Hozak","T. Yoshino","A.L. Cohn","R. Obermannova","G. Bodoky","R. Garcia-Carbonero","T.-E. Ciuleanu","D.C. Portnoy","J. Prausová","K. Muro","R.W. Siegel","R.J. Konrad","H. Ouyang","S.A. Melemed","D. Ferry","F. Nasroulah","E. Van Cutsem"],"twitterCount":17,"altmetricId":30375879},{"title":"Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with …","googleId":"nd2kB4tfcM4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50406-9/abstract","googleCitationCount":53,"googleAuthor":"J Brody"},{"title":"Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment …","googleId":"WAIpjOgnfGAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459954","googleCitationCount":47,"googleAuthor":"J Taieb","doi":"10.1093/annonc/mdz208","elsevierAuthor":"Taieb J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"29","altmetricAuthors":["J. Taieb","Q. Shi","L. Pederson","S. Alberts","N. Wolmark","E. Van Cutsem","A. de Gramont","R. Kerr","A. Grothey","S. Lonardi","T. Yoshino","G. Yothers","F.A. Sinicrope","A. Zaanan","T. André"],"twitterCount":34,"altmetricId":63076326},{"title":"Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after …","googleId":"46IxcFkiSocJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30259-5/abstract","googleCitationCount":47,"googleAuthor":"TK Owonikoko"},{"title":"JAVELIN renal 101: a randomized, Phase III study of avelumab+ axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)","googleId":"7ycuXzG_e7YJ","googleLink":"https://researchers.mq.edu.au/files/117842959/Publisher_version_open_access_.pdf","googleCitationCount":48,"googleAuthor":"K Penkov"},{"title":"Corrections to “Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”","googleId":"ya4axIpRsIQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31702-8/abstract","googleCitationCount":55,"googleAuthor":"S Mahner"},{"title":"Adjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis","googleId":"hQu2ROH9aHQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604011","googleCitationCount":34,"googleAuthor":"","doi":"10.1093/annonc/mdz394.041","elsevierAuthor":"Kokorovic A.","publicationName":"Canadian Urological Association Journal","elsevierCoverDate":"2020-04-28","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"3","altmetricAuthors":["C.L. Vale","M. Brihoum","S. Chabaud","A. Cook","D. Fisher","S. Forcat","C. Fraser-Browne","A. Herschtal","A. Kneebone","S. Nénan","C. Parker","M.K.B. Parmar","M. Pearse","P. Richaud","E. Rogozińska","P. Sargos","M.R. Sydes","J.F. Tierney"],"twitterCount":3,"altmetricId":68179447},{"title":"Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information","googleId":"BxJyYr852YUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454689","googleCitationCount":55,"googleAuthor":"S Kim","doi":"10.1093/annonc/mdy022","elsevierAuthor":"Kim S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"44","altmetricAuthors":["S. Kim","H.S. Kim","E. Kim","M.G. Lee","E.-C. Shin","S. Paik","S. Kim"],"twitterCount":11,"altmetricId":31969911},{"title":"Optimizing panel-based tumor mutational burden (TMB) measurement","googleId":"S1HxzZuQ0lgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459930","googleCitationCount":47,"googleAuthor":"J Budczies","doi":"10.1093/annonc/mdz205","elsevierAuthor":"Budczies J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"32","altmetricAuthors":["J. Budczies","M. Allgäuer","K. Litchfield","E. Rempel","P. Christopoulos","D. Kazdal","V. Endris","M. Thomas","S. Fröhling","S. Peters","C. Swanton","P. Schirmacher","A. Stenzinger"],"twitterCount":33,"altmetricId":63079759},{"title":"Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial","googleId":"V7m10H-CD6EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454628","googleCitationCount":59,"googleAuthor":"","doi":"10.1093/annonc/mdy012","elsevierAuthor":"Rugo H.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"44","altmetricAuthors":["H.S. Rugo","V. Diéras","K.A. Gelmon","R.S. Finn","D.J. Slamon","M. Martin","P. Neven","Y. Shparyk","A. Mori","D.R. Lu","H. Bhattacharyya","C.H.u.a.n.g. Bartlett","S. Iyer","S. Johnston","J. Ettl","N. Harbeck"],"twitterCount":14,"altmetricId":32034272},{"title":"Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer","googleId":"eziLk_KxKjYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603686","googleCitationCount":37,"googleAuthor":"H Wildiers","doi":"10.1093/annonc/mdz394.008","elsevierCitationCount":0,"altmetricAuthors":["V.C. Diéras","H.S. Han","B. Kaufman","H. Wildiers","M. Friedlander","J.-P. Ayoub","S.L. Puhalla","I. Bondarenko","M. Campone","E.H. Jakobsen","M. Jalving","C. Oprean","M. Palácová","Y.H. Park","Y. Shparyk","E. Yañez","M. Dudley","C.K. Ratajczak","D. Maag","B.K. Arun"],"twitterCount":0,"altmetricId":68179385},{"title":"IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs …","googleId":"s2ZbG56JeBoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604072","googleCitationCount":35,"googleAuthor":"ID Davis","doi":"10.1093/annonc/mdz394.047","elsevierAuthor":"Fender H.E.","publicationName":"Best Practice Onkologie","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"0","altmetricAuthors":["E. Grande","M. Galsky","J.A. Arranz Arija","M. De Santis","I.D. Davis","U.F.F. De Giorgi","M. Mencinger","E. Kikuchi","X. Garcia del Muro","M. Gumus","M. Özgüroğlu","A. Rezazadeh Kalebasty","S.H. Park","B.Y. Alekseev","F.A.B. Schutz","J.-R. Li","A. Mecke","S. Mariathasan","A. Thastrom","A. Bamias"],"twitterCount":2,"altmetricId":68179454},{"title":"Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial","googleId":"DsYea6thfiUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311676","googleCitationCount":42,"googleAuthor":"","doi":"10.1093/annonc/mdz080","elsevierAuthor":"Hofman V.","publicationName":"Lung Cancer","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"1","altmetricAuthors":["O. Trédan","Q. Wang","D. Pissaloux","P. Cassier","A. de la Fouchardière","J. Fayette","F. Desseigne","I. Ray-Coquard","C. de la Fouchardière","D. Frappaz","P.-E. Heudel","A. Bonneville-Levard","A. Fléchon","M. Sarabi","P. Guibert","T. Bachelot","M. Pérol","B. You","N. Bonnin","O. Collard","C. Leyronnas","V. Attignon","C. Baudet","E. Sohier","J.-P. Villemin","A. Viari","S. Boyault","S. Lantuejoul","S. Paindavoine","I. Treillleux","C. Rodriguez","V. Agrapart","V. Corset","G. Garin","S. Chabaud","D. Pérol","J.-Y. Blay"],"twitterCount":44,"altmetricId":57207578},{"title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a …","googleId":"Dtv_9UGKk2AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311184","googleCitationCount":42,"googleAuthor":"O Chinot","doi":"10.1093/annonc/mdz032","elsevierAuthor":"Yang H.","publicationName":"Journal of Cellular Physiology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"1 December 2020","elsevierCitationCount":"0","altmetricAuthors":["H. Ghesquieres","M. Chevrier","M. Laadhari","O. Chinot","S. Choquet","C. Moluçon-Chabrot","P. Beauchesne","R. Gressin","F. Morschhauser","A. Schmitt","E. Gyan","K. Hoang-Xuan","E. Nicolas-Virelizier","N. Cassoux","V. Touitou","M. Le Garff-Tavernier","A. Savignoni","I. Turbiez","V. Soumelis","C. Houillier","C. Soussain"],"twitterCount":48,"altmetricId":54771429},{"title":"Fluoropyrimidine (FP)+ bevacizumab (BEV)+ atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL–a …","googleId":"CnozItgixTkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50411-2/abstract","googleCitationCount":44,"googleAuthor":"A Grothey"},{"title":"Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic …","googleId":"_TruGkshOrMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342334","googleCitationCount":44,"googleAuthor":"F Diehl","doi":"10.1093/annonc/mdy417","elsevierAuthor":"Kruger S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"27","altmetricAuthors":["S. Kruger","V. Heinemann","C. Ross","F. Diehl","D. Nagel","S. Ormanns","S. Liebmann","I. Prinz-Bravin","C.B. Westphalen","M. Haas","A. Jung","T. Kirchner","M. von Bergwelt-Baildon","S. Boeck","S. Holdenrieder"],"twitterCount":60,"altmetricId":50019933},{"title":"Crizotinib in c-MET-or ROS1-positive NSCLC: results of the AcSé phase II trial","googleId":"sqRXiDd8Py0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325606","googleCitationCount":42,"googleAuthor":"J Mazières","doi":"10.1093/annonc/mdz407","elsevierAuthor":"Moro-Sibilot D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"30","altmetricAuthors":["D. Moro-Sibilot","N. Cozic","M. Pérol","J. Mazières","J. Otto","P.J. Souquet","R. Bahleda","M. Wislez","G. Zalcman","S.D. Guibert","F. Barlési","B. Mennecier","I. Monnet","R. Sabatier","S. Bota","C. Dubos","V. Verriele","V. Haddad","G. Ferretti","A. Cortot","F. De Fraipont","M. Jimenez","N. Hoog-Labouret","G. Vassal"],"twitterCount":33,"altmetricId":67695583},{"title":"KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)","googleId":"9VGjLlghH7wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603704","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdz394.010","elsevierCitationCount":0,"altmetricAuthors":["J. Cortés","O. Lipatov","S.-A. Im","A. Gonçalves","K.S. Lee","P. Schmid","K. Tamura","L. Testa","I. Witzel","S. Ohtani","S. Zambelli","N. Harbeck","F. André","R. Dent","X. Zhou","V. Karantza","J.A. Mejia","E.P. Winer"],"twitterCount":0,"altmetricId":68179391},{"title":"Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach","googleId":"08Pe7nwlSfEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48876-5/abstract","googleCitationCount":43,"googleAuthor":"UN Lassen"},{"title":"Targeting the PI3-kinase pathway in triple-negative breast cancer","googleId":"yltm_eoRTw4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312396","googleCitationCount":41,"googleAuthor":"","doi":"10.1093/annonc/mdz133","elsevierAuthor":"Xu M.","publicationName":"Aging","elsevierCoverDate":"2021-01-15","elsevierCoverDisplayDate":"15 January 2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate …","googleId":"IQkfwHD4KNsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590627","googleCitationCount":32,"googleAuthor":"D Campbell","doi":"10.1093/annonc/mdz248.003","elsevierAuthor":"Marhold M.","publicationName":"Memo - Magazine of European Medical Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0},{"title":"First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma","googleId":"McdKD_h4194J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590329","googleCitationCount":42,"googleAuthor":"YY Janjigian","doi":"10.1093/annonc/mdz247.143","elsevierCitationCount":0,"altmetricAuthors":["Y.Y. Janjigian","S. Maron","J.F. Chou","A.R. Gabler","M.Z. Simmons","P. Momtaz","M. Shcherba","G.Y. Ku","E. Won","F. Sanchez-Vega","H. Gerdes","D.P. Kelsen","D.H. Ilson","D. Solit","N. Schultz","P.M. Shah","M. Capanu","J.F. Hechtman","M. Lamendola-Essel"],"twitterCount":0,"altmetricId":68179431},{"title":"Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian …","googleId":"g34MC1v7YkUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604138","googleCitationCount":33,"googleAuthor":"IL Ray-Coquard","doi":"10.1093/annonc/mdz394.053","elsevierCitationCount":0,"altmetricAuthors":["I.L. Ray-Coquard","P. Pautier","S. Pignata","D. Pérol","A. González-Martín","P. Sevelda","K. Fujiwara","I.B. Vergote","N. Colombo","J. Mäenpää","F. Selle","J. Sehouli","D. Lorusso","E M Guerra Alia","C. Lefeuvre-Plesse","U. Canzler","A. Lortholary","F. Marmé","E. Pujade-Lauraine","P. Harter"],"twitterCount":0,"altmetricId":68179382},{"title":"Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of …","googleId":"VEewJf0Hu6kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312827","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdz163","elsevierAuthor":"Gomez-Roca C.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"27","altmetricAuthors":["C.A. Gomez-Roca","A. Italiano","C. Le Tourneau","P.A. Cassier","M. Toulmonde","S.P. D’Angelo","M. Campone","K.L. Weber","D. Loirat","M.A. Cannarile","A.-M. Jegg","C. Ries","R. Christen","G. Meneses-Lorente","W. Jacob","I. Klaman","C.-H. Ooi","C. Watson","K. Wonde","B. Reis","F. Michielin","D. Rüttinger","J.-P. Delord","J.-Y. Blay"],"twitterCount":1,"altmetricId":60889699},{"title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","googleId":"1Gdv-h0Gr3gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341407","googleCitationCount":50,"googleAuthor":"","doi":"10.1093/annonc/mdy226","elsevierAuthor":"Tetzlaff M.T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"39","altmetricAuthors":["M.T. Tetzlaff","J.L. Messina","J.E. Stein","X. Xu","R.N. Amaria","C.U. Blank","B.A. van de Wiel","P.M. Ferguson","R.V. Rawson","M.I. Ross","A.J. Spillane","J.E. Gershenwald","R.P.M. Saw","A.C.J. van Akkooi","W.J. van Houdt","T.C. Mitchell","A.M. Menzies","G.V. Long","J.A. Wargo","M.A. Davies","V.G. Prieto","J.M. Taube","R.A. Scolyer"],"twitterCount":40,"altmetricId":44119329},{"title":"Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone …","googleId":"q-aW8DuuEI0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341705","googleCitationCount":47,"googleAuthor":"","doi":"10.1093/annonc/mdy249","elsevierAuthor":"Hong R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"35","altmetricAuthors":["R.L. Hong","C.F. Hsiao","L.L. Ting","J.Y. Ko","C.W. Wang","J.T.C. Chang","P.J. Lou","H.M. Wang","M.H. Tsai","S.C. Lai","T.W. Liu"],"twitterCount":7,"altmetricId":45571496},{"title":"Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for …","googleId":"5s9MQ2NMZO4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50458-6/abstract","googleCitationCount":42,"googleAuthor":"V Velcheti"},{"title":"Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer","googleId":"cJDlrTiTRyMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454719","googleCitationCount":51,"googleAuthor":"N Priedigkeit","doi":"10.1093/annonc/mdy025","elsevierAuthor":"Hartmaier R.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"37","altmetricAuthors":["R.J. Hartmaier","S.E. Trabucco","N. Priedigkeit","J.H. Chung","C.A. Parachoniak","P. Vanden Borre","S. Morley","M. Rosenzweig","L.M. Gay","M.E. Goldberg","J. Suh","S.M. Ali","J. Ross","B. Leyland-Jones","B. Young","C. Williams","B. Park","M. Tsai","B. Haley","J. Peguero","R.D. Callahan","I. Sachelarie","J. Cho","J.M. Atkinson","A. Bahreini","A.M. Nagle","S.L. Puhalla","R.J. Watters","Z. Erdogan-Yildirim","L. Cao","S. Oesterreich","A. Mathew","P.C. Lucas","N.E. Davidson","A.M. Brufsky","G.M. Frampton","P.J. Stephens","J. Chmielecki","A.V. Lee"],"twitterCount":55,"altmetricId":31937265},{"title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA …","googleId":"yhogiUBXn4kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354997","googleCitationCount":48,"googleAuthor":"","doi":"10.1093/annonc/mdx787","elsevierAuthor":"Fossard G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"36","altmetricAuthors":["G. Fossard","F. Broussais","I. Coelho","S. Bailly","E. Nicolas-Virelizier","E. Toussaint","C. Lancesseur","F. Le Bras","E. Willems","E. Tchernonog","T. Chalopin","R. Delarue","R. Gressin","A. Chauchet","E. Gyan","G. Cartron","C. Bonnet","C. Haioun","G. Damaj","P. Gaulard","L. Fornecker","H. Ghesquières","O. Tournilhac","M. Gomes da Silva","R. Bouabdallah","G. Salles","E. Bachy"],"twitterCount":35,"altmetricId":30681455},{"title":"Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the …","googleId":"0MebEzG64wIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321015","googleCitationCount":47,"googleAuthor":"C Cremolini","doi":"10.1093/annonc/mdy140","elsevierAuthor":"Cremolini C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"40","altmetricAuthors":["C. Cremolini","C. Antoniotti","S. Lonardi","F. Bergamo","E. Cortesi","G. Tomasello","R. Moretto","M. Ronzoni","P. Racca","F. Loupakis","A. Zaniboni","G. Tonini","A. Buonadonna","F. Marmorino","G. Allegrini","C. Granetto","G. Masi","V. Zagonel","E. Sensi","G. Fontanini","L. Boni","A. Falcone"],"twitterCount":23,"altmetricId":39288798},{"title":"Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients","googleId":"3GpLyzqtnMoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345521","googleCitationCount":42,"googleAuthor":"JL Perez-Gracia","doi":"10.1093/annonc/mdy089","elsevierAuthor":"Rodríguez-Ruiz M.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"34","altmetricAuthors":["M.E. Rodríguez-Ruiz","J.L. Perez-Gracia","I. Rodríguez","C. Alfaro","C. Oñate","G. Pérez","I. Gil-Bazo","A. Benito","S. Inogés","A. López-Diaz de Cerio","M. Ponz-Sarvise","L. Resano","P. Berraondo","B. Barbés","S. Martin-Algarra","A. Gúrpide","M.F. Sanmamed","C. de Andrea","A.M. Salazar","I. Melero"],"twitterCount":11,"altmetricId":34632490},{"title":"Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study","googleId":"gFl3-e4UZEYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341754","googleCitationCount":41,"googleAuthor":"","doi":"10.1093/annonc/mdy256","elsevierAuthor":"De Vos S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"33","altmetricAuthors":["S. de Vos","L.J. Swinnen","D. Wang","E. Reid","N. Fowler","J. Cordero","M. Dunbar","S.H. Enschede","C. Nolan","A.M. Petrich","J.A. Ross","A.H. Salem","M. Verdugo","S. Agarwal","L. Zhou","M. Kozloff","L.J. Nastoupil","C.R. Flowers"],"twitterCount":16,"altmetricId":45809351},{"title":"Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative …","googleId":"Tmzq_-ul8E0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341328","googleCitationCount":43,"googleAuthor":"L Malorni","doi":"10.1093/annonc/mdy214","elsevierAuthor":"Malorni L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"37","altmetricAuthors":["L. Malorni","G. Curigliano","A.M. Minisini","S. Cinieri","C.A. Tondini","K. D’Hollander","G. Arpino","A. Bernardo","A. Martignetti","C. Criscitiello","F. Puglisi","M. Pestrin","G. Sanna","E. Moretti","E. Risi","C. Biagioni","A. McCartney","L. Boni","M. Buyse","I. Migliaccio","L. Biganzoli","A. Di Leo"],"twitterCount":35,"altmetricId":43586983},{"title":"A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results","googleId":"7mOFh48MmssJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589633","googleCitationCount":35,"googleAuthor":"J Llovet","doi":"10.1093/annonc/mdz247.073","elsevierAuthor":"Pinter M.","publicationName":"JAMA Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"3","altmetricAuthors":[],"twitterCount":0},{"title":"Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More …","googleId":"zmzE8yWnucEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325898","googleCitationCount":25,"googleAuthor":"JMS Bartlett","doi":"10.1093/annonc/mdz289","elsevierAuthor":"Bartlett J.M.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"18","altmetricAuthors":["J.M.S. Bartlett","D.C. Sgroi","K. Treuner","Y. Zhang","I. Ahmed","T. Piper","R. Salunga","E.F. Brachtel","S.J. Pirrie","C.A. Schnabel","D.W. Rea"],"twitterCount":15,"altmetricId":65601327},{"title":"CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC","googleId":"9vGOynXF3HQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596880","googleCitationCount":32,"googleAuthor":"","doi":"10.1093/annonc/mdz260.002","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Efficacy of PI3K inhibitors in advanced breast cancer","googleId":"fpx7lM_LjGEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034374X","googleCitationCount":35,"googleAuthor":"F Andre","doi":"10.1093/annonc/mdz381","elsevierAuthor":"Duggan M.R.","publicationName":"Aging","elsevierCoverDate":"2021-01-15","elsevierCoverDisplayDate":"15 January 2021","elsevierCitationCount":"0","altmetricAuthors":["B. Verret","J. Cortes","T. Bachelot","F. Andre","M. Arnedos"],"twitterCount":6,"altmetricId":73183780},{"title":"Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer","googleId":"cArXuAfWad4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342358","googleCitationCount":38,"googleAuthor":"P Cottu","doi":"10.1093/annonc/mdy448","elsevierAuthor":"Cottu P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"30","altmetricAuthors":["P. Cottu","V. D'Hondt","S. Dureau","F. Lerebours","I. Desmoulins","P.-E. Heudel","F.P. Duhoux","C. Levy","M.-A. Mouret-Reynier","F. Dalenc","J.-S. Frenel","C. Jouannaud","L. Venat-Bouvet","S. Nguyen","J.-M. Ferrero","J.-L. Canon","J. Grenier","C. Callens","D. Gentien","J. Lemonnier","A. Vincent-Salomon","S. Delaloge"],"twitterCount":49,"altmetricId":49515809},{"title":"Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer","googleId":"wjQPzV-QDo0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316710","googleCitationCount":49,"googleAuthor":"L Friboulet","doi":"10.1093/annonc/mdx705","elsevierAuthor":"Favazza L.A.","publicationName":"Modern Pathology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast …","googleId":"39qHxHyYTlMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341225","googleCitationCount":43,"googleAuthor":"R Coleman","doi":"10.1093/annonc/mdy201","elsevierAuthor":"Yardley D.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"37","altmetricAuthors":["D.A. Yardley","R. Coleman","P. Conte","J. Cortes","A. Brufsky","M. Shtivelband","R. Young","C. Bengala","H. Ali","J. Eakel","A. Schneeweiss","L. de la Cruz-Merino","S. Wilks","J. O’Shaughnessy","S. Glück","H. Li","J. Miller","D. Barton","N. Harbeck"],"twitterCount":46,"altmetricId":43409127},{"title":"Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients","googleId":"Saws194IJzUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349944","googleCitationCount":49,"googleAuthor":"M Lambertini","doi":"10.1093/annonc/mdx639","elsevierAuthor":"Lambertini M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"37","altmetricAuthors":["M. Lambertini","O. Goldrat","A.R. Ferreira","J. Dechene","H.A. Azim Jr","J. Desir","A. Delbaere","M.-D. t’Kint de Roodenbeke","E. de Azambuja","M. Ignatiadis","I. Demeestere"],"twitterCount":43,"altmetricId":27248526},{"title":"Context matters—consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials","googleId":"YxGnAiwPREoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311317","googleCitationCount":34,"googleAuthor":"E Fontana","doi":"10.1093/annonc/mdz052","elsevierAuthor":"Xie Y.H.","publicationName":"Signal Transduction and Targeted Therapy","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"1 December 2020","elsevierCitationCount":"46","altmetricAuthors":["E. Fontana","K. Eason","A. Cervantes","R. Salazar","A. Sadanandam"],"twitterCount":5,"altmetricId":56081343},{"title":"What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis","googleId":"2o93TR0d-F4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345405","googleCitationCount":45,"googleAuthor":"IR White","doi":"10.1093/annonc/mdy071","elsevierAuthor":"Vale C.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"34","altmetricAuthors":["C.L. Vale","D.J. Fisher","I.R. White","J.R. Carpenter","S. Burdett","N.W. Clarke","K. Fizazi","G. Gravis","N.D. James","M.D. Mason","M.K.B. Parmar","L.H. Rydzewska","C.J. Sweeney","M.R. Spears","M.R. Sydes","J.F. Tierney"],"twitterCount":17,"altmetricId":33680499},{"title":"Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma","googleId":"zpHVKPgqZhEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350070","googleCitationCount":48,"googleAuthor":"E Ghorani","doi":"10.1093/annonc/mdx687","elsevierAuthor":"Ghorani E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"37","altmetricAuthors":["E. Ghorani","R. Rosenthal","N. McGranahan","J.L. Reading","M. Lynch","K.S. Peggs","C. Swanton","S.A. Quezada"],"twitterCount":16,"altmetricId":28237091},{"title":"Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions","googleId":"GJWU25bDTYkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345582","googleCitationCount":41,"googleAuthor":"EEW Cohen","doi":"10.1093/annonc/mdy102","elsevierAuthor":"Haddad R.I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"30","altmetricAuthors":["R.I. Haddad","M. Posner","R. Hitt","E.E.W. Cohen","J. Schulten","J.-L. Lefebvre","J.B. Vermorken"],"twitterCount":40,"altmetricId":35366342},{"title":"Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide","googleId":"w99YVEXzsH0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341420","googleCitationCount":38,"googleAuthor":"F Scotté","doi":"10.1093/annonc/mdy228","elsevierAuthor":"Scotté F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"30","altmetricAuthors":["F. Scotté","P. Bossi","E. Carola","T. Cudennec","P. Dielenseger","F. Gomes","S. Knox","F. Strasser"],"twitterCount":63,"altmetricId":45079755},{"title":"CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer","googleId":"BRzdf1031OUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345491","googleCitationCount":41,"googleAuthor":"","doi":"10.1093/annonc/mdy085","elsevierAuthor":"Smeby J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"31","altmetricAuthors":["J. Smeby","A. Sveen","M.A. Merok","S.A. Danielsen","I.A. Eilertsen","M.G. Guren","R. Dienstmann","A. Nesbakken","R.A. Lothe"],"twitterCount":10,"altmetricId":34279367},{"title":"How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer","googleId":"5-2L4DxJ1PAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312037","googleCitationCount":32,"googleAuthor":"S Peters","doi":"10.1093/annonc/mdz109","elsevierAuthor":"Reinmuth N.","publicationName":"Onkologe","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["S. Peters","M. Reck","E.F. Smit","T. Mok","M.D. Hellmann"],"twitterCount":152,"altmetricId":57830669},{"title":"Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants","googleId":"iRLLQHPhEfIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312049","googleCitationCount":31,"googleAuthor":"C Ay","doi":"10.1093/annonc/mdz111","elsevierAuthor":"Sorigue M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-07-01","elsevierCoverDisplayDate":"1 July 2019","elsevierCitationCount":"0","altmetricAuthors":["C. Ay","J. Beyer-Westendorf","I. Pabinger"],"twitterCount":171,"altmetricId":58171838},{"title":"Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients","googleId":"_nzkQ6SAG-0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454781","googleCitationCount":43,"googleAuthor":"E Pectasides","doi":"10.1093/annonc/mdy034","elsevierAuthor":"Kim S.T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"35","altmetricAuthors":["S.T. Kim","K.C. Banks","E. Pectasides","S.Y. Kim","K. Kim","R.B. Lanman","A. Talasaz","J. An","M.G. Choi","J.H. Lee","T.S. Sohn","J.M. Bae","S. Kim","S.H. Park","J.O. Park","Y.S. Park","H.Y. Lim","N.K.D. Kim","W. Park","H. Lee","A.J. Bass","K. Kim","W.K. Kang","J. Lee"],"twitterCount":14,"altmetricId":32543953},{"title":"Waldenström's macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","googleId":"iUFI1cMahvEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31695-3/abstract","googleCitationCount":35,"googleAuthor":"E Kastritis"},{"title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma","googleId":"_TamHOAeuMwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345302","googleCitationCount":43,"googleAuthor":"W Jurczak","doi":"10.1093/annonc/mdy056","elsevierAuthor":"Jurczak W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"32","altmetricAuthors":["W. Jurczak","P.L. Zinzani","G. Gaidano","A. Goy","M. Provencio","Z. Nagy","T. Robak","K. Maddocks","C. Buske","S. Ambarkhane","M. Winderlich","M. Dirnberger-Hertweck","R. Korolkiewicz","K.A. Blum"],"twitterCount":11,"altmetricId":33203750},{"title":"Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE …","googleId":"Rfgoqy9ugfkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349002","googleCitationCount":42,"googleAuthor":"HG Wirsching","doi":"10.1093/annonc/mdy120","elsevierAuthor":"Wirsching H.G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"34","altmetricAuthors":["H.-G. Wirsching","G. Tabatabai","U. Roelcke","A.F. Hottinger","F. Jörger","A. Schmid","L. Plasswilm","D. Schrimpf","C. Mancao","D. Capper","K. Conen","T. Hundsberger","F. Caparrotti","R. von Moos","C. Riklin","J. Felsberg","P. Roth","D.T.W. Jones","S. Pfister","E.J. Rushing","L. Abrey","G. Reifenberger","L. Held","A. von Deimling","A. Ochsenbein","M. Weller"],"twitterCount":13,"altmetricId":36244143},{"title":"Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors","googleId":"OcT33W3-ynMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350525","googleCitationCount":47,"googleAuthor":"C Albany","doi":"10.1093/annonc/mdx731","elsevierAuthor":"Albany C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"44","altmetricAuthors":["C. Albany","N. Adra","A.C. Snavely","C. Cary","T.A. Masterson","R.S. Foster","K. Kesler","T.M. Ulbright","L. Cheng","M. Chovanec","F. Taza","K. Ku","M.J. Brames","N.H. Hanna","L.H. Einhorn"],"twitterCount":8,"altmetricId":28803336},{"title":"Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue","googleId":"0m4C53yZBWQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342371","googleCitationCount":35,"googleAuthor":"MC Vegliante","doi":"10.1093/annonc/mdy450","elsevierAuthor":"Wei T.","publicationName":"Journal of Cancer Research and Clinical Oncology","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"March 2021","elsevierCitationCount":"0","altmetricAuthors":["S. Ciavarella","M.C. Vegliante","M. Fabbri","S. De Summa","F. Melle","G. Motta","V. De Iuliis","G. Opinto","A. Enjuanes","S. Rega","A. Gulino","C. Agostinelli","A. Scattone","S. Tommasi","A. Mangia","F. Mele","G. Simone","A.F. Zito","G. Ingravallo","U. Vitolo","A. Chiappella","C. Tarella","A.M. Gianni","A. Rambaldi","P.L. Zinzani","B. Casadei","E. Derenzini","G. Loseto","A. Pileri","V. Tabanelli","S. Fiori","A. Rivas-Delgado","A. López-Guillermo","T. Venesio","A. Sapino","E. Campo","C. Tripodo","A. Guarini","S.A. Pileri"],"twitterCount":8,"altmetricId":49565840},{"title":"Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) …","googleId":"exQLpop4URMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49923-7/abstract","googleCitationCount":43,"googleAuthor":""},{"title":"Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?","googleId":"IKVOgxvMniQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459875","googleCitationCount":46,"googleAuthor":"S Heeke","doi":"10.1093/annonc/mdz196","elsevierAuthor":"Hofman P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"34","altmetricAuthors":["P. Hofman","S. Heeke","C. Alix-Panabières","K. Pantel"],"twitterCount":36,"altmetricId":62584131},{"title":"A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer","googleId":"ftZkpvQEy4gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604187","googleCitationCount":30,"googleAuthor":"W Brady","doi":"10.1093/annonc/mdz394.058","elsevierAuthor":"De Thaye E.","publicationName":"Scientific Reports","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"1 December 2020","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0},{"title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase …","googleId":"ldY6Wor-mcsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325576","googleCitationCount":37,"googleAuthor":"J Mizusawa","doi":"10.1093/annonc/mdz402","elsevierAuthor":"Morizane C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"24","altmetricAuthors":["C. Morizane","T. Okusaka","J. Mizusawa","H. Katayama","M. Ueno","M. Ikeda","M. Ozaka","N. Okano","K. Sugimori","A. Fukutomi","H. Hara","N. Mizuno","H. Yanagimoto","K. Wada","K. Tobimatsu","K. Yane","S. Nakamori","H. Yamaguchi","A. Asagi","S. Yukisawa","Y. Kojima","K. Kawabe","Y. Kawamoto","R. Sugimoto","T. Iwai","K. Nakamura","H. Miyakawa","T. Yamashita","A. Hosokawa","T. Ioka","N. Kato","K. Shioji","K. Shimizu","T. Nakagohri","K. Kamata","H. Ishii","J. Furuse"],"twitterCount":15,"altmetricId":67509306},{"title":"Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours","googleId":"Tgqxylw0bP4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586689","googleCitationCount":33,"googleAuthor":"MG Fakih","doi":"10.1093/annonc/mdz244.008","elsevierAuthor":"Kattan W.E.","publicationName":"Biochemical Journal","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0},{"title":"A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with …","googleId":"XTj-dKLPALQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603601","googleCitationCount":30,"googleAuthor":"","doi":"10.1093/annonc/mdz394","elsevierAuthor":"Demartino P.C.","publicationName":"JAMA Internal Medicine","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["K. Fizazi","A. Maillard","N. Penel","G. Baciarello","D. Allouache","G. Daugaard","A. Van de Wouw","G. Soler","E. Vauleon","L. Chaigneau","R. Janssen","F. Losa Gaspa","R. Morales Barrera","C. Balana","D. Tosi","B. Chauffert","C.A. Schnabel","G. Martineau","S. Culine","I. Borget"],"twitterCount":1,"altmetricId":67579395},{"title":"Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors","googleId":"c5uc3zECzYoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312281","googleCitationCount":35,"googleAuthor":"MD Hellmann","doi":"10.1093/annonc/mdz113","elsevierAuthor":"Hirano H.","publicationName":"Japanese Journal of Clinical Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"1 January 2021","elsevierCitationCount":"0","altmetricAuthors":["M.D. Hellmann","T.-W. Kim","C.B. Lee","B.-C. Goh","W.H. Miller","D.-Y. Oh","R. Jamal","C.-E. Chee","L.Q.M. Chow","J.F. Gainor","J. Desai","B.J. Solomon","M. Das Thakur","B. Pitcher","P. Foster","G. Hernandez","M.J. Wongchenko","E. Cha","Y.-J. Bang","L.L. Siu","J. Bendell"],"twitterCount":9,"altmetricId":58342287},{"title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish …","googleId":"7v36ISbrmggJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311081","googleCitationCount":30,"googleAuthor":"R Garcia-Sanz","doi":"10.1093/annonc/mdz009","elsevierAuthor":"von Tresckow B.","publicationName":"Hematologic Malignancies","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":["R. Garcia-Sanz","A. Sureda","F. de la Cruz","M. Canales","A.P. Gonzalez","J.L. Pinana","A. Rodriguez","A. Gutierrez","E. Domingo-Domenech","B. Sanchez-Gonzalez","G. Rodriguez","J. Lopez","M. Moreno","M.J. Rodriguez-Salazar","S. Jimenez-Cabrera","M.D. Caballero","C. Martinez"],"twitterCount":65,"altmetricId":54123189},{"title":"Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II …","googleId":"Xi6pgvJcNVAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609816","googleCitationCount":24,"googleAuthor":"","doi":"10.1093/annonc/mdz278","elsevierAuthor":"Weiss J.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"17","altmetricAuthors":["J.M. Weiss","T. Csoszi","M. Maglakelidze","R.J. Hoyer","J.T. Beck","M. Domine Gomez","A. Lowczak","R. Aljumaily","C.M. Rocha Lima","R.V. Boccia","W. Hanna","P. Nikolinakos","V.K. Chiu","T.K. Owonikoko","S.R. Schuster","M.A. Hussein","D.A. Richards","P. Sawrycki","I. Bulat","J.T. Hamm","L.L. Hart","S. Adler","J.M. Antal","A.Y. Lai","J.A. Sorrentino","Z. Yang","R.K. Malik","S.R. Morris","P.J. Roberts","K.H. Dragnev"],"twitterCount":85,"altmetricId":65832399},{"title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)","googleId":"2YoX13n8AQIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49078-9/abstract","googleCitationCount":39,"googleAuthor":""},{"title":"Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions","googleId":"G2AOastoQf8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419621721","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdz338.077","elsevierCitationCount":0,"altmetricAuthors":["Pasi A. Jänne","Joel W. Neal","D.R. Camidge","Alexander Spira","Zofia Piotrowska","Leora Horn","Daniel B. Costa","Anne Tsao","Jyoti Patel","Shirish Gadgeel","Lyudmila Bazhenova","Viola W Zhu","Howard West","Sylvie Vincent","Jian Zhu","Shuanglian Li","Gregory J. Riely"],"twitterCount":0,"altmetricId":68314288},{"title":"OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant …","googleId":"0tsNO6QGSpkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350641","googleCitationCount":43,"googleAuthor":"DM Provencher","doi":"10.1093/annonc/mdx754","elsevierAuthor":"Provencher D.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"26","altmetricAuthors":["D.M. Provencher","C.J. Gallagher","W.R. Parulekar","J.A. Ledermann","D.K. Armstrong","M. Brundage","C. Gourley","I. Romero","A. Gonzalez-Martin","M. Feeney","P. Bessette","M. Hall","J.I. Weberpals","G. Hall","S.K. Lau","P. Gauthier","M. Fung-Kee-Fung","E.A. Eisenhauer","C. Winch","D. Tu","H.J. MacKay"],"twitterCount":31,"altmetricId":29362902},{"title":"Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the …","googleId":"wu2l1553meYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31045-2/abstract","googleCitationCount":39,"googleAuthor":"S Peters"},{"title":"Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA","googleId":"RVX2Q5TKAzEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931155X","googleCitationCount":28,"googleAuthor":"S Sandhu","doi":"10.1093/annonc/mdz048","elsevierAuthor":"Keller L.","publicationName":"British Journal of Cancer","elsevierCoverDate":"2021-01-19","elsevierCoverDisplayDate":"19 January 2021","elsevierCitationCount":"2","altmetricAuthors":["L. Tan","S. Sandhu","R.J. Lee","J. Li","J. Callahan","S. Ftouni","N. Dhomen","P. Middlehurst","A. Wallace","J. Raleigh","A. Hatzimihalis","M.A. Henderson","M. Shackleton","A. Haydon","V. Mar","D.E. Gyorki","D. Oudit","M.A. Dawson","R.J. Hicks","P. Lorigan","G.A. McArthur","R. Marais","S.Q. Wong","S.-J. Dawson"],"twitterCount":19,"altmetricId":56633253},{"title":"A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with an MYC-regulated SNP rs6983267","googleId":"lgJq764m2EkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355012","googleCitationCount":42,"googleAuthor":"J Gong","doi":"10.1093/annonc/mdx789","elsevierAuthor":"Gong J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"39","altmetricAuthors":[],"twitterCount":0},{"title":"BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with …","googleId":"bF6-xN0csoQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311718","googleCitationCount":27,"googleAuthor":"","doi":"10.1093/annonc/mdz086","elsevierAuthor":"Malik N.","publicationName":"Biochemical Journal","elsevierCoverDate":"2019-10-30","elsevierCoverDisplayDate":"30 October 2019","elsevierCitationCount":"2","altmetricAuthors":["N.C. Turner","E. Alarcón","A.C. Armstrong","M. Philco","Y.A. López Chuken","M.-P. Sablin","K. Tamura","A. Gómez Villanueva","J.A. Pérez-Fidalgo","S.Y.A. Cheung","C. Corcoran","M. Cullberg","B.R. Davies","E.C. de Bruin","A. Foxley","J.P.O. Lindemann","R. Maudsley","M. Moschetta","E. Outhwaite","M. Pass","P. Rugman","G. Schiavon","M. Oliveira"],"twitterCount":13,"altmetricId":56944981},{"title":"IMpower132: efficacy of atezolizumab (atezo)+ carboplatin (carbo)/cisplatin (cis)+ pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous …","googleId":"sXw_bfOpDGsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50457-4/abstract","googleCitationCount":37,"googleAuthor":""},{"title":"Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+ cobimetinib and atezolizumab monotherapy vs regorafenib in …","googleId":"g6KV-0HjOu8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34066-9/abstract","googleCitationCount":44,"googleAuthor":"F Ciardiello"},{"title":"Pre-specified interim analysis of GALAHAD: a phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and …","googleId":"QaKgNGYqg6AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604035","googleCitationCount":30,"googleAuthor":"MR Smith","doi":"10.1093/annonc/mdz394.043","elsevierCitationCount":0,"altmetricAuthors":["M.R. Smith","S.K. Sandhu","W.K. Kelly","H.I. Scher","E. Efstathiou","P.N. Lara","E.Y. Yu","D.J. George","K.N. Chi","F. Saad","J. Summa","J.M. Freedman","G.E. Mason","E. Zhu","D. Ricci","J.S. Simon","S. Cheng","K. Fizazi"],"twitterCount":0,"altmetricId":76694492},{"title":"Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001","googleId":"EM4ODdMcr88J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43453-4/abstract","googleCitationCount":34,"googleAuthor":""},{"title":"Biological background of the genomic variations of cf-DNA in healthy individuals","googleId":"Vl0F2c7sxd4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310737","googleCitationCount":30,"googleAuthor":"","doi":"10.1093/annonc/mdy513","elsevierAuthor":"Liu J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"20","altmetricAuthors":["J. Liu","X. Chen","J. Wang","S. Zhou","C.L. Wang","M.Z. Ye","X.Y. Wang","Y. Song","Y.Q. Wang","L.T. Zhang","R.H. Wu","H.M. Yang","S.D. Zhu","M.Z. Zhou","X.C. Zhang","H.M. Zhu","Z.Y. Qian"],"twitterCount":77,"altmetricId":51614606},{"title":"Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in …","googleId":"Y27Ab4e_nEEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960983X","googleCitationCount":22,"googleAuthor":"G Villacampa","doi":"10.1093/annonc/mdz287","elsevierAuthor":"Dienstmann R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"16","altmetricAuthors":["R. Dienstmann","G. Villacampa","A. Sveen","M.J. Mason","D. Niedzwiecki","A. Nesbakken","V. Moreno","R.S. Warren","R.A. Lothe","J. Guinney"],"twitterCount":55,"altmetricId":65563712},{"title":"Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms","googleId":"thQg4b1NgbUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350756","googleCitationCount":39,"googleAuthor":"F Blackhall","doi":"10.1093/annonc/mdx790","elsevierAuthor":"Kordbacheh T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"35","altmetricAuthors":["T. Kordbacheh","J. Honeychurch","F. Blackhall","C. Faivre-Finn","T. Illidge"],"twitterCount":48,"altmetricId":32847099},{"title":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast …","googleId":"qxb0mfJK-zsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311615","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdz061","elsevierAuthor":"Poggio F.","publicationName":"JCO Oncology Practice","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"9","altmetricAuthors":["T. Bachelot","E. Ciruelos","A. Schneeweiss","F. Puglisi","T. Peretz-Yablonski","I. Bondarenko","S. Paluch-Shimon","A. Wardley","J.-L. Merot","Y. du Toit","V. Easton","N. Lindegger","D. Miles","Kamel Bouzid","Mario Campone","Bruno Coudert","Zbigniew Nowecki","Hassan Errihani","Florence Dalenc","Ana Ferreira","Max Mano","Francesco Ricci","Haralabos Kalofonos","Claudia Andreetta","Filippo Montemurro","Sophie Barrett","Qingyuan Zhang","Dimitris Mavroudis","Juan Matus","Carlos Beato","Xichun Hu","Rabab Gaafar","Hamdy Abdel Azeem","Christophe Perrin","Johannes Ettl","Istvan Lang","Sunil Verma","Huiping Li","Etienne Brain","Oliver Hoffmann","Anna Cariello","Carlo Tondini","Taher Altwegeiri","Niklas Loman","Michael Lux","Antonio Frassoldati","Zeba Aziz","Fernando Salas","Joanna Streb","Andrzej Wronski","Salomón Menjón Beltrán","Irfan Cicin","Peter Schmid","Robert Laing","Zhongsheng Tong","Katalin Boer","Balazs Juhasz","Luca Gianni","Giuseppe Curigliano","Alejandro Juarez","Snezana Susnjar","Erika Matos","Ruchan Uslu","Hans Wildiers","Marcelo Cruz","Hugues Bourgeois","Raquel von Schumann","Salomón Stemmer","Flavia Morales Vásquez","Adriana Dominguez","Marek Wojtukiewicz","Jasna Trifunovic","Jose Juan Illarramendi","Laura Garcia","Yann Izarzugaza Peron","Maria Jose Echarri","Natliia Voitko","Duncan Wheatley","Simon Waters","Richard De Boer","Guy Jerusalem","Véronique Cocquyt","Carlos Barrios","Lawrence Panasci","Johanna Mattson","Minna Tanner","Michel Gozy","Georgios Vasilopoulos","Janos Revesz","Luciano Latini","Cesare Gridelli","Jesus Lazaro","Antonio Gonzalez","Agusti Barnadas Molins","Eduardo Martinez","Jesús Alarcón","Ana Arance","Leif Klint","Oleksiy Kovalyov","Richard Baird","Belinda Yeo","Nicole McCarthy","Richard Greil","Shusen Wang","Xavier Artignan","Paule Augereau","Ingolf Juhasz-Boess","Roger Ngan","Hadassah Goldberg","Francesco Di Costanzo","Francesco Ferraù","Eduardas Aleknavicius","Kamran Rashid","Luís Costa","Jose Angel Garcia","Luis Ruiz de la Cruz","Rafael López López","Olga Del Val","Ozgur Ozyilkan","Fathi Azribi","Mark Verrill","Nicholas Turner","Jane Beith","Andreas Petzer","Jurandyr Andrade","Vanessa Bernstein","Daniel Rayson","Ibtessam Saad Eldin","Mihaëla Achille","Volkmar Mueller","Alessandra Gennari","Stefano Cascinu","Marwan Ghosn","Nagi El-Saghir","Joan Van den Bosch","Rianne Oosterkamp","Monika Kukulska","Ignacio Pelaez","Carolina Hernandez","Maria del Mar Gordon","Elsa Dalmau","Jose Luis Alonso","Sercan Aksoy","Hasan Senol Coskun","Yaroslav Shparyk","Mohini Varughese","Udaiveer Panwar","Lisa Barraclough","Nicola Levitt","Jonathan Hicks","Anna Rigg","Mark Allen","Cecila Castillo","Luis Enrique Fein","Robin Stuart-Harris","Christian Singer","Herbert Stoeger","Sasha Smiljanic","Jifeng Feng","Miguel Cedeño","Jean Francois Berdah","Hubert Orfeuvre","Anthony Goncalves","Eva-Maria Grischke","Eike Simon","Steffen Wagner","Anna Efremidou","Konstantinos Papazisis","Ella Evron","Moshe Inbar","Noa Ben Baruch","David Geffen","Natalya Karminsky","Enzo Maria Ruggeri","Cavanna Luigi","Donatella Grasso","Elona Juozaityte","Jeronimo Rafael Rodriguez Cid","Henk Roerdink","Neelum Siddiqi","José Luís Passos Coelho","Elisa Garcia Garre","Andres Garcia","Noelia Martínez Jañez","Maria Helena Lopez Ceballos","Mireia Mele","María García","Alberto Arcediano","Karen McAdam","Timothy Perren","Jonathan Hicks","Wendy Taylor","Alison Humphreys","Raul Vera","Luis Alberto Kaen","Günther Steger","Johannes Andel","Jacques de Grève","Manon Huizing","Roberto Hegg","Anil Joy","Sandeep Sehdev","Riina Kütner","Johanna Ruohola","Nadine Dohollou","Jessica Grosjean","Philippe Laplaige","Rémy Largillier","Philippe Martin","Virginie Pottier","Jerome Alexandre","Bernd Christensen","Dirk-Michael Zahm","Fariba Khandan","Hans-Joachim Lueck","Georgios Fountzilas","Georgeta Fried","Alice Giacobino","Andrea Bonetti","Yanin Chavarri Guerra","Laurens Van Warmerdam","Annette Van der Velden","Suzan Vrijaldenhoven","Felix de Jongh","Milagros Cavero","Raquel Andres Conejero","Adolfo Murias","Salvador Saura","Amparo Oltra","Andres Redondo","Nuria Ribelles","Kilian Bachmeier","Johnathan Joffe","Prabir Chakraborti","Mark Beresford","Mohammad Butt","Christopher Poole","Gassan Yordi","Natasha Woodward","Gilberto Amorim","Nadia Califaretti","Susan Fox","Andre Robidoux","NanLi Li","Nenxiao Li","Jun Jiang","Tannia Soria","Peeter Padrik","Outi Saarni","Dominique Genet","Stéphanie Catala","Hugues Barletta","Luis Teixeira","Thomas Facchini","Tobias Hesse","Thorsten Kühn","Angelika Ober","Roland Repp","Willibald Schroeder","Dimitrios Pectasides","Gyorgy Bodoky","Zsuzsanna Kahan","Irina Jiveliouk","Ora Rosengarten","Oscar Alabiso","Mario Perez","Yes Van de Wouw","Jolanta Smok-Kalwat","Margarida Damasceno","Gabriela Sousa","Omalkhair Abulkhair","Antonio Antón Torres","Maria Purificación Martinez","Jesús Garcia Mata","Marta Santisteban Jesús Florián Jerico","Antonio Llombart","Rosa Sanchez","Juan Carlos Torrego","Clara Olier Garate","Cesar Rodriguez","Rosa Llorente","Diego Soto de Prado","Javier Cortés","Cristina Llorca","Antonio Galán","Gemma Viñas Villaro","Ulrik Narbe","Helena Granstam Bjömeklett","Sarah Westwell","Jackie Newby","Mariam Jafri","Robinson Rodríguez","Isabel Alonso"],"twitterCount":14,"altmetricId":55963846},{"title":"Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications","googleId":"8-5nGcFfh-IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931244X","googleCitationCount":32,"googleAuthor":"B Surmann","doi":"10.1093/annonc/mdz140","elsevierAuthor":"Ushkalova E.A.","publicationName":"Farmakoekonomika","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":["J. Witte","K. Mehlis","B. Surmann","R. Lingnau","O. Damm","W. Greiner","E.C. Winkler"],"twitterCount":52,"altmetricId":59825560},{"title":"RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI …","googleId":"hg-h3xCw_0EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349762","googleCitationCount":48,"googleAuthor":"N Normanno","doi":"10.1093/annonc/mdx417","elsevierAuthor":"Normanno N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"40","altmetricAuthors":["N. Normanno","R. Esposito Abate","M. Lambiase","L. Forgione","C. Cardone","A. Iannaccone","A. Sacco","A.M. Rachiglio","E. Martinelli","D. Rizzi","S. Pisconti","M. Biglietto","R. Bordonaro","T. Troiani","T.P. Latiano","F. Giuliani","S. Leo","A. Rinaldi","E. Maiello","F. Ciardiello"],"twitterCount":12,"altmetricId":27413261},{"title":"Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial","googleId":"vuVmkjkJ76AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587488","googleCitationCount":28,"googleAuthor":"A Cercek","doi":"10.1093/annonc/mdz246.005","elsevierAuthor":"Sartore-Bianchi A.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"4","altmetricAuthors":["J.H. Strickler","T. Zemla","F.-S. Ou","A. Cercek","C. Wu","F.A. Sanchez","J. Hubbard","B. Jaszewski","L. Bandel","B. Schweitzer","D. Niedzwiecki","N. Kemeny","P.M. Boland","K. Ng","T. Bekaii-Saab"],"twitterCount":0,"altmetricId":68179407},{"title":"Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and …","googleId":"nGtxw5h62GgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350549","googleCitationCount":39,"googleAuthor":"AM Udager","doi":"10.1093/annonc/mdx736","elsevierAuthor":"Udager A.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"32","altmetricAuthors":["A.M. Udager","J.B. McHugh","C.M. Goudsmit","H.C. Weigelin","M.S. Lim","K.S.J Elenitoba-Johnson","B.L. Betz","T.E. Carey","N.A. Brown"],"twitterCount":10,"altmetricId":29108386},{"title":"Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial","googleId":"WNw8KdGG1d8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311950","googleCitationCount":26,"googleAuthor":"I Garcia-Murillas","doi":"10.1093/annonc/mdz085","elsevierAuthor":"Hrebien S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"20","altmetricAuthors":["S. Hrebien","V. Citi","I. Garcia-Murillas","R. Cutts","K. Fenwick","I. Kozarewa","R. McEwen","J. Ratnayake","R. Maudsley","T.H. Carr","E.C. de Bruin","G. Schiavon","M. Oliveira","N. Turner"],"twitterCount":44,"altmetricId":56944915},{"title":"Registrational results of LOXO-292 in patients with RET-altered thyroid cancers","googleId":"0-t99iZiuDYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604539","googleCitationCount":26,"googleAuthor":"A Drilon","doi":"10.1093/annonc/mdz394.093","elsevierAuthor":"Dadu R.","publicationName":"Endocrine-Related Cancer","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC …","googleId":"JlSB7lImorUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321106","googleCitationCount":35,"googleAuthor":"J Mateo","doi":"10.1093/annonc/mdy172","elsevierAuthor":"Lorente D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"30","altmetricAuthors":["D. Lorente","D. Olmos","J. Mateo","D. Dolling","D. Bianchini","G. Seed","P. Flohr","M. Crespo","I. Figueiredo","S. Miranda","H.I. Scher","L.W.M.M. Terstappen","J.S. de Bono"],"twitterCount":43,"altmetricId":40868638},{"title":"Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were …","googleId":"7VJCiuB1Y_UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33687-7/abstract","googleCitationCount":37,"googleAuthor":"F Meric-Bernstam"},{"title":"Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines","googleId":"u-98sAqANuAJ","googleLink":"https://www.researchgate.net/profile/Fabio_Trippa/publication/325949870_Diarrhoea_in_adult_cancer_patients_ESMO_Clinical_Practice_Guidelines/links/5c9a73c545851506d72d9cff/Diarrhoea-in-adult-cancer-patients-ESMO-Clinical-Practice-Guidelines.pdf","googleCitationCount":37,"googleAuthor":"NI Cherny"},{"title":"Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment …","googleId":"O-BA9Uz0KpgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603790","googleCitationCount":30,"googleAuthor":"J Taieb","doi":"10.1093/annonc/mdz394.019","elsevierAuthor":"Schraa S.J.","publicationName":"BMC Cancer","elsevierCoverDate":"2020-08-20","elsevierCoverDisplayDate":"20 August 2020","elsevierCitationCount":"1","altmetricAuthors":["J. Taieb","V. Taly","D. Vernerey","C. Bourreau","J. Bennouna","R. Faroux","J. Desrame","O. Bouche","C. Borg","J. Egreteau","L. Mineur","C. Lepere","G. Deplanque","C. Mulot","C. Louvet","M. Mabro","M. Ychou","A. de Gramont","T. Andre","P. Laurent-Puig"],"twitterCount":0,"altmetricId":68179400},{"title":"RET fusions in a small subset of advanced colorectal cancers at risk of being neglected","googleId":"d9nlJM-GtpkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348902","googleCitationCount":40,"googleAuthor":"F Pietrantonio","doi":"10.1093/annonc/mdy090","elsevierAuthor":"Pietrantonio F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"35","altmetricAuthors":["F. Pietrantonio","F. Di Nicolantonio","A.B. Schrock","J. Lee","F. Morano","G. Fucà","P. Nikolinakos","A. Drilon","J.F. Hechtman","J. Christiansen","K. Gowen","G.M. Frampton","P. Gasparini","D. Rossini","C. Gigliotti","S.T. Kim","M. Prisciandaro","J. Hodgson","A. Zaniboni","V.K. Chiu","M. Milione","R. Patel","V. Miller","A. Bardelli","L. Novara","L. Wang","S.M. Pupa","G. Sozzi","J. Ross","M. Di Bartolomeo","A. Bertotti","S. Ali","L. Trusolino","A. Falcone","F. de Braud","C. Cremolini"],"twitterCount":9,"altmetricId":34417765},{"title":"Epigenetic modifiers as new immunomodulatory therapies in solid tumours","googleId":"nO4muLjCS34J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454884","googleCitationCount":33,"googleAuthor":"S Aspeslagh","doi":"10.1093/annonc/mdy050","elsevierAuthor":"Aspeslagh S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"27","altmetricAuthors":["S. Aspeslagh","D. Morel","J.-C. Soria","S. Postel-Vinay"],"twitterCount":54,"altmetricId":32856905},{"title":"Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer","googleId":"3EZHtU2FiRAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310233","googleCitationCount":30,"googleAuthor":"","doi":"10.1093/annonc/mdy505","elsevierAuthor":"Wang J.T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"20","altmetricAuthors":["J.T. Wang","H. Li","H. Zhang","Y.F. Chen","Y.F. Cao","R.C. Li","C. Lin","Y.C. Wei","X.N. Xiang","H.J. Fang","H.Y. Zhang","Y. Gu","X. Liu","R.J. Zhou","H. Liu","H.Y. He","W.J. Zhang","Z.B. Shen","J. Qin","J.J. Xu"],"twitterCount":4,"altmetricId":51600572},{"title":"Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors","googleId":"stJ-r3IG89wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342032562X","googleCitationCount":33,"googleAuthor":"J Vardy","doi":"10.1093/annonc/mdz410","elsevierAuthor":"Lange M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"18","altmetricAuthors":["M. Lange","F. Joly","J Vardy","T. Ahles","M. Dubois","L. Tron","G. Winocur","M.B. De Ruiter","H. Castel"],"twitterCount":32,"altmetricId":68809692},{"title":"A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant …","googleId":"H9PCtq6DUYgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350446","googleCitationCount":44,"googleAuthor":"","doi":"10.1093/annonc/mdx698","elsevierAuthor":"Zhang L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"23","altmetricAuthors":["L. Zhang","S. Lu","J. Feng","A. Dechaphunkul","J. Chang","D. Wang","S. Chessari","C. Lanzarotti","K. Jordan","M. Aapro"],"twitterCount":3,"altmetricId":28074108},{"title":"Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group","googleId":"ShcmN2lrzUAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312700","googleCitationCount":31,"googleAuthor":"M Donoghue","doi":"10.1093/annonc/mdz136","elsevierAuthor":"Mandelker D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"18","altmetricAuthors":["D. Mandelker","M. Donoghue","S. Talukdar","C. Bandlamudi","P. Srinivasan","M. Vivek","S. Jezdic","H. Hanson","K. Snape","A. Kulkarni","L. Hawkes","J.-Y Douillard","S.E. Wallace","E. Rial-Sebbag","F. Meric-Bersntam","A. George","D. Chubb","C. Loveday","M. Ladanyi","M.F. Berger","B.S. Taylor","C. Turnbull"],"twitterCount":76,"altmetricId":59892898},{"title":"ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with …","googleId":"NcEKQkK9BeMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354821","googleCitationCount":39,"googleAuthor":"M Hutchings","doi":"10.1093/annonc/mdx413","elsevierAuthor":"Buske C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"29","altmetricAuthors":["C. Buske","M. Hutchings","M. Ladetto","V. Goede","U. Mey","P. Soubeyran","M. Spina","R. Stauder","M. Trněný","U. Wedding","P. Fields","Christian Buske","Martin Dreyling","Andrés J M Ferreri","Paul Fields","Gianluca Gaidano","Valentin Goede","Martin Hutchings","Marco Ladetto","Steven Le Gouill","Stefano Luminari","Ulrich Mey","Peter de Nully Brown","Michael Pfreundschuh","Christiane Pott","Norbert Schmitz","Pierre Soubeyran","Michele Spina","Reinhard Stauder","Anna Sureda Balari","Marek Trněný","Gustaaf van Imhoff","Jan Walewski","Ulrich Wedding","Alberto Zamò","Emanuele Zucca"],"twitterCount":51,"altmetricId":29621864},{"title":"Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast …","googleId":"aPOX45bC4y0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310877","googleCitationCount":29,"googleAuthor":"AA Brandes","doi":"10.1093/annonc/mdz007","elsevierAuthor":"Dieci M.V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"16","altmetricAuthors":["M.V. Dieci","P. Conte","G. Bisagni","A.A. Brandes","A. Frassoldati","L. Cavanna","A. Musolino","F. Giotta","A. Rimanti","O. Garrone","E. Bertone","K. Cagossi","S. Sarti","A. Ferro","F. Piacentini","A. Maiorana","E. Orvieto","M. Sanders","F. Miglietta","S. Balduzzi","R. D’Amico","V. Guarneri"],"twitterCount":95,"altmetricId":54061583},{"title":"Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized …","googleId":"js2-M_CPsvEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311585","googleCitationCount":30,"googleAuthor":"","doi":"10.1093/annonc/mdz058","elsevierAuthor":"Vienot A.","publicationName":"Clinics and Research in Hepatology and Gastroenterology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0","altmetricAuthors":["S.T. Kim","J.H. Kang","J. Lee","H.W. Lee","S.Y. Oh","J.S. Jang","M.A. Lee","B.S. Sohn","S.Y. Yoon","H.J. Choi","J.H. Hong","M.-J. Kim","S. Kim","Y.S. Park","J.O. Park","H.Y. Lim"],"twitterCount":18,"altmetricId":55805741},{"title":"Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+ trastuzumab emtansine (T-DM1) vs …","googleId":"Mg52z8zrtAgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585271","googleCitationCount":29,"googleAuthor":"LA Emens","doi":"10.1093/annonc/mdz242","elsevierAuthor":"Donahue B.S.","publicationName":"Clinical Journal of Oncology Nursing","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0","altmetricAuthors":["L.A. Emens","F.J. Esteva","M. Beresford","C. Saura","M. De Laurentiis","S.-B. Kim","S.-A. Im","Y. Wang","A. Mani","J. Shah","H. Liu","S. de Haas","M. Patre","S. Loi"],"twitterCount":0,"altmetricId":67710000},{"title":"Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a …","googleId":"g2A1yxVoo3MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341298","googleCitationCount":33,"googleAuthor":"M Ignatiadis","doi":"10.1093/annonc/mdy211","elsevierAuthor":"Ignatiadis M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"28","altmetricAuthors":["M. Ignatiadis","S. Litière","F. Rothe","S. Riethdorf","C. Proudhon","T. Fehm","K. Aalders","H. Forstbauer","P.A. Fasching","E. Brain","P. Vuylsteke","E. Guardiola","R. Lorenz","K. Pantel","K. Tryfonidis","W. Janni","M. Piccart","C. Sotiriou","B. Rack","J.-Y. Pierga"],"twitterCount":24,"altmetricId":43599217},{"title":"Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?","googleId":"sSPFbNDwv74J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350689","googleCitationCount":38,"googleAuthor":"PC Chou","doi":"10.1093/annonc/mdx766","elsevierAuthor":"Yang M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"32","altmetricAuthors":["M. Yang","M.E. Forbes","R.L. Bitting","S.S. O'Neill","P -C Chou","U. Topaloglu","L.D. Miller","G.A. Hawkins","S.C. Grant","B.R. DeYoung","W.J. Petty","K. Chen","B.C. Pasche","W. Zhang"],"twitterCount":113,"altmetricId":30295626},{"title":"A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable …","googleId":"83ZYG67gc8oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50420-3/abstract","googleCitationCount":37,"googleAuthor":""},{"title":"Are liquid biopsies a surrogate for tissue EGFR testing?","googleId":"dZ0zv7H09PoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316722","googleCitationCount":35,"googleAuthor":"J Remon","doi":"10.1093/annonc/mdx706","elsevierAuthor":"Goldman J.W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"29","altmetricAuthors":["J.W. Goldman","Z.S. Noor","J. Remon","B. Besse","N. Rosenfeld"],"twitterCount":81,"altmetricId":33296231},{"title":"Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification","googleId":"rF_cAGb2yhYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348999","googleCitationCount":36,"googleAuthor":"","doi":"10.1093/annonc/mdy119","elsevierAuthor":"Liu L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"27","altmetricAuthors":["L. Liu","J.M. Toung","A.F. Jassowicz","R. Vijayaraghavan","H. Kang","R. Zhang","K.M. Kruglyak","H.J. Huang","T. Hinoue","H. Shen","N.S. Salathia","D.S. Hong","A. Naing","V. Subbiah","S.A. Piha-Paul","M. Bibikova","G. Granger","B. Barnes","R. Shen","K. Gutekunst","S. Fu","A.M. Tsimberidou","C. Lu","C. Eng","S.L. Moulder","E.S. Kopetz","R.N. Amaria","F. Meric-Bernstam","P.W. Laird","J.-B. Fan","F. Janku"],"twitterCount":11,"altmetricId":36466262},{"title":"Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K …","googleId":"3xJWImk5ue0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420343726","googleCitationCount":25,"googleAuthor":"D Eiger","doi":"10.1093/annonc/mdz280","elsevierAuthor":"Xu X.","publicationName":"Journal of Cellular Physiology","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["M. Brandão","R. Caparica","D. Eiger","E. de Azambuja"],"twitterCount":16,"altmetricId":73049327},{"title":"Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized …","googleId":"h-KmQLwSnKUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348951","googleCitationCount":37,"googleAuthor":"S Hayoz","doi":"10.1093/annonc/mdy105","elsevierAuthor":"Ruhstaller T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"31","altmetricAuthors":["T. Ruhstaller","P. Thuss-Patience","S. Hayoz","S. Schacher","J.R. Knorrenschild","A. Schnider","L. Plasswilm","W. Budach","W. Eisterer","H. Hawle","C. Mariette","V. Hess","W. Mingrone","M. Montemurro","M. Girschikofsky","S.C. Schmidt","M. Bitzer","L. Bedenne","P. Brauchli","M. Stahl"],"twitterCount":24,"altmetricId":35366906},{"title":"FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer","googleId":"IhQez76oQiEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312918","googleCitationCount":25,"googleAuthor":"P Nuciforo","doi":"10.1093/annonc/mdz177","elsevierAuthor":"Oliveira M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"17","altmetricAuthors":["M. Oliveira","C. Saura","P. Nuciforo","I. Calvo","J. Andersen","J.L. Passos-Coelho","M. Gil Gil","B. Bermejo","D.A. Patt","E. Ciruelos","L. de la Peña","N. Xu","M. Wongchenko","Z. Shi","S.M. Singel","S.J. Isakoff"],"twitterCount":8,"altmetricId":61440986},{"title":"Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite …","googleId":"x98I5RIl2xEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603959","googleCitationCount":27,"googleAuthor":"K Shitara","doi":"10.1093/annonc/mdz394.035","elsevierAuthor":"Petrelli F.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"6","altmetricAuthors":["K. Shitara","E. Van Cutsem","Y.-J. Bang","C.S. Fuchs","L. Wyrwicz","K.W. Lee","I. Kudaba","M. Garrido","H. Cheol Chung","H.R. Castro","W. Mansoor","M I F M Braghiroli","E. Goekkurt","J. Chao","Z.A. Wainberg","U. Kher","S. Shah","S.P. Kang","J. Tabernero"],"twitterCount":0,"altmetricId":68179427},{"title":"Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","googleId":"ZWpnw0ZzBBQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310920","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdz036","elsevierAuthor":"Condorelli R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"23","altmetricAuthors":["R. Condorelli","F. Mosele","B. Verret","T. Bachelot","P.L. Bedard","J. Cortes","D.M. Hyman","D. Juric","I. Krop","I. Bieche","C. Saura","C. Sotiriou","F. Cardoso","S. Loibl","F. Andre","N.C. Turner"],"twitterCount":67,"altmetricId":54809487},{"title":"Lifestyle factors and risk of sporadic colorectal cancer by microsatellite instability status: a systematic review and meta-analyses","googleId":"EO2boc02XogJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454938","googleCitationCount":32,"googleAuthor":"PR Carr","doi":"10.1093/annonc/mdy059","elsevierAuthor":"Carr P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"23","altmetricAuthors":["P.R. Carr","E. Alwers","S. Bienert","J. Weberpals","M. Kloor","H. Brenner","M. Hoffmeister"],"twitterCount":15,"altmetricId":32964714},{"title":"Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy …","googleId":"mkEum991BwIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931230X","googleCitationCount":23,"googleAuthor":"","doi":"10.1093/annonc/mdz122","elsevierAuthor":"Tamminga M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-07-01","elsevierCoverDisplayDate":"1 July 2019","elsevierCitationCount":"1","altmetricAuthors":["R.Y. Tay","F. Fernández-Gutiérrez","V. Foy","K. Burns","J. Pierce","K. Morris","L. Priest","J. Tugwood","L. Ashcroft","C.R. Lindsay","C. Faivre-Finn","C. Dive","F. Blackhall"],"twitterCount":23,"altmetricId":59548932},{"title":"Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and …","googleId":"Aze7hvTc_BQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32760-7/abstract","googleCitationCount":29,"googleAuthor":"RS Herbst"},{"title":"PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from …","googleId":"b3kGa1DtEb8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604497","googleCitationCount":22,"googleAuthor":"MC Garassino","doi":"10.1093/annonc/mdz394.089","elsevierCitationCount":0,"altmetricAuthors":["L. Paz-Ares","J.W. Goldman","M.C. Garassino","M. Dvorkin","D. Trukhin","G. Statsenko","K. Hotta","J.H. Ji","M.J. Hochmair","O. Voitko","L. Havel","A. Poltoratskiy","G. Losonczy","N. Reinmuth","Y. Shrestha","N. Patel","H. Mann","H. Jiang","M. Özgüroğlu","Y. Chen"],"twitterCount":0,"altmetricId":68818517},{"title":"Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases","googleId":"zgADMXTMMgQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355085","googleCitationCount":38,"googleAuthor":"","doi":"10.1093/annonc/mdx797","elsevierAuthor":"Turner N.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"31","altmetricAuthors":["N.C. Turner","R.S. Finn","M. Martin","S.-A. Im","A. DeMichele","J. Ettl","V. Diéras","S. Moulder","O. Lipatov","M. Colleoni","M. Cristofanilli","D.R. Lu","A. Mori","C. Giorgetti","S. Iyer","C. Huang Bartlett","K.A. Gelmon"],"twitterCount":52,"altmetricId":31577212},{"title":"Gender medicine and oncology: report and consensus of an ESMO workshop","googleId":"NxybZTWA4R0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325643","googleCitationCount":25,"googleAuthor":"S Oertelt-Prigione","doi":"10.1093/annonc/mdz414","elsevierAuthor":"Wagner A.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"16","altmetricAuthors":["A.D. Wagner","S. Oertelt-Prigione","A. Adjei","T. Buclin","V. Cristina","C. Csajka","G. Coukos","U. Dafni","G.-P. Dotto","M. Ducreux","J. Fellay","J. Haanen","A. Hocquelet","I. Klinge","V. Lemmens","A. Letsch","M. Mauer","M. Moehler","S. Peters","B.C. Özdemir"],"twitterCount":67,"altmetricId":68747829},{"title":"Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients","googleId":"6tfIGvxzDlcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311640","googleCitationCount":28,"googleAuthor":"JH Lee","doi":"10.1093/annonc/mdz075","elsevierAuthor":"Keller L.","publicationName":"British Journal of Cancer","elsevierCoverDate":"2021-01-19","elsevierCoverDisplayDate":"19 January 2021","elsevierCitationCount":"2","altmetricAuthors":["J.H. Lee","R.P. Saw","J.F. Thompson","S. Lo","A.J. Spillane","K.F. Shannon","J.R. Stretch","J. Howle","A.M. Menzies","M.S. Carlino","R.F. Kefford","G.V. Long","R.A. Scolyer","H. Rizos"],"twitterCount":76,"altmetricId":56942134},{"title":"Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO","googleId":"Y28UjvI_tF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454574","googleCitationCount":39,"googleAuthor":"C Cremolini","doi":"10.1093/annonc/mdy004","elsevierAuthor":"Dell'Aquila E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"30","altmetricAuthors":[],"twitterCount":0},{"title":"Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial","googleId":"oX-EbV8o7XwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350495","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdx716","elsevierAuthor":"Ek L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"30","altmetricAuthors":["L. Ek","E. Gezelius","B. Bergman","P.O. Bendahl","H. Anderson","J. Sundberg","M. Wallberg","U. Falkmer","S. Verma","M. Belting"],"twitterCount":33,"altmetricId":28283539},{"title":"Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study","googleId":"4-jXpDH9DOEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350586","googleCitationCount":38,"googleAuthor":"","doi":"10.1093/annonc/mdx742","elsevierAuthor":"Pettersson A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"30","altmetricAuthors":["A. Pettersson","D. Robinson","H. Garmo","L. Holmberg","P. Stattin"],"twitterCount":3,"altmetricId":29584000},{"title":"Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 …","googleId":"eLDZdL4LwFsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934236X","googleCitationCount":29,"googleAuthor":"L Marandino","doi":"10.1093/annonc/mdy449","elsevierAuthor":"Marandino L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"24","altmetricAuthors":["L. Marandino","A. La Salvia","C. Sonetto","E. De Luca","D. Pignataro","C. Zichi","R.F. Di Stefano","E. Ghisoni","P. Lombardi","A. Mariniello","M.L. Reale","E. Trevisi","G. Leone","L. Muratori","M. Marcato","P. Bironzo","S. Novello","M. Aglietta","G.V. Scagliotti","F. Perrone","M. Di Maio"],"twitterCount":181,"altmetricId":49480452},{"title":"InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly …","googleId":"22-PQuHEO-8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50413-6/abstract","googleCitationCount":30,"googleAuthor":"S Rao"},{"title":"Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the …","googleId":"eZA3ClSM_PYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341997","googleCitationCount":28,"googleAuthor":"","doi":"10.1093/annonc/mdy326","elsevierAuthor":"Thomas M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"21","altmetricAuthors":["M. Thomas","S. Ponce-Aix","A. Navarro","J. Riera-Knorrenschild","M. Schmidt","E. Wiegert","K. Kapp","B. Wittig","C. Mauri","M. Dómine Gómez","J. Kollmeier","P. Sadjadian","K -P Fröhling","R.M. Huber","M. Wolf","Georg Pall","Veerle Surmont","Léon Bosquee","Paul Germonpré","Wolfgang Brückl","Christina Grah","Christian Herzmann","Rumo Leistner","Andreas Meyer","Lothar Müller","Oliver Schmalz","Christian Scholz","Michael Schröder","Monika Serke","Claas Wesseler","Christian Brandts","Hans-Georg Kopp","Wolfgang Blau","Frank Griesinger","Maria Rosario Garcia Campelo","Yolanda Garcia Garcia","José Manuel Trigo Perez"],"twitterCount":23,"altmetricId":46819165},{"title":"Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis","googleId":"MwOJQ9vxOyEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325941","googleCitationCount":27,"googleAuthor":"AR Ferreira","doi":"10.1093/annonc/mdz298","elsevierAuthor":"Ferreira A.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"20","altmetricAuthors":["A.R. Ferreira","A. Di Meglio","B. Pistilli","A.S. Gbenou","M. El-Mouhebb","S. Dauchy","C. Charles","F. Joly","S. Everhard","M. Lambertini","C. Coutant","P. Cottu","F. Lerebours","T. Petit","F. Dalenc","P. Rouanet","A. Arnaud","A. Martin","J. Berille","P.A. Ganz","A.H. Partridge","S. Delaloge","S. Michiels","F. Andre","I. Vaz-Luis"],"twitterCount":62,"altmetricId":68071659},{"title":"Phase II study of olaparib (O) and durvalumab (D)(MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast …","googleId":"TydcdbeVsAsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594030","googleCitationCount":23,"googleAuthor":"S Postel-Vinay","doi":"10.1093/annonc/mdz253.017","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Overview of the relevance of PI3K pathway in HR-positive breast cancer","googleId":"r3cKMq3JT7EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420343738","googleCitationCount":24,"googleAuthor":"N Vasan","doi":"10.1093/annonc/mdz281","elsevierAuthor":"Vasan N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"0","altmetricAuthors":["N. Vasan","E. Toska","M. Scaltriti"],"twitterCount":13,"altmetricId":73059115},{"title":"Recent advances in circulating nucleic acids in oncology","googleId":"llW4tJsV08sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310919","googleCitationCount":27,"googleAuthor":"","doi":"10.1093/annonc/mdz031","elsevierAuthor":"Otandault A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"22","altmetricAuthors":["A. Otandault","P. Anker","Z. Al Amir Dache","V. Guillaumon","R. Meddeb","B. Pastor","E. Pisareva","C. Sanchez","R. Tanos","G. Tousch","H. Schwarzenbach","A.R. Thierry"],"twitterCount":2,"altmetricId":59251483},{"title":"Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study","googleId":"Sl_YwOfw4wsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934548X","googleCitationCount":34,"googleAuthor":"CKY Ng","doi":"10.1093/annonc/mdy083","elsevierAuthor":"Ng C.K.Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"28","altmetricAuthors":["C.K.Y. Ng","G.G. Di Costanzo","N. Tosti","V. Paradiso","M. Coto-Llerena","G. Roscigno","V. Perrina","C. Quintavalle","T. Boldanova","S. Wieland","G. Marino-Marsilia","M. Lanzafame","L. Quagliata","G. Condorelli","M.S. Matter","R. Tortora","M.H. Heim","L.M. Terracciano","S. Piscuoglio"],"twitterCount":3,"altmetricId":34225863},{"title":"MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy …","googleId":"KXK8bYznZqIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603728","googleCitationCount":21,"googleAuthor":"","doi":"10.1093/annonc/mdz394.012","elsevierCitationCount":0,"altmetricAuthors":["S.M. Tolaney","A.M. Wardley","S. Zambelli","J. Hilton","T. Troso-Sandoval","F. Ricci","S.-A. Im","S.-B. Kim","S.R.D. Johnston","A. Chan","S. Goel","K. Catron","Z. Yang","C. Gainford","F. André"],"twitterCount":0,"altmetricId":67755514},{"title":"Molecular pathology of tumors of the central nervous system","googleId":"-OSUrllH0x0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312839","googleCitationCount":28,"googleAuthor":"","doi":"10.1093/annonc/mdz164","elsevierAuthor":"Kristensen B.W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"12","altmetricAuthors":["B.W. Kristensen","L.P. Priesterbach-Ackley","J.K. Petersen","P. Wesseling"],"twitterCount":25,"altmetricId":61245987},{"title":"Insulin resistance and body composition in cancer patients","googleId":"NSShSoL3hKMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316801","googleCitationCount":35,"googleAuthor":"","doi":"10.1093/annonc/mdx815","elsevierAuthor":"Dev R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"23","altmetricAuthors":["R Dev","E. Bruera","S. Dalal"],"twitterCount":47,"altmetricId":33923088},{"title":"Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform …","googleId":"f-zpVhV9gsoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35514-0/abstract","googleCitationCount":32,"googleAuthor":"R Herold"},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative …","googleId":"tFwE2CDFyu4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310002","googleCitationCount":23,"googleAuthor":"F Lordick","doi":"10.1093/annonc/mdy498","elsevierAuthor":"Muro K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"22","altmetricAuthors":["K. Muro","F. Lordick","T. Tsushima","G. Pentheroudakis","E. Baba","Z. Lu","B.C. Cho","I.M. Nor","M. Ng","L -T Chen","K. Kato","J. Li","M -H Ryu","W I Wan Zamaniah","W -P Yong","K -H Yeh","T.E. Nakajima","K. Shitara","H. Kawakami","Y. Narita","T. Yoshino","E. Van Cutsem","E. Martinelli","E.C. Smyth","D. Arnold","H. Minami","J. Tabernero","J -Y Douillard"],"twitterCount":9,"altmetricId":51601317},{"title":"Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study","googleId":"-q2ZBmdIUsQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348963","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdy106","elsevierAuthor":"Gramatzki D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"20","altmetricAuthors":["D. Gramatzki","P. Roth","E.J. Rushing","J. Weller","N. Andratschke","S. Hofer","D. Korol","L. Regli","A. Pangalu","M. Pless","J. Oberle","R. Bernays","H. Moch","S. Rohrmann","M. Weller"],"twitterCount":25,"altmetricId":35024177},{"title":"Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of …","googleId":"nKloUUhDlH4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348975","googleCitationCount":28,"googleAuthor":"","doi":"10.1093/annonc/mdy117","elsevierAuthor":"Rieger C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"20","altmetricAuthors":["C.T. Rieger","B. Liss","S. Mellinghoff","D. Buchheidt","O.A. Cornely","G. Egerer","W.J. Heinz","M. Hentrich","G. Maschmeyer","K. Mayer","M. Sandherr","G. Silling","A. Ullmann","M.J.G.T. Vehreschild","M. von Lilienfeld-Toal","H.H. Wolf","N. Lehners"],"twitterCount":55,"altmetricId":39155698},{"title":"Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial","googleId":"8P5jNf2i44cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318897","googleCitationCount":34,"googleAuthor":"AD Colevas","doi":"10.1093/annonc/mdy411","elsevierAuthor":"Colevas A.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"30","altmetricAuthors":["A.D. Colevas","R. Bahleda","F. Braiteh","A. Balmanoukian","I. Brana","N.G. Chau","I. Sarkar","L. Molinero","W. Grossman","F. Kabbinavar","M. Fassò","C. O’Hear","J. Powderly"],"twitterCount":2,"altmetricId":48517974},{"title":"Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer","googleId":"oT5RrFs8UbYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349786","googleCitationCount":37,"googleAuthor":"S Siena","doi":"10.1093/annonc/mdx504","elsevierAuthor":"Siena S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"27","altmetricAuthors":["S. Siena","A. Sartore-Bianchi","R. Garcia-Carbonero","M. Karthaus","D. Smith","J. Tabernero","E. Van Cutsem","X. Guan","M. Boedigheimer","A. Ang","B. Twomey","B.A. Bach","A.S. Jung","A. Bardelli"],"twitterCount":14,"altmetricId":24770149},{"title":"Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer","googleId":"Au9RDXHm_cMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341729","googleCitationCount":32,"googleAuthor":"","doi":"10.1093/annonc/mdy251","elsevierAuthor":"Hanna G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"26","altmetricAuthors":["G.J. Hanna","J.G. Supplee","Y. Kuang","U. Mahmood","C.J. Lau","R.I. Haddad","P.A. Jänne","C.P. Paweletz"],"twitterCount":8,"altmetricId":45298596},{"title":"Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer","googleId":"sWJkGW2cAN0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459942","googleCitationCount":28,"googleAuthor":"J Zhang","doi":"10.1093/annonc/mdz207","elsevierAuthor":"Kudo Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"22","altmetricAuthors":["Y. Kudo","C. Haymaker","J. Zhang","A. Reuben","D.Y. Duose","J. Fujimoto","S. Roy-Chowdhuri","L.M. Solis Soto","H. Dejima","E.R. Parra","B. Mino","R. Abraham","N. Ikeda","A. Vaporcyan","D. Gibbons","J. Zhang","F.F. Lang","R. Luthra","J.J. Lee","C. Moran","J.T. Huse","H. Kadara","I.I. Wistuba"],"twitterCount":19,"altmetricId":63415578},{"title":"Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients","googleId":"vxP9MCH8BvEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316709","googleCitationCount":37,"googleAuthor":"J Remon","doi":"10.1093/annonc/mdx704","elsevierAuthor":"Remon J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"21","altmetricAuthors":["J. Remon","C.E. Steuer","S.S. Ramalingam","E. Felip"],"twitterCount":3,"altmetricId":33489658},{"title":"Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications","googleId":"8Lhub5gERssJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459814","googleCitationCount":20,"googleAuthor":"R Nicolle","doi":"10.1093/annonc/mdz181","elsevierAuthor":"Martens S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"9","altmetricAuthors":["S. Martens","P. Lefesvre","R. Nicolle","A.V. Biankin","F. Puleo","J.L. Van Laethem","I. Rooman"],"twitterCount":2,"altmetricId":62257344},{"title":"Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)","googleId":"2loUKQP38moJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50466-5/abstract","googleCitationCount":29,"googleAuthor":"RS Herbst"},{"title":"Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial","googleId":"RtZCCORwjCwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49797-4/abstract","googleCitationCount":30,"googleAuthor":"K Brock"},{"title":"Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer","googleId":"9FTG-ZVFNYEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342450","googleCitationCount":23,"googleAuthor":"Y Wan","doi":"10.1093/annonc/mdy458","elsevierAuthor":"Wan Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"17","altmetricAuthors":["Y. Wan","B. Liu","H. Lei","B. Zhang","Y. Wang","H. Huang","S. Chen","Y. Feng","L. Zhu","Y. Gu","Q. Zhang","H. Ma","S.-Y. Zheng"],"twitterCount":8,"altmetricId":50127108},{"title":"Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of …","googleId":"TfuAuQSE-FUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354961","googleCitationCount":35,"googleAuthor":"","doi":"10.1093/annonc/mdx774","elsevierAuthor":"Schöffski P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"23","altmetricAuthors":["P. Schöffski","A. Wozniak","B. Kasper","S. Aamdal","M.G. Leahy","P. Rutkowski","S. Bauer","H. Gelderblom","A. Italiano","L.H. Lindner","I. Hennig","S. Strauss","B. Zakotnik","A. Anthoney","L. Albiges","J.-Y. Blay","P. Reichardt","J. Sufliarsky","W.T.A. van der Graaf","M. Debiec-Rychter","R. Sciot","T. Van Cann","S. Marréaud","T. Raveloarivahy","S. Collette","S. Stacchiotti"],"twitterCount":11,"altmetricId":34764069},{"title":"BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab …","googleId":"_pbYZDbSygEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30959-7/abstract","googleCitationCount":25,"googleAuthor":"S Kopetz"},{"title":"Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and …","googleId":"c1H9oTITIU8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355127","googleCitationCount":32,"googleAuthor":"AK Godwin","doi":"10.1093/annonc/mdx821","elsevierAuthor":"Sharma P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"25","altmetricAuthors":["P. Sharma","W.E. Barlow","A.K. Godwin","H. Pathak","K. Isakova","D. Williams","K.M. Timms","A.R. Hartman","R.J. Wenstrup","H.M. Linden","D. Tripathy","G.N. Hortobagyi","D.F. Hayes"],"twitterCount":26,"altmetricId":30831608},{"title":"Evolutionary dynamics of residual disease in human glioblastoma","googleId":"2tBZ5ry8hPEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310725","googleCitationCount":23,"googleAuthor":"G Caravagna","doi":"10.1093/annonc/mdy506","elsevierAuthor":"Spiteri I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"9","altmetricAuthors":["I. Spiteri","G. Caravagna","G.D. Cresswell","A. Vatsiou","D. Nichol","A. Acar","L. Ermini","K. Chkhaidze","B. Werner","R. Mair","E. Brognaro","R.G.W. Verhaak","G. Sanguinetti","S.G.M. Piccirillo","C. Watts","A. Sottoriva"],"twitterCount":124,"altmetricId":51782352},{"title":"Phase II study of olaparib+ durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)","googleId":"FfyCXormmyoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594029","googleCitationCount":21,"googleAuthor":"","doi":"10.1093/annonc/mdz253.016","elsevierAuthor":"Gupta N.","publicationName":"Oncotarget","elsevierCoverDate":"2021-01-05","elsevierCoverDisplayDate":"5 January 2021","elsevierCitationCount":"0","altmetricAuthors":["Y. Drew","B. Kaufman","S. Banerjee","A. Lortholary","S.H. Hong","Y.H. Park","S. Zimmermann","P. Roxburgh","M. Ferguson","R.H. Alvarez","S. Domchek","C. Gresty","H.K. Angell","V Rocher Ros","K. Meyer","M. Lanasa","P. Herbolsheimer","M. de Jonge"],"twitterCount":0,"altmetricId":68179394},{"title":"Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review","googleId":"3JFW5E76ihgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454823","googleCitationCount":29,"googleAuthor":"A Quintela","doi":"10.1093/annonc/mdy038","elsevierAuthor":"Arnold D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"24","altmetricAuthors":["D. Arnold","G.W. Prager","A. Quintela","A. Stein","S. Moreno Vera","N. Mounedji","J. Taieb"],"twitterCount":30,"altmetricId":33212369},{"title":"Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach","googleId":"Gxcr7M-j_jsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342395","googleCitationCount":26,"googleAuthor":"J Guigay","doi":"10.1093/annonc/mdy452","elsevierAuthor":"Galot R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"22","altmetricAuthors":["R. Galot","C. Le Tourneau","J. Guigay","L. Licitra","I. Tinhofer","A. Kong","C. Caballero","C. Fortpied","J. Bogaerts","A.-S. Govaerts","D. Staelens","T. Raveloarivahy","L. Rodegher","J.-F. Laes","E. Saada-Bouzid","J.-P. Machiels"],"twitterCount":7,"altmetricId":49785509},{"title":"REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer …","googleId":"0IyMIZT1uYUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310336","googleCitationCount":25,"googleAuthor":"K Shitara","doi":"10.1093/annonc/mdy526","elsevierAuthor":"Shitara K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"10","altmetricAuthors":["K. Shitara","T. Yamanaka","T. Denda","Y. Tsuji","K. Shinozaki","Y. Komatsu","Y. Kobayashi","J. Furuse","H. Okuda","M. Asayama","K. Akiyoshi","Y. Kagawa","T. Kato","E. Oki","T. Ando","Y. Hagiwara","Y. Ohashi","T. Yoshino"],"twitterCount":10,"altmetricId":52264645},{"title":"Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC","googleId":"jQjwSZkTEPgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603984","googleCitationCount":25,"googleAuthor":"DG Duda","doi":"10.1093/annonc/mdz394.038","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized …","googleId":"59XRyXBbRwcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341249","googleCitationCount":28,"googleAuthor":"MJ Maurer","doi":"10.1093/annonc/mdy203","elsevierAuthor":"Maurer M.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"23","altmetricAuthors":["M.J. Maurer","T.M. Habermann","Q. Shi","N. Schmitz","D. Cunningham","M. Pfreundschuh","J.F. Seymour","U. Jaeger","C. Haioun","H. Tilly","H. Ghesquieres","F. Merli","M. Ziepert","R. Herbrecht","J. Flament","T. Fu","C.R. Flowers","B. Coiffier"],"twitterCount":40,"altmetricId":43631582},{"title":"A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with …","googleId":"U-CCvi3pCCsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350380","googleCitationCount":34,"googleAuthor":"L Wang","doi":"10.1093/annonc/mdx689","elsevierAuthor":"Wang L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"31","altmetricAuthors":["L. Wang","S.M. Dehm","D.W. Hillman","H. Sicotte","W. Tan","M. Gormley","V. Bhargava","R. Jimenez","F. Xie","P. Yin","S. Qin","F. Quevedo","B.A. Costello","H.C. Pitot","T. Ho","A.H. Bryce","Z. Ye","Y. Li","P. Eiken","P.T. Vedell","P. Barman","B.P. McMenomy","T.D. Atwell","R.E. Carlson","M. Ellingson","B.W. Eckloff","R. Qin","F. Ou","S.N. Hart","H. Huang","J. Jen","E.D. Wieben","K.R. Kalari","R.M. Weinshilboum","L. Wang","M. Kohli"],"twitterCount":9,"altmetricId":27843262},{"title":"Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 …","googleId":"xnKXuBOa33kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603844","googleCitationCount":20,"googleAuthor":"A Sartore-Bianchi","doi":"10.1093/annonc/mdz394.024","elsevierAuthor":"Rizzetto F.","publicationName":"European Radiology Experimental","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0},{"title":"Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer","googleId":"YFb0XUsUREUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419580139","googleCitationCount":17,"googleAuthor":"D Hyman","doi":"10.1093/annonc/mdz431.002","elsevierAuthor":"Harada G.","publicationName":"Current Treatment Options in Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"2","altmetricAuthors":[],"twitterCount":0},{"title":"From hepatitis C virus infection to B-cell lymphoma","googleId":"Rlx4XBGYNr0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349907","googleCitationCount":32,"googleAuthor":"E Bachy","doi":"10.1093/annonc/mdx635","elsevierAuthor":"Couronné L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"24","altmetricAuthors":["L. Couronné","E. Bachy","S. Roulland","B. Nadel","F. Davi","M. Armand","D. Canioni","J.M. Michot","C. Visco","L. Arcaini","C. Besson","O. Hermine"],"twitterCount":9,"altmetricId":27410156},{"title":"Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma","googleId":"S2k0Z1pUAEAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320976","googleCitationCount":28,"googleAuthor":"J Lewin","doi":"10.1093/annonc/mdy124","elsevierAuthor":"Lewin J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"19","altmetricAuthors":["J. Lewin","L. Sayers","D. Kee","I. Walpole","A. Sanelli","L. te Marvelde","A. Herschtal","J. Spillane","D. Gyorki","D. Speakman","V. Estall","S. Donahoe","M. Pohl","K. Pope","M. Chua","S. Sandhu","G.A. McArthur","C.J. McCormack","M. Henderson","R.J. Hicks","M. Shackleton"],"twitterCount":10,"altmetricId":36747028},{"title":"Efficacy and safety of nivolumab (Nivo)+ ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: results from CheckMate 358","googleId":"zMFU0IFcgp8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604199","googleCitationCount":21,"googleAuthor":"RW Naumann","doi":"10.1093/annonc/mdz394.059","elsevierCitationCount":0,"altmetricAuthors":["R.W. Naumann","A. Oaknin","T. Meyer","J.M. Lopez-Picazo","C. Lao","Y.-J. Bang","V. Boni","W.H. Sharfman","J.C. Park","L.A. Devriese","K. Harano","C.H. Chung","S.L. Topalian","K. Zaki","T. Chen","J. Gu","B. Li","A. Barrows","A. Horvath","K.N. Moore"],"twitterCount":0,"altmetricId":93776674},{"title":"Early evolutionary divergence between papillary and anaplastic thyroid cancers","googleId":"bZoPXsZwPtMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349026","googleCitationCount":26,"googleAuthor":"FM Mancuso","doi":"10.1093/annonc/mdy123","elsevierAuthor":"Capdevila J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"0","altmetricAuthors":["J. Capdevila","R. Mayor","F.M. Mancuso","C. Iglesias","G. Caratù","I. Matos","C. Zafón","J. Hernando","A. Petit","P. Nuciforo","J.M. Cameselle-Teijeiro","C. Álvarez","J.A. Recio","J. Tabernero","X. Matias-Guiu","A. Vivancos","J. Seoane"],"twitterCount":10,"altmetricId":36688683},{"title":"An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies","googleId":"nnpcydVVlxkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591189","googleCitationCount":19,"googleAuthor":"R Jones","doi":"10.1093/annonc/mdz249.001","elsevierCitationCount":0,"altmetricAuthors":["T. Powles","A. Balar","G. Gravis","R. Jones","A. Ravaud","J. Florence","P. Grivas","D.P. Petrylak","M. Galsky","J. Carles","S. Sridhar","H.-T. Arkenau","D. Carroll","J. DeCesare","F. Mercier","D. Hodgson","J. Stone","J. Cosaert","D. Landers"],"twitterCount":0,"altmetricId":68179462},{"title":"Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer","googleId":"nHN3cfhjJGYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50424-0/abstract","googleCitationCount":28,"googleAuthor":"ND James"},{"title":"Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach","googleId":"x1D2NaIvnm0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325862","googleCitationCount":14,"googleAuthor":"A Anazodo","doi":"10.1093/annonc/mdz284","elsevierAuthor":"Salama M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"6","altmetricAuthors":["M. Salama","A. Anazodo","T.K. Woodruff"],"twitterCount":29,"altmetricId":65057913},{"title":"Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection","googleId":"B_BuGIWqMwkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34190-0/abstract","googleCitationCount":27,"googleAuthor":"EP Scully"},{"title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical–pathological features and intratumor …","googleId":"G97EY5ClyK8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345508","googleCitationCount":32,"googleAuthor":"F Lunardi","doi":"10.1093/annonc/mdy086","elsevierAuthor":"Pasello G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"24","altmetricAuthors":["G. Pasello","G. Zago","F. Lunardi","L. Urso","I. Kern","G. Vlacic","F. Grosso","M. Mencoboni","G.L. Ceresoli","M. Schiavon","F. Pezzuto","A. Pavan","S.E. Vuljan","P. Del Bianco","P. Conte","F. Rea","F. Calabrese"],"twitterCount":3,"altmetricId":34084842},{"title":"Bevacizumab+ chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial …","googleId":"r8X0HbEgJzEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419351312","googleCitationCount":31,"googleAuthor":"J Taieb","doi":"10.1093/annonc/mdx529","elsevierAuthor":"Gilabert M.","publicationName":"Journal of Geriatric Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0","altmetricAuthors":["T. Aparicio","O. Bouché","J. Taieb","E. Maillard","S. Kirscher","P.-L. Etienne","R. Faroux","F. Khemissa Akouz","F. El Hajbi","C. Locher","Y. Rinaldi","T. Lecomte","S. Lavau-Denes","M. Baconnier","A. Oden-Gangloff","D. Genet","E. Paillaud","F. Retornaz","E. François","L. Bedenne"],"twitterCount":9,"altmetricId":26718707},{"title":"Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial","googleId":"cJUUvTTpos0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341432","googleCitationCount":26,"googleAuthor":"","doi":"10.1093/annonc/mdy229","elsevierAuthor":"Corrie P.G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"0","altmetricAuthors":["P.G. Corrie","A. Marshall","P.D. Nathan","P. Lorigan","M. Gore","S. Tahir","G. Faust","C.G. Kelly","M. Marples","S.J. Danson","E. Marshall","S.J. Houston","R.E. Board","A.M. Waterston","J.P. Nobes","M. Harries","S. Kumar","A. Goodman","A. Dalgleish","A. Martin-Clavijo","S. Westwell","R. Casasola","D. Chao","A. Maraveyas","P.M. Patel","C.H. Ottensmeier","D. Farrugia","A. Humphreys","B. Eccles","G. Young","E.O. Barker","C. Harman","M. Weiss","K.A. Myers","A. Chhabra","S.H. Rodwell","J.A. Dunn","M.R. Middleton","Paul Nathan","Paul Lorigan","Peter Dziewulski","Sonja Holikova","Udaiveer Panwar","Saad Tahir","Guy Faust","Anne Thomas","Pippa Corrie","Bhawna Sirohi","Charles Kelly","Mark Middleton","Maria Marples","Sarah Danson","James Lester","Ernest Marshall","Mazhar Ajaz","Stephen Houston","Ruth Board","David Eaton","Ashita Waterston","Jenny Nobes","Suat Loo","Gill Gray","Helen Stubbings","Martin Gore","Mark Harries","Satish Kumar","Andrew Goodman","Angus Dalgleish","Agustin Martin-Clavijo","Jerry Marsden","Sarah Westwell","Richard Casasola","David Chao","Anthony Maraveyas","Ernest Marshall","Poulam Patel","Christian Ottensmeier","David Farrugia","Alison Humphreys","Bryony Eccles","Renata Dega","Chris Herbert","Christopher Price","Murray Brunt","Martin Scott-Brown","Joanna Hamilton","Richard Larry Hayward","John Smyth","Pamela Woodings","Neena Nayak","Lorna Burrows","Virginia Wolstenholme","John Wagstaff","Marianne Nicolson","Andrew Wilson","Clare Barlow","Christopher Scrase","Timothy Podd","Michael Gonzalez","John Stewart","Martin Highley","Virginia Wolstenholme","Simon Grumett","Andrew Goodman","Toby Talbot","Kannon Nathan","Robert Coltart","Bruce Gee","Martin Gore","David Farrugia","Agustin Martin-Clavijo","Jerry Marsden","Christopher Price","David Farrugia","Kannon Nathan","Robert Coltart","Kannon Nathan","Robert Coltart"],"twitterCount":22,"altmetricId":45079668},{"title":"Progestin-associated shift of meningioma mutational landscape","googleId":"V90YADzxXlkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354882","googleCitationCount":30,"googleAuthor":"","doi":"10.1093/annonc/mdx763","elsevierAuthor":"Peyre M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"20","altmetricAuthors":["M. Peyre","S. Gaillard","C. de Marcellus","M. Giry","F. Bielle","C. Villa","A.L. Boch","H. Loiseau","B. Baussart","L. Cazabat","M.L. Raffin-Sanson","M. Sanson","M. Kalamarides"],"twitterCount":4,"altmetricId":30071339},{"title":"Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for …","googleId":"smZ_tgrg7msJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310257","googleCitationCount":21,"googleAuthor":"","doi":"10.1093/annonc/mdy512","elsevierAuthor":"Zugazagoitia J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"17","altmetricAuthors":["J. Zugazagoitia","I. Ramos","J.M. Trigo","M. Palka","A. Gómez-Rueda","E. Jantus-Lewintre","C. Camps","D. Isla","P. Iranzo","S. Ponce-Aix","R. García-Campelo","M. Provencio","F. Franco","R. Bernabé","O. Juan-Vidal","E. Felip","J. de Castro","J.M. Sanchez-Torres","I. Faul","R.B. Lanman","P. Garrido","L. Paz-Ares"],"twitterCount":28,"altmetricId":52471600},{"title":"Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO)","googleId":"7e4fZViTeOkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591207","googleCitationCount":17,"googleAuthor":"","doi":"10.1093/annonc/mdz249.003","elsevierCitationCount":0,"altmetricAuthors":["M.S. Van der Heijden","N. van Dijk","L. Smit","K. Hendricksen","J.M. de Feijter","E. Bekers","E. Hooijberg","C.C.N. van Rooijen","A. Broeks","Y. Lubeck","K. Sikorska","T.N. Schumacher","P. Kvistborg","T. Boellaard","C.U. Blank","B.W. van Rhijn"],"twitterCount":0,"altmetricId":68179457},{"title":"Artificial intelligence for melanoma diagnosis: how can we deliver on the promise?","googleId":"e8u8DQgTCh0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34114-6/abstract","googleCitationCount":29,"googleAuthor":"VJ Mar"},{"title":"Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers","googleId":"UlTYYiNbI9EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312384","googleCitationCount":24,"googleAuthor":"K Nones","doi":"10.1093/annonc/mdz132","elsevierAuthor":"Foulkes W.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-07-01","elsevierCoverDisplayDate":"1 July 2019","elsevierCitationCount":"0","altmetricAuthors":["K. Nones","J. Johnson","F. Newell","A.M. Patch","H. Thorne","S.H. Kazakoff","X.M. de Luca","M.T. Parsons","K. Ferguson","L.E. Reid","A.E. McCart Reed","S. Srihari","V. Lakis","A.L. Davidson","P. Mukhopadhyay","O. Holmes","Q. Xu","S. Wood","C. Leonard","J. Beesley","J.M. Harris","D. Barnes","A. Degasperi","M.A. Ragan","A.B. Spurdle","K.K. Khanna","S.R. Lakhani","J.V. Pearson","S. Nik-Zainal","G. Chenevix-Trench","N. Waddell","P.T. Simpson"],"twitterCount":57,"altmetricId":60525683},{"title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung …","googleId":"8z2OHoHDekkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311603","googleCitationCount":22,"googleAuthor":"","doi":"10.1093/annonc/mdz060","elsevierAuthor":"Blumenthal G.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-05-01","elsevierCoverDisplayDate":"May 2019","elsevierCitationCount":"16","altmetricAuthors":["G.M. Blumenthal","Y. Gong","K. Kehl","P. Mishra-Kalyani","K.B. Goldberg","S. Khozin","P.G. Kluetz","G.R. Oxnard","R. Pazdur"],"twitterCount":66,"altmetricId":55943907},{"title":"The Macrophage 'Do not eat me'signal, CD47, is a clinically validated cancer immunotherapy target","googleId":"ld6xbcHXvWcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31086-5/abstract","googleCitationCount":22,"googleAuthor":""},{"title":"Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the …","googleId":"rDvJA9goAgYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350513","googleCitationCount":30,"googleAuthor":"MGE Verdam","doi":"10.1093/annonc/mdx726","elsevierAuthor":"Noordman B.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"18","altmetricAuthors":["B.J. Noordman","M.G.E Verdam","S.M. Lagarde","J. Shapiro","M.C.C.M. Hulshof","M.I. van Berge Henegouwen","B.P.L. Wijnhoven","G.A.P. Nieuwenhuijzen","J.J. Bonenkamp","M.A. Cuesta","J.Th.M. Plukker","E.J. Spillenaar Bilgen","E.W. Steyerberg","A. van der Gaast","M.A.G. Sprangers","J.J.B. van Lanschot"],"twitterCount":9,"altmetricId":29850778},{"title":"IMpower131: progression-free survival (PFS) and overall survival (OS) analysis of a randomised Phase III study of atezolizumab+ carboplatin+ paclitaxel or nab …","googleId":"qtda6Fnh9u8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50468-9/abstract","googleCitationCount":25,"googleAuthor":""},{"title":"Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials","googleId":"IOb38PUvRtMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34240-1/abstract","googleCitationCount":25,"googleAuthor":"K Hess"},{"title":"Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens","googleId":"grujUqpfw64J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311974","googleCitationCount":19,"googleAuthor":"W Ye","doi":"10.1093/annonc/mdz102","elsevierAuthor":"Hannigan B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"13","altmetricAuthors":["B. Hannigan","W. Ye","M. Mehrotra","V. Lam","A. Bolivar","S. Zalles","B.A. Barkoh","D. Duose","P.C. Hu","R. Broaddus","J. Stewart","J. Heymach","L.J. Medeiros","I. Wistuba","R. Luthra","S. Roy-Chowdhuri"],"twitterCount":26,"altmetricId":57319578},{"title":"Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium","googleId":"MWkCKOn1BfYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341547","googleCitationCount":27,"googleAuthor":"","doi":"10.1093/annonc/mdy210","elsevierAuthor":"Kenis C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"21","altmetricAuthors":["C. Kenis","L. Decoster","J. Flamaing","P.R. Debruyne","I. De Groof","C. Focan","F. Cornélis","V. Verschaeve","C. Bachmann","D. Bron","S. Luce","G. Debugne","H. Van den Bulck","J.-C. Goeminne","D. Schrijvers","K. Geboers","B. Petit","C. Langenaeken","R. Van Rijswijk","P. Specenier","G. Jerusalem","J.-P. Praet","K. Vandenborre","J.-P. Lobelle","M. Lycke","K. Milisen","H. Wildiers"],"twitterCount":29,"altmetricId":43728969},{"title":"Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer","googleId":"lNFfQDkVvhIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419551171","googleCitationCount":21,"googleAuthor":"A Amatu","doi":"10.1093/annonc/mdz383","elsevierAuthor":"Amatu A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"1 November 2019","elsevierCitationCount":"17","altmetricAuthors":["A. Amatu","A. Sartore-Bianchi","K. Bencardino","E.G. Pizzutilo","F. Tosi","S. Siena"],"twitterCount":32,"altmetricId":70762900},{"title":"The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation","googleId":"6Z2UXopOlXYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349981","googleCitationCount":31,"googleAuthor":"M Riester","doi":"10.1093/annonc/mdx645","elsevierAuthor":"Riester M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"19","altmetricAuthors":["M. Riester","Q. Xu","A. Moreira","J. Zheng","F. Michor","R.J. Downey"],"twitterCount":1,"altmetricId":27642341},{"title":"Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden","googleId":"dqOK4yydhNEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311706","googleCitationCount":22,"googleAuthor":"","doi":"10.1093/annonc/mdz084","elsevierAuthor":"Sabatini M.E.","publicationName":"British Journal of Cancer","elsevierCoverDate":"2020-02-04","elsevierCoverDisplayDate":"4 February 2020","elsevierCitationCount":"6","altmetricAuthors":["D. Hashim","E. Genden","M. Posner","M. Hashibe","P. Boffetta"],"twitterCount":12,"altmetricId":56641788},{"title":"IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo)+ carboplatin+ etoposide in extensive-stage SCLC (ES-SCLC)","googleId":"xdN7rYsjtF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598702","googleCitationCount":30,"googleAuthor":"AS Mansfield","doi":"10.1093/annonc/mdz264","elsevierCitationCount":0,"altmetricAuthors":["M. Reck","S.V. Liu","A.S. Mansfield","T.S.K. Mok","A. Scherpereel","N. Reinmuth","M.C. Garassino","JCastro De Carpeno","R. Califano","M. Nishio","F. Orlandi","J A Alatorre Alexander","T.A. Leal","Y. Cheng","J.-S. Lee","S. Lam","M. McCleland","Y. Deng","S. Phan","L. Horn"],"twitterCount":0,"altmetricId":68818519},{"title":"De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study","googleId":"ZhfooX04w4QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311937","googleCitationCount":26,"googleAuthor":"","doi":"10.1093/annonc/mdz055","elsevierAuthor":"Goldner M.","publicationName":"Future Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"0","altmetricAuthors":["V. Guarneri","M.V. Dieci","G. Bisagni","A. Frassoldati","G.V. Bianchi","G.L. De Salvo","E. Orvieto","L. Urso","T. Pascual","L. Paré","P. Galván","M. Ambroggi","C.A. Giorgi","G. Moretti","G. Griguolo","R. Vicini","A. Prat","P.F. Conte"],"twitterCount":25,"altmetricId":55762168},{"title":"Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant …","googleId":"3r3mww53iX8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454690","googleCitationCount":26,"googleAuthor":"MJ Birrer","doi":"10.1093/annonc/mdy023","elsevierAuthor":"Banerjee S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"20","altmetricAuthors":["S. Banerjee","A.M. Oza","M.J. Birrer","E.P. Hamilton","J. Hasan","A. Leary","K.N. Moore","B. Mackowiak-Matejczyk","J. Pikiel","I. Ray-Coquard","P. Trask","K. Lin","E. Schuth","A. Vaze","Y. Choi","J.C. Marsters","D.J. Maslyar","V. Lemahieu","Y. Wang","E.W. Humke","J.F. Liu"],"twitterCount":8,"altmetricId":32502144},{"title":"Muscle protein anabolism in advanced cancer patients: response to protein and amino acids support, and to physical activity","googleId":"CGr03QMpcLUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316783","googleCitationCount":27,"googleAuthor":"","doi":"10.1093/annonc/mdx809","elsevierAuthor":"Antoun S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"16","altmetricAuthors":["S Antoun","B Raynard"],"twitterCount":179,"altmetricId":33934740},{"title":"Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC)","googleId":"a2ySe8Qr7Z8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604114","googleCitationCount":25,"googleAuthor":"MO Grimm","doi":"10.1093/annonc/mdz394.051","elsevierAuthor":"Ravi P.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"4","altmetricAuthors":["M.-O. Grimm","M. Schmidinger","I. Duran Martinez","G. Schinzari","E. Esteban","M. Schmitz","U. Schumacher","G. Baretton","P. Barthelemy","B. Melichar","N. Charnley","D. Schrijvers","L. Albiges"],"twitterCount":0,"altmetricId":68179443},{"title":"Risk profiling based on p16 and HPV DNA more accurately predicts location of disease relapse in patients with oropharyngeal squamous cell carcinoma","googleId":"ueg1xNLivs4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311093","googleCitationCount":17,"googleAuthor":"JH Rasmussen","doi":"10.1093/annonc/mdz010","elsevierAuthor":"Dickinsoni A.","publicationName":"PLoS ONE","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"0","altmetricAuthors":["J.H. Rasmussen","C. Grønhøj","K. Håkansson","J. Friborg","E. Andersen","G. Lelkaitis","J.P. Klussmann","C. Wittekindt","S. Wagner","I.R. Vogelius","C. von Buchwald"],"twitterCount":13,"altmetricId":54330471},{"title":"INVICTUS: a Phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as≥ 4th-line therapy in patients with …","googleId":"DYN4OGko_wYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604473","googleCitationCount":19,"googleAuthor":"H Gelderblom","doi":"10.1093/annonc/mdz394.087","elsevierCitationCount":0,"altmetricAuthors":["M. von Mehren","C. Serrano","S. Bauer","H. Gelderblom","S. George","M. Heinrich","P. Schöffski","J. Zalcberg","P. Chi","R.L. Jones","P. Reichardt","S. Attia","G. D’Amato","J. Meade","K. Shi","R. Ruiz-Soto","J.-Y. Blay"],"twitterCount":0,"altmetricId":94802418},{"title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on adjuvant therapy","googleId":"jRlAdvzt20cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604205","googleCitationCount":17,"googleAuthor":"","doi":"10.1093/annonc/mdz394.060","elsevierCitationCount":0,"altmetricAuthors":["C.L. Creutzberg","A. Leon-Castillo","S.M. de Boer","M.E. Powell","L.R. Mileshkin","H.J. Mackay","A. Leary","H.W. Nijman","N. Singh","P. Pollock","A. Fyles","C. Haie-Meder","V T H B M Smit","R.J. Edmondson","H. Putter","H.C. Kitchener","E.J. Crosbie","M. de Bruyn","R. Nout","T. Bosse"],"twitterCount":0,"altmetricId":69765980},{"title":"Advances in targeted alpha therapy for prostate cancer","googleId":"qeZvW6dmJH4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325850","googleCitationCount":14,"googleAuthor":"G De Vincentis","doi":"10.1093/annonc/mdz270","elsevierAuthor":"De Vincentis G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"8","altmetricAuthors":["G. De Vincentis","W. Gerritsen","J.E. Gschwend","M. Hacker","V. Lewington","J.M. O’Sullivan","M. Oya","M. Pacilio","C. Parker","N. Shore","O. Sartor"],"twitterCount":15,"altmetricId":65058034},{"title":"Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial","googleId":"pvXM_NAmOz8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321040","googleCitationCount":28,"googleAuthor":"E Fokas","doi":"10.1093/annonc/mdy143","elsevierAuthor":"Fokas E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"20","altmetricAuthors":["E. Fokas","R. Fietkau","A. Hartmann","W. Hohenberger","R. Grützmann","M. Ghadimi","T. Liersch","P. Ströbel","G.G. Grabenbauer","U. Graeven","R -D Hofheinz","C -H Köhne","C. Wittekind","R. Sauer","M. Kaufmann","T. Hothorn","C. Rödel"],"twitterCount":16,"altmetricId":39964932},{"title":"Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC …","googleId":"E4XkErDxfX8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49289-2/abstract","googleCitationCount":24,"googleAuthor":""},{"title":"The use of antidepressants in oncology: a review and practical tips for oncologists","googleId":"qU1Vmn_j-c4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349804","googleCitationCount":29,"googleAuthor":"L Grassi","doi":"10.1093/annonc/mdx526","elsevierAuthor":"Grassi L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"15","altmetricAuthors":["L. Grassi","M.G. Nanni","G. Rodin","M. Li","R. Caruso"],"twitterCount":21,"altmetricId":27194596},{"title":"Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types","googleId":"crLgaWCIdLwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342085","googleCitationCount":23,"googleAuthor":"T Pascual","doi":"10.1093/annonc/mdy335","elsevierAuthor":"Paré L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"19","altmetricAuthors":["L. Paré","T. Pascual","E. Seguí","C. Teixidó","M. Gonzalez-Cao","P. Galván","A. Rodríguez","B. González","M. Cuatrecasas","E. Pineda","A. Torné","G. Crespo","S. Martin-Algarra","E. Pérez-Ruiz","Ò Reig","M. Viladot","C. Font","B. Adamo","M. Vidal","L. Gaba","M. Muñoz","I. Victoria","G. Ruiz","N. Viñolas","B. Mellado","J. Maurel","J. Garcia-Corbacho","M Á Molina-Vila","M. Juan","J.M. Llovet","N. Reguart","A. Arance","A. Prat"],"twitterCount":43,"altmetricId":47143494},{"title":"Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of …","googleId":"MSh6nWxhVTkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311159","googleCitationCount":20,"googleAuthor":"L Danilova","doi":"10.1093/annonc/mdz019","elsevierAuthor":"Stein J.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-04-01","elsevierCoverDisplayDate":"April 2019","elsevierCitationCount":"17","altmetricAuthors":["J.E. Stein","A. Soni","L. Danilova","T.R. Cottrell","T.F. Gajewski","F.S. Hodi","S. Bhatia","W.J. Urba","W.H. Sharfman","M. Wind-Rotolo","R. Edwards","E.J. Lipson","J.M. Taube"],"twitterCount":2,"altmetricId":54661642},{"title":"Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for …","googleId":"Ly-xjGYuG7wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604412","googleCitationCount":16,"googleAuthor":"V Velcheti","doi":"10.1093/annonc/mdz394.081","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer","googleId":"_VYZDZroF5kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354973","googleCitationCount":29,"googleAuthor":"BS Sørensen","doi":"10.1093/annonc/mdx778","elsevierAuthor":"Schou J.V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"24","altmetricAuthors":["J.V. Schou","F.O. Larsen","B.S. Sørensen","R. Abrantes","A.K. Boysen","J.S. Johansen","B.V. Jensen","D.L. Nielsen","K.L. Spindler"],"twitterCount":18,"altmetricId":30605052},{"title":"A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with …","googleId":"eXb0Pb9DxDEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350008","googleCitationCount":33,"googleAuthor":"P Nuciforo","doi":"10.1093/annonc/mdx647","elsevierAuthor":"Nuciforo P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"22","altmetricAuthors":["P. Nuciforo","T. Pascual","J. Cortés","A. Llombart-Cussac","R. Fasani","L. Paré","M. Oliveira","P. Galvan","N. Martínez","B. Bermejo","M. Vidal","S. Pernas","R. López","M. Muñoz","I. Garau","L. Manso","J. Alarcón","E. Martínez","V. Rodrik-Outmezguine","J.C. Brase","P. Villagrasa","A. Prat","E. Holgado"],"twitterCount":51,"altmetricId":27348669},{"title":"Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small …","googleId":"52y4nZCSp3UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581212","googleCitationCount":17,"googleAuthor":"","doi":"10.1093/annonc/mdz437.001","elsevierAuthor":"Chiang C.L.","publicationName":"Targeted Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"1 August 2020","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0},{"title":"A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors","googleId":"JoRsCB8XTA8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932109X","googleCitationCount":25,"googleAuthor":"","doi":"10.1093/annonc/mdy171","elsevierAuthor":"Ferrarotto R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"21","altmetricAuthors":["R. Ferrarotto","G. Eckhardt","A. Patnaik","P. LoRusso","L. Faoro","J.V. Heymach","A.M. Kapoun","L. Xu","P. Munster"],"twitterCount":7,"altmetricId":41052902},{"title":"Body mass index and 20 specific cancers: re-analyses of dose–response meta-analyses of observational studies","googleId":"fJG7prhy-BoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355103","googleCitationCount":29,"googleAuthor":"EK Choi","doi":"10.1093/annonc/mdx819","elsevierAuthor":"Choi E.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"19","altmetricAuthors":["E.K. Choi","H.B. Park","K.H. Lee","J.H. Park","M. Eisenhut","H.J. van der Vliet","G. Kim","J.I. Shin"],"twitterCount":28,"altmetricId":30992091},{"title":"Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer","googleId":"lS8eu5BjU1IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309998","googleCitationCount":21,"googleAuthor":"YX Feng","doi":"10.1093/annonc/mdy497","elsevierAuthor":"Sokol E.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"10","altmetricAuthors":["E.S. Sokol","Y.X. Feng","D.X. Jin","A. Basudan","A.V. Lee","J.M. Atkinson","J. Chen","P.J. Stephens","G.M. Frampton","P.B. Gupta","J.S. Ross","J.H. Chung","S. Oesterreich","S.M. Ali","R.J. Hartmaier"],"twitterCount":46,"altmetricId":51499493},{"title":"Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China","googleId":"o7MGi_c7O-EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609750","googleCitationCount":14,"googleAuthor":"","doi":"10.1093/annonc/mdz231","elsevierAuthor":"Ji M.F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"11","altmetricAuthors":["M.F. Ji","W. Sheng","W.M. Cheng","M.H. Ng","B.H. Wu","X. Yu","K.R. Wei","F.G. Li","S.F. Lian","P.P. Wang","W. Quan","L. Deng","X.H. Li","X.D. Liu","Y.L. Xie","S.J. Huang","S.X. Ge","S.L. Huang","X.J. Liang","S.M. He","H.W. Huang","S.L. Xia","P.S. Ng","H.L. Chen","S.H. Xie","Q. Liu","M.H. Hong","J. Ma","Y. Yuan","N.S. Xia","J. Zhang","S.M. Cao"],"twitterCount":19,"altmetricId":64484932},{"title":"Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non …","googleId":"doO7r7oysoQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50481-1/abstract","googleCitationCount":23,"googleAuthor":"N Reguart"},{"title":"Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer","googleId":"9rmS9po1tKgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325989","googleCitationCount":24,"googleAuthor":"","doi":"10.1093/annonc/mdz390","elsevierAuthor":"Tarazona N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"16","altmetricAuthors":["N. Tarazona","F. Gimeno-Valiente","V. Gambardella","S. Zuñiga","P. Rentero-Garrido","M. Huerta","S. Roselló","C. Martinez-Ciarpaglini","J.A. Carbonell-Asins","F. Carrasco","A. Ferrer-Martínez","G. Bruixola","T. Fleitas","J. Martín","R. Tébar-Martínez","D. Moro","J. Castillo","A. Espí","D. Roda","A. Cervantes"],"twitterCount":58,"altmetricId":67409608},{"title":"Triumph: primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (PTS) with metastatic colorectal cancer (mCRC) with HER2 …","googleId":"n9BfcJJvHrIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587476","googleCitationCount":20,"googleAuthor":"Y Nakamura","doi":"10.1093/annonc/mdz246.004","elsevierCitationCount":0,"altmetricAuthors":["Y. Nakamura","W. Okamoto","T. Kato","H. Hasegawa","K. Kato","S. Iwasa","T. Esaki","Y. Komatsu","T. Masuishi","T. Nishina","S. Nomura","M. Fukui","S. Matsuda","A. Sato","S. Fujii","J.I. Odegaard","S. Olsen","T. Yoshino"],"twitterCount":0,"altmetricId":68179403},{"title":"Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support","googleId":"TxgNThEKQucJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934181X","googleCitationCount":24,"googleAuthor":"GH Lyman","doi":"10.1093/annonc/mdy311","elsevierAuthor":"Lyman G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"14","altmetricAuthors":["G.H. Lyman","L. Yau","R. Nakov","A. Krendyukov"],"twitterCount":72,"altmetricId":46234257},{"title":"Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial","googleId":"4NQc1m_sS90J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354894","googleCitationCount":26,"googleAuthor":"TE Witzig","doi":"10.1093/annonc/mdx764","elsevierAuthor":"Witzig T.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"19","altmetricAuthors":["T.E. Witzig","K. Tobinai","L. Rigacci","T. Ikeda","A. Vanazzi","M. Hino","Y. Shi","J. Mayer","L.J. Costa","C.D. Bermudez Silva","J. Zhu","D. Belada","K. Bouabdallah","J.G. Kattan","J. Kuruvilla","W.S. Kim","J.-F. Larouche","M. Ogura","M. Ozcan","L. Fayad","C. Wu","J. Fan","A.-L. Louveau","M. Voi","F. Cavalli"],"twitterCount":17,"altmetricId":30534021},{"title":"The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer","googleId":"42c2AQFuvg0J","googleLink":"https://www.researchgate.net/profile/Gianluca_Masi/publication/334295334_O-013Impact_of_age_and_gender_on_safety_and_efficacy_of_first-line_FOLFOXIRIbevacizumab_in_mCRC_a_pooled_analysis_of_TRIBE_and_TRIBE2_studies/links/5dd2cbc3299bf1b74b4e18ec/O-013Impact-of-age-and-gender-on-safety-and-efficacy-of-first-line-FOLFOXIRI-bevacizumab-in-mCRC-a-pooled-analysis-of-TRIBE-and-TRIBE2-studies.pdf","googleCitationCount":19,"googleAuthor":"M Shah"},{"title":"Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma","googleId":"rbSkmHINoksJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350045","googleCitationCount":31,"googleAuthor":"SJ Kim","doi":"10.1093/annonc/mdx684","elsevierAuthor":"Kwong Y.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"22","altmetricAuthors":["Y.L. Kwong","S.J. Kim","E. Tse","S.Y. Oh","J.Y. Kwak","H.S. Eom","Y.R. Do","Y.C. Mun","S.R. Lee","H.J. Shin","C. Suh","S.S. Chuang","Y.S. Lee","S.T. Lim","K. Izutsu","R. Suzuki","T. Relander","F. d’Amore","N. Schmitz","A. Jaccard","W.S. Kim"],"twitterCount":2,"altmetricId":28046339},{"title":"Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A …","googleId":"G_kf_BTjScMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49394-0/abstract","googleCitationCount":26,"googleAuthor":""},{"title":"MONARCH 2: overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer","googleId":"PVTN2slrZ5QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603662","googleCitationCount":18,"googleAuthor":"J Sohn","doi":"10.1093/annonc/mdz394.006","elsevierCitationCount":0,"altmetricAuthors":["G.W. Sledge","M. Toi","P. Neven","J. Sohn","K. Inoue","X. Pivot","O. Burdaeva","M. Okera","N. Masuda","P.A. Kaufman","H. Koh","E.-M. Grischke","P.F. Conte","Y. Lu","S. Barriga","K. Hurt","M. Frenzel","S.R.D. Johnston","A. Llombart-Cussac"],"twitterCount":0,"altmetricId":67755513},{"title":"Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the …","googleId":"TuSfcSrt8BYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591268","googleCitationCount":17,"googleAuthor":"TK Choueiri","doi":"10.1093/annonc/mdz249.009","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma …","googleId":"-gH0bvWgbwEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50421-5/abstract","googleCitationCount":23,"googleAuthor":"S Roychowdhury"},{"title":"T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression","googleId":"Sep5QdX7cBoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321003","googleCitationCount":27,"googleAuthor":"A Draghi","doi":"10.1093/annonc/mdy139","elsevierAuthor":"Andersen R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"19","altmetricAuthors":["R. Andersen","T.H. Borch","A. Draghi","A. Gokuldass","M.A.H. Rana","M. Pedersen","M. Nielsen","P. Kongsted","J.W. Kjeldsen","M.C.W. Westergaard","H.D. Radic","C.A. Chamberlain","L.R. Hölmich","H.W. Hendel","M.S. Larsen","Ö Met","I.M. Svane","M. Donia"],"twitterCount":76,"altmetricId":39272539},{"title":"Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically …","googleId":"B4fBIsU9Q1oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49217-X/abstract","googleCitationCount":22,"googleAuthor":"A Hollebecque"},{"title":"Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma","googleId":"6b-CHagAf4oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311986","googleCitationCount":17,"googleAuthor":"J Yu","doi":"10.1093/annonc/mdz103","elsevierAuthor":"Huang A.","publicationName":"Signal Transduction and Targeted Therapy","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"1 December 2020","elsevierCitationCount":"3","altmetricAuthors":[],"twitterCount":0},{"title":"A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma","googleId":"pTJeizM-EmQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454616","googleCitationCount":24,"googleAuthor":"MY Wang","doi":"10.1093/annonc/mdy011","elsevierAuthor":"Li X.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"22","altmetricAuthors":["X.C. Li","M.Y. Wang","M. Yang","H.J. Dai","B.F. Zhang","W. Wang","X.L. Chu","X. Wang","H. Zheng","R.F. Niu","W. Zhang","K.X. Chen"],"twitterCount":2,"altmetricId":32039916},{"title":"A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)","googleId":"Sg0McIKl18MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49397-6/abstract","googleCitationCount":24,"googleAuthor":"CM Annunziata"},{"title":"Current status of immune checkpoint inhibition in early-stage NSCLC","googleId":"F5k74PO6DsAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931289X","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdz175","elsevierAuthor":"Vansteenkiste J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"12","altmetricAuthors":["J. Vansteenkiste","E. Wauters","B. Reymen","C.J. Ackermann","S. Peters","D. De Ruysscher"],"twitterCount":6,"altmetricId":61322183},{"title":"PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?","googleId":"jQUHhjHLuOEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45455-0/abstract","googleCitationCount":27,"googleAuthor":"O Lambotte"},{"title":"S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer …","googleId":"t7rM46hJoHcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355097","googleCitationCount":28,"googleAuthor":"","doi":"10.1093/annonc/mdx816","elsevierAuthor":"Yamada Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"21","altmetricAuthors":["Y. Yamada","T. Denda","M. Gamoh","I. Iwanaga","S. Yuki","H. Shimodaira","M. Nakamura","T. Yamaguchi","H. Ohori","K. Kobayashi","M. Tsuda","Y. Kobayashi","Y. Miyamoto","M. Kotake","K. Shimada","A. Sato","S. Morita","S. Takahashi","Y. Komatsu","C. Ishioka"],"twitterCount":14,"altmetricId":30978825},{"title":"Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only …","googleId":"PSMJHz_g9HYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934205X","googleCitationCount":26,"googleAuthor":"","doi":"10.1093/annonc/mdy332","elsevierAuthor":"Yang B.","publicationName":"Acta Biochimica Polonica","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":["A. Dietz","G. Wichmann","T. Kuhnt","L. Pfreundner","R. Hagen","M. Scheich","O. Kölbl","M.G. Hautmann","J. Strutz","F. Schreiber","U. Bockmühl","V. Schilling","P. Feyer","M. de Wit","G. Maschmeyer","M. Jungehülsing","U. Schroeder","B. Wollenberg","C. Sittel","M. Münter","T. Lenarz","J.P. Klussmann","O. Guntinas-Lichius","C. Rudack","H.T. Eich","T. Foerg","S. Preyer","M. Westhofen","H.J. Welkoborsky","D. Esser","D. Thurnher","S. Remmert","H. Sudhoff","M. Görner","J. Bünzel","V. Budach","S. Held","M. Knödler","F. Lordick","S. Wiegand","K. Vogel","A. Boehm","M. Flentje","U. Keilholz"],"twitterCount":12,"altmetricId":47338731},{"title":"Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions","googleId":"gyxyVqAau4YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342097","googleCitationCount":24,"googleAuthor":"DB Costa","doi":"10.1093/annonc/mdy336","elsevierAuthor":"Piotrowska Z.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"20","altmetricAuthors":["Z. Piotrowska","D.B. Costa","G.R. Oxnard","M. Huberman","J.F. Gainor","I.T. Lennes","A. Muzikansky","A.T. Shaw","C.G. Azzoli","R.S. Heist","L.V. Sequist"],"twitterCount":18,"altmetricId":50256024},{"title":"An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial)","googleId":"6Zw2I3UKrooJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309810","googleCitationCount":21,"googleAuthor":"","doi":"10.1093/annonc/mdy464","elsevierAuthor":"Mehta C.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"14","altmetricAuthors":["C.R. Mehta","L. Liu","C. Theuer"],"twitterCount":16,"altmetricId":50255900},{"title":"Randomized phase III ANGEL study of rivoceranib (apatinib)+ best supportive care (BSC) vs placebo+ BSC in patients with advanced/metastatic gastric …","googleId":"1A8_QawQBrMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603947","googleCitationCount":19,"googleAuthor":"YK Kang","doi":"10.1093/annonc/mdz394.034","elsevierCitationCount":0,"altmetricAuthors":["Y.-K. Kang","W.K. Kang","M. Di Bartolomeo","I. Chau","H.H. Yoon","S. Cascinu","M.-H. Ryu","J.G. Kim","K.-W. Lee","S.C. Oh","A. Takashima","A. Kryzhanivska","Y. Chao","V. Vladimirov","L. Evesque","M. Schenker","A. McGinn","N. Sankar","L. Wyrwicz","N. Boku"],"twitterCount":0,"altmetricId":68179421},{"title":"Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic …","googleId":"7hFAPDMoQdsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309792","googleCitationCount":20,"googleAuthor":"G Bodoky","doi":"10.1093/annonc/mdy461","elsevierAuthor":"Yoshino T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"13","altmetricAuthors":["T. Yoshino","D.C. Portnoy","R. Obermannová","G. Bodoky","J. Prausová","R. Garcia-Carbonero","T. Ciuleanu","P. García-Alfonso","A.L. Cohn","E. Van Cutsem","K. Yamazaki","S. Lonardi","K. Muro","T.W. Kim","K. Yamaguchi","A. Grothey","J. O’Connor","J. Taieb","S.R. Wijayawardana","R.R. Hozak","F. Nasroulah","J. Tabernero"],"twitterCount":28,"altmetricId":49972736},{"title":"Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International …","googleId":"xQbj7CEj29kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350392","googleCitationCount":26,"googleAuthor":"A Bamias","doi":"10.1093/annonc/mdx692","elsevierAuthor":"Bamias A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"0","altmetricAuthors":["A. Bamias","K. Tzannis","L.C. Harshman","S.J. Crabb","Y.-N. Wong","S. Kumar Pal","U. De Giorgi","S. Ladoire","N. Agarwal","E.Y. Yu","G. Niegisch","A. Necchi","C.N. Sternberg","S. Srinivas","A. Alva","U. Vaishampayan","L. Cerbone","M. Liontos","J. Rosenberg","T. Powles","J. Bellmunt","M.D. Galsky"],"twitterCount":4,"altmetricId":27922268},{"title":"Nivolumab (NIVO)+ low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung …","googleId":"M1pTCaU6dAYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604357","googleCitationCount":15,"googleAuthor":"S Peters","doi":"10.1093/annonc/mdz394.075","elsevierAuthor":"Dong A.","publicationName":"Journal of Gene Medicine","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["S. Peters","S.S. Ramalingam","L. Paz-Ares","R. Bernabe Caro","B. Zurawski","S.-W. Kim","A. Alexandru","L. Lupinacci","E. de la Mora Jimenez","H. Sakai","I. Albert","A. Vergnenegre","M. Reck","H. Borghaei","J.R. Brahmer","K.J. O’Byrne","W.J. Geese","P. Bhagavatheeswaran","F.E. Nathan","M.D. Hellmann"],"twitterCount":0,"altmetricId":68179412},{"title":"Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial","googleId":"XkJC-HzspRsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342024","googleCitationCount":21,"googleAuthor":"","doi":"10.1093/annonc/mdy329","elsevierAuthor":"Staehler M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"16","altmetricAuthors":["M. Staehler","R.J. Motzer","D.J. George","H.S. Pandha","F. Donskov","B. Escudier","A.J. Pantuck","A. Patel","L. DeAnnuntis","H. Bhattacharyya","K. Ramaswamy","G. Zanotti","X. Lin","M. Lechuga","L. Serfass","J. Paty","A. Ravaud"],"twitterCount":7,"altmetricId":47890809},{"title":"Pilot randomized trial of an electronic symptom monitoring intervention for hospitalized patients with cancer","googleId":"58qX7XXIVQgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931021X","googleCitationCount":17,"googleAuthor":"RD Nipp","doi":"10.1093/annonc/mdy488","elsevierAuthor":"Nipp R.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"12","altmetricAuthors":["R.D. Nipp","A. El-Jawahri","M. Ruddy","C. Fuh","B. Temel","S.M. D'Arpino","B.J. Cashavelly","V.A. Jackson","D.P. Ryan","E.P. Hochberg","J.A. Greer","J.S. Temel"],"twitterCount":37,"altmetricId":56035411},{"title":"A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer","googleId":"xFuVGlEqvyYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350100","googleCitationCount":27,"googleAuthor":"","doi":"10.1093/annonc/mdx691","elsevierAuthor":"Criscitiello C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"19","altmetricAuthors":["C. Criscitiello","M.A. Bayar","G. Curigliano","F.W. Symmans","C. Desmedt","H. Bonnefoi","B. Sinn","G. Pruneri","C. Vicier","J.Y. Pierga","C. Denkert","S. Loibl","C. Sotiriou","S. Michiels","F. André"],"twitterCount":22,"altmetricId":27917420},{"title":"FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus …","googleId":"yvVADTcEIYAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592055","googleCitationCount":15,"googleAuthor":"N Colombo","doi":"10.1093/annonc/mdz250","elsevierAuthor":"Fabrizio D.A.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Advances in the systemic treatment of melanoma brain metastases","googleId":"8Eis8SZnbawJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321143","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdy185","elsevierAuthor":"Glitza Oliva I.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"16","altmetricAuthors":["I.C. Glitza Oliva","G. Schvartsman","H. Tawbi"],"twitterCount":20,"altmetricId":42361582},{"title":"Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal …","googleId":"rrb4MMBTzvUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311160","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdz020","elsevierAuthor":"Ning X.","publicationName":"Journal of Biochemical and Molecular Toxicology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"1 July 2020","elsevierCitationCount":"1","altmetricAuthors":["C. Zhao","J. Miao","G. Shen","J. Li","M. Shi","N. Zhang","G. Hu","X. Chen","X. Hu","S. Wu","J. Chen","X. Shao","L. Wang","F. Han","H. Mai","M.L.K. Chua","C. Xie"],"twitterCount":3,"altmetricId":54590126},{"title":"Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy","googleId":"X3FpqKpxPOQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312438","googleCitationCount":22,"googleAuthor":"","doi":"10.1093/annonc/mdz139","elsevierAuthor":"Hamfjord J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-07-01","elsevierCoverDisplayDate":"1 July 2019","elsevierCitationCount":"14","altmetricAuthors":["J. Hamfjord","T.K. Guren","O. Dajani","J.S. Johansen","B. Glimelius","H. Sorbye","P. Pfeiffer","O.C. Lingjærde","K.M. Tveit","E.H. Kure","N. Pallisgaard","K.-L.G. Spindler"],"twitterCount":27,"altmetricId":60084286},{"title":"HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?","googleId":"AYg7pe0SmcUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34119-5/abstract","googleCitationCount":26,"googleAuthor":"S Mahner"},{"title":"Impact of prediagnostic smoking and smoking cessation on colorectal cancer prognosis: a meta-analysis of individual patient data from cohorts within the …","googleId":"hohreMbynu8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350665","googleCitationCount":26,"googleAuthor":"JM Ordóñez-Mena","doi":"10.1093/annonc/mdx761","elsevierAuthor":"Ordóñez-Mena J.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"19","altmetricAuthors":["J.M. Ordóñez-Mena","V. Walter","B. Schöttker","M. Jenab","M.G. O’Doherty","F. Kee","B. Bueno-de-Mesquita","P.H.M. Peeters","B.H. Stricker","R. Ruiter","A. Hofman","S. Söderberg","P. Jousilahti","K. Kuulasmaa","N.D. Freedman","T. Wilsgaard","A. Wolk","L.M. Nilsson","A. Tjønneland","J.R. Quirós","F J B van Duijnhoven","P.D. Siersema","P. Boffetta","A. Trichopoulou","H. Brenner"],"twitterCount":33,"altmetricId":30378629},{"title":"Meeting report from the joint IARC–NCI International cancer seminar series: a focus on colorectal cancer","googleId":"DsrZK-Rp-gUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311251","googleCitationCount":17,"googleAuthor":"MJ Gunter","doi":"10.1093/annonc/mdz044","elsevierAuthor":"Gunter M.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-04-01","elsevierCoverDisplayDate":"April 2019","elsevierCitationCount":"8","altmetricAuthors":["M.J. Gunter","S. Alhomoud","M. Arnold","H. Brenner","J. Burn","G. Casey","A.T. Chan","A.J. Cross","E. Giovannucci","R. Hoover","R. Houlston","M. Jenkins","P. Laurent-Puig","U. Peters","D. Ransohoff","E. Riboli","R. Sinha","Z.K. Stadler","P. Brennan","S.J. Chanock"],"twitterCount":11,"altmetricId":55071294},{"title":"Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies","googleId":"swBGN60j_j8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593863","googleCitationCount":15,"googleAuthor":"D Le","doi":"10.1093/annonc/mdz253","elsevierAuthor":"Gupta N.","publicationName":"Oncotarget","elsevierCoverDate":"2021-01-05","elsevierCoverDisplayDate":"5 January 2021","elsevierCitationCount":"0","altmetricAuthors":["L.A. Diaz","D. Le","M. Maio","P.A. Ascierto","R. Geva","D. Motola-Kuba","T. André","E. Van Cutsem","M. Gottfried","E. Elez","J.-P. Delord","D. Jäger","T.W. Kim","R. Guimbaud","T. Yoshino","M. Chen","K. Norwood","P. Marinello","A. Marabelle"],"twitterCount":0,"altmetricId":69537240},{"title":"Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of …","googleId":"iIQVL6SPcWkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604096","googleCitationCount":15,"googleAuthor":"N Agarwal","doi":"10.1093/annonc/mdz394.049","elsevierAuthor":"Cardillo T.M.","publicationName":"Oncotarget","elsevierCoverDate":"2020-10-27","elsevierCoverDisplayDate":"27 October 2020","elsevierCitationCount":"0","altmetricAuthors":["S.T. Tagawa","A. Balar","D.P. Petrylak","P. Grivas","N. Agarwal","C.N. Sternberg","Q. Hong","A. Gladden","C. Kanwal","P. Siemon-Hryczyk","T. Goswami","L.M. Itri","Y. Loriot"],"twitterCount":0,"altmetricId":68179460},{"title":"Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in …","googleId":"Nyb_mj5OEWoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603935","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdz394.033","elsevierAuthor":"Ikegame K.","publicationName":"Japanese Journal of Cancer and Chemotherapy","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"0","altmetricAuthors":["J. Ji","L. Shen","Z. Li","X. Zhang","H. Liang","Y. Xue","Y. Wang","Z. Zhou","J. Yu","L. Chen","Y. Du","G. Li","G. Xiao","D. Wu","Y. Zhou","C. Dang","Y. He","Z. Zhang","Y. Sun","Y. Li"],"twitterCount":0,"altmetricId":68179425},{"title":"A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC)","googleId":"7opP6sVHBi8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50430-6/abstract","googleCitationCount":22,"googleAuthor":"C Albany"},{"title":"Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib","googleId":"M-zIDvNotN8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342032559X","googleCitationCount":12,"googleAuthor":"P Hammel","doi":"10.1093/annonc/mdz406","elsevierAuthor":"Hammel P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"9","altmetricAuthors":["P. Hammel","H.L. Kindler","M. Reni","E. Van Cutsem","T. Macarulla","M.J. Hall","J.O. Park","D. Hochhauser","D. Arnold","D.-Y. Oh","A. Reinacher-Schick","G. Tortora","H. Algül","E.M. O’Reilly","D. McGuinness","K.Y. Cui","S. Joo","H.K. Yoo","N. Patel","T. Golan"],"twitterCount":10,"altmetricId":67471721},{"title":"Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer …","googleId":"I0p5ITwTiz4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310373","googleCitationCount":17,"googleAuthor":"PM Webb","doi":"10.1093/annonc/mdy541","elsevierAuthor":"Webb P.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"12","altmetricAuthors":["P.M. Webb","R. Na","E. Weiderpass","H.O. Adami","K.E. Anderson","K.A. Bertrand","E. Botteri","T.M. Brasky","L.A. Brinton","C. Chen","J.A. Doherty","L. Lu","S.E. McCann","K.B. Moysich","S. Olson","S. Petruzella","J.R. Palmer","A.E. Prizment","C. Schairer","V.W. Setiawan","A.B. Spurdle","B. Trabert","N. Wentzensen","L. Wilkens","H.P. Yang","H. Yu","H.A. Risch","S.J. Jordan"],"twitterCount":11,"altmetricId":54968060},{"title":"Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer","googleId":"BbjhiPIAHV0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931885X","googleCitationCount":22,"googleAuthor":"AJ Armstrong","doi":"10.1093/annonc/mdy406","elsevierAuthor":"Armstrong A.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"12","altmetricAuthors":["A.J. Armstrong","P. Lin","C.S. Higano","C.N. Sternberg","G. Sonpavde","B. Tombal","A.J. Templeton","K. Fizazi","D. Phung","E.K. Wong","A. Krivoshik","T.M. Beer"],"twitterCount":17,"altmetricId":48064297},{"title":"Physical activity in relation to risk of prostate cancer: a systematic review and meta-analysis","googleId":"jIjfB10CDSEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345429","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdy073","elsevierAuthor":"Benke I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"14","altmetricAuthors":["I.N. Benke","M.F. Leitzmann","G. Behrens","D. Schmid"],"twitterCount":3,"altmetricId":33803990},{"title":"PD-1 blockade with nivolumab in endemic Kaposi sarcoma","googleId":"reD3H_rI-_sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45459-8/abstract","googleCitationCount":25,"googleAuthor":""},{"title":"Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion","googleId":"SIU1amTP2bwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419551195","googleCitationCount":21,"googleAuthor":"EM O'reilly","doi":"10.1093/annonc/mdz385","elsevierAuthor":"O'Reilly E.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"1 November 2019","elsevierCitationCount":"17","altmetricAuthors":["E.M. O’Reilly","J.F. Hechtman"],"twitterCount":23,"altmetricId":68309417},{"title":"Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer","googleId":"2-7H6KWmKREJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345442","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdy075","elsevierAuthor":"Liang F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"16","altmetricAuthors":["F. Liang","S. Zhang","Q. Wang","W. Li"],"twitterCount":3,"altmetricId":42261595},{"title":"KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for …","googleId":"UIRHWToeoOoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420345506","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdz453.002","elsevierCitationCount":0,"altmetricAuthors":["S. Gadgeel","D. Rodriguez-Abreu","E. Felip","E. Esteban","G. Speranza","M. Reck","R. Hui","M. Boyer","E.B. Garon","H. Horinouchi","R. Cristescu","D. Aurora-Garg","J. Lunceford","J. Kobie","M. Ayers","B. Piperdi","M.C. Pietanza","M.C. Garassino"],"twitterCount":0,"altmetricId":73140505},{"title":"5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+ IPI) combination therapy in advanced melanoma","googleId":"3GXbb48SKIEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604254","googleCitationCount":11,"googleAuthor":"JMG Larkin","doi":"10.1093/annonc/mdz394.065","elsevierCitationCount":0,"altmetricAuthors":["J.M.G. Larkin","V. Chiarion-Sileni","R. Gonzalez","J.J. Grob","P. Rutkowski","C. Lao","C.L. Cowey","D. Schadendorf","J. Wagstaff","R. Dummer","P.F. Ferrucci","M. Smylie","D. Hogg","A. Hill","I. Marquez-Rodas","J B A G Haanen","J. Rizzo","A. Balogh","F.S. Hodi","J. Wolchok"],"twitterCount":0,"altmetricId":94102418},{"title":"Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for …","googleId":"uKQP4Wz61dgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325540","googleCitationCount":16,"googleAuthor":"","doi":"10.1093/annonc/mdz399","elsevierAuthor":"Yoshioka H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"7","altmetricAuthors":["H. Yoshioka","M. Shimokawa","T. Seto","S. Morita","Y. Yatabe","I. Okamoto","J. Tsurutani","M. Satouchi","T. Hirashima","S. Atagi","K. Shibata","H. Saito","S. Toyooka","N. Yamamoto","K. Nakagawa","T. Mitsudomi"],"twitterCount":7,"altmetricId":67341095},{"title":"Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An …","googleId":"cZ5XBovNdmwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604102","googleCitationCount":14,"googleAuthor":"RS Kaplan","doi":"10.1093/annonc/mdz394.050","elsevierAuthor":"Greco F.","publicationName":"Current Drug Targets","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1","altmetricAuthors":["T.Q.G. Eisen","E. Frangou","B. Smith","A. Ritchie","R.S. Kaplan","B. Oza","I.D. Davis","M.R. Stockler","L. Albiges","B. Escudier","J.M.G. Larkin","A. Bex","S. Joniau","B.W. Hancock","G.G. Hermann","J. Bellmunt","E. Hodgkinson","P. Hanlon","M.K.B. Parmar","A.M. Meade"],"twitterCount":1,"altmetricId":68179439},{"title":"Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium","googleId":"8FMktI4iiF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312712","googleCitationCount":17,"googleAuthor":"","doi":"10.1093/annonc/mdz138","elsevierAuthor":"Kreimer A.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"12","altmetricAuthors":["A.R. Kreimer","A. Ferreiro-Iglesias","M. Nygard","N. Bender","L. Schroeder","A. Hildesheim","H.A. Robbins","M. Pawlita","H. Langseth","N.F. Schlecht","L.F. Tinker","I. Agalliu","S.W. Smoller","E. Ness-Jensen","K. Hveem","G. D’Souza","K. Visvanathan","B. May","G. Ursin","E. Weiderpass","G.G. Giles","R.L. Milne","Q. Cai","W.J. Blot","W. Zheng","S.J. Weinstein","D. Albanes","N. Brenner","J. Hoffman-Bolton","R. Kaaks","A. Barricarte","A. Tjønneland","C. Sacerdote","A. Trichopoulou","R.C.H. Vermeulen","W.-Y. Huang","N.D. Freedman","P. Brennan","T. Waterboer","M. Johansson"],"twitterCount":47,"altmetricId":61929719},{"title":"Stevens–Johnson syndrome during nivolumab treatment of NSCLC","googleId":"uAc3wAiT0LgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34995-6/abstract","googleCitationCount":26,"googleAuthor":"F Bertolini"},{"title":"Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations","googleId":"vlUUT8WS6uYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49503-3/abstract","googleCitationCount":22,"googleAuthor":"AL Ho"},{"title":"Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA)","googleId":"BzXj6JTEc9EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604345","googleCitationCount":14,"googleAuthor":"GR Oxnard","doi":"10.1093/annonc/mdz394.074","elsevierCitationCount":0,"altmetricAuthors":["G.R. Oxnard","E.A. Klein","M.V. Seiden","E. Hubbell","O. Venn","A. Jamshidi","N. Zhang","J.F. Beausang","S. Gross","K.N. Kurtzman","E.T. Fung","B. Allen","A.P. Fields","H. Liu","M.A. Sekeres","D.A. Richards","P.P. Yu","A.M. Aravanis","A.-R. Hartman","M.C. Liu"],"twitterCount":1,"altmetricId":67530415},{"title":"Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line …","googleId":"ez8qmwSqUAkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341286","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdy209","elsevierAuthor":"Zhang J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"16","altmetricAuthors":["J. Zhang","Y. Lin","X.J. Sun","B.Y. Wang","Z.H. Wang","J.F. Luo","L.P. Wang","S. Zhang","J. Cao","Z.H. Tao","J. Wu","Z.M. Shao","W.T. Yang","X.C. Hu"],"twitterCount":14,"altmetricId":43716698},{"title":"A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma","googleId":"oKawZ9q_OwUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32642-0/abstract","googleCitationCount":25,"googleAuthor":"J Abramson"},{"title":"EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort …","googleId":"DKytDmeaZZMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325928","googleCitationCount":21,"googleAuthor":"J Bellmunt","doi":"10.1093/annonc/mdz296","elsevierAuthor":"Horwich A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"15","altmetricAuthors":["A. Horwich","M. Babjuk","J. Bellmunt","H.M. Bruins","T.M. De Reijke","M. De Santis","S. Gillessen","N. James","S. Maclennan","J. Palou","T. Powles","M.J. Ribal","S.F. Shariat","T. Van Der Kwast","E. Xylinas","N. Agarwal","T. Arends","A. Bamias","A. Birtle","P.C. Black","B.H. Bochner","M. Bolla","J.L. Boormans","A. Bossi","A. Briganti","I. Brummelhuis","M. Burger","D. Castellano","R. Cathomas","A. Chiti","A. Choudhury","E. Compérat","S. Crabb","S. Culine","B. De Bari","W. DeBlok","P.J.L. De Visschere","K. Decaestecker","K. Dimitropoulos","J.L. Dominguez-Escrig","S. Fanti","V. Fonteyne","M. Frydenberg","J.J. Futterer","G. Gakis","B. Geavlete","P. Gontero","B. Grubmüller","S. Hafeez","D.E. Hansel","A. Hartmann","D. Hayne","A.M. Henry","V. Hernandez","H. Herr","K. Herrmann","P. Hoskin","J. Huguet","B.A. Jereczek-Fossa","R. Jones","A.M. Kamat","V. Khoo","A.E. Kiltie","S. Krege","S. Ladoire","P.C. Lara","A. Leliveld","E. Linares-Espinós","V. Løgager","A. Lorch","Y. Loriot","R. Meijer","M. Carmen Mir","M. Moschini","H. Mostafid","A.-C. Müller","C.R. Müller","J. N’Dow","A. Necchi","Y. Neuzillet","J.R. Oddens","J. Oldenburg","S. Osanto","W.J.G. Oyen","L. Pacheco-Figueiredo","H. Pappot","M.I. Patel","B.R. Pieters","K. Plass","M. Remzi","M. Retz","J. Richenberg","M. Rink","F. Roghmann","J.E. Rosenberg","M. Rouprêt","O. Rouvière","C. Salembier","A. Salminen","P. Sargos","S. Sengupta","A. Sherif","R.J. Smeenk","A. Smits","A. Stenzl","G.N. Thalmann","B. Tombal","B. Turkbey","S. Vahr Lauridsen","R. Valdagni","A.G. Van Der Heijden","H. Van Poppel","M.D. Vartolomei","E. Veskimäe","A. Vilaseca","F.A. Vives Rivera","T. Wiegel","P. Wiklund","A. Williams","R. Zigeuner","J.A. Witjes"],"twitterCount":98,"altmetricId":70779014},{"title":"Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial","googleId":"3LMeyIHHBPYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582254","googleCitationCount":14,"googleAuthor":"HR Kim","doi":"10.1093/annonc/mdz446","elsevierAuthor":"Nault J.C.","publicationName":"Hepatology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"4","altmetricAuthors":[],"twitterCount":0},{"title":"Cancer mortality in Europe in 2015 and an overview of trends since 1990","googleId":"DmXfIFSav7MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312931","googleCitationCount":12,"googleAuthor":"P Bertuccio","doi":"10.1093/annonc/mdz179","elsevierAuthor":"Bertuccio P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"12","altmetricAuthors":[],"twitterCount":0},{"title":"Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer","googleId":"Ss2zX1CeqbQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310749","googleCitationCount":18,"googleAuthor":"AM Ben-David","doi":"10.1093/annonc/mdy515","elsevierAuthor":"Evron E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"15","altmetricAuthors":["E. Evron","A.M. Ben-David","H. Goldberg","G. Fried","B. Kaufman","R. Catane","M.R. Pfeffer","D.B. Geffen","P. Chernobelsky","T. Karni","R. Abdah-Bortnyak","O. Rosengarten","D. Matceyevsky","M. Inbar","A. Kuten","B.W. Corn"],"twitterCount":35,"altmetricId":51816640},{"title":"Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial","googleId":"7VrYy7MOOYEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49253-3/abstract","googleCitationCount":20,"googleAuthor":""},{"title":"CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors","googleId":"-U42AytoZk0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590615","googleCitationCount":14,"googleAuthor":"ES Antonarakis","doi":"10.1093/annonc/mdz248.002","elsevierCitationCount":0,"altmetricAuthors":["E.S. Antonarakis","P Isaacsson Velho","N. Agarwal","V Sacristan Santos","B.L. Maughan","R. Pili","N. Adra","C.N. Sternberg","P.J. Vlachostergios","S.T. Tagawa","A.H. Bryce","A.L. McNatty","Z.R. Reichert","R. Dreicer","O. Sartor","T.L. Lotan","M. Hussain"],"twitterCount":15,"altmetricId":71393076},{"title":"A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer","googleId":"YjsZe06k-poJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49398-8/abstract","googleCitationCount":21,"googleAuthor":""},{"title":"Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK …","googleId":"XQR-ImLJkfIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325953","googleCitationCount":29,"googleAuthor":"HJ Lenz","doi":"10.1093/annonc/mdz387","elsevierAuthor":"Stintzing S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"14","altmetricAuthors":["S. Stintzing","P. Wirapati","H.-J. Lenz","D. Neureiter","L. Fischer von Weikersthal","T. Decker","A. Kiani","F. Kaiser","S. Al-Batran","T. Heintges","C. Lerchenmüller","C. Kahl","G. Seipelt","F. Kullmann","M. Moehler","W. Scheithauer","S. Held","D.P. Modest","A. Jung","T. Kirchner","D. Aderka","S. Tejpar","V. Heinemann"],"twitterCount":48,"altmetricId":70346696},{"title":"Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer","googleId":"WI68VFTWPK4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310798","googleCitationCount":18,"googleAuthor":"R Sundar","doi":"10.1093/annonc/mdy550","elsevierAuthor":"Sundar R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"14","altmetricAuthors":["R. Sundar","K.K. Huang","A. Qamra","K.-M. Kim","S.T. Kim","W.K. Kang","A.L.K. Tan","J. Lee","P. Tan"],"twitterCount":18,"altmetricId":53743119},{"title":"Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled …","googleId":"5MK2c0hYhzkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341626","googleCitationCount":19,"googleAuthor":"HJ Lenz","doi":"10.1093/annonc/mdy241","elsevierAuthor":"Van Cutsem E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"12","altmetricAuthors":["E. Van Cutsem","T. Yoshino","H.J. Lenz","S. Lonardi","A. Falcone","M.L. Limón","M. Saunders","A. Sobrero","Y.S. Park","R. Ferreiro","Y.S. Hong","J. Tomasek","H. Taniguchi","F. Ciardiello","J. Stoehr","Z. Oum’Hamed","S. Vlassak","M. Studeny","G. Argiles"],"twitterCount":27,"altmetricId":45079730},{"title":"Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study","googleId":"6-m33z3H0nkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50050-3/abstract","googleCitationCount":18,"googleAuthor":"I Bondarenko"},{"title":"Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final …","googleId":"3pBPcxo6FFwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350094","googleCitationCount":25,"googleAuthor":"A du Bois","doi":"10.1093/annonc/mdx690","elsevierAuthor":"Möbus V.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"16","altmetricAuthors":["V. Möbus","C. Jackisch","H.J. Lück","A. du Bois","C. Thomssen","W. Kuhn","U. Nitz","A. Schneeweiss","J. Huober","N. Harbeck","G. von Minckwitz","I.B. Runnebaum","A. Hinke","G.E. Konecny","M. Untch","C. Kurbacher"],"twitterCount":7,"altmetricId":27878158},{"title":"3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo) adjuvant ipilimumab (IPI)+ nivolumab (NIVO) in macroscopic stage III …","googleId":"EIlLpk01leoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595242","googleCitationCount":13,"googleAuthor":"CU Blank","doi":"10.1093/annonc/mdz255.003","elsevierAuthor":"Fountzila E.","publicationName":"ecancermedicalscience","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non …","googleId":"E7cPqiQtX3UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034549X","googleCitationCount":12,"googleAuthor":"RS Herbst","doi":"10.1093/annonc/mdz453.001","elsevierCitationCount":0,"altmetricAuthors":["R.S. Herbst","G. Lopes","D.M. Kowalski","K. Kasahara","Y.-L. Wu","G. De Castro","B.C. Cho","H.Z. Turna","R. Cristescu","D. Aurora-Garg","J. Lunceford","J. Kobie","M. Ayers","M.C. Pietanza","B. Piperdi","T.S.K. Mok"],"twitterCount":2,"altmetricId":73717671},{"title":"Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort","googleId":"QDf00-oG_A0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604394","googleCitationCount":17,"googleAuthor":"S Peters","doi":"10.1093/annonc/mdz394.079","elsevierCitationCount":0,"altmetricAuthors":["S.M. Gadgeel","T.S.K. Mok","S. Peters","J.A.A. Alexander","N.B. Leighl","V. Sriuranpong","M. Perol","G. De Castro","E. Nadal","F. De Marinis","J.-Y. Han","M. Yan","T. Riehl","E. Schleifman","S.M. Paul","S. Mocci","D. Shames","M.S. Mathisen","R. Dziadziuszko"],"twitterCount":0,"altmetricId":68179415},{"title":"Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer","googleId":"RusJqw5o9F4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348987","googleCitationCount":19,"googleAuthor":"T Murata","doi":"10.1093/annonc/mdy118","elsevierAuthor":"Katakami N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"9","altmetricAuthors":["N. Katakami","T. Harada","T. Murata","K. Shinozaki","M. Tsutsumi","T. Yokota","M. Arai","Y. Tada","M. Narabayashi","N. Boku"],"twitterCount":5,"altmetricId":44340026},{"title":"A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the …","googleId":"nI_nTyI351kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342309","googleCitationCount":17,"googleAuthor":"EC Smyth","doi":"10.1093/annonc/mdy407","elsevierAuthor":"Smyth E.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"15","altmetricAuthors":["E.C. Smyth","G. Nyamundanda","D. Cunningham","E. Fontana","C. Ragulan","I.B. Tan","S.J. Lin","A. Wotherspoon","M. Nankivell","M. Fassan","A. Lampis","J.C. Hahne","A.R. Davies","J. Lagergren","J.A. Gossage","N. Maisey","M. Green","J.L. Zylstra","W.H. Allum","R.E. Langley","P. Tan","N. Valeri","A. Sadanandam"],"twitterCount":24,"altmetricId":51805870},{"title":"Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel (D), oxaliplatin (O) and S-1 (S)(DOS) followed by surgery and adjuvant S-1, vs …","googleId":"Td3McEwog0kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603923","googleCitationCount":16,"googleAuthor":"YK Kang","doi":"10.1093/annonc/mdz394.032","elsevierAuthor":"Oshima T.","publicationName":"Oncotarget","elsevierCoverDate":"2020-07-28","elsevierCoverDisplayDate":"28 July 2020","elsevierCitationCount":"0","altmetricAuthors":["Y.-K. Kang","J.H. Yook","Y.-K. Park","Y.-W. Kim","J. Kim","M.-H. Ryu","S.Y. Rha","I.-J. Chung","I.-H. Kim","S.C. Oh","C.-H. Yoo","J.-H. Choi","D.Y. Zang","G. Kim","Y. Lee","S.-H. Noh"],"twitterCount":0,"altmetricId":68179423},{"title":"Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their …","googleId":"6EwgpzkqDNsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341559","googleCitationCount":23,"googleAuthor":"Z Sztupinszki","doi":"10.1093/annonc/mdy216","elsevierAuthor":"Diossy M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"0","altmetricAuthors":["M. Diossy","L. Reiniger","Z. Sztupinszki","M. Krzystanek","K.M. Timms","C. Neff","C. Solimeno","D. Pruss","A.C. Eklund","E. Tóth","O. Kiss","O. Rusz","G. Cserni","T. Zombori","B. Székely","J. Kulka","J. Tímár","I. Csabai","Z. Szallasi"],"twitterCount":31,"altmetricId":43908309},{"title":"Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial","googleId":"R7Zbo3ROuJwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341237","googleCitationCount":20,"googleAuthor":"V Scott","doi":"10.1093/annonc/mdy202","elsevierAuthor":"Arnedos M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"16","altmetricAuthors":["M. Arnedos","M.A. Bayar","B. Cheaib","V. Scott","I. Bouakka","A. Valent","J. Adam","V. Leroux-Kozal","V. Marty","A. Rapinat","C. Mazouni","B. Sarfati","I. Bieche","C. Balleyguier","D. Gentien","S. Delaloge","M. Lacroix-Triki","S. Michiels","F. Andre"],"twitterCount":12,"altmetricId":43587846},{"title":"Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant …","googleId":"MZkk_g1ZvK0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604230","googleCitationCount":12,"googleAuthor":"DE Gyorki","doi":"10.1093/annonc/mdz394.063","elsevierCitationCount":0,"altmetricAuthors":["R. Dummer","D.E. Gyorki","J. Hyngstrom","A. Berger","R. Conry","L. Demidov","A. Sharma","S.A. Treichel","K. Gorski","A. Anderson","M. Faries","M.I. Ross"],"twitterCount":0,"altmetricId":68179432},{"title":"TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers","googleId":"XRSQh-bBR4EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587282","googleCitationCount":13,"googleAuthor":"A Drilon","doi":"10.1093/annonc/mdz244.068","elsevierAuthor":"Dadu R.","publicationName":"Endocrine-Related Cancer","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers","googleId":"3CGS3IsilM4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318836","googleCitationCount":17,"googleAuthor":"D Głodzik","doi":"10.1093/annonc/mdy404","elsevierAuthor":"Głodzik D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"10","altmetricAuthors":["D. Głodzik","C. Purdie","I.H. Rye","P.T. Simpson","J. Staaf","P.N. Span","H.G. Russnes","S. Nik-Zainal"],"twitterCount":34,"altmetricId":48917975},{"title":"A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ …","googleId":"fRhXJknAZ0cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311949","googleCitationCount":18,"googleAuthor":"J Veeraraghavan","doi":"10.1093/annonc/mdz076","elsevierAuthor":"Veeraraghavan J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"16","altmetricAuthors":["J. Veeraraghavan","C. De Angelis","R. Mao","T. Wang","S. Herrera","A.C. Pavlick","A. Contreras","P. Nuciforo","I.A. Mayer","A. Forero","R. Nanda","M.P. Goetz","J.C. Chang","A.C. Wolff","I.E. Krop","S.A.W. Fuqua","A. Prat","S.G. Hilsenbeck","B. Weigelt","J.S. Reis-Filho","C. Gutierrez","C.K. Osborne","M.F. Rimawi","R. Schiff"],"twitterCount":27,"altmetricId":57587642},{"title":"Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma","googleId":"R2Qwv5iK2DUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312001","googleCitationCount":14,"googleAuthor":"AD King","doi":"10.1093/annonc/mdz106","elsevierAuthor":"King A.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"13","altmetricAuthors":["A.D. King","J.K.S. Woo","Q.Y. Ai","J.S.M. Chan","W.K.J. Lam","I.O.L. Tse","K.S. Bhatia","B.C.Y. Zee","E.P. Hui","B.B.Y. Ma","R.W.K. Chiu","A.C. van Hasselt","A.T.C. Chan","Y.M.D. Lo","K.C.A. Chan"],"twitterCount":14,"altmetricId":62926320},{"title":"Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC","googleId":"dnFv8ZEF0TcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32757-7/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"Development of adaptive immune effector therapies in solid tumors","googleId":"pn7jB1r8bZIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325874","googleCitationCount":10,"googleAuthor":"F Lanza","doi":"10.1093/annonc/mdz285","elsevierAuthor":"Comoli P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"12","altmetricAuthors":["P. Comoli","C. Chabannon","U. Koehl","F. Lanza","A. Urbano-Ispizua","M. Hudecek","A. Ruggeri","S. Secondino","C. Bonini","P. Pedrazzoli"],"twitterCount":6,"altmetricId":65366901},{"title":"ARCTIC: Durvalumab+ tremelimumab and durvalumab monotherapy vs SoC in≥ 3L advanced NSCLC treatment","googleId":"kdfctA5xk9MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49791-3/abstract","googleCitationCount":18,"googleAuthor":"SV Orlov"},{"title":"Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation","googleId":"k7UyrTgk3mUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341183","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdy197","elsevierAuthor":"Morano F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"16","altmetricAuthors":["F. Morano","S. Corallo","M. Niger","L. Barault","M. Milione","R. Berenato","R. Moretto","G. Randon","M. Antista","A. Belfiore","A. Raimondi","F. Nichetti","A. Martinetti","L. Battaglia","F. Perrone","G. Pruneri","A. Falcone","M. Di Bartolomeo","F. de Braud","F. Di Nicolantonio","C. Cremolini","F. Pietrantonio"],"twitterCount":9,"altmetricId":43246899},{"title":"Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer","googleId":"QRoFFWkU-ZMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932112X","googleCitationCount":17,"googleAuthor":"L Horn","doi":"10.1093/annonc/mdy177","elsevierAuthor":"Gerber D.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"13","altmetricAuthors":["D.E. Gerber","L. Horn","M. Boyer","R. Sanborn","R. Natale","R. Palmero","P. Bidoli","I. Bondarenko","P. Germonpre","D. Ghizdavescu","A. Kotsakis","H. Lena","G. Losonczy","K. Park","W -C Su","M. Tang","J. Lai","N.L. Kallinteris","J.S. Shan","M. Reck","D.R. Spigel"],"twitterCount":15,"altmetricId":41458627},{"title":"The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?","googleId":"g8tUvyl-4UYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345375","googleCitationCount":22,"googleAuthor":"A Grothey","doi":"10.1093/annonc/mdy064","elsevierAuthor":"Sobrero A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"18","altmetricAuthors":["A. Sobrero","A. Grothey","T. Iveson","R. Labianca","T. Yoshino","J. Taieb","T. Maughan","M. Buyse","T. André","J. Meyerhardt","A.F. Shields","I. Souglakos","J.-Y. Douillard","A. Cervantes"],"twitterCount":40,"altmetricId":32964727},{"title":"Neuronal autoantibodies associated with cognitive impairment in melanoma patients","googleId":"ZfHJQDb-fMYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931169X","googleCitationCount":16,"googleAuthor":"","doi":"10.1093/annonc/mdz083","elsevierAuthor":"Bartels F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-05-01","elsevierCoverDisplayDate":"May 2019","elsevierCitationCount":"9","altmetricAuthors":["F. Bartels","T. Strönisch","K. Farmer","K. Rentzsch","F. Kiecker","C. Finke"],"twitterCount":20,"altmetricId":56644744},{"title":"Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the …","googleId":"lRNtKpufmv0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349889","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdx630","elsevierAuthor":"Nabieva N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"18","altmetricAuthors":["N. Nabieva","S. Kellner","T. Fehm","L. Häberle","J. de Waal","M. Rezai","B. Baier","G. Baake","H.-C. Kolberg","M. Guggenberger","M. Warm","N. Harbeck","R. Wuerstlein","J.-U. Deuker","P. Dall","B. Richter","G. Wachsmann","C. Brucker","J.W. Siebers","N. Fersis","T. Kuhn","C. Wolf","H.-W. Vollert","G.-P. Breitbach","W. Janni","R. Landthaler","A. Kohls","D. Rezek","T. Noesselt","G. Fischer","S. Henschen","T. Praetz","V. Heyl","T. Kühn","T. Krauss","C. Thomssen","A. Hohn","H. Tesch","C. Mundhenke","A. Hein","C. Rauh","C.M. Bayer","A. Jacob","K. Schmidt","E. Belleville","S.Y. Brucker","S. Kümmel","M.W. Beckmann","D. Wallwiener","P. Hadji","P.A. Fasching"],"twitterCount":2,"altmetricId":31915496},{"title":"Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket'trial","googleId":"pi-01BkZC7QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30513-7/abstract","googleCitationCount":17,"googleAuthor":"J Harding"},{"title":"Pembrolizumab (pembro)+ chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in …","googleId":"L7XK79b7QqIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604400","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdz394.080","elsevierCitationCount":0,"altmetricAuthors":["L. Paz-Ares","D. Vicente","A. Tafreshi","A. Robinson","H. Soto Parra","J. Mazières","B. Hermes","I. Cicin","B. Medgyasszay","B. Beatrix","J. Rodríguez Cid","I. Okamoto","S. Lee","R. Ramlau","V. Vladimirov","Y. Cheng","X. Deng","T. Bas","B. Piperdi","B. Halmos"],"twitterCount":1,"altmetricId":67579432},{"title":"BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) …","googleId":"u-bpLVJKA18J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587543","googleCitationCount":11,"googleAuthor":"TR Halfdanarson","doi":"10.1093/annonc/mdz246.011","elsevierAuthor":"Chen E.X.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"13","altmetricAuthors":[],"twitterCount":0},{"title":"Cancer mortality in the elderly in 11 countries worldwide, 1970–2015","googleId":"9nB-JV49mk4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931292X","googleCitationCount":11,"googleAuthor":"M Malvezzi","doi":"10.1093/annonc/mdz178","elsevierAuthor":"Carioli G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"7","altmetricAuthors":["G. Carioli","M. Malvezzi","P. Bertuccio","D. Hashim","S. Waxman","E. Negri","P. Boffetta","C. La Vecchia"],"twitterCount":1,"altmetricId":72747787},{"title":"Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment","googleId":"QrolSTmxn5IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309809","googleCitationCount":16,"googleAuthor":"IR Weir","doi":"10.1093/annonc/mdy462","elsevierAuthor":"Weir I.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"11","altmetricAuthors":["I.R. Weir","G.D. Marshall","J.I. Schneider","J.A. Sherer","E.M. Lord","B. Gyawali","M.K. Paasche-Orlow","E.J. Benjamin","L. Trinquart"],"twitterCount":84,"altmetricId":49889013},{"title":"Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer","googleId":"71ltQAxZVHgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935063X","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdx753","elsevierAuthor":"de Boer S.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"18","altmetricAuthors":["S.M. de Boer","B.G. Wortman","T. Bosse","M.E. Powell","N. Singh","H. Hollema","G. Wilson","M.N. Chowdhury","L. Mileshkin","J. Pyman","D. Katsaros","S. Carinelli","A. Fyles","C.M. McLachlin","C. Haie-Meder","P. Duvillard","R.A. Nout","K.W. Verhoeven-Adema","H. Putter","C.L. Creutzberg","V.T.H.B.M. Smit"],"twitterCount":16,"altmetricId":29621993},{"title":"Translational insights into gastrointestinal stromal tumor and current clinical advances","googleId":"zuZ7BhGK_6oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341961","googleCitationCount":14,"googleAuthor":"MC Heinrich","doi":"10.1093/annonc/mdy309","elsevierAuthor":"Hemming M.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"9","altmetricAuthors":["M.L. Hemming","M.C. Heinrich","S. Bauer","S. George"],"twitterCount":2,"altmetricId":46473287},{"title":"Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective …","googleId":"W4mtmUjUBisJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311263","googleCitationCount":15,"googleAuthor":"L Abar","doi":"10.1093/annonc/mdz045","elsevierAuthor":"Abar L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-04-01","elsevierCoverDisplayDate":"April 2019","elsevierCitationCount":"12","altmetricAuthors":["L. Abar","J.G. Sobiecki","M. Cariolou","N. Nanu","A.R. Vieira","C. Stevens","D. Aune","D.C. Greenwood","D.S.M. Chan","T. Norat"],"twitterCount":4,"altmetricId":55392621},{"title":"Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence …","googleId":"rKo_d3VxsaYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604242","googleCitationCount":10,"googleAuthor":"D Schadendorf","doi":"10.1093/annonc/mdz394.064","elsevierCitationCount":0,"altmetricAuthors":["D. Schadendorf","J.C. Hassel","M. Fluck","T. Eigentler","C. Loquai","M. Berneburg","R. Gutzmer","F. Meier","P. Mohr","A. Hauschild","J.C. Becker","C. Menzer","F. Kiecker","E. Dippel","J.-C. Simon","B. Conrad","C. Garbe","S. Körner","E. Livingstone","L. Zimmer"],"twitterCount":0,"altmetricId":68179433},{"title":"EV-103: initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","googleId":"LjYPNpazzngJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591177","googleCitationCount":12,"googleAuthor":"","doi":"10.1093/annonc/mdz249","elsevierAuthor":"Joshi M.","publicationName":"Cancer Medicine","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0","altmetricAuthors":["C.J. Hoimes","J.E. Rosenberg","S. Srinivas","D.P. Petrylak","M. Milowsky","J.R. Merchan","M.A. Bilen","S. Gupta","A.-S. Carret","N. Yuan","A. Melhem-Bertrandt","T. Flaig"],"twitterCount":0,"altmetricId":68179459},{"title":"LBA3 Nivolumab (NIVO)+ platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC …","googleId":"UB47kBIJdJ8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034552X","googleCitationCount":10,"googleAuthor":"","doi":"10.1093/annonc/mdz453.004","elsevierAuthor":"Remon J.","publicationName":"Translational Cancer Research","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"1 April 2020","elsevierCitationCount":"2","altmetricAuthors":["L. Paz-Ares","T.E. Ciuleanu","X. Yu","P. Salman","A. Pluzanski","A. Nagrial","L. Havel","R. Kowalyszyn","C. Audigier-Valette","Y.-L. Wu","H. Borghaei","M.D. Hellmann","J. Brahmer","M. Reck","S. Ramalingam","L. Zhang","P. Bhagavatheeswaran","F.E. Nathan","K.J. O'Byrne"],"twitterCount":1,"altmetricId":72849082},{"title":"Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients","googleId":"2ZkMv8lgAx8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934164X","googleCitationCount":17,"googleAuthor":"J Fredsøe","doi":"10.1093/annonc/mdy243","elsevierAuthor":"Schmidt L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"13","altmetricAuthors":["L. Schmidt","J. Fredsøe","H. Kristensen","S.H. Strand","A. Rasmussen","S. Høyer","M. Borre","P. Mouritzen","T. Ørntoft","K.D. Sørensen"],"twitterCount":8,"altmetricId":45102965},{"title":"Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath","googleId":"YhpGzTX_1DcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609828","googleCitationCount":17,"googleAuthor":"M Muller","doi":"10.1093/annonc/mdz279","elsevierAuthor":"De Vries R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"14","altmetricAuthors":["R. de Vries","M. Muller","V. van der Noort","W.S.M.E. Theelen","R.D. Schouten","K. Hummelink","S.H. Muller","M. Wolf-Lansdorf","J.W.F. Dagelet","K. Monkhorst","A.H. Maitland-van der Zee","P. Baas","P.J. Sterk","M.M. van den Heuvel"],"twitterCount":78,"altmetricId":66757648},{"title":"Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) …","googleId":"wEhNMgAOtrQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30051-1/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and …","googleId":"0B_6P--tdXkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341717","googleCitationCount":16,"googleAuthor":"CA Voltin","doi":"10.1093/annonc/mdy250","elsevierAuthor":"Voltin C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"12","altmetricAuthors":["C.-A. Voltin","H. Goergen","C. Baues","M. Fuchs","J. Mettler","S. Kreissl","J. Oertl","B. Klaeser","A. Moccia","A. Drzezga","A. Engert","P. Borchmann","M. Dietlein","C. Kobe"],"twitterCount":17,"altmetricId":45006236},{"title":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower …","googleId":"jvU9psOBTO4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459905","googleCitationCount":19,"googleAuthor":"O Türeci","doi":"10.1093/annonc/mdz199","elsevierAuthor":"Türeci O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"15","altmetricAuthors":["O. Türeci","U. Sahin","H. Schulze-Bergkamen","Z. Zvirbule","F. Lordick","D. Koeberle","P. Thuss-Patience","T. Ettrich","D. Arnold","F. Bassermann","S.E. Al-Batran","K. Wiechen","K. Dhaene","D. Maurus","M. Gold","C. Huber","A. Krivoshik","A. Arozullah","J.W. Park","M. Schuler"],"twitterCount":17,"altmetricId":62903590},{"title":"Multi-institutional competing risks analysis of distant brain failure and salvage patterns after upfront radiosurgery without whole brain radiotherapy for brain …","googleId":"Ew02-3G-JAQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350562","googleCitationCount":19,"googleAuthor":"","doi":"10.1093/annonc/mdx740","elsevierAuthor":"McTyre E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"11","altmetricAuthors":[],"twitterCount":0},{"title":"Human endogenous retroviruses and their implication for immunotherapeutics of cancer","googleId":"ReeXC9-NowMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318915","googleCitationCount":21,"googleAuthor":"AM Bjerregaard","doi":"10.1093/annonc/mdy413","elsevierAuthor":"Attermann A.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"15","altmetricAuthors":["A.S. Attermann","A -M Bjerregaard","S.K. Saini","K. Grønbæk","S.R. Hadrup"],"twitterCount":6,"altmetricId":48734563},{"title":"Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a …","googleId":"v-VNA55SDYYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311226","googleCitationCount":18,"googleAuthor":"Y Bi","doi":"10.1093/annonc/mdz037","elsevierAuthor":"Czarnecka A.M.","publicationName":"Expert Opinion on Drug Safety","elsevierCoverDate":"2020-04-02","elsevierCoverDisplayDate":"2 April 2020","elsevierCitationCount":"1","altmetricAuthors":["Y. Bi","J. Liu","B. Furmanski","H. Zhao","J. Yu","C. Osgood","A. Ward","P. Keegan","B.P. Booth","A. Rahman","Y. Wang"],"twitterCount":18,"altmetricId":54902761},{"title":"Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to …","googleId":"KOG_AcRQSzsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596867","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdz260","elsevierAuthor":"Vavala T.","publicationName":"Journal of Clinical Pathology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["L.Q. Chow","F. Barlesi","E.M. Bertino","M.J. van den Bent","H. Wakelee","P.Y. Wen","C.-H. Chiu","S. Orlov","M. Majem","R. Chiari","M. McKeage","C.-J. Yu","F.K. Hurtado","P Cazorla Arratia","Y. Song","F. Branle","M. Shi","D.-W. Kim"],"twitterCount":0,"altmetricId":68976397},{"title":"Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor","googleId":"vrXLOmpkcssJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31280-3/abstract","googleCitationCount":14,"googleAuthor":"JY Blay"},{"title":"Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001 …","googleId":"Xn06f8Ktfq0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596909","googleCitationCount":11,"googleAuthor":"AS Mansfield","doi":"10.1093/annonc/mdz260.004","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) …","googleId":"7OjVEeecLcYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604266","googleCitationCount":12,"googleAuthor":"H Gogas","doi":"10.1093/annonc/mdz394.066","elsevierCitationCount":0,"altmetricAuthors":["A.M. Arance","H. Gogas","B. Dreno","K.T. Flaherty","L. Demidov","D. Stroyakovskiy","Z. Eroglu","P.F. Ferrucci","J. Pigozzo","P. Rutkowski","J. Mackiewicz","I. Rooney","A. Voulgari","S. Troutman","B. Pitcher","Y. Yan","J.M.G. Larkin"],"twitterCount":0,"altmetricId":68179437},{"title":"Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas","googleId":"sPCILO20Tw8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341158","googleCitationCount":17,"googleAuthor":"T Lesluyes","doi":"10.1093/annonc/mdy194","elsevierAuthor":"Le Guellec S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"12","altmetricAuthors":[],"twitterCount":0},{"title":"Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407","googleId":"whQ4QbeLsfYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596910","googleCitationCount":14,"googleAuthor":"","doi":"10.1093/annonc/mdz260.005","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or …","googleId":"6y7OCylAkyQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341742","googleCitationCount":16,"googleAuthor":"RL Jones","doi":"10.1093/annonc/mdy253","elsevierAuthor":"Jones R.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"14","altmetricAuthors":["R.L. Jones","G.D. Demetri","S.M. Schuetze","M. Milhem","A. Elias","B.A. Van Tine","J. Hamm","S. McCarthy","G. Wang","T. Parekh","R. Knoblauch","M.L. Hensley","R.G. Maki","S. Patel","M. von Mehren"],"twitterCount":14,"altmetricId":46213186},{"title":"KEYNOTE-427 cohort A: pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)","googleId":"6w9xRMIoNboJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49260-0/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"On the need to adjust for multiplicity in confirmatory clinical trials with master protocols","googleId":"YN3bWWuIEqMJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6503623/","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdz038","elsevierAuthor":"Stallard N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-04-01","elsevierCoverDisplayDate":"April 2019","elsevierCitationCount":"10","altmetricAuthors":["N. Stallard","S. Todd","D. Parashar","P.K. Kimani","L.A. Renfro"],"twitterCount":4,"altmetricId":57071495},{"title":"Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ …","googleId":"HHxIrzN0D90J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609804","googleCitationCount":8,"googleAuthor":"RJ Young","doi":"10.1093/annonc/mdz271","elsevierAuthor":"Solomon B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"7","altmetricAuthors":["B. Solomon","R.J. Young","M. Bressel","J. Cernelc","P. Savas","H. Liu","D. Urban","A. Thai","C. Cooper","T. Fua","P. Neeson","S. Loi","S.V. Porceddu","D. Rischin"],"twitterCount":22,"altmetricId":64842426},{"title":"Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?","googleId":"HSL2uEL21x4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350598","googleCitationCount":18,"googleAuthor":"GD Stewart","doi":"10.1093/annonc/mdx743","elsevierAuthor":"Figlin R.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"12","altmetricAuthors":["R.A. Figlin","B.C. Leibovich","G.D. Stewart","S. Negrier"],"twitterCount":5,"altmetricId":29432510},{"title":"Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from> 4000 men with metastatic castration …","googleId":"h-isco5sVRMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590639","googleCitationCount":10,"googleAuthor":"JS de Bono","doi":"10.1093/annonc/mdz248.004","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 …","googleId":"W42m9bsjJEkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50429-X/abstract","googleCitationCount":16,"googleAuthor":"P Sharma"},{"title":"Three-versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology …","googleId":"C5docYF6XnQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312980","googleCitationCount":11,"googleAuthor":"J Souglakos","doi":"10.1093/annonc/mdz193","elsevierAuthor":"Souglakos J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"8","altmetricAuthors":["J. Souglakos","I. Boukovinas","S. Kakolyris","S. Xynogalos","N. Ziras","A. Athanasiadis","N. Androulakis","A. Christopoulou","M. Vaslamatzis","A. Ardavanis","C. Emmanouilides","I. Bompolaki","C. Kourousis","P. Makrantonakis","C. Christofyllakis","E. Athanasiadis","N. Kentepozidis","A. Karampeazis","U. Katopodi","A. Anagnosopoulos","G. Papadopoulos","E. Prinarakis","A. Kalisperi","D. Mavroudis","V. Georgoulias"],"twitterCount":9,"altmetricId":62595012},{"title":"Introducing whole-genome sequencing into routine cancer care: the Genomics England 100 000 Genomes Project","googleId":"5wKE82e5TP4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45492-6/abstract","googleCitationCount":21,"googleAuthor":"C Turnbull"},{"title":"Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) …","googleId":"Zoq1NlqiFYEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48485-8/abstract","googleCitationCount":15,"googleAuthor":""},{"title":"Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: a French Sarcoma Group (FSG)/US National Cancer Institute phase II collaborative …","googleId":"SBxqqFC1CaQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50473-2/abstract","googleCitationCount":15,"googleAuthor":""},{"title":"Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001","googleId":"28wh4aQLRL0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30062-6/abstract","googleCitationCount":13,"googleAuthor":"RC Doebele"},{"title":"Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the …","googleId":"aYqOwqacxX4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318770","googleCitationCount":13,"googleAuthor":"E Calvo","doi":"10.1093/annonc/mdy398","elsevierAuthor":"Smoragiewicz M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"9","altmetricAuthors":["M. Smoragiewicz","J. Bogaerts","E. Calvo","A. Marabelle","A. Perrone","L. Seymour","A. Shalabi","L.L. Siu","J. Tabernero","G. Giaccone","M. Atkins","U. Banerji","S. Bates","J. Bogaerts","E. Calvo","F. De Braud","J.Y. Douillard","G. Giaccone","P. Keegan","R. Kumar","P. LoRusso","A. Marabelle","A. Perrone","F. Pignatti","R. Plummer","L. Seymour","G. Schwartz","A. Shalabi","G. Shapiro","L.L. Siu","M. Smoragiewicz","J. Tabernero","P. Therasse","A. Yang"],"twitterCount":16,"altmetricId":48064239},{"title":"Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)","googleId":"T_ZkwSFNi9YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50450-1/abstract","googleCitationCount":16,"googleAuthor":"T Cascone"},{"title":"Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164","googleId":"fum4WBDNkx4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33707-X/abstract","googleCitationCount":16,"googleAuthor":"D Le"},{"title":"Phase II study evaluating trifluridine/tipiracil+ bevacizumab and capecitabine+ bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients …","googleId":"JV5gyM7CEboJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33708-1/abstract","googleCitationCount":17,"googleAuthor":""},{"title":"Different menopausal hormone regimens and risk of breast cancer","googleId":"KoDhSU0EaOQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341304","googleCitationCount":13,"googleAuthor":"N Brusselaers","doi":"10.1093/annonc/mdy212","elsevierAuthor":"Brusselaers N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"10","altmetricAuthors":["N. Brusselaers","R.M. Tamimi","P. Konings","B. Rosner","H.-O. Adami","J. Lagergren"],"twitterCount":5,"altmetricId":43906632},{"title":"Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial","googleId":"68rXpXmeGXsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30419-3/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy","googleId":"ZF82SFTckCYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349920","googleCitationCount":19,"googleAuthor":"S Jain","doi":"10.1093/annonc/mdx637","elsevierAuthor":"Jain S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"12","altmetricAuthors":["S. Jain","C.A. Lyons","S.M. Walker","S. McQuaid","S.O. Hynes","D.M. Mitchell","B. Pang","G.E. Logan","A.M. McCavigan","D. O’Rourke","D.G. McArt","S.S. McDade","I.G. Mills","K.M. Prise","L.A. Knight","C.J. Steele","P.W. Medlow","V. Berge","B. Katz","D.A. Loblaw","D.P. Harkin","J.A. James","J.M. O'sullivan","R.D. Kennedy","D.J. Waugh"],"twitterCount":11,"altmetricId":27853119},{"title":"Preliminary results of a ph2a study to evaluate the clinical efficacy and safety of erdafitinib in Asian patients with biomarker-selected advanced cholangiocarcinoma …","googleId":"RNuAT5d9ahwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49086-8/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"Clinic-pathological pattern of hepatocellular carcinoma (HCC) in Egypt","googleId":"J0z1b6T62TcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33755-X/abstract","googleCitationCount":15,"googleAuthor":"H Elghazaly"},{"title":"Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy","googleId":"bYVAfJ7ElAsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310853","googleCitationCount":12,"googleAuthor":"J Vidal","doi":"10.1093/annonc/mdz005","elsevierAuthor":"Vidal J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"6","altmetricAuthors":["J. Vidal","B. Bellosillo","C. Santos Vivas","P. García-Alfonso","A. Carrato","M.T. Cano","R. García-Carbonero","E. Élez","F. Losa","B. Massutí","M. Valladares-Ayerbes","J.M. Viéitez","J.L. Manzano","D. Azuara","J. Gallego","S. Pairet","G. Capellá","R. Salazar","J. Tabernero","E. Aranda","C. Montagut"],"twitterCount":4,"altmetricId":57816501},{"title":"Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics","googleId":"PfzOf6mXy14J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318903","googleCitationCount":19,"googleAuthor":"","doi":"10.1093/annonc/mdy412","elsevierAuthor":"Ligtenberg K.G.","publicationName":"JAAD Case Reports","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"0","altmetricAuthors":["M. Nikanjam","P.R. Cohen","S. Kato","J.K. Sicklick","R. Kurzrock"],"twitterCount":9,"altmetricId":48372337},{"title":"Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC","googleId":"-TYPnW4rfi0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49776-7/abstract","googleCitationCount":14,"googleAuthor":"C Faivre-Finn"},{"title":"A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head …","googleId":"nKmlcJ_x_tUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49501-X/abstract","googleCitationCount":16,"googleAuthor":"EEW Cohen"},{"title":"Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine-or FOLFIRINOX-based induction chemotherapy (NEOLAP) …","googleId":"ljWYHnSvVyMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588913","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdz247","elsevierAuthor":"Pinter M.","publicationName":"JAMA Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"3","altmetricAuthors":["V. Kunzmann","H. Algül","E. Goekkurt","G.M. Siegler","U.M. Martens","D. Waldschmidt","U. Pelzer","E. Hennes","M. Fuchs","J. Siveke","F. Kullmann","S. Boeck","T.J. Ettrich","P. Ferenczy","R. Keller","C.-T. Germer","H. Stein","I. Hartlapp","I. Klein","V. Heinemann"],"twitterCount":0,"altmetricId":69058759},{"title":"Activity of larotrectinib in TRK fusion lung cancer","googleId":"XIBRQdmZkL8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30060-2/abstract","googleCitationCount":12,"googleAuthor":"A Drilon"},{"title":"Initial results of Phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior …","googleId":"sSIojlFg_bQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50068-0/abstract","googleCitationCount":14,"googleAuthor":"M Heinrich"},{"title":"Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a …","googleId":"d83tG3ZZQn4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32591-6/abstract","googleCitationCount":11,"googleAuthor":"J Remon"},{"title":"Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2","googleId":"URsX6_3tfgEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342103","googleCitationCount":12,"googleAuthor":"K Chang","doi":"10.1093/annonc/mdy337","elsevierAuthor":"Chang K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"11","altmetricAuthors":["K. Chang","J.A. Willis","J. Reumers","M.W. Taggart","F.A. San Lucas","S. Thirumurthi","P. Kanth","D.A. Delker","C.H. Hagedorn","P.M. Lynch","L.M. Ellis","E.T. Hawk","P.A. Scheet","S. Kopetz","J. Arts","J. Guinney","R. Dienstmann","E. Vilar"],"twitterCount":17,"altmetricId":47085226},{"title":"Phase II study of tepotinib+ gefitinib (TEP+ GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)","googleId":"-IR_F2bHA5MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49790-1/abstract","googleCitationCount":15,"googleAuthor":""},{"title":"Durvalumab activity in previously treated patients who stopped durvalumab without disease progression","googleId":"ZDJIpcmjKtsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593875","googleCitationCount":7,"googleAuthor":"JC Soria","doi":"10.1093/annonc/mdz253.001","elsevierCitationCount":0,"altmetricAuthors":["S. Sheth","C. Gao","N. Mueller","P. Martinez","J.-C. Soria"],"twitterCount":1,"altmetricId":67588144},{"title":"A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors","googleId":"lwi5Pm4ueKMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32724-3/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets) …","googleId":"8pwtEE2GtV0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595229","googleCitationCount":10,"googleAuthor":"GV Long","doi":"10.1093/annonc/mdz255.001","elsevierAuthor":"Phadke M.","publicationName":"Experimental Dermatology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["G.V. Long","V.G. Atkinson","S. Lo","S.K. Sandhu","M. Brown","M. Gonzalez","A. Guminski","R.A. Scolyer","L. Emmett","A.M. Menzies","G.A. McArthur"],"twitterCount":0,"altmetricId":68179435},{"title":"Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors","googleId":"hmakyT2ThpwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309901","googleCitationCount":12,"googleAuthor":"","doi":"10.1093/annonc/mdy476","elsevierAuthor":"Lenaerts L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"8","altmetricAuthors":["L. Lenaerts","P. Vandenberghe","N. Brison","H. Che","M. Neofytou","M. Verheecke","L. Leemans","C. Maggen","B. Dewaele","L. Dehaspe","S. Vanderschueren","D. Dierickx","V. Vandecaveye","F. Amant","J.R. Vermeesch"],"twitterCount":12,"altmetricId":50524777},{"title":"Struggling with nutrition in patients with advanced cancer: Nutrition and nourishment—focusing on metabolism and supportive care","googleId":"4JlfDG4yCFcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316813","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdy093","elsevierAuthor":"Arends J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"February 2018","elsevierCitationCount":"9","altmetricAuthors":["J Arends"],"twitterCount":3,"altmetricId":40927523},{"title":"Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ …","googleId":"_IUT7LbfCD8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596922","googleCitationCount":8,"googleAuthor":"","doi":"10.1093/annonc/mdz260.006","elsevierCitationCount":0,"altmetricAuthors":["T.S.K. Mok","A.T. Shaw","R.D. Camidge","S.M. Gadgeel","R. Rosell","R. Dziadziuszko","D.-W. Kim","M. Perol","S.-H. Ou","W. Bordogna","V. Smoljanović","M. Hilton","S. Peters"],"twitterCount":0,"altmetricId":67768424},{"title":"NGS-based profiling reveals a critical contributing role of somatic D-loop mtDNA mutations in HBV-related hepatocarcinogenesis","googleId":"W6HxnPjeaW0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311998","googleCitationCount":8,"googleAuthor":"","doi":"10.1093/annonc/mdz105","elsevierAuthor":"Yin C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"5","altmetricAuthors":[],"twitterCount":0},{"title":"Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers","googleId":"DTxfE1-adboJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454872","googleCitationCount":15,"googleAuthor":"NJ Birkbak","doi":"10.1093/annonc/mdy049","elsevierAuthor":"Birkbak N.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"12","altmetricAuthors":["N.J. Birkbak","Y. Li","S. Pathania","A. Greene-Colozzi","M. Dreze","C. Bowman-Colin","Z. Sztupinszki","M. Krzystanek","M. Diossy","N. Tung","P.D. Ryan","J.E. Garber","D.P. Silver","J.D. Iglehart","Z.C. Wang","D. Szuts","Z. Szallasi","A.L. Richardson"],"twitterCount":22,"altmetricId":33510294},{"title":"Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune …","googleId":"N0YY9E9vWZ0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30016-X/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"Training in communication of oncology clinicians: a position paper based on the third consensus meeting among European experts in 2018","googleId":"rpvmicisVyMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342152","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdy343","elsevierAuthor":"Stiefel F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"9","altmetricAuthors":["F. Stiefel","A. Kiss","P. Salmon","S. Peters","D. Razavi","A. Cervantes","A. Margulies","C. Bourquin","Céline Bourquin","Andrés Cervantes","Sarah Dauchy","Vikki Entwistle","Luigi Grassi","Patrick Jermann","Wolf Langewitz","Anita Margulies","Solange Peters","Darius Razavi","Pär Salander","Peter Salmon","Ellen Smets","Wolfgang Söllner","Gilbert Zulian","Jürg Bernhard","Gabriella Bianchi Micheli","Christoph Hürny","Alexander Kiss","Patrick Nemeshazy","Friedrich Stiefel","Brigitta Wössmer"],"twitterCount":2,"altmetricId":51094309},{"title":"Prognostic markers for colorectal cancer: estimating ploidy and stroma","googleId":"AEp90PAaGGkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935505X","googleCitationCount":28,"googleAuthor":"HE Danielsen","doi":"10.1093/annonc/mdx794","elsevierAuthor":"Tijhuis A.E.","publicationName":"Molecular Cytogenetics","elsevierCoverDate":"2019-05-14","elsevierCoverDisplayDate":"14 May 2019","elsevierCitationCount":"10","altmetricAuthors":["H.E. Danielsen","T.S. Hveem","E. Domingo","M. Pradhan","A. Kleppe","R.A. Syvertsen","I. Kostolomov","J.A. Nesheim","H.A. Askautrud","A. Nesbakken","R.A. Lothe","A. Svindland","N. Shepherd","M. Novelli","E. Johnstone","I. Tomlinson","R. Kerr","D.J. Kerr"],"twitterCount":13,"altmetricId":30981443},{"title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: Results from a phase I cohort","googleId":"hfyI4X625RsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49505-7/abstract","googleCitationCount":14,"googleAuthor":"A Ravaud"},{"title":"Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)","googleId":"SUZ9CGVFySsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586665","googleCitationCount":8,"googleAuthor":"A Drilon","doi":"10.1093/annonc/mdz244.006","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)","googleId":"R7Q2jxfXe6sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454902","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdy052","elsevierAuthor":"MacNeill A.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"22","altmetricAuthors":[],"twitterCount":16,"altmetricId":32843035},{"title":"A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results …","googleId":"6i5UummQzPYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50049-7/abstract","googleCitationCount":15,"googleAuthor":"JL Pujol"},{"title":"Corrections to “Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”","googleId":"W2kW2oceqAcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31701-6/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding","googleId":"PMmSXqJi_LQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355061","googleCitationCount":16,"googleAuthor":"PF Thall","doi":"10.1093/annonc/mdx795","elsevierAuthor":"Yan F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"9","altmetricAuthors":["F. Yan","P.F. Thall","K.H. Lu","M.R. Gilbert","Y. Yuan"],"twitterCount":37,"altmetricId":30719776},{"title":"Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic …","googleId":"KzjZjdRKzpwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321088","googleCitationCount":15,"googleAuthor":"L Schwartzberg","doi":"10.1093/annonc/mdy169","elsevierAuthor":"Schwartzberg L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"12","altmetricAuthors":["L. Schwartzberg","E. Roeland","Z. Andric","D. Kowalski","J. Radic","D. Voisin","G. Rizzi","R. Navari","R.J. Gralla","M. Karthaus"],"twitterCount":19,"altmetricId":40523356},{"title":"Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer","googleId":"Rw-_3Hq-l-UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341663","googleCitationCount":12,"googleAuthor":"B Basu","doi":"10.1093/annonc/mdy245","elsevierAuthor":"Basu B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"8","altmetricAuthors":["B. Basu","M.G. Krebs","R. Sundar","R.H. Wilson","J. Spicer","R. Jones","M. Brada","D.C. Talbot","N. Steele","A.H. Ingles Garces","W. Brugger","E.A. Harrington","J. Evans","E. Hall","H. Tovey","F.M. de Oliveira","S. Carreira","K. Swales","R. Ruddle","F.I. Raynaud","B. Purchase","J.C. Dawes","M. Parmar","A.J. Turner","N. Tunariu","S. Banerjee","J.S. de Bono","U. Banerji"],"twitterCount":28,"altmetricId":45247921},{"title":"Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","googleId":"Gs_18euEWSYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355024","googleCitationCount":15,"googleAuthor":"AF Herrera","doi":"10.1093/annonc/mdx791","elsevierAuthor":"Herrera A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"9","altmetricAuthors":["A.F. Herrera","J. Palmer","P. Martin","S. Armenian","N.-C. Tsai","N. Kennedy","F. Sahebi","T. Cao","L.E. Budde","M. Mei","T. Siddiqi","L. Popplewell","S.T. Rosen","L.W. Kwak","A. Nademanee","S.J. Forman","R. Chen"],"twitterCount":11,"altmetricId":30741521},{"title":"Avoiding over-and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?","googleId":"tnCSfKiAFEYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312347","googleCitationCount":12,"googleAuthor":"A Matikas","doi":"10.1093/annonc/mdz126","elsevierAuthor":"Zerdes I.","publicationName":"Molecular Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"3","altmetricAuthors":["A. Matikas","T. Foukakis","S. Swain","J. Bergh"],"twitterCount":3,"altmetricId":61553153},{"title":"Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote …","googleId":"vTTAnrfAo-UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49733-0/abstract","googleCitationCount":15,"googleAuthor":"CU Blank"},{"title":"Chemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: A randomized, open-label, phase III trial","googleId":"rI-CjIc7UEoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)59320-6/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 …","googleId":"oPZk42tSSQoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350653","googleCitationCount":15,"googleAuthor":"D Cella","doi":"10.1093/annonc/mdx759","elsevierAuthor":"Cella D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"15","altmetricAuthors":["D. Cella","S. Traina","T. Li","K. Johnson","K.F. Ho","A. Molina","N.D. Shore"],"twitterCount":5,"altmetricId":30291451},{"title":"18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) …","googleId":"PRMOPP4n9DYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604321","googleCitationCount":8,"googleAuthor":"AM Menzies","doi":"10.1093/annonc/mdz394.072","elsevierAuthor":"Pelster M.S.","publicationName":"Current Treatment Options in Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"1 February 2020","elsevierCitationCount":"5","altmetricAuthors":[],"twitterCount":0},{"title":"Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)","googleId":"IIGNdluRZEwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598726","googleCitationCount":9,"googleAuthor":"","doi":"10.1093/annonc/mdz264.002","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)","googleId":"1o27HQJgVNUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49268-5/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Therapeutic advantage of genetically engineered Salmonella typhimurium carrying short hairpin RNA against inhibin alpha subunit in cancer treatment","googleId":"6C2RUZpSm1AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341614","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdy240","elsevierAuthor":"Yoon W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"8","altmetricAuthors":["W. Yoon","Y. Yoo","Y.S. Chae","S.-H. Kee","B.M. Kim"],"twitterCount":1,"altmetricId":70381528},{"title":"BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib+ MEK inhibitor binimetinib+ anti–epidermal growth factor receptor antibody …","googleId":"i78V2ZpoX7AJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33713-5/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)","googleId":"wI2O4utGDfcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959528X","googleCitationCount":8,"googleAuthor":"D Rischin","doi":"10.1093/annonc/mdz255.007","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)","googleId":"Jy3jJ8va4gMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592079","googleCitationCount":8,"googleAuthor":"V Makker","doi":"10.1093/annonc/mdz250.002","elsevierCitationCount":0,"altmetricAuthors":["V. Makker","M.H. Taylor","C. Aghajanian","A. Oaknin","J. Mier","A.L. Cohn","M Romeo Marin","R Bratos Lorenzo","M.S. Brose","C. DiSimone","M.J. Messing","D.E. Stepan","C.E. Dutcus","J. Wu","E.V. Schmidt","R.J. Orlowski","P. Sachdev","R. Shumaker","A Casado Herraez"],"twitterCount":0,"altmetricId":68179395},{"title":"Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)","googleId":"2goHhcDf9kIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341945463X","googleCitationCount":16,"googleAuthor":"JP Machiels","doi":"10.1093/annonc/mdy013","elsevierAuthor":"Machiels J.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"13","altmetricAuthors":["J.-P. Machiels","P. Bossi","J. Menis","M. Lia","C. Fortpied","Y. Liu","R. Lhommel","M. Lemort","S. Schmitz","S. Canevari","L. De Cecco","M. Guzzo","R. Bianchi","P. Quattrone","F. Crippa","T. Duprez","Y. Lalami","M. Quiriny","N. de Saint Aubain","P.M. Clement","R. Coropciuc","E. Hauben","L.F. Licitra"],"twitterCount":7,"altmetricId":31726438},{"title":"Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC","googleId":"uYSpjXssdI8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50453-7/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous …","googleId":"QH2-VdfZMYsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604175","googleCitationCount":7,"googleAuthor":"PA Konstantinopoulos","doi":"10.1093/annonc/mdz394.057","elsevierAuthor":"Schleicher E.M.","publicationName":"PLoS Genetics","elsevierCoverDate":"2020-11-02","elsevierCoverDisplayDate":"2 November 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in …","googleId":"ZcMyUm9_bLUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349932","googleCitationCount":17,"googleAuthor":"","doi":"10.1093/annonc/mdx638","elsevierAuthor":"Blackwell K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"10","altmetricAuthors":["K. Blackwell","P. Gascon","A. Krendyukov","S. Gattu","Y. Li","N. Harbeck"],"twitterCount":13,"altmetricId":28235600},{"title":"CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications","googleId":"EbEPj3dhQLIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454835","googleCitationCount":16,"googleAuthor":"","doi":"10.1093/annonc/mdy039","elsevierAuthor":"Holmes P.M.","publicationName":"Transactions of the Royal Society of South Africa","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"3","altmetricAuthors":["A. Laroche-Clary","C. Lucchesi","C. Rey","S. Verbeke","A. Bourdon","V. Chaire","M.-P. Algéo","S. Cousin","M. Toulmonde","V. Vélasco","J. Shutzman","A. Savina","F. Le Loarer","A. Italiano"],"twitterCount":8,"altmetricId":32701660},{"title":"Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402 …","googleId":"fXs_21pmSw8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49702-0/abstract","googleCitationCount":12,"googleAuthor":"JMP Rodriguez"},{"title":"Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess","googleId":"CxpwHk0n__EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32593-X/abstract","googleCitationCount":7,"googleAuthor":"J Ciccolini"},{"title":"Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer","googleId":"AyA8rab9h-YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310415","googleCitationCount":9,"googleAuthor":"T Huang","doi":"10.1093/annonc/mdy546","elsevierAuthor":"Huang T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"5","altmetricAuthors":["T. Huang","S.S. Tworoger","W.C. Willett","M.J. Stampfer","B.A. Rosner"],"twitterCount":3,"altmetricId":53259501},{"title":"Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in checkmate 9KD","googleId":"6ZJbXrwKE1wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604059","googleCitationCount":6,"googleAuthor":"","doi":"10.1093/annonc/mdz394.045","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice","googleId":"wYOPlx1Qcz0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349890","googleCitationCount":15,"googleAuthor":"D Cunningham","doi":"10.1093/annonc/mdx631","elsevierAuthor":"Moorcraft S.Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"11","altmetricAuthors":["S.Y. Moorcraft","D. Gonzalez de Castro","D. Cunningham","T. Jones","B.A. Walker","C. Peckitt","L.C. Yuan","M. Frampton","R. Begum","Z. Eltahir","A. Wotherspoon","L.S. Teixeira Mendes","S. Hulkki Wilson","A. Gillbanks","C. Baratelli","N. Fotiadis","A. Patel","C. Braconi","N. Valeri","M. Gerlinger","S. Rao","D. Watkins","I. Chau","N. Starling"],"twitterCount":2,"altmetricId":31915530},{"title":"Safety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) in patients (pts) with BRAF-mutated metastatic …","googleId":"hKdrcqMzaLcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595230","googleCitationCount":9,"googleAuthor":"","doi":"10.1093/annonc/mdz255.002","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1–positive advanced NSCLC: pooled analysis from KEYNOTE-010 …","googleId":"ZLNLGxi6yekJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30052-3/abstract","googleCitationCount":12,"googleAuthor":"P Baas"},{"title":"Hyperprogression during immunotherapy: do we really want to know?","googleId":"ZmOi6P0b4ekJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31252-9/abstract","googleCitationCount":8,"googleAuthor":"S Champiat"},{"title":"Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic …","googleId":"6tYypZ2h6ZsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454847","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdy040","elsevierAuthor":"Tahara M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"15","altmetricAuthors":["M. Tahara","N. Kiyota","T. Yokota","Y. Hasegawa","K. Muro","S. Takahashi","T. Onoe","A. Homma","J. Taguchi","M. Suzuki","K. Minato","K. Yane","S. Ueda","H. Hara","K. Saijo","T. Yamanaka"],"twitterCount":5,"altmetricId":32543956},{"title":"Atezolizumab+ bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study","googleId":"64oxgXJJl6IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43117-7/abstract","googleCitationCount":12,"googleAuthor":""},{"title":"Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study","googleId":"uNP2m2WV8e8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592572","googleCitationCount":6,"googleAuthor":"","doi":"10.1093/annonc/mdz250.052","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study)","googleId":"QcO9t0yY9KkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604126","googleCitationCount":8,"googleAuthor":"IB Vergote","doi":"10.1093/annonc/mdz394.052","elsevierCitationCount":0,"altmetricAuthors":["A. González Martín","B. Pothuri","I.B. Vergote","R.D. Christensen","W. Graybill","M.R. Mirza","C. McCormick","D. Lorusso","P. Hoskins","G. Freyer","F. Backes","K. Baumann","A. Redondo","R.G. Moore","C. Vulsteke","R.E. O’Cearbhaill","B. Lund","Y. Li","D. Gupta","B.J. Monk"],"twitterCount":0,"altmetricId":68011604},{"title":"Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib+ trametinib (D+ T) in patients (pts) with resected BRAF V600 …","googleId":"JsQPi7YFWAQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50444-6/abstract","googleCitationCount":13,"googleAuthor":"GV Long"},{"title":"Primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated …","googleId":"axZKfNw5nEwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604424","googleCitationCount":7,"googleAuthor":"S Azevedo","doi":"10.1093/annonc/mdz394.082","elsevierCitationCount":0,"altmetricAuthors":["A. Ardizzoni","S. Azevedo","B. Rubio Viquiera","D. Rodriguez Abreu","J. Alatorre-Alexander","H.J. Smit","J. Yu","K. Syrigos","H. Patel","J. Tolson","A. Cardona","P. Perez Moreno","T. Newsom-Davis"],"twitterCount":1,"altmetricId":67584403},{"title":"Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab","googleId":"cMlfn6VU-ysJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419598751","googleCitationCount":6,"googleAuthor":"D Daniel","doi":"10.1093/annonc/mdz264.006","elsevierCitationCount":0,"altmetricAuthors":["D. Daniel","V. Kuchava","I. Bondarenko","O. Ivashchuk","D. Spigel","A. Dasgupta","S. Reddy","T. Melkadze","J. Jaal","I. Kudaba","L. Hart","A. Matitashvili","K.D. Koynov","Z. Yang","S.G. Wolfe","R. Malik","S.R. Morris","J.M. Antal","J. Goldschmidt"],"twitterCount":0,"altmetricId":100059240},{"title":"Benefit of prostate radiotherapy for patients with lymph node only or< 4 bone metastasis and no visceral metastases: Exploratory analyses of metastatic site …","googleId":"SpuphOViGsoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590664","googleCitationCount":8,"googleAuthor":"ND James","doi":"10.1093/annonc/mdz248.007","elsevierCitationCount":0,"altmetricAuthors":["S.A. Ali","A. Hoyle","N.D. James","C. Parker","C. Brawley","G. Attard","H. Douis","M.D. Mason","M.K.B. Parmar","M.R. Sydes","N.W. Clarke"],"twitterCount":10,"altmetricId":68933720},{"title":"Intratumoral (it) injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (IPI) triggers durable responses in PD-1 inhibitor refractory …","googleId":"cO0sU3L7qqUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49700-7/abstract","googleCitationCount":11,"googleAuthor":"C Bernatchez"},{"title":"Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial","googleId":"Oy7HXk1zuqQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454768","googleCitationCount":14,"googleAuthor":"E Itti","doi":"10.1093/annonc/mdy031","elsevierAuthor":"Sobhani I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"10","altmetricAuthors":["I. Sobhani","E. Itti","A. Luciani","I. Baumgaertner","R. Layese","T. André","M. Ducreux","J.-M. Gornet","G. Goujon","T. Aparicio","J. Taieb","J.-B. Bachet","F. Hemery","A. Retbi","M. Mons","R. Flicoteaux","B. Rhein","S. Baron","I. Cherrak","P. Rufat","P. Le Corvoisier","N. de’Angelis","P.-A. Natella","H. Maoulida","C. Tournigand","I. Durand Zaleski","S. Bastuji-Garin"],"twitterCount":61,"altmetricId":32159988},{"title":"Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option","googleId":"GH5N_3OE6AoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311767","googleCitationCount":10,"googleAuthor":"SN Westin","doi":"10.1093/annonc/mdz104","elsevierAuthor":"Buechel M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-05-01","elsevierCoverDisplayDate":"May 2019","elsevierCitationCount":"7","altmetricAuthors":["M. Buechel","T.J. Herzog","S.N. Westin","R.L. Coleman","B.J. Monk","K.N. Moore"],"twitterCount":2,"altmetricId":57337328},{"title":"Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase …","googleId":"2hoJ72fIdV8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311123","googleCitationCount":10,"googleAuthor":"S Delaloge","doi":"10.1093/annonc/mdz016","elsevierAuthor":"Delaloge S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-04-01","elsevierCoverDisplayDate":"April 2019","elsevierCitationCount":"7","altmetricAuthors":["S. Delaloge","D. Cella","Y. Ye","M. Buyse","A. Chan","C.H. Barrios","F.A. Holmes","J. Mansi","H. Iwata","B. Ejlertsen","B. Moy","S.K.L. Chia","M. Gnant","S. Smichkoska","A. Ciceniene","N. Martinez","S. Filipović","N.E. Ben-Baruch","A.A. Joy","S.T. Langkjer","F. Senecal","R.H. de Boer","S. Moran","B. Yao","R. Bryce","A. Auerbach","L. Fallowfield","M. Martin"],"twitterCount":17,"altmetricId":54336549},{"title":"Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer","googleId":"9NlQ6H8tKXQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350604","googleCitationCount":15,"googleAuthor":"DD Yang","doi":"10.1093/annonc/mdx744","elsevierAuthor":"Yang D.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"10","altmetricAuthors":["D.D. Yang","A. Krasnova","K.T. Nead","T.K. Choueiri","J.C. Hu","K.E. Hoffman","J.B. Yu","D.E. Spratt","F.Y. Feng","Q.-D. Trinh","P.L. Nguyen"],"twitterCount":25,"altmetricId":30795661},{"title":"Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients …","googleId":"Mqc4-PyeEJkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30534-4/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor","googleId":"aYF3EntCHi0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34107-9/abstract","googleCitationCount":15,"googleAuthor":"V Subbiah"},{"title":"Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors","googleId":"PjjArsRkw-QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49609-9/abstract","googleCitationCount":10,"googleAuthor":"R Leidner"},{"title":"CCTG IND. 231: a phase 1 trial evaluating CX-5461 in patients with advanced solid tumors","googleId":"4uKDHuV3B-QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32636-5/abstract","googleCitationCount":15,"googleAuthor":"DW Cescon"},{"title":"Phase (Ph) II study of MBG453+ spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy","googleId":"1iXmwrgh7_gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594145","googleCitationCount":7,"googleAuthor":"DW Kim","doi":"10.1093/annonc/mdz253.028","elsevierAuthor":"Morganti S.","publicationName":"ecancermedicalscience","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas","googleId":"40Oc9WgQXiIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32634-1/abstract","googleCitationCount":15,"googleAuthor":"J Abramson"},{"title":"Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus iv paclitaxel in patients with advanced gastric cancer after failure …","googleId":"Hsrby8tNKUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345296","googleCitationCount":12,"googleAuthor":"YK Kang","doi":"10.1093/annonc/mdy055","elsevierAuthor":"Kang Y.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"9","altmetricAuthors":["Y.-K. Kang","M.-H. Ryu","S.H. Park","J.G. Kim","J.W. Kim","S.-H. Cho","Y.-I. Park","S.R. Park","S.Y. Rha","M.J. Kang","J.Y. Cho","S.Y. Kang","S.Y. Roh","B.-Y. Ryoo","B.-H. Nam","Y.-W. Jo","K.-E. Yoon","S.C. Oh"],"twitterCount":43,"altmetricId":32964700},{"title":"Molecular screening to select therapy for advanced cancer?","googleId":"7DkpRHL1apYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31172-X/abstract","googleCitationCount":11,"googleAuthor":"IF Tannock"},{"title":"A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer","googleId":"u31LmrWx5v0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312359","googleCitationCount":10,"googleAuthor":"RJ Kelly","doi":"10.1093/annonc/mdz128","elsevierAuthor":"Kelly R.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-07-01","elsevierCoverDisplayDate":"1 July 2019","elsevierCitationCount":"7","altmetricAuthors":["R.J. Kelly","F.A. Shepherd","A. Krivoshik","F. Jie","L. Horn"],"twitterCount":28,"altmetricId":60228860},{"title":"Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)","googleId":"Fh_YjwOALCUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597368","googleCitationCount":7,"googleAuthor":"TM Kim","doi":"10.1093/annonc/mdz260.051","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors","googleId":"OIehBdTihvwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345454","googleCitationCount":14,"googleAuthor":"JR Infante","doi":"10.1093/annonc/mdy076","elsevierAuthor":"Italiano A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"9","altmetricAuthors":["A. Italiano","J.R. Infante","G.I. Shapiro","K.N. Moore","P.M. LoRusso","E. Hamilton","S. Cousin","M. Toulmonde","S. Postel-Vinay","S. Tolaney","E.M. Blackwood","S. Mahrus","F.V. Peale","X. Lu","A. Moein","J. Epler","K. DuPree","M. Tagen","E.R. Murray","J.L. Schutzman","J.O. Lauchle","A. Hollebecque","J.-C. Soria"],"twitterCount":6,"altmetricId":33852406},{"title":"Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced …","googleId":"WLbR1J3w_A0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49163-1/abstract","googleCitationCount":11,"googleAuthor":"T Meyer"},{"title":"Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration …","googleId":"x-7m5RVTDDYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609762","googleCitationCount":6,"googleAuthor":"R Kurzrock","doi":"10.1093/annonc/mdz232","elsevierAuthor":"Kurzrock R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"5","altmetricAuthors":["R. Kurzrock","L.A. Gurski","R.W. Carlson","D.S. Ettinger","S.M. Horwitz","S.K. Kumar","L. Million","M. von Mehren","A.B. Benson"],"twitterCount":48,"altmetricId":64567083},{"title":"Results of a multi-institutional, randomized, non-inferiority, phase III trial of accelerated fractionation versus standard fractionation in radiation therapy for T1 …","googleId":"QtTaE6_4btYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341945480X","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdy036","elsevierAuthor":"Kodaira T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"14","altmetricAuthors":["T. Kodaira","Y. Kagami","T. Shibata","N. Shikama","Y. Nishimura","S. Ishikura","K. Nakamura","Y. Saito","Y. Matsumoto","T. Teshima","Y. Ito","T. Akimoto","K. Nakata","T. Toshiyasu","K. Nakagawa","Y. Nagata","T. Nishimura","T. Uno","M. Kataoka","A. Yorozu","M. Hiraoka"],"twitterCount":5,"altmetricId":32821242},{"title":"Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated","googleId":"eJ5hosmQbnQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344252","googleCitationCount":6,"googleAuthor":"A De Giglio","doi":"10.1093/annonc/mdz449","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity","googleId":"boqZl4EOZzoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454653","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdy015","elsevierAuthor":"Hofheinz R.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"14","altmetricAuthors":["R.-D. Hofheinz","S. Lorenzen","J. Trojan","J. Ocvirk","T.J. Ettrich","S.-E. Al-Batran","H. Schulz","N. Homann","H.-P. Feustel","M. Schatz","M. Kripp","N. Schulte","M. Tetyusheva","S. Heeger","S. Vlassak","K. Merx"],"twitterCount":4,"altmetricId":31912508},{"title":"Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the …","googleId":"b6E2Ur4zWawJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355073","googleCitationCount":14,"googleAuthor":"CK Lee","doi":"10.1093/annonc/mdx796","elsevierAuthor":"Friedlander M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"11","altmetricAuthors":["M. Friedlander","J. Rau","C.K. Lee","W. Meier","A. Lesoin","J.-W. Kim","A. Poveda","M. Buck","G. Scambia","M. Shimada","F. Hilpert","M.T. King","P. Debruyne","A. Bologna","S. Malander","B.J. Monk","E. Petru","P. Calvert","T.J. Herzog","C. Barrett","A. du Bois"],"twitterCount":2,"altmetricId":30629433},{"title":"ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly …","googleId":"lbsUPJQO2zYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50426-4/abstract","googleCitationCount":12,"googleAuthor":"F Saad"},{"title":"Updated overall survival (OS) from extended follow up in ARCHER 1050: a randomized Phase III study comparing dacomitinib with gefitinib as first-line …","googleId":"YN1Kh9RfAu4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582230","googleCitationCount":6,"googleAuthor":"","doi":"10.1093/annonc/mdz446.018","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?","googleId":"s8cL_m4puMIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35013-6/abstract","googleCitationCount":12,"googleAuthor":"M Fiorentino"},{"title":"Expression III: patients' expectations and preferences regarding physician–patient relationship and clinical management—results of the international NOGGO …","googleId":"KOASZnTMoL0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454811","googleCitationCount":12,"googleAuthor":"S Alavi","doi":"10.1093/annonc/mdy037","elsevierAuthor":"Oskay-Özcelik G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"9","altmetricAuthors":["G. Oskay-Özcelik","S. Alavi","R. Richter","M. Keller","R. Chekerov","S.C. Cecere","G. Cormio","F. Joly","J.E. Kurtz","A. du Bois","M. Maciejewski","M. Jedryka","I. Vergote","E. Van Nieuwenhuysen","A. Casado","C. Mendiola","P. Achimas-Cadariu","C. Vlad","D. Reimer","A.G. Zeimet","M. Friedlander","J. Sehouli"],"twitterCount":3,"altmetricId":32701641},{"title":"Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously …","googleId":"MSJ5QK4RFF8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43122-0/abstract","googleCitationCount":10,"googleAuthor":"F Meric-Bernstam"},{"title":"Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it","googleId":"YoEFZIdJIZoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35074-4/abstract","googleCitationCount":14,"googleAuthor":"V Prasad"},{"title":"No association between circulating concentrations of vitamin D and risk of lung cancer: an analysis in 20 prospective studies in the Lung Cancer Cohort …","googleId":"I3HqJpuqZmQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934894X","googleCitationCount":12,"googleAuthor":"DC Muller","doi":"10.1093/annonc/mdy104","elsevierAuthor":"Muller D.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"7","altmetricAuthors":["D.C. Muller","A.M. Hodge","A. Fanidi","D. Albanes","X.M. Mai","X.O. Shu","S.J. Weinstein","T.L. Larose","X. Zhang","J. Han","M.J. Stampfer","S.A. Smith-Warner","J. Ma","J.M. Gaziano","H.D. Sesso","V.L. Stevens","M.L. McCullough","T.M. Layne","R. Prentice","M. Pettinger","C.A. Thomson","W. Zheng","Y.T. Gao","N. Rothman","Y.B. Xiang","H. Cai","R. Wang","J.M. Yuan","W.P. Koh","L.M. Butler","Q. Cai","W.J. Blot","J. Wu","P.M. Ueland","Ø. Midttun","A. Langhammer","K. Hveem","M. Johansson","J. Hultdin","K. Grankvist","A.A. Arslan","L. Le Marchand","G. Severi","M. Johansson","P. Brennan"],"twitterCount":48,"altmetricId":35139574},{"title":"Validation of a clinicopathological and gene expression profile (CP-GEP) model for sentinel lymph node metastasis in primary cutaneous melanoma","googleId":"lckIDNYs8wgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595357","googleCitationCount":7,"googleAuthor":"D Tempel","doi":"10.1093/annonc/mdz255.014","elsevierAuthor":"Grossman D.","publicationName":"JAMA Dermatology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"7","altmetricAuthors":[],"twitterCount":0},{"title":"Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer","googleId":"rXGjs_y8pU4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32638-9/abstract","googleCitationCount":15,"googleAuthor":""},{"title":"Statistical challenges posed by uncontrolled master protocols: sensitivity analysis of the vemurafenib study","googleId":"9Rbe3njT4QkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342449","googleCitationCount":8,"googleAuthor":"BP Hobbs","doi":"10.1093/annonc/mdy457","elsevierAuthor":"Hobbs B.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"5","altmetricAuthors":["B.P. Hobbs","M.J. Kane","D.S. Hong","R. Landin"],"twitterCount":2,"altmetricId":49913950},{"title":"Nivolumab in non-small-cell lung cancer with EGFR mutation","googleId":"CgfPpTQire8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35486-9/abstract","googleCitationCount":13,"googleAuthor":"YH Kim"},{"title":"Management of toxicity to isoform α-specific PI3K inhibitors","googleId":"9TTVrHvfHxAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420343763","googleCitationCount":12,"googleAuthor":"","doi":"10.1093/annonc/mdz440","elsevierAuthor":"Nunnery S.E.","publicationName":"Annals of oncology : official journal of the European Society for Medical Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"5","altmetricAuthors":["S.E. Nunnery","I.A. Mayer"],"twitterCount":15,"altmetricId":68916417},{"title":"Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers","googleId":"FQcv3-eYVm8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342115","googleCitationCount":10,"googleAuthor":"","doi":"10.1093/annonc/mdy338","elsevierAuthor":"Chen X.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"6","altmetricAuthors":["X. Chen","Y. Li","T. Ouyang","J. Li","T. Wang","Z. Fan","T. Fan","B. Lin","Y. Xie"],"twitterCount":8,"altmetricId":47169845},{"title":"Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up","googleId":"5BzUywwZaEgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49321-6/abstract","googleCitationCount":12,"googleAuthor":""},{"title":"Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) …","googleId":"aPKEGScWGv4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589372","googleCitationCount":5,"googleAuthor":"A Hollebecque","doi":"10.1093/annonc/mdz247.047","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma …","googleId":"l6JJo1kXZW4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588974","googleCitationCount":7,"googleAuthor":"T Meyer","doi":"10.1093/annonc/mdz247.006","elsevierAuthor":"Nault J.C.","publicationName":"Hepatology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"4","altmetricAuthors":[],"twitterCount":0},{"title":"FOxTROT: An international randomised controlled trial in 1053 patients evaluating neoadjuvant chemotherapy (NAC) for colon cancer. On behalf of the …","googleId":"k_cjYQxhFnYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587440","googleCitationCount":5,"googleAuthor":"D Morton","doi":"10.1093/annonc/mdz246.001","elsevierCitationCount":0,"altmetricAuthors":["D. Morton"],"twitterCount":0,"altmetricId":68179398},{"title":"Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer","googleId":"7JP9nIFlCLUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341171","googleCitationCount":9,"googleAuthor":"FR Hirsch","doi":"10.1093/annonc/mdy196","elsevierAuthor":"Bonomi P.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"6","altmetricAuthors":["P.D. Bonomi","D. Gandara","F.R. Hirsch","K.M. Kerr","C. Obasaju","L. Paz-Ares","C. Bellomo","J.D. Bradley","P.A. Bunn Jr","M. Culligan","J.R. Jett","E.S. Kim","C.J. Langer","R.B. Natale","S. Novello","M. Pérol","S.S. Ramalingam","M. Reck","C.H. Reynolds","E.F. Smit","M.A. Socinski","D.R. Spigel","J.F. Vansteenkiste","H. Wakelee","N. Thatcher"],"twitterCount":3,"altmetricId":43728956},{"title":"Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the …","googleId":"isw9la_ioCYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590597","googleCitationCount":9,"googleAuthor":"MR Smith","doi":"10.1093/annonc/mdz248","elsevierAuthor":"Vlachostergios P.J.","publicationName":"Prostate","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["M.R. Smith","F. Saad","S. Chowdhury","S. Oudard","B.A. Hadaschik","J.N. Graff","D. Olmos","P.N. Mainwaring","J.Y. Lee","H. Uemura","P. De Porre","A. Smith","K. Zhang","A. Lopez-Gitlitz","E.J. Small"],"twitterCount":0,"altmetricId":67711678},{"title":"Updated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or …","googleId":"xMKTts7-O1sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49123-0/abstract","googleCitationCount":11,"googleAuthor":"S Kondo"},{"title":"Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): the phase III ATTRACTION-3 study","googleId":"N0EdnZcrUSEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603881","googleCitationCount":7,"googleAuthor":"M Takahashi","doi":"10.1093/annonc/mdz394.028","elsevierCitationCount":0,"altmetricAuthors":["B.C. Cho","K. Kato","M. Takahashi","M. Okada","C.-Y. Lin","K. Chin","S. Kadowaki","M.-J. Ahn","Y. Hamamoto","Y. Doki","C.-C. Yen","Y. Kubota","S.-B. Kim","C.-H. Hsu","E. Holtved","I. Xynos","M. Kodani","Y. Kitagawa"],"twitterCount":0,"altmetricId":68179422},{"title":"Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and …","googleId":"gIQR-2j1Y6gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325588","googleCitationCount":10,"googleAuthor":"S Lonardi","doi":"10.1093/annonc/mdz403","elsevierAuthor":"Marmorino F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"7","altmetricAuthors":["F. Marmorino","D. Rossini","S. Lonardi","R. Moretto","G. Zucchelli","G. Aprile","E. Dell’Aquila","M. Ratti","F. Bergamo","G. Masi","F. Urbano","M. Ronzoni","M. Libertini","B. Borelli","G. Randon","A. Buonadonna","G. Allegrini","N. Pella","V. Ricci","A. Boccaccino","T.P. Latiano","S. Cordio","A. Passardi","E. Tamburini","L. Boni","A. Falcone","C. Cremolini"],"twitterCount":5,"altmetricId":67958321},{"title":"Association between depth of response and overall survival: exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) …","googleId":"l9k_1iz6fEoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591633","googleCitationCount":5,"googleAuthor":"TK Choueiri","doi":"10.1093/annonc/mdz249.046","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations","googleId":"2yPh6yh2ulIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30053-5/abstract","googleCitationCount":11,"googleAuthor":"DWT Lim"},{"title":"Making immunotherapy 'cold'tumours 'hot'by chemotherapy-induced mutations—a misconception","googleId":"P2_ewO_wzVsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31089-0/abstract","googleCitationCount":9,"googleAuthor":"T Helleday"},{"title":"Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer","googleId":"BJMq0Cpl0u0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341638","googleCitationCount":11,"googleAuthor":"JC Soria","doi":"10.1093/annonc/mdy242","elsevierAuthor":"Soria J.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"10","altmetricAuthors":["J.-C. Soria","S.N. Ho","M. Varella-Garcia","A.J. Iafrate","B.J. Solomon","A.T. Shaw","F. Blackhall","T.S. Mok","Y.-L. Wu","K. Pestova","K.D. Wilner","A. Polli","J. Paolini","S. Lanzalone","S. Green","D.R. Camidge"],"twitterCount":14,"altmetricId":45027879},{"title":"Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or …","googleId":"The5kMy8YSkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585301","googleCitationCount":6,"googleAuthor":"MA Colleoni","doi":"10.1093/annonc/mdz242.003","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II …","googleId":"VdNs2SrAoL8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581819","googleCitationCount":7,"googleAuthor":"JCH Yang","doi":"10.1093/annonc/mdz437.061","elsevierAuthor":"Johne A.","publicationName":"Investigational New Drugs","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"1 October 2020","elsevierCitationCount":"2","altmetricAuthors":[],"twitterCount":0},{"title":"A comparison of matched interim analysis publications and final analysis publications in oncology clinical trials","googleId":"GWZ3oyaCQh4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342346","googleCitationCount":8,"googleAuthor":"C Wayant","doi":"10.1093/annonc/mdy447","elsevierAuthor":"Wayant C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"5","altmetricAuthors":["C. Wayant","M. Vassar"],"twitterCount":6,"altmetricId":49668326},{"title":"Early-drug development in the era of immuno-oncology: are we ready to face the challenges?","googleId":"W-YwwoO5kkoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341390","googleCitationCount":9,"googleAuthor":"M Oliva","doi":"10.1093/annonc/mdy225","elsevierAuthor":"De Olza M.O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"0","altmetricAuthors":["M. Ochoa de Olza","M. Oliva","C. Hierro","I. Matos","J. Martin-Liberal","E. Garralda"],"twitterCount":3,"altmetricId":44204639},{"title":"A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC","googleId":"46Bv31sYuJEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959127X","googleCitationCount":5,"googleAuthor":"E Jonasch","doi":"10.1093/annonc/mdz249.010","elsevierCitationCount":0,"altmetricAuthors":["E. Jonasch","E.R. Plimack","T. Bauer","J.R. Merchan","K.P. Papadopoulos","D.F. McDermott","M.D. Michaelson","L.J. Appleman","S. Thamake","N. Zojwalla","T.K. Choueiri"],"twitterCount":0,"altmetricId":72883858},{"title":"Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a …","googleId":"mDKlvjyCsmgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934565X","googleCitationCount":10,"googleAuthor":"","doi":"10.1093/annonc/mdy113","elsevierAuthor":"Iacoboni G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"4","altmetricAuthors":["G. Iacoboni","E. Zucca","M. Ghielmini","A. Stathis"],"twitterCount":25,"altmetricId":35730251},{"title":"Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): results from the randomized …","googleId":"yR1dG1NTmbQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604333","googleCitationCount":7,"googleAuthor":""},{"title":"MONARCHplus: a phase III trial of abemaciclib plus nonsteroidal aromatase inhibitor (NSAI) or fulvestrant (F) for women with HR+/HER2-advanced breast …","googleId":"lkSmc2IP4c8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603741","googleCitationCount":6,"googleAuthor":"","doi":"10.1093/annonc/mdz394.014","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results","googleId":"-Jcm_XzhbzsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49908-0/abstract","googleCitationCount":9,"googleAuthor":"JS Lee"},{"title":"LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood …","googleId":"rphT06jAE5oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420345488","googleCitationCount":4,"googleAuthor":"RS Herbst","doi":"10.1093/annonc/mdz453","elsevierAuthor":"Remon J.","publicationName":"Translational Cancer Research","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"1 April 2020","elsevierCitationCount":"2","altmetricAuthors":[],"twitterCount":0},{"title":"Keynote-407 China extension study: pembrolizumab (pembro) plus chemotherapy in Chinese patients with metastatic squamous NSCLC","googleId":"Fe-OFza8cSYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582242","googleCitationCount":6,"googleAuthor":"","doi":"10.1093/annonc/mdz446.019","elsevierCitationCount":0,"altmetricAuthors":["Y. Cheng","L. Zhang","J. Hu","D. Wang","C. Hu","J. Zhou","L. Wu","L. Cao","J. Liu","H. Zhang","H. Sun","Z. Wang","H. Gao","J. Ge","H. Wang","Y. Tian","B. Piperdi","L. Paz-Ares"],"twitterCount":0,"altmetricId":71576429},{"title":"Phase III study of gefitinib (G) versus gefitinib+ carboplatin+ pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer …","googleId":"bU4S9l_diEsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49795-0/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer …","googleId":"6sYSgzh7bLMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344264","googleCitationCount":7,"googleAuthor":"A Drakaki","doi":"10.1093/annonc/mdz449.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"OpACIN-neo: a multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO)","googleId":"FbykJDO-4GwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50443-4/abstract","googleCitationCount":11,"googleAuthor":"CU Blank"},{"title":"The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma","googleId":"fOS_3nB9Y8sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350458","googleCitationCount":12,"googleAuthor":"F Bertucci","doi":"10.1093/annonc/mdx699","elsevierAuthor":"Bertucci F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"11","altmetricAuthors":["F. Bertucci","A. De Nonneville","P. Finetti","D. Perrot","M. Nilbert","A. Italiano","A. Le Cesne","K.M. Skubitz","J.Y. Blay","D. Birnbaum"],"twitterCount":13,"altmetricId":27885093},{"title":"Nivolumab plus low-dose IPILIMUMAB as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817","googleId":"ICPr6eSAdRUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344793","googleCitationCount":6,"googleAuthor":"","doi":"10.1093/annonc/mdz451.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) …","googleId":"YQKTst0WitMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50400-8/abstract","googleCitationCount":10,"googleAuthor":"M Cristofanilli"},{"title":"Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers","googleId":"uxWyi4nJSngJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594224","googleCitationCount":5,"googleAuthor":"","doi":"10.1093/annonc/mdz253.036","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer","googleId":"12cCb0AAurYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350082","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdx688","elsevierAuthor":"Overman M.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"0","altmetricAuthors":["M.J. Overman","L. Adam","K. Raghav","J. Wang","B. Kee","D. Fogelman","C. Eng","E. Vilar","R. Shroff","A. Dasari","R. Wolff","J. Morris","E. Karunasena","R. Pisanic","N. Azad","S. Kopetz"],"twitterCount":1,"altmetricId":27823714},{"title":"Redefining the IGCCCG classification in advanced non-seminoma","googleId":"snClG7sVDIwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591190","googleCitationCount":7,"googleAuthor":"G Daugaard","doi":"10.1093/annonc/mdz249.002","elsevierCitationCount":0,"altmetricAuthors":["S. Gillessen","L. Collette","G. Daugaard","R. de Wit","A. Tryakin","C. Albany","O. Stahl","K. Fizazi","J.A. Gietema","U.F.F. De Giorgi","A.R. Hansen","D. Feldman","F. Cafferty","T. Tandstad","X. Garcia del Muro","R.A. Huddart","C.J. Sweeney","D.Y.C. Heng","N. Sauve","J. Beyer"],"twitterCount":3,"altmetricId":80845509},{"title":"Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors","googleId":"EbBelKVZwlkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312086","googleCitationCount":8,"googleAuthor":"","doi":"10.1093/annonc/mdz120","elsevierAuthor":"Marcucci G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"4","altmetricAuthors":["G. Marcucci","G. Beltrami","A. Tamburini","J.J. Body","C.B. Confavreux","P. Hadji","G. Holzer","D. Kendler","N. Napoli","D.D. Pierroz","R. Rizzoli","M.L. Brandi"],"twitterCount":44,"altmetricId":60762353},{"title":"Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib+ fulvestrant: results from MONALEESA-3","googleId":"47mR_Vw6Yl4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48711-5/abstract","googleCitationCount":11,"googleAuthor":"FJ Esteva"},{"title":"Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses","googleId":"aGs7bdOwwdwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31080-4/abstract","googleCitationCount":8,"googleAuthor":"C Abbosh"},{"title":"First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma","googleId":"y8LzN8HfCPcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35522-X/abstract","googleCitationCount":11,"googleAuthor":"S Turajlic"},{"title":"First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B","googleId":"ZCyxD4-GM8wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959161X","googleCitationCount":7,"googleAuthor":"RA Gafanov","doi":"10.1093/annonc/mdz249.044","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001","googleId":"-tZuKFYzY_AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586987","googleCitationCount":5,"googleAuthor":"C Rolfo","doi":"10.1093/annonc/mdz244.038","elsevierAuthor":"Russo A.","publicationName":"Current Oncology Reports","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"6","altmetricAuthors":[],"twitterCount":0},{"title":"First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A","googleId":"1lFDicpHL2sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591621","googleCitationCount":5,"googleAuthor":"JMG Larkin","doi":"10.1093/annonc/mdz249.045","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid–inducible gene I (RIG-I) activator MK-4621 in patients with …","googleId":"gai3XoXpTL8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50407-0/abstract","googleCitationCount":11,"googleAuthor":"E Calvo"},{"title":"Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients","googleId":"bVK78XT20YIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419583338","googleCitationCount":6,"googleAuthor":"","doi":"10.1093/annonc/mdz239.013","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the …","googleId":"wrGX6_M83lEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49922-5/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data","googleId":"d7EHdWetjYsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49080-7/abstract","googleCitationCount":9,"googleAuthor":"YK Kang"},{"title":"The immune profile of small HER2-positive breast cancers: A secondary analysis from the APT trial","googleId":"EVWrH3BmzFwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311287","googleCitationCount":7,"googleAuthor":"R Barroso-Sousa","doi":"10.1093/annonc/mdz047","elsevierAuthor":"Barroso-Sousa R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-04-01","elsevierCoverDisplayDate":"April 2019","elsevierCitationCount":"4","altmetricAuthors":["R. Barroso-Sousa","W.T. Barry","H. Guo","D. Dillon","Y.B. Tan","K. Fuhrman","W. Osmani","A. Getz","M. Baltay","C. Dang","D. Yardley","B. Moy","P.K. Marcom","E.A. Mittendorf","I.E. Krop","E.P. Winer","S.M. Tolaney"],"twitterCount":17,"altmetricId":55174996},{"title":"Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced …","googleId":"2VaILcEkmnwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419602899","googleCitationCount":6,"googleAuthor":"RL Jones","doi":"10.1093/annonc/mdz283","elsevierAuthor":"Chen H.","publicationName":"Aging","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Next-generation immunotherapies for lymphoma: one foot in the future","googleId":"9dkmkb6RV1AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355243","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdy032","elsevierAuthor":"Manson G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"10","altmetricAuthors":["G. Manson","R. Houot"],"twitterCount":13,"altmetricId":32083075},{"title":"Updated data of epitopes-HPV02 trial and external validation of efficacy of DCF in prospective epitopes-HPV01 study in advanced anal squamous cell …","googleId":"RkiRlFEsgJUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587555","googleCitationCount":5,"googleAuthor":"S Kim","doi":"10.1093/annonc/mdz246.012","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics","googleId":"dpNkqauvhCoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31117-2/abstract","googleCitationCount":9,"googleAuthor":"H Hackl"},{"title":"Immunotherapy is not for all comers in chemotherapy-refractory advanced gastric cancer. Better predictive biomarkers are needed","googleId":"8VIe_zPSaEUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34204-8/abstract","googleCitationCount":9,"googleAuthor":"EC Smyth"},{"title":"Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head …","googleId":"qXp2ni0-4BcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49506-9/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced …","googleId":"DG3nr_4XfrsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49261-2/abstract","googleCitationCount":10,"googleAuthor":"N Agarwal"},{"title":"Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas","googleId":"yLfzu97XHLAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350690","googleCitationCount":11,"googleAuthor":"LI Gordon","doi":"10.1093/annonc/mdx768","elsevierAuthor":"Karmali R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"7","altmetricAuthors":["R. Karmali","E. Kimby","M. Ghielmini","I.W. Flinn","L.I. Gordon","E. Zucca"],"twitterCount":3,"altmetricId":30290850},{"title":"Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study","googleId":"aC4gGUBb4_cJ","googleLink":"https://vbn.aau.dk/ws/files/306929894/Six_cycles_of_R_CHOP_21_are_not_inferior_to_eight_cycles_for_treatment_of_diffuse_large_B_cell_lymphoma_A_Nordic_Lymphoma_Group_population_based_study.pdf","googleCitationCount":9,"googleAuthor":"JL Biccler","doi":"10.1093/annonc/mdy184","elsevierAuthor":"Wästerlid T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"4","altmetricAuthors":["T. Wästerlid","J.L. Biccler","P.N. Brown","M. Bøgsted","G. Enblad","J. Mészáros Jørgensen","J.H. Christensen","B.E. Wahlin","K.E. Smedby","T.C. El-Galaly","M. Jerkeman"],"twitterCount":2,"altmetricId":42382662},{"title":"Bevacizumab plus chemotherapy versus chemotherapy alone as first-line treatment for patients with RAS mutant unresectable colorectal liver-limited metastases: A …","googleId":"w0gnXY9HLy4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)60380-7/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder …","googleId":"2PulFdXf-o0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49584-7/abstract","googleCitationCount":10,"googleAuthor":"A Naing"},{"title":"Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results …","googleId":"95YtTGz5SEgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959665X","googleCitationCount":7,"googleAuthor":"S Peters","doi":"10.1093/annonc/mdz259","elsevierAuthor":"Geng Y.","publicationName":"Cancer Medicine","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["S. Peters","E. Felip","U. Dafni","A. Tufman","M. Guckenberger","A. Irigoyen","E. Nadal","A. Becker","H. Vees","M. Pless","A. Martinez-Marti","M. Lambrecht","N. Andratschke","Z. Tsourti","A.-C. Piguet","H. Roschitzki-Voser","M. Rabaglio-Poretti","R.A. Stahel","J.F. Vansteenkiste","D. De Ruysscher"],"twitterCount":0,"altmetricId":68179416},{"title":"MEDIOLA: a phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours–new ovarian cancer …","googleId":"YLPWSpAo1kwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48914-X/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"Quantitative lymph node burden as a 'very-high-risk'factor identifying head and neck cancer patients benefiting from postoperative chemoradiation","googleId":"Q1WS5orRUmcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309949","googleCitationCount":8,"googleAuthor":"ZS Zumsteg","doi":"10.1093/annonc/mdy490","elsevierAuthor":"Zumsteg Z.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"0","altmetricAuthors":["Z.S. Zumsteg","M. Luu","S. Kim","M. Tighiouart","A. Mita","K.S. Scher","D.J. Lu","S.L. Shiao","J. Mallen-St. Clair","A.S. Ho"],"twitterCount":1,"altmetricId":63984554},{"title":"Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials","googleId":"Z7lSCNBIwzYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50283-6/abstract","googleCitationCount":8,"googleAuthor":"M Mau-Sorensen"},{"title":"Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis","googleId":"3j03RdQHacEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31245-1/abstract","googleCitationCount":7,"googleAuthor":"M Rota"},{"title":"Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib …","googleId":"v-Niy_nMe2UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49084-4/abstract","googleCitationCount":12,"googleAuthor":"PR Galle"},{"title":"VELIA/GOG-3005: Integration of veliparib with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian …","googleId":"2ewGa1j8zuAJ","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/veliagog-3005-integration-of-veliparib-with-front-line-chemothera","googleCitationCount":7,"googleAuthor":"","doi":"10.1093/annonc/mdz394","elsevierAuthor":"Demartino P.C.","publicationName":"JAMA Internal Medicine","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["K. Fizazi","A. Maillard","N. Penel","G. Baciarello","D. Allouache","G. Daugaard","A. Van de Wouw","G. Soler","E. Vauleon","L. Chaigneau","R. Janssen","F. Losa Gaspa","R. Morales Barrera","C. Balana","D. Tosi","B. Chauffert","C.A. Schnabel","G. Martineau","S. Culine","I. Borget"],"twitterCount":1,"altmetricId":67579395},{"title":"Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)","googleId":"3UH3BEffnpMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49083-2/abstract","googleCitationCount":8,"googleAuthor":"TY Kim"},{"title":"Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple negative breast …","googleId":"K-dNdkkiFYYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585817","googleCitationCount":5,"googleAuthor":"C Denkert","doi":"10.1093/annonc/mdz242.054","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients","googleId":"dxWeF3qG5rUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32758-9/abstract","googleCitationCount":9,"googleAuthor":"K Homicsko"},{"title":"Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2 …","googleId":"EEfgpRzu7cUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959696X","googleCitationCount":6,"googleAuthor":"S Siena","doi":"10.1093/annonc/mdz260.010","elsevierAuthor":"Russo A.","publicationName":"Current Oncology Reports","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"6","altmetricAuthors":[],"twitterCount":0},{"title":"Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: results …","googleId":"GW-Lz2YKnqcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50434-3/abstract","googleCitationCount":8,"googleAuthor":"JA Ledermann"},{"title":"Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer","googleId":"fZM3KUUnHG0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49027-3/abstract","googleCitationCount":9,"googleAuthor":"S Takahashi"},{"title":"CARRIE: A randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and …","googleId":"7awphYJB_DUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50422-7/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease","googleId":"Cd8LHiDHBBkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341389","googleCitationCount":10,"googleAuthor":"A Kamoun","doi":"10.1093/annonc/mdy224","elsevierAuthor":"Kamoun A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"10","altmetricAuthors":["A. Kamoun","G. Cancel-Tassin","G. Fromont","N. Elarouci","L. Armenoult","M. Ayadi","J. Irani","X. Leroy","A. Villers","G. Fournier","L. Doucet","S. Boyault","L. Brureau","L. Multigner","A. Diedhiou","M. Roupret","E. Compérat","P. Blanchet","A. de Reyniès","O. Cussenot"],"twitterCount":36,"altmetricId":44204653},{"title":"Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L) 1","googleId":"Iv32EbsCZC8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49598-7/abstract","googleCitationCount":8,"googleAuthor":"S Champiat"},{"title":"Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results …","googleId":"YMmdJZltyYkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593310","googleCitationCount":7,"googleAuthor":"D Rischin","doi":"10.1093/annonc/mdz252.011","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Genetic landscape of ultra-stable chronic lymphocytic leukemia patients","googleId":"LiLrQuW9ZC4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454677","googleCitationCount":10,"googleAuthor":"J Wang","doi":"10.1093/annonc/mdy021","elsevierAuthor":"Raponi S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"10","altmetricAuthors":["S. Raponi","I. Del Giudice","M. Marinelli","J. Wang","L. Cafforio","C. Ilari","A. Piciocchi","M. Messina","S. Bonina","S. Tavolaro","M. Bordyuh","P. Mariglia","N. Peragine","F.R. Mauro","S. Chiaretti","S. Molica","M. Gentile","A. Visentin","L. Trentin","G.M. Rigolin","A. Cuneo","F. Diop","D. Rossi","G. Gaidano","A. Guarini","R. Rabadan","R. Foà"],"twitterCount":4,"altmetricId":32083070},{"title":"Pembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second …","googleId":"EABTlbOmLvcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589761","googleCitationCount":5,"googleAuthor":"","doi":"10.1093/annonc/mdz247.086","elsevierCitationCount":0,"altmetricAuthors":["J. Chen","S. Luo","S. Qin","Y. Cheng","Z. Li","Y. Fan","X. Yuan","W. Li","Y. Sun","X. Yin","X. Lin","Y. Bai","T. Liu","J. Zhang","Y. Cui","P. Bhagia","S.P. Kang","W. Lu","Y. Zhou","L. Shen"],"twitterCount":0,"altmetricId":68179429},{"title":"A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL","googleId":"QE0S46-Aj7UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589669","googleCitationCount":7,"googleAuthor":"DJ Pinato","doi":"10.1093/annonc/mdz247.076","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Chemotherapy in localized soft tissue sarcoma: will we soon have to treat grade 1 tumors? Update on CINSARC performances","googleId":"cIUIuJvEg3UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30982-2/abstract","googleCitationCount":8,"googleAuthor":"T Valentin"},{"title":"Cancer mortality and predictions for 2018 in selected Australasian countries and Russia","googleId":"dvPl-t3kVGYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309937","googleCitationCount":5,"googleAuthor":"M Malvezzi","doi":"10.1093/annonc/mdy489","elsevierAuthor":"Carioli G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"5","altmetricAuthors":["G. Carioli","M. Malvezzi","P. Bertuccio","F. Levi","P. Boffetta","E. Negri","C. La Vecchia"],"twitterCount":8,"altmetricId":52481649},{"title":"Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: a multicenter open label phase II trial (NVALT19)","googleId":"_LTLTO-_LPQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604527","googleCitationCount":5,"googleAuthor":"R Cornelissen","doi":"10.1093/annonc/mdz394.092","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors","googleId":"_HQWIYeHDY8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49611-7/abstract","googleCitationCount":8,"googleAuthor":"CS Denlinger"},{"title":"Comparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC)","googleId":"uG702wmLxQkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30282-0/abstract","googleCitationCount":11,"googleAuthor":""},{"title":"Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a …","googleId":"OoQCIphKtwsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604278","googleCitationCount":5,"googleAuthor":"","doi":"10.1093/annonc/mdz394.067","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop","googleId":"Emp4rT3XMzQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31251-7/abstract","googleCitationCount":5,"googleAuthor":"AMM Eggermont"},{"title":"Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy","googleId":"1cOysXW6k6IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50437-9/abstract","googleCitationCount":10,"googleAuthor":"H Mehanna"},{"title":"Phase I study of gefitinib (G)+ durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR …","googleId":"wj4LaT7SnicJ","googleLink":"https://mdanderson.elsevierpure.com/en/publications/phase-i-study-of-gefitinib-g-durvalumab-d-for-locally-advancedmet","googleCitationCount":6,"googleAuthor":"SW Kim","doi":"10.1093/annonc/mdz067.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st-and 2nd-line treatment of unresectable mCRC","googleId":"MYOX_PG4AKsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30960-3/abstract","googleCitationCount":7,"googleAuthor":"S Lonardi"},{"title":"Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma","googleId":"JmMefyRg44YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591840","googleCitationCount":4,"googleAuthor":"MM Regan","doi":"10.1093/annonc/mdz249.067","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumours","googleId":"8DHg7aJj4n4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594157","googleCitationCount":4,"googleAuthor":"C Massard","doi":"10.1093/annonc/mdz253.029","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo)+ nab-paclitaxel (nab-P) vs placebo+ nab-P in treatment-naive …","googleId":"4GqWk8juhtMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50399-4/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"MSR1 repeats modulate gene expression and affect risk of breast and prostate cancer","googleId":"Qn5RhGQtpkcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345478","googleCitationCount":9,"googleAuthor":"","doi":"10.1093/annonc/mdy082","elsevierAuthor":"Rose A.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"6","altmetricAuthors":["A.M. Rose","A. Krishan","C.F. Chakarova","L. Moya","S.K. Chambers","M. Hollands","J.C. Illingworth","S.M.G. Williams","H.E. McCabe","A.Z. Shah","C.N.A. Palmer","A. Chakravarti","J.N. Berg","J. Batra","S.S. Bhattacharya"],"twitterCount":34,"altmetricId":33842672},{"title":"PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P)+ trastuzumab (T) with or without chemotherapy both followed by T-DM1 in …","googleId":"CqDBCIlOHewJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48709-7/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO …","googleId":"UV1SvNxckN4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341262","googleCitationCount":8,"googleAuthor":"E Fokas","doi":"10.1093/annonc/mdy205","elsevierAuthor":"Hofheinz R.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"5","altmetricAuthors":["R.-D. Hofheinz","D. Arnold","E. Fokas","M. Kaufmann","T. Hothorn","G. Folprecht","R. Fietkau","W. Hohenberger","M. Ghadimi","T. Liersch","G.G. Grabenbauer","R. Sauer","C. Rödel","U. Graeven"],"twitterCount":13,"altmetricId":43450244},{"title":"Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an …","googleId":"5bgptQfyjK8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345363","googleCitationCount":9,"googleAuthor":"I Bondarenko","doi":"10.1093/annonc/mdy063","elsevierAuthor":"Martin M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"5","altmetricAuthors":["M. Martin","M. Campone","I. Bondarenko","D. Sakaeva","S. Krishnamurthy","L. Roman","L. Lebedeva","J.-C. Vedovato","M. Aapro"],"twitterCount":11,"altmetricId":33152865},{"title":"Docetaxel for hormone-naïve prostate cancer (PCa): Results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial","googleId":"46_DHhXzPr0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590688","googleCitationCount":4,"googleAuthor":"ND James","doi":"10.1093/annonc/mdz248.008a","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma","googleId":"qfBg97Wo8Q8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419600323","googleCitationCount":4,"googleAuthor":"C Borg","doi":"10.1093/annonc/mdz268.030","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma","googleId":"NBQeKINiMXQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459899","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz198","elsevierAuthor":"Mayer E.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"4","altmetricAuthors":["E.L. Mayer","A. DeMichele","H.S. Rugo","K. Miller","A.G. Waks","S.E. Come","T. Mulvey","R. Jeselsohn","B. Overmoyer","H. Guo","W.T. Barry","C. Huang Bartlett","M. Koehler","E.P. Winer","H.J. Burstein"],"twitterCount":47,"altmetricId":62879509},{"title":"A multi-center phase IIA trial to assess the safety and efficacy of BL-8040 (a CXCR4 inhibitor) in combination with pembrolizumab and chemotherapy in …","googleId":"WxMK8lvpk1MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344781","googleCitationCount":5,"googleAuthor":"M Hidalgo","doi":"10.1093/annonc/mdz451","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Activity of EGFR antibody in non-V600 BRAF mutant metastatic colorectal cancer","googleId":"CTBYx5KxG54J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30991-3/abstract","googleCitationCount":8,"googleAuthor":"Y Wang"},{"title":"HER2: Defining a Neu target in non-small-cell lung cancer","googleId":"qxVMKBjHj2EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31096-8/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian …","googleId":"lpARJ9VcD0kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960414X","googleCitationCount":5,"googleAuthor":"E Swisher","doi":"10.1093/annonc/mdz394.054","elsevierAuthor":"Henriksen J.R.","publicationName":"Journal of Ovarian Research","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1","altmetricAuthors":["R.L. Coleman","G.F. Fleming","M.F. Brady","E. Swisher","K.D. Steffensen","M. Friedlander","A. Okamoto","K. Moore","N. Ben-Baruch","T.L. Werner","A. Oaknin","J.-H. Nam","C.A. Leath","S. Nicum","D. Cella","D.M. Sullivan","P.J. Ansell","M. Dinh","C. Aghajanian","M.A. Bookman"],"twitterCount":0,"altmetricId":68846535},{"title":"Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia","googleId":"fhEJJB4kmLMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355218","googleCitationCount":9,"googleAuthor":"","doi":"10.1093/annonc/mdy019","elsevierAuthor":"Khoury H.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"8","altmetricAuthors":["H.J. Khoury","C. Gambacorti-Passerini","T.H. Brümmendorf"],"twitterCount":10,"altmetricId":32327211},{"title":"Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment","googleId":"kanofeyHxO4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311135","googleCitationCount":5,"googleAuthor":"","doi":"10.1093/annonc/mdz017","elsevierAuthor":"Weibring K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-04-01","elsevierCoverDisplayDate":"April 2019","elsevierCitationCount":"1","altmetricAuthors":["K. Weibring","C. Nord","O. Ståhl","J. Eberhard","K. Sandberg","H. Johansson","S. Arver","A. Giwercman","G. Cohn-Cedermark"],"twitterCount":28,"altmetricId":56011586},{"title":"First report of AURORA, the Breast International Group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts)","googleId":"6wd0BT809esJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30420-X/abstract","googleCitationCount":6,"googleAuthor":"F Hilbers"},{"title":"Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib","googleId":"Z7FK_hRE6tAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43119-0/abstract","googleCitationCount":7,"googleAuthor":"C Barone"},{"title":"Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy","googleId":"HqdEDhcKhH8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350677","googleCitationCount":9,"googleAuthor":"P Boffetta","doi":"10.1093/annonc/mdx762","elsevierAuthor":"Boffetta P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"0","altmetricAuthors":["P. Boffetta","L. Righi","C. Ciocan","C. Pelucchi","C. La Vecchia","C. Romano","M. Papotti","E. Pira"],"twitterCount":1,"altmetricId":29979868},{"title":"Efficacy and safety of nintedanib+ docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated …","googleId":"xu0f8S430HYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597125","googleCitationCount":6,"googleAuthor":"S Haas","doi":"10.1093/annonc/mdz260.027","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib …","googleId":"_VChNlQP92gJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34063-3/abstract","googleCitationCount":10,"googleAuthor":"P Galle"},{"title":"Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus …","googleId":"1GV9Brp-_yAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590998","googleCitationCount":5,"googleAuthor":"KN Chi","doi":"10.1093/annonc/mdz248.040","elsevierAuthor":"Merseburger A.S.","publicationName":"Aktuelle Urologie","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus …","googleId":"1GV9Brp-_yAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590998","googleCitationCount":5,"googleAuthor":"KN Chi","doi":"10.1093/annonc/mdz248.040","elsevierAuthor":"Merseburger A.S.","publicationName":"Aktuelle Urologie","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial","googleId":"zM44t18gR_sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49393-9/abstract","googleCitationCount":7,"googleAuthor":"IL Ray-Coquard"},{"title":"Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study","googleId":"7sVWQyyh4c0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43457-1/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"The landscape of NTRK fusions in Chinese patients with solid tumor","googleId":"sRlNzIBDgwoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48501-3/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Characterization of response to nivolumab plus ipilimumab (N+ I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc) …","googleId":"e7iXe_XL5M0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49264-8/abstract","googleCitationCount":10,"googleAuthor":"BI Rini"},{"title":"Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on …","googleId":"IJmeWtf8n5UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419309895","googleCitationCount":6,"googleAuthor":"A Matikas","doi":"10.1093/annonc/mdy475","elsevierAuthor":"Matikas A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"1 January 2019","elsevierCitationCount":"6","altmetricAuthors":["A. Matikas","T. Foukakis","V. Moebus","R. Greil","N. -O. Bengtsson","G.G. Steger","M. Untch","H. Johansson","M. Hellström","P. Malmström","M. Gnant","S. Loibl","J. Bergh"],"twitterCount":2,"altmetricId":50255927},{"title":"Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy …","googleId":"9Lx0s8HabOQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30262-5/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the …","googleId":"_2RJZjMbiYsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589700","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz247.080","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study","googleId":"22cY5a_u7iwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604291","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz394.069","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally …","googleId":"sgwxApH68sUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310786","googleCitationCount":6,"googleAuthor":"K Hutcheson","doi":"10.1093/annonc/mdy549","elsevierAuthor":"Haddad R.I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"4","altmetricAuthors":[],"twitterCount":0},{"title":"ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk'patients","googleId":"MiGZJQS89bAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341067","googleCitationCount":7,"googleAuthor":"M Hutchings","doi":"10.1093/annonc/mdy167","elsevierAuthor":"Hutchings M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"5","altmetricAuthors":["M. Hutchings","M. Ladetto","C. Buske","P. de Nully Brown","A.J.M. Ferreri","M. Pfreundschuh","N. Schmitz","A. Sureda Balari","G. van Imhoff","J. Walewski"],"twitterCount":38,"altmetricId":43889263},{"title":"Early detection of pancreatic ductal adenocarcinoma using methylation signatures in circulating tumour DNA","googleId":"mUSHNspINhkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589049","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz247.013","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Initial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer","googleId":"XZfS_yDtzlYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48878-9/abstract","googleCitationCount":9,"googleAuthor":"M Voskoboynik"},{"title":"Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic …","googleId":"pBA4_G-SPE4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49507-0/abstract","googleCitationCount":8,"googleAuthor":"EEW Cohen"},{"title":"Exaggeration of PFS by blinded, independent, central review (BICR)","googleId":"OrG4tubPNTsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310269","googleCitationCount":6,"googleAuthor":"V Gebski","doi":"10.1093/annonc/mdy514","elsevierAuthor":"Stone A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"5","altmetricAuthors":["A. Stone","V. Gebski","R. Davidson","R. Bloomfield","J.W. Bartlett","A. Sabin"],"twitterCount":19,"altmetricId":51615515},{"title":"Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients …","googleId":"cOXfWgY_1T0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604229","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz394.062","elsevierAuthor":"Walker A.J.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":["J. Bourhis","X. Sun","Y. Pointreau","C. Sire","C. Le Tourneau","A. Coutte","M.-C. Kaminsky-Forrett","M. Alfonsi","P. Boisselier","L. Martin","J.-P. Delord","F. Clatot","J. Miroir","F. Rolland","P. Crompton","S. Brienza","S.A. Szyldergemajn","C. Even","Y. Tao"],"twitterCount":0,"altmetricId":68179410},{"title":"Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer","googleId":"s_qbrsj3-BQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355139","googleCitationCount":8,"googleAuthor":"F Khosrow-Khavar","doi":"10.1093/annonc/mdx822","elsevierAuthor":"Khosrow-Khavar F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"5","altmetricAuthors":["F. Khosrow-Khavar","H. Yin","A. Barkun","N. Bouganim","L. Azoulay"],"twitterCount":1,"altmetricId":31204468},{"title":"Frequency and clinicopathological characteristics of biliary tract carcinomas harboring the FGFR2-fusion gene: a prospective observational study (PRELUDE …","googleId":"ac0K3DdcUUcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589402","googleCitationCount":5,"googleAuthor":"A Naganuma","doi":"10.1093/annonc/mdz247.050","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Development and analytical validation of a plasma-based tumor mutational burden (TMB) score from next-generation sequencing panels","googleId":"97OmJZUbU38J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48557-8/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS)","googleId":"Gg0zJkQzSaoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49288-0/abstract","googleCitationCount":8,"googleAuthor":"I Duran"},{"title":"Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular …","googleId":"NL7MyRiTDTIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30530-7/abstract","googleCitationCount":5,"googleAuthor":"R Miksad"},{"title":"Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L) 1 targeting monoclonal antibodies","googleId":"rk7Uk4nTELAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30106-1/abstract","googleCitationCount":8,"googleAuthor":"LA Mauti"},{"title":"Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours","googleId":"fxCno9y9_nQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594364","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz253.050","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2","googleId":"OShqCjpI3AEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603777","googleCitationCount":5,"googleAuthor":"RC Doebele","doi":"10.1093/annonc/mdz394.017","elsevierAuthor":"Russo A.","publicationName":"Current Oncology Reports","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"6","altmetricAuthors":[],"twitterCount":0},{"title":"Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240","googleId":"MqbuC3LLxu0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30535-6/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA","googleId":"-Gqh8RNS8v0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604436","googleCitationCount":4,"googleAuthor":"N Peled","doi":"10.1093/annonc/mdz394.083","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants","googleId":"rg4aRYHymYIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312050","googleCitationCount":4,"googleAuthor":"TP Mourikis","doi":"10.1093/annonc/mdz112","elsevierAuthor":"Marra A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"1","altmetricAuthors":["M. Messaoudene","T.P. Mourikis","J. Michels","Y. Fu","M. Bonvalet","M. Lacroix-Trikki","B. Routy","A. Fluckiger","S. Rusakiewicz","M.P. Roberti","S. Cotteret","C. Flament","V. Poirier-Colame","N. Jacquelot","F. Ghiringhelli","A. Caignard","A.M.M. Eggermont","G. Kroemer","A. Marabelle","M. Arnedos","C. Vicier","S. Dogan","F. Jaulin","S -J Sammut","W. Cope","C. Caldas","S. Delaloge","N. McGranahan","F. André","L. Zitvogel"],"twitterCount":24,"altmetricId":58642604},{"title":"Breaking avelumab resistance with combined ipilimumab and nivolumab in metastatic Merkel cell carcinoma?","googleId":"ZzWJpOxPQq4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)60974-9/abstract","googleCitationCount":4,"googleAuthor":"M Goebeler"},{"title":"Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells","googleId":"sy8X2EDvFd8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32102-7/abstract","googleCitationCount":9,"googleAuthor":"C Reduzzi"},{"title":"BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with …","googleId":"EoK116VmAIQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604151","googleCitationCount":5,"googleAuthor":"N Colombo","doi":"10.1093/annonc/mdz394.055","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study","googleId":"Ke1NtfewcV0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311639","googleCitationCount":8,"googleAuthor":"","doi":"10.1093/annonc/mdz074","elsevierAuthor":"Joly F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-05-01","elsevierCoverDisplayDate":"May 2019","elsevierCitationCount":"6","altmetricAuthors":["F. Joly","D. Ahmed-Lecheheb","E. Kalbacher","N. Heutte","B. Clarisse","J.M. Grellard","F. Gernier","D. Berton-Rigaud","O. Tredan","M. Fabbro","A.M. Savoye","J.E. Kurtz","J. Alexandre","P. Follana","V. Delecroix","N. Dohollou","C. Roemer-Becuwe","G. De Rauglaudre","A. Lortholary","K. Prulhiere","A. Lesoin","A. Zannetti","S. N’Guyen","S. Trager-Maury","L. Chauvenet","S. Abadie Lacourtoisie","A. Gompel","C. Lhommé","A. Floquet","P. Pautier"],"twitterCount":13,"altmetricId":56910071},{"title":"Methylation in cell-free DNA for early cancer detection","googleId":"qTUhgCxAneQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34910-5/abstract","googleCitationCount":11,"googleAuthor":"FF de la Cruz"},{"title":"Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)","googleId":"wbzaTQ0J9fIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34064-5/abstract","googleCitationCount":10,"googleAuthor":"K Shitara"},{"title":"Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting …","googleId":"-dvwUuBFYzkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49104-7/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumour (TGCT): characterization of hepatic adverse reactions (ARs)","googleId":"qsIQCAhT4lwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603182","googleCitationCount":3,"googleAuthor":"H Gelderblom","doi":"10.1093/annonc/mdz283.029","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Phase II study of pembrolizumab with enzalutamide (Enz) in metastatic, castration-resistant prostate cancer (mCRPC): 30 patient expansion with examination …","googleId":"PknI-lUseN8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590640","googleCitationCount":4,"googleAuthor":"JN Graff","doi":"10.1093/annonc/mdz248.005","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small …","googleId":"ofX1tZ97urAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419580383","googleCitationCount":3,"googleAuthor":"V Subbiah","doi":"10.1093/annonc/mdz431","elsevierAuthor":"Harada G.","publicationName":"Current Treatment Options in Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"2","altmetricAuthors":[],"twitterCount":0},{"title":"CHLOROBRAIN phase IB trial: The addition of chloroquine, an autophagy inhibitor, to concurrent radiation and temozolomide for newly diagnosed …","googleId":"KbMqFzUSgjQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586471","googleCitationCount":4,"googleAuthor":"I Compter","doi":"10.1093/annonc/mdz243.035","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Genomic characteristics and predicted ancestry of NTRK1/2/3 and ROS1 fusion-positive tumours from> 165,000 pan-solid tumours","googleId":"c1ST_xKjQ24J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586653","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz244.005","elsevierAuthor":"Russo A.","publicationName":"Current Oncology Reports","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"6","altmetricAuthors":[],"twitterCount":0},{"title":"Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC","googleId":"reiw4tDd1lQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45491-4/abstract","googleCitationCount":8,"googleAuthor":"IV Bempt"},{"title":"Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors","googleId":"_NHHrFpPaNcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50440-9/abstract","googleCitationCount":7,"googleAuthor":"IM Rodas"},{"title":"Prognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: A systematic review and meta-analysis","googleId":"bvqTgtGDQVIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419583211","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz239","elsevierCitationCount":0,"altmetricAuthors":["M.G. McNamara","T. Jacobs","M. Frizziero","R. Pihlak","A. Lamarca","R. Hubner","J.W. Valle","E. Amir"],"twitterCount":2,"altmetricId":67616759},{"title":"Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial","googleId":"ksZUTftglUAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589712","googleCitationCount":5,"googleAuthor":"","doi":"10.1093/annonc/mdz247.081","elsevierAuthor":"Zhang C.H.","publicationName":"Current Gene Therapy","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0},{"title":"On the right TRK: from oncogene discovery to cancer therapeutics","googleId":"KewhpccVYiYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)55115-8/abstract","googleCitationCount":3,"googleAuthor":"M Barbacid"},{"title":"Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)","googleId":"pkplFhe9OFUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49325-3/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)","googleId":"moTCul8Dd6YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30118-8/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or …","googleId":"3EFTLs8XT2AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591281","googleCitationCount":3,"googleAuthor":"TK Choueiri","doi":"10.1093/annonc/mdz249.011","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells","googleId":"YQuQ0fI90WUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594388","googleCitationCount":5,"googleAuthor":"","doi":"10.1093/annonc/mdz253.052","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Radiomics to predict response to immunotherapy, bridging the gap from proof of concept to clinical applicability?","googleId":"MZjlnOnzhZQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31212-8/abstract","googleCitationCount":4,"googleAuthor":"N Paragios"},{"title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer …","googleId":"exBE5CKpzxsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43120-7/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with …","googleId":"E6Vk8Gjv91YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593462","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz252.026","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach","googleId":"hByNxCw893MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43057-3/abstract","googleCitationCount":6,"googleAuthor":"DSW Tan"},{"title":"Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations","googleId":"FFHoMYpLHiQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49793-7/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (PTS) with …","googleId":"ILa2QrTyCNYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49701-9/abstract","googleCitationCount":7,"googleAuthor":"H Gogas"},{"title":"Improved survival in metastatic germ-cell cancer","googleId":"WoZ4C1ZU4N0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350574","googleCitationCount":8,"googleAuthor":"J Beyer","doi":"10.1093/annonc/mdx741","elsevierAuthor":"Fankhauser C.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"5","altmetricAuthors":[],"twitterCount":0},{"title":"Prospective, multicenter registry trial to evaluate the clinical feasibility of targeted axillary dissection (TAD) in patients (pts) with breast cancer (BC) and core …","googleId":"-X1aZfiz550J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584034","googleCitationCount":4,"googleAuthor":"M Reinisch","doi":"10.1093/annonc/mdz240.003","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus …","googleId":"1N9RO0A0CC4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311688","googleCitationCount":10,"googleAuthor":"","doi":"10.1093/annonc/mdz082","elsevierAuthor":"Santos C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-05-01","elsevierCoverDisplayDate":"May 2019","elsevierCitationCount":"6","altmetricAuthors":["C. Santos","D. Azuara","J.M. Viéitez","D. Páez","E. Falcó","E. Élez","C. López-López","M. Valladares","L. Robles-Díaz","P. García-Alfonso","C. Bugés","G. Durán","A. Salud","V. Navarro","G. Capellá","E. Aranda","R. Salazar"],"twitterCount":7,"altmetricId":56699914},{"title":"A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC …","googleId":"Axnebzzsj1oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49405-2/abstract","googleCitationCount":7,"googleAuthor":"RE O'Cearbhaill"},{"title":"Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project","googleId":"L1EumcapPtQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349877","googleCitationCount":9,"googleAuthor":"U Dafni","doi":"10.1093/annonc/mdx629","elsevierAuthor":"Kerr K.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"7","altmetricAuthors":["K.M. Kerr","U. Dafni","K. Schulze","E. Thunnissen","L. Bubendorf","H. Hager","S. Finn","W. Biernat","L. Vliegen","J.H. Losa","A. Marchetti","R. Cheney","A. Warth","E.-J. Speel","F. Blackhall","K. Monkhorst","E. Jantus Lewintre","V. Tischler","C. Clark","J. Bertran-Alamillo","P. Meldgaard","K. Gately","A. Wrona","P. Vandenberghe","E. Felip","G. De Luca","S. Savic","T. Muley","E.F. Smit","A.-M.C. Dingemans","L. Priest","P. Baas","C. Camps","W. Weder","V. Polydoropoulou","T.R. Geiger","R. Kammler","T. Sumiyoshi","M.A. Molina","D.S. Shames","R.A. Stahel","S. Peters"],"twitterCount":6,"altmetricId":29482446},{"title":"Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer …","googleId":"fSY7723lzXIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590652","googleCitationCount":5,"googleAuthor":"JR Osborne","doi":"10.1093/annonc/mdz248.006","elsevierAuthor":"Vlachostergios P.J.","publicationName":"Prostate","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Novel polyurea/polyurethane nanocapsules loaded with a tambjamine analog to improve cancer chemotherapy delivery and safety in lung cancer","googleId":"hW8cYuGDlp0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960089X","googleCitationCount":3,"googleAuthor":"A Arias","doi":"10.1093/annonc/mdz268.088","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)","googleId":"yo2UfzeWQ9QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49164-3/abstract","googleCitationCount":7,"googleAuthor":"T Meyer"},{"title":"Dissociated responses in patients with metastatic solid tumours treated with immunotherapy","googleId":"frcdHFz2Zz4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594935","googleCitationCount":4,"googleAuthor":"X Paoletti","doi":"10.1093/annonc/mdz253.107","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)","googleId":"yJASw6h6rkIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596673","googleCitationCount":4,"googleAuthor":"J Naidoo","doi":"10.1093/annonc/mdz259.002","elsevierAuthor":"Geng Y.","publicationName":"Cancer Medicine","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with …","googleId":"12CcdXNKCfcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49396-4/abstract","googleCitationCount":7,"googleAuthor":"V Moreno"},{"title":"High eosinophils lymphocyte ratio (ELR) related with subtype of breast cancer in Sanglah General Hospital, Bali","googleId":"oaHWuhNvDssJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43014-7/abstract","googleCitationCount":6,"googleAuthor":"AAW Lestari"},{"title":"Identification of a novel crizotinib-sensitive MET–ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing","googleId":"DGLcXY6_vVIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34242-5/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"TiNivo: tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC): final results","googleId":"IN2ZAma8EnMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591608","googleCitationCount":4,"googleAuthor":"S Negrier","doi":"10.1093/annonc/mdz249.043","elsevierCitationCount":0,"altmetricAuthors":["P. Barthelemy","B. Escudier","S. Negrier","A. Ravaud","M.N. Needle","L. Albiges"],"twitterCount":0,"altmetricId":76294921},{"title":"Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study …","googleId":"qggBJD9a4wwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312852","googleCitationCount":5,"googleAuthor":"","doi":"10.1093/annonc/mdz168","elsevierAuthor":"Borchmann S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"6","altmetricAuthors":["S. Borchmann","H. Müller","I. Hude","M. Fuchs","P. Borchmann","A. Engert"],"twitterCount":19,"altmetricId":61173998},{"title":"High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: First results of the AcSé pembrolizumab study","googleId":"3e62PtuMWVoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594820","googleCitationCount":3,"googleAuthor":"JY Blay","doi":"10.1093/annonc/mdz253.096","elsevierCitationCount":0,"altmetricAuthors":["J.-Y. Blay","N. Penel","I.L. Ray-Coquard","R. Schott","E. Saada-Bouzid","F. Bertucci","C.M. Chevreau","E. Bompas","E. Coquan","S. Cousin","P. Soulié","A. Le Cesne","O. Mir","T. Ryckewaert","M. Brahmi","N. Hoog-Labouret","D. Couch","S. Chevret","J.-C. Soria","C. Massard"],"twitterCount":0,"altmetricId":92074547},{"title":"Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study","googleId":"4RgfXXB91GsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344343","googleCitationCount":3,"googleAuthor":"A Cortellini","doi":"10.1093/annonc/mdz449.009","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)","googleId":"wa-NvtqVoAgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30018-3/abstract","googleCitationCount":8,"googleAuthor":"A Hollebecque"},{"title":"Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (PTS)","googleId":"mp9K3_U8oL0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49271-5/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Efficacy and safety of first-line durvalumab (D)±tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m …","googleId":"b8LcIsIcr9wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30261-3/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Therapeutic drug monitoring of oral anticancer drugs-preliminary results of a prospective study","googleId":"W5k8d2UdlDQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586641","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz244.004","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer …","googleId":"x9yg4o0qsQ4J","googleLink":"https://www.researchgate.net/profile/Arun_Azad/publication/328455745_792OA_randomized_phase_II_study_of_cabazitaxel_CAB_vs_ABI_abiraterone_or_ENZ_enzalutamide_in_poor_prognosis_metastatic_castration-resistant_prostate_cancer_mCRPC/links/5bdad964299bf1124fb20b99/792OA-randomized-phase-II-study-of-cabazitaxel-CAB-vs-ABI-abiraterone-or-ENZ-enzalutamide-in-poor-prognosis-metastatic-castration-resistant-prostate-cancer-mCRPC.pdf","googleCitationCount":7,"googleAuthor":"KN Chi"},{"title":"Patients and physicians' satisfaction with telemedicine (TM) in cancer care and factors that correlate with a positive patient's experience","googleId":"n5PdAVekb4sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599239","googleCitationCount":4,"googleAuthor":"T Abbas","doi":"10.1093/annonc/mdz265.037","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA)","googleId":"AOWi8m4UCv8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30515-0/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma …","googleId":"HLmNZ2rYVtwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341955116X","googleCitationCount":5,"googleAuthor":"","doi":"10.1093/annonc/mdz382","elsevierAuthor":"Bielack S.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"1 November 2019","elsevierCitationCount":"4","altmetricAuthors":[],"twitterCount":0},{"title":"Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation …","googleId":"2KintmRMi6cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50432-X/abstract","googleCitationCount":7,"googleAuthor":"N Colombo"},{"title":"Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors","googleId":"N-DJLkVNhUMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35046-X/abstract","googleCitationCount":10,"googleAuthor":"JM Michot"},{"title":"CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): A …","googleId":"hVhx1z_lOTcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50449-5/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"Understanding patterns of pathologic response following neoadjuvant immunotherapy for solid tumors","googleId":"wZRwMlqwP8EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34141-9/abstract","googleCitationCount":7,"googleAuthor":"LM Sholl"},{"title":"Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell …","googleId":"uPWZfFwn83gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593991","googleCitationCount":4,"googleAuthor":"V Makker","doi":"10.1093/annonc/mdz253.013","elsevierCitationCount":0,"altmetricAuthors":["C.-H. Lee","A.Y. Shah","V. Makker","M.H. Taylor","D. Shaffer","J.J. Hsieh","A.L. Cohn","C. DiSimone","A Pinto Marin","D.W. Rasco","S.G. Ribe","D.A. Richards","D.E. Stepan","C.E. Dutcus","J. Wu","E.V. Schmidt","R.F. Perini","R.J. Motzer"],"twitterCount":0,"altmetricId":68179445},{"title":"Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) …","googleId":"k0CL5401In0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49258-2/abstract","googleCitationCount":6,"googleAuthor":"G Couchy"},{"title":"IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib plus nivolumab in advanced soft tissue and bone …","googleId":"xi2eNKKHCE8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419602917","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz283.002","elsevierAuthor":"Chen H.","publicationName":"Aging","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Analysis of tumour samples from SOLO1: frequency of BRCA specific loss of heterozygosity (LOH) and progression-free survival (PFS) according to …","googleId":"KkrDcw230UEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419592110","googleCitationCount":3,"googleAuthor":"C Gourley","doi":"10.1093/annonc/mdz250.006","elsevierAuthor":"Fabrizio D.A.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours","googleId":"uZZBBqJgbtUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43045-7/abstract","googleCitationCount":6,"googleAuthor":"V Subbiah"},{"title":"Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a …","googleId":"AMOF66wjPykJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591372","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz249.020","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Phase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression","googleId":"zxDOEt4tFjwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49513-6/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a …","googleId":"QFDL9MeZUX4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49218-1/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations","googleId":"iMyptmkb4qAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43458-3/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Impact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer …","googleId":"oWQibnv50MYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590925","googleCitationCount":3,"googleAuthor":"E Castro","doi":"10.1093/annonc/mdz248.033","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"A new ProTide, NUC-1031, combined with cisplatin for the first-line treatment of advanced biliary tract cancer (ABC-08)","googleId":"SBoGx6_4TE4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49219-3/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Novel treatment options in the management of metastatic castration-naïve prostate cancer; which treatment modality to choose?","googleId":"tTPSvydvdLIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419609683","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz210","elsevierAuthor":"Belderbos B.P.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"3","altmetricAuthors":["B.P.S. Belderbos","R. de Wit","M.P.J. Lolkema","R.H.J. Mathijssen","R.J. van Soest"],"twitterCount":7,"altmetricId":64034534},{"title":"Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of ALKA-372-001, STARTRK-1 and …","googleId":"MhlCcH1Dj0cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30058-4/abstract","googleCitationCount":5,"googleAuthor":"A Drilon"},{"title":"A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)","googleId":"202ljc2qi_UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49590-2/abstract","googleCitationCount":6,"googleAuthor":"M Hidalgo"},{"title":"Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: long-term outcomes of the INSIGHT study","googleId":"SHUxNIw4yZ4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419581236","googleCitationCount":3,"googleAuthor":"DW Kim","doi":"10.1093/annonc/mdz437.003","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Excellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1","googleId":"8H7rRIsg6pwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594212","googleCitationCount":5,"googleAuthor":"S Gupta","doi":"10.1093/annonc/mdz253.035","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous …","googleId":"GHZFoxBDHvgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597721","googleCitationCount":3,"googleAuthor":"I Bondarenko","doi":"10.1093/annonc/mdz260.087","elsevierCitationCount":0,"altmetricAuthors":["M. Reck","A. Luft","I. Bondarenko","S. Shevnia","D. Trukhin","N.V. Kovalenko","K. Vacharadze","F. Andrea","A. Hontsa","J. Choi","D. Shin"],"twitterCount":0,"altmetricId":68237440},{"title":"A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous …","googleId":"GHZFoxBDHvgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597721","googleCitationCount":3,"googleAuthor":"I Bondarenko","doi":"10.1093/annonc/mdz260.087","elsevierCitationCount":0,"altmetricAuthors":["M. Reck","A. Luft","I. Bondarenko","S. Shevnia","D. Trukhin","N.V. Kovalenko","K. Vacharadze","F. Andrea","A. Hontsa","J. Choi","D. Shin"],"twitterCount":0,"altmetricId":68237440},{"title":"A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort)(NCT02601950)","googleId":"uIQHn2fE7OcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50077-1/abstract","googleCitationCount":6,"googleAuthor":"RL Jones"},{"title":"Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8","googleId":"zsV_I6ViyJUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48486-X/abstract","googleCitationCount":9,"googleAuthor":"P Laurent-Puig"},{"title":"Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV-negative oropharyngeal cancer","googleId":"a0838eudHKIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593334","googleCitationCount":4,"googleAuthor":"V Noronha","doi":"10.1093/annonc/mdz252.013","elsevierAuthor":"Prabhash K.","publicationName":"Indian Journal of Cancer","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"1 February 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Brigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): the use via expanded access to brigatinib (UVEA-Brig) study","googleId":"VVgT55uDczAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597526","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz260.067","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): a planned interim analysis","googleId":"7HM5X7gZd8QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48961-8/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"Effects of antibiotics and proton pump inhibitors in NSCLC patients treated with atezolizumab and docetaxel: pooled analysis of the OAK and POPLAR trials","googleId":"ypuHZ3N8lJoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32664-X/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on …","googleId":"_tkom3OgKyYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599719","googleCitationCount":3,"googleAuthor":"G Zalcman","doi":"10.1093/annonc/mdz266","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation","googleId":"AlKpG67mLt0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35517-6/abstract","googleCitationCount":8,"googleAuthor":"V Prasad"},{"title":"Personalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) …","googleId":"dYyiaYjvhP0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959322X","googleCitationCount":3,"googleAuthor":"J Guigay","doi":"10.1093/annonc/mdz252.002","elsevierCitationCount":0,"altmetricAuthors":["J. Guigay","A. Auperin","C. Mertens","C. Even","L. Geoffrois","D. Cupissol","F. Rolland","C. Sire","J. Fayette","F. Peyrade","E. Blot","P. Debourdeau","L. Bozec","O. Capitain","Y. Pointreau","C. Brard","C. Michel","D. Schwob","C. Ortholan","H. Le Caer"],"twitterCount":0,"altmetricId":68179408},{"title":"Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase …","googleId":"jA5w4dxJwEUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310221","googleCitationCount":5,"googleAuthor":"D Schadendorf","doi":"10.1093/annonc/mdy500","elsevierAuthor":"Urbonas V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"3","altmetricAuthors":["V. Urbonas","D. Schadendorf","L. Zimmer","S. Danson","E. Marshall","P. Corrie","M. Wheater","E. Plummer","C. Mauch","C. Scudder","M. Goff","S.B. Love","S.B. Mohammed","M.R. Middleton"],"twitterCount":27,"altmetricId":51193087},{"title":"Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse …","googleId":"AGT8yDUzRAwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454793","googleCitationCount":5,"googleAuthor":"E Ollier","doi":"10.1093/annonc/mdy035","elsevierAuthor":"Trone J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"4","altmetricAuthors":["J.C. Trone","E. Ollier","C. Chapelle","L. Bertoletti","M. Cucherat","P. Mismetti","N. Magné","S. Laporte"],"twitterCount":10,"altmetricId":32701613},{"title":"First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+ locally advanced or metastatic …","googleId":"1pcTlI0Rld8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591360","googleCitationCount":7,"googleAuthor":"","doi":"10.1093/annonc/mdz249.019","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis","googleId":"Djaa9aJh6-0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34561-2/abstract","googleCitationCount":7,"googleAuthor":"H Uno"},{"title":"Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment","googleId":"lIDini_Z_jQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31120-2/abstract","googleCitationCount":6,"googleAuthor":"F Conforti"},{"title":"Divining responder populations from survival data","googleId":"DxPLrBUZ-2AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419311962","googleCitationCount":4,"googleAuthor":"S Ventz","doi":"10.1093/annonc/mdz087","elsevierAuthor":"Shervin T.","publicationName":"Neuro-Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"1 July 2020","elsevierCitationCount":"0","altmetricAuthors":["R. Rahman","S. Ventz","G. Fell","A.M. Vanderbeek","L. Trippa","B.M. Alexander"],"twitterCount":6,"altmetricId":57089690},{"title":"Applicability of the Lung Immune Prognostic Index (LIPI) in patients with metastatic solid tumors when treated with Immune Checkpoint Inhibitors (ICI) in early clinical …","googleId":"PvfSsvT5LKYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30013-4/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Vitamin B6 catabolism and lung cancer risk: results from the Lung Cancer Cohort Consortium (LC3)","googleId":"-sGV04b9ZXQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419310828","googleCitationCount":3,"googleAuthor":"H Zuo","doi":"10.1093/annonc/mdz002","elsevierAuthor":"Zuo H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"3","altmetricAuthors":["H. Zuo","P.M. Ueland","Ø Midttun","G.S. Tell","A. Fanidi","W. Zheng","X. Shu","Y. Xiang","J. Wu","R. Prentice","M. Pettinger","C.A. Thomson","G.G. Giles","A. Hodge","Q. Cai","W.J. Blot","M. Johansson","J. Hultdin","K. Grankvist","V.L. Stevens","M.L. McCullough","S.J. Weinstein","D. Albanes","R.G. Ziegler","N.D. Freedman","N.E. Caporaso","A. Langhammer","K. Hveem","M. Næss","J.E. Buring","I. Lee","J.M. Gaziano","G. Severi","X. Zhang","M.J. Stampfer","J. Han","A. Zeleniuch-Jacquotte","L.L. Marchand","J. Yuan","R. Wang","W. Koh","Y. Gao","U. Ericson","K. Visvanathan","M.R. Jones","C. Relton","P. Brennan","M. Johansson","A. Ulvik"],"twitterCount":2,"altmetricId":55104577},{"title":"Update on the phase II SUMMIT trial: Neratinib+ fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer","googleId":"mFPiGnNqjqkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30302-3/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous …","googleId":"C4yv7hcD0rYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582126","googleCitationCount":3,"googleAuthor":"SK Sandhu","doi":"10.1093/annonc/mdz446.007","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Pharmacokinetics (PK), safety, and efficacy of trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced …","googleId":"xuL_iwInvN8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585520","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz242.025","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Updated results of M7824 (MSB0011359C): a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line (2L) NSCLC","googleId":"xtOf0Fm0HWIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49875-X/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)","googleId":"B_B8s3LvPd0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597885","googleCitationCount":4,"googleAuthor":"AB Bourla","doi":"10.1093/annonc/mdz260.103","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence …","googleId":"zwg2g7sIzhkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49244-2/abstract","googleCitationCount":5,"googleAuthor":"M Akce"},{"title":"Efficacy and safety of isatuximab plus pomalidomide and dexamethasone in East Asian patients with relapsed/refractory multiple myeloma: A subgroup …","googleId":"UKhFf-qiTuUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419579431","googleCitationCount":3,"googleAuthor":"MC Wang","doi":"10.1093/annonc/mdz427.003","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"NCI-MATCH arms N & P: phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (Mut/del) or PTEN protein …","googleId":"WKJaqQzaQlwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48885-6/abstract","googleCitationCount":6,"googleAuthor":"O Jegede"},{"title":"Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies","googleId":"Faa6rKSZe2sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49122-9/abstract","googleCitationCount":7,"googleAuthor":"SJ Klempner"},{"title":"Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer","googleId":"4h7XLnw8nw0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344872","googleCitationCount":2,"googleAuthor":"I Marquez-Rodas","doi":"10.1093/annonc/mdz451.009","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Efficacy and safety of nintedanib+ docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated …","googleId":"3ydErE3j5G4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344446","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz449.020","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"TRIBE2: A phase III, randomized strategy study by GONO in the 1st-and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts)","googleId":"VStRIiT5upgJ","googleLink":"https://www.researchgate.net/profile/Gianluca_Masi/publication/328503649_LBA20TRIBE2_A_phase_III_randomized_strategy_study_by_GONO_in_the_1st-_and_2nd-line_treatment_of_unresectable_metastatic_colorectal_cancer_mCRC_patients_pts/links/5dd2cbc04585156b351e8234/LBA20TRIBE2-A-phase-III-randomized-strategy-study-by-GONO-in-the-1st-and-2nd-line-treatment-of-unresectable-metastatic-colorectal-cancer-mCRC-patients-pts.pdf","googleCitationCount":7,"googleAuthor":"S Lonardi"},{"title":"Population pharmacokinetic analyses for talazoparib (TALA) in cancer patients","googleId":"zdZdSBVbaGQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48898-4/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Not only tumor but also therapy heterogeneity","googleId":"yPEyYUtkJRMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34999-3/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials","googleId":"leJr73uXJtkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48725-5/abstract","googleCitationCount":6,"googleAuthor":"M Elmeliegy"},{"title":"Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor","googleId":"CsokYC2ZV6UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34197-3/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results","googleId":"HNYnz896378J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50392-1/abstract","googleCitationCount":6,"googleAuthor":"C Hulme"},{"title":"FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting …","googleId":"T3_2w3N17WAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587890","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz246.046","elsevierAuthor":"Seid H.","publicationName":"Swiss Medical Weekly","elsevierCoverDate":"2020-11-24","elsevierCoverDisplayDate":"24 November 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Anlotinib for advanced hepatocellular carcinoma: Interim results from the phase II ALTER0802 study","googleId":"R5-UvHVZPAQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589670","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz247.077","elsevierAuthor":"Zhang C.H.","publicationName":"Current Gene Therapy","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0},{"title":"IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo)+ …","googleId":"dP8XbDbw4OwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30152-8/abstract","googleCitationCount":5,"googleAuthor":"S Peters"},{"title":"100,000 genomes project: Integrating whole genome sequencing (WGS) data into clinical practice","googleId":"pd3owMfB99AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419619010","googleCitationCount":2,"googleAuthor":"J Mitchell","doi":"10.1093/annonc/mdz413.006","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"30 months relapse-free survival, overall survival, and long-term toxicity update of (neo) adjuvant ipilimumab (ipi)+ nivolumab (nivo) in macroscopic stage III melanoma …","googleId":"uVN0BgNONXAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32759-0/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Pleural mesothelioma: is the surgeon still there?","googleId":"QHIGoicQKRUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934116X","googleCitationCount":6,"googleAuthor":"I Opitz","doi":"10.1093/annonc/mdy195","elsevierAuthor":"Opitz I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"1","altmetricAuthors":["I. Opitz","W. Weder"],"twitterCount":1,"altmetricId":73207186},{"title":"Phase II trial of HER2-PET/CT using 68Ga-anti-HER2 VHH1 for characterization of HER2 presence in brain metastases of breast cancer patients","googleId":"D5iOGmfxCc4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30353-9/abstract","googleCitationCount":4,"googleAuthor":"M Keyaerts"},{"title":"The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case–control and Mendelian randomization study in the European …","googleId":"dfJBOzJqmk4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312098","googleCitationCount":4,"googleAuthor":"KS Byrne","doi":"10.1093/annonc/mdz121","elsevierAuthor":"Smith Byrne K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"1 June 2019","elsevierCitationCount":"3","altmetricAuthors":["K. Smith Byrne","P.N. Appleby","T.J. Key","M.V. Holmes","G.K. Fensom","A. Agudo","E. Ardanaz","H. Boeing","H.B. Bueno-de-Mesquita","M.D. Chirlaque","R. Kaaks","N. Larrañaga","D. Palli","A. Perez-Cornago","J.R. Quirós","F. Ricceri","M.J. Sánchez","G. Tagliabue","K.K. Tsilidis","R. Tumino","R.T. Fortner","P. Ferrari","E. Riboli","H. Lilja","R.C. Travis"],"twitterCount":20,"altmetricId":58826730},{"title":"Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD …","googleId":"I-4f5XrMMysJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595679","googleCitationCount":2,"googleAuthor":"SK Sandhu","doi":"10.1093/annonc/mdz255.046","elsevierAuthor":"Morganti S.","publicationName":"ecancermedicalscience","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"A novel pretherapeutic gene expression-based risk score for treatment guidance in gastric cancer","googleId":"0kEXAVRxX1kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350057","googleCitationCount":8,"googleAuthor":"A Hapfelmeier","doi":"10.1093/annonc/mdx685","elsevierAuthor":"Bauer L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"7","altmetricAuthors":["L. Bauer","A. Hapfelmeier","S. Blank","M. Reiche","J. Slotta-Huspenina","M. Jesinghaus","A. Novotny","T. Schmidt","B. Grosser","M. Kohlruss","W. Weichert","K. Ott","G. Keller"],"twitterCount":2,"altmetricId":33068644},{"title":"Oral bisphosphonate use and lung cancer incidence among postmenopausal women","googleId":"azihxASBIVIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348914","googleCitationCount":5,"googleAuthor":"JL Freudenheim","doi":"10.1093/annonc/mdy097","elsevierAuthor":"Tao M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"4","altmetricAuthors":["M.H. Tao","S. Chen","J.L. Freudenheim","J.A. Cauley","K.C. Johnson","X. Mai","G.E. Sarto","H. Wakelee","P. Boffetta","J. Wactawski-Wende"],"twitterCount":18,"altmetricId":35013924},{"title":"Durable anti-tumor activity of the multi-targeted inhibitor lenvatinib in patients with advanced or metastatic thymic carcinoma: Preliminary results from a …","googleId":"JsffEb0BREgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599744","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz266.003","elsevierCitationCount":0,"altmetricAuthors":["S. Itoh","M. Satouchi","J. Sato","Y. Okuma","S. Niho","H. Mizugaki","H. Murakami","Y. Fujisaka","T. Kozuki","K. Nakamura","Y. Nagasaka","M. Kawasaki","T. Yamada","A. Kuchiba","N. Yamamoto"],"twitterCount":0,"altmetricId":68946554},{"title":"A novel bispecific BCMAxCD3 T cell-engaging antibody that treat multiple myeloma (MM) with minimal cytokine secretion","googleId":"qBPIrrCb_7AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419601468","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz269.038","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability","googleId":"F9gE0H5vyFUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50279-4/abstract","googleCitationCount":5,"googleAuthor":"J Martin-Liberal"},{"title":"Multiple-cohort analysis investigating FGFR3 alteration as a predictor of non-response to neoadjuvant pembrolizumab (pembro) in muscle-invasive bladder …","googleId":"iYGyAXl2PrIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591219","googleCitationCount":5,"googleAuthor":"A Briganti","doi":"10.1093/annonc/mdz249.004","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Phase II study of cetuximab rechallenge in patients with RAS wild-type metastatic colorectal cancer: E-Rechallenge trial","googleId":"1b8-qnsI4g8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48947-3/abstract","googleCitationCount":6,"googleAuthor":"E Shinozaki"},{"title":"Passion for immune checkpoint blockade in triple negative breast cancer: comment on the IMpassion130 study","googleId":"kBjNBT-v-bEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30988-3/abstract","googleCitationCount":6,"googleAuthor":"S Loi"},{"title":"Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication","googleId":"Aiy0S5jwlmkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341948","googleCitationCount":7,"googleAuthor":"L Xie"},{"title":"Survival outcomes in stage IV small-cell lung cancer (IV-SCLC): Analysis from SEER database","googleId":"fr0HUE5jnSwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344628","googleCitationCount":2,"googleAuthor":"MD Gomez","doi":"10.1093/annonc/mdz449.038","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: Pooled analysis based on the GBG …","googleId":"DDv6qX5H1fMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30376-X/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"A phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT part A, B)","googleId":"vbexyfXAgH4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586720","googleCitationCount":5,"googleAuthor":"M Dillon","doi":"10.1093/annonc/mdz244.012","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Durvalumab+ monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)","googleId":"Bjk8T9XWrfQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594133","googleCitationCount":3,"googleAuthor":"M Cho","doi":"10.1093/annonc/mdz253.027","elsevierAuthor":"Zhou P.","publicationName":"Aging","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"METEOR-1: a phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours","googleId":"MM784Tc0Lj8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586604","googleCitationCount":6,"googleAuthor":"LL Siu","doi":"10.1093/annonc/mdz244","elsevierAuthor":"Dadu R.","publicationName":"Endocrine-Related Cancer","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"0","altmetricAuthors":["L.L. Siu","D.W. Rasco","S Postel Vinay","P Martin Romano","J. Menis","F.L. Opdam","K.M. Heinhuis","J.L. Egger","S.A. Gorman","R. Parasrampuria","K. Wang","B.E. Kremer","M.M. Gounder"],"twitterCount":0,"altmetricId":86749818},{"title":"PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy","googleId":"PrZYxMYAA_YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30186-3/abstract","googleCitationCount":4,"googleAuthor":""},{"title":"Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell …","googleId":"79wZyRWvoQEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454665","googleCitationCount":7,"googleAuthor":"MJ Awan","doi":"10.1093/annonc/mdy018","elsevierAuthor":"Awan M.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"5","altmetricAuthors":["M.J. Awan","L. Nedzi","D. Wang","V. Tumati","B. Sumer","X.-J. Xie","I. Smith","J. Truelson","R. Hughes","L.L. Myers","P. Lavertu","S. Wong","M. Yao"],"twitterCount":2,"altmetricId":31945538},{"title":"Comparison of immuno-oncology (IO) biomarkers in adenocarcinoma (ACB), urothelial carcinoma (UCB) and squamous cell carcinoma (SCCB) of the bladder …","googleId":"C-1XEyHC5q0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591463","googleCitationCount":3,"googleAuthor":"AB Schrock","doi":"10.1093/annonc/mdz249.029","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Alpelisib (ALP)+ fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): Management and time course of …","googleId":"oQppqByNKqsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585465","googleCitationCount":3,"googleAuthor":"F André","doi":"10.1093/annonc/mdz242.019","elsevierAuthor":"Donahue B.S.","publicationName":"Clinical Journal of Oncology Nursing","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II","googleId":"z2E74tiDVPgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350471","googleCitationCount":13,"googleAuthor":"I Sestak","doi":"10.1093/annonc/mdx713","elsevierAuthor":"Sestak I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"7","altmetricAuthors":["I. Sestak","S.G. Smith","A. Howell","J.F. Forbes","J. Cuzick"],"twitterCount":27,"altmetricId":30070469},{"title":"Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting","googleId":"WulZALHnYxgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30992-5/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial","googleId":"J8alWGTBcEQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49798-6/abstract","googleCitationCount":6,"googleAuthor":"S Peters"},{"title":"Prospective testing of circulating tumour DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology","googleId":"v_dRr6l4kF4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419583363","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz239.016","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer","googleId":"rWHYVw3pLmIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35520-6/abstract","googleCitationCount":7,"googleAuthor":"C Abbosh"},{"title":"BRCA1/2 testing in HER2-advanced breast cancer (ABC): Results from the European component of a multi-country real-world study","googleId":"qbeJhOLnt5MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585143","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz241","elsevierAuthor":"Untch M.","publicationName":"Geburtshilfe und Frauenheilkunde","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"1 June 2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"NRG1-fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option","googleId":"ZYYytu1qVxkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30807-5/abstract","googleCitationCount":3,"googleAuthor":"B Weinberg"},{"title":"Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours","googleId":"DZin-WFLbh0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586690","googleCitationCount":3,"googleAuthor":"AR Parikh","doi":"10.1093/annonc/mdz244.009","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced …","googleId":"CcVG-7Wo73wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49819-0/abstract","googleCitationCount":5,"googleAuthor":"L Mezquita"},{"title":"Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer …","googleId":"XrBCZADY8pYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585659","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz242.038","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Real-world data on nivolumab treatment in Asian patients with advanced hepatocellular carcinoma","googleId":"4QZ2XKqg88EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49160-6/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours","googleId":"y8iEV3ILn1oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590585","googleCitationCount":3,"googleAuthor":"A Drilon","doi":"10.1093/annonc/mdz247.169","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?","googleId":"AQk2kGntoj0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420325886","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz286","elsevierAuthor":"Simmet V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"1","altmetricAuthors":["V. Simmet","L. Eberst","A. Marabelle","P.A. Cassier"],"twitterCount":2,"altmetricId":65605825},{"title":"Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950)","googleId":"LbLRR1QH8ssJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50329-5/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Outcome and mutational landscape of patients with PIK3CA-mutated metastatic breast cancer (mBC)","googleId":"gtkC0EYeKYIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30417-X/abstract","googleCitationCount":4,"googleAuthor":"A Lusque"},{"title":"New designs in early clinical drug development","googleId":"FfIjyVlSDqMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341945984X","googleCitationCount":2,"googleAuthor":"A Mansinho","doi":"10.1093/annonc/mdz191","elsevierAuthor":"Mansinho A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"2","altmetricAuthors":["A. Mansinho","V. Boni","M. Miguel","E. Calvo"],"twitterCount":6,"altmetricId":67765046},{"title":"Cancer stigma related to beliefs of patients and care providers","googleId":"qEQMHjtaC9IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49997-3/abstract","googleCitationCount":5,"googleAuthor":"H Malhotra"},{"title":"Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy","googleId":"tuUrEWciQPIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584010","googleCitationCount":3,"googleAuthor":"G Bataillon","doi":"10.1093/annonc/mdz240.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Phase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC)","googleId":"IixMObcX2doJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49159-X/abstract","googleCitationCount":5,"googleAuthor":"C Barone"},{"title":"Efficacy of afatinib in the clinical practice: First results of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany","googleId":"7MAhmurffwgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49861-X/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Real life use of talimogene laherparepvec in melanoma in centers in Austria and Switzerland","googleId":"WZAmoDRAzPkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595539","googleCitationCount":2,"googleAuthor":"C Hoeller","doi":"10.1093/annonc/mdz255.032","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO: A phase II, randomised, multicentre study …","googleId":"27Fs3gJtFJsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48911-4/abstract","googleCitationCount":6,"googleAuthor":"A Krämer"},{"title":"Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma …","googleId":"0h-UvuzlqlwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50448-3/abstract","googleCitationCount":6,"googleAuthor":"N Meyer"},{"title":"Mixture-cure modeling for resected stage III/IV melanoma in the phase III CheckMate 238 trial","googleId":"SW9v8XEooG4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419595412","googleCitationCount":2,"googleAuthor":"M Kurt","doi":"10.1093/annonc/mdz255.020","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?","googleId":"zVN3XqkU3XgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34553-3/abstract","googleCitationCount":6,"googleAuthor":"LA Diaz"},{"title":"Phase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced …","googleId":"77WKt7vB2NQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594182","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz253.032","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients","googleId":"KYiN-WlIBF4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596946","googleCitationCount":2,"googleAuthor":"JM Janssen","doi":"10.1093/annonc/mdz260.008","elsevierAuthor":"Aghai F.","publicationName":"Analytical and Bioanalytical Chemistry","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic …","googleId":"3qpqT2NenAgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586628","googleCitationCount":6,"googleAuthor":"A Naing","doi":"10.1093/annonc/mdz244.002","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Pharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid …","googleId":"D8Qm5dbghikJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586860","googleCitationCount":2,"googleAuthor":"J Evans","doi":"10.1093/annonc/mdz244.026","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence …","googleId":"rPMFejUfIfkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30705-7/abstract","googleCitationCount":3,"googleAuthor":"J Knox"},{"title":"Intracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting","googleId":"tGhrxE_2C8kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419596958","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz260.009","elsevierAuthor":"Tabbò F.","publicationName":"Current Oncology Reports","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes","googleId":"m7demNaXHzYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)32604-1/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7. 1) in a …","googleId":"afD_1o2WMEkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589414","googleCitationCount":3,"googleAuthor":"S Kasper","doi":"10.1093/annonc/mdz247.051","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"WGS implementation in standard cancer diagnostics for every cancer patient (WIDE)","googleId":"02qI_6dBvKAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959617X","googleCitationCount":2,"googleAuthor":"L Bosch","doi":"10.1093/annonc/mdz257.003","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+ I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma …","googleId":"dB6_QWc55DAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49263-6/abstract","googleCitationCount":6,"googleAuthor":"BI Rini"},{"title":"Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated …","googleId":"hgOrPzbIFEIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586744","googleCitationCount":2,"googleAuthor":"M Voskoboynik","doi":"10.1093/annonc/mdz244.014","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Antibody therapy targeting CD19 for B-cell non-Hodgkin's lymphoma","googleId":"7b7f52cXm1IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34554-5/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Phase I Clinical Study for Validation of Fimaporfin-Based Photochemical Internalisation: A Novel Technology for Enhancing Cellular Immune Responses …","googleId":"qA9jNlWbkyYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344963","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz451.018","elsevierCitationCount":0,"altmetricAuthors":["P.K. Selbo","S. Janetzki","M.J.P. Welters","M. Håkerud","A.G. Nedberg","V.T. Edwards","H. Olivecrona","S.H. van der Burg","T. Otterhaug","A. Hogset"],"twitterCount":4,"altmetricId":73554914},{"title":"Phase II multicenter open label study of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study)","googleId":"ffZwBxGmT6QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960428X","googleCitationCount":2,"googleAuthor":"H Jespersen","doi":"10.1093/annonc/mdz394.068","elsevierCitationCount":0,"altmetricAuthors":["H. Jespersen","R. Olofsson Bagge","G. Ullenhag","A. Carneiro","H. Helgadottir","I. Ljuslinder","M. Levin","C. All-Eriksson","B. Andersson","U. Stierner","L.M. Nilsson","J.A. Nilsson","L. Ny"],"twitterCount":1,"altmetricId":68305311},{"title":"Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option","googleId":"Dx12fVzxsFoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419600967","googleCitationCount":3,"googleAuthor":"K Tolba","doi":"10.1093/annonc/mdz268.096","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced …","googleId":"2S3PhaN0jG4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49165-5/abstract","googleCitationCount":5,"googleAuthor":"T Yau"},{"title":"Phase I combination dose-finding/phase II expansion cohorts of lenvatinib+ etoposide+ ifosfamide in patients (pts) aged 2 to≤ 25 years with relapsed …","googleId":"dNKjQ3iilMQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341960298X","googleCitationCount":2,"googleAuthor":"R Venkatramani","doi":"10.1093/annonc/mdz283.009","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Assessing the clinical relevance of drug-drug interactions (DDI) with darolutamide (DARO)","googleId":"YI_MIgnKgNYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591062","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz248.047","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer","googleId":"upXe_EbA6AwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49862-1/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of …","googleId":"SnMi6rDf79wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49192-8/abstract","googleCitationCount":5,"googleAuthor":"S Nomura"},{"title":"Genomic medicine France 2025","googleId":"RDbuA1CJBJoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45473-2/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Comprehensive genomic profiling (CGP) of carcinoma of unknown primary origin (CUP): Retrospective molecular classification of potentially eligible patients …","googleId":"lcZoy9TOIo0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604540","googleCitationCount":4,"googleAuthor":"L Mileshkin","doi":"10.1093/annonc/mdz394.094","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal …","googleId":"9D9lBdM51P4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419587567","googleCitationCount":4,"googleAuthor":"J Webster","doi":"10.1093/annonc/mdz246.013","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an …","googleId":"ElEXkI3qIx4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30802-6/abstract","googleCitationCount":4,"googleAuthor":"J Riedl"},{"title":"Analytic validation of tumor mutational burden as a companion diagnostic for combination immunotherapy in non-small cell lung cancer","googleId":"8_GW3SVfrIMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48482-2/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer","googleId":"SUE2pIt70EsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419584666","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz240.067","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Single cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CheckRad …","googleId":"NErDi8rtr6cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959336X","googleCitationCount":2,"googleAuthor":"M Eckstein","doi":"10.1093/annonc/mdz252.016","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments","googleId":"D8yiNVBk3bsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)58092-9/abstract","googleCitationCount":3,"googleAuthor":""},{"title":"Safety and efficacy of the oral CXCR4 inhibitor X4P-001+ axitinib in advanced renal cell carcinoma patients: an analysis of subgroup responses by prior …","googleId":"Y1Ehd4Qtk8oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341959398X","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz253.012","elsevierCitationCount":0,"altmetricAuthors":["D.F. McDermott","U. Vaishampayan","M. Matrana","S.Y. Rha","A Zurita Saavedra","T. Ho","B. Keam","J.-L. Lee","R. Joseph","S. Ali","W. Stadler","N.B. Haas","S. Sundararajan","S.H. Park","R. Mowat","J. Picus","A.Z. Dudek","Y. Zakharia","L. Gan","M.B. Atkins"],"twitterCount":0,"altmetricId":68179444},{"title":"Prognostic utility of HPV specific testing in addition to p16 immunohistochemistry in oropharyngeal squamous cell carcinoma","googleId":"ys_QIPbDK_YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34198-5/abstract","googleCitationCount":6,"googleAuthor":"A Santambrogio"},{"title":"Gastric cancer in young Latin women: bad prognostic factors and outcomes","googleId":"B9eRc92XZUYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30664-7/abstract","googleCitationCount":4,"googleAuthor":"M Herrera"},{"title":"Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): Analysis of patients with central nervous …","googleId":"HRQjPB3zpxYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419597289","googleCitationCount":2,"googleAuthor":"G Metro","doi":"10.1093/annonc/mdz260.043","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): preliminary results from the phase IIIb, international, open-label …","googleId":"86URG_FAnVgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33699-3/abstract","googleCitationCount":6,"googleAuthor":"A Falcone"},{"title":"Phase II study of cetuximab rechallenge in patients with RAS wild-type metastatic colorectal cancer: E-Rechallenge trial","googleId":"FlutAU2M_2oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)62207-6/abstract","googleCitationCount":3,"googleAuthor":""},{"title":"Correlation of various clinical, imaging and laboratory parameters with outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune …","googleId":"24OcWWMgBTkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30115-2/abstract","googleCitationCount":5,"googleAuthor":"K Rounis"},{"title":"An international randomized cross-over bio-equivalence study of oral paclitaxel+ HM30181 compared with weekly intravenous (IV) paclitaxel in patients with …","googleId":"tVq3UvRtUpwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586999","googleCitationCount":2,"googleAuthor":"C Jackson","doi":"10.1093/annonc/mdz244.039","elsevierCitationCount":0,"altmetricAuthors":["C G C A Jackson","S. Deva","K. Bayston","B. McLaren","P. Barlow","N.A. Hung","K. Clarke","E. Segelov","T.-Y. Chao","M.-S. Dai","H.-T. Yen","D. Cutler","D. Kramer","J. Zhi","W.-K. Chan","M -F R Kwan","C.-T. Hung"],"twitterCount":0,"altmetricId":67894406},{"title":"Revisiting surveillance schemes for cancer survivors","googleId":"mIWaWB4rZ44J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31201-3/abstract","googleCitationCount":3,"googleAuthor":"Ø Holme"},{"title":"Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma","googleId":"uigtFEVq2q4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419312748","googleCitationCount":4,"googleAuthor":"","doi":"10.1093/annonc/mdz143","elsevierAuthor":"Gambardella V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"2","altmetricAuthors":["V. Gambardella","T. Fleitas","N. Tarazona","J.M. Cejalvo","F. Gimeno-Valiente","C. Martinez-Ciarpaglini","M. Huerta","S. Roselló","J. Castillo","D. Roda","A. Cervantes"],"twitterCount":10,"altmetricId":59850131},{"title":"SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)","googleId":"D1-ZHc_ZHFgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419604308","googleCitationCount":2,"googleAuthor":"S Danson","doi":"10.1093/annonc/mdz394.070","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: the circulating cell-free genome atlas (CCGA) study","googleId":"7eINOEgSKLwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48476-7/abstract","googleCitationCount":5,"googleAuthor":"MC Liu"},{"title":"NY-ESO-1 and LAGE1A: An emerging target for cell therapies in solid tumours","googleId":"Jt8-Npq6L1gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594418","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz253.055","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"RAISEing VEGF-D's importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients","googleId":"ZanpkEJT3NcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35523-1/abstract","googleCitationCount":5,"googleAuthor":"P Carmeliet"},{"title":"Initial results of a phase II study of nivolumab and ipilimumab in metastatic adrenal tumours","googleId":"RJhAO-HorzcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419591992","googleCitationCount":2,"googleAuthor":"MA Habra","doi":"10.1093/annonc/mdz249.082","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Not only gene mutation matters: Development of flow cytometry panel to determine BRCA2 deficiency for personalised therapy by PARP inhibitors in …","googleId":"hEOyUqqtvVoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419619587","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz413.063","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC) …","googleId":"1Aijnu-5Ks0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49409-X/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Atezolizumab+ bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150","googleId":"MDhk9wDWOy4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49243-0/abstract","googleCitationCount":7,"googleAuthor":"MP Ducreux"},{"title":"A phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I1 cohort …","googleId":"1obQciRoQDYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593218","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz252.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer","googleId":"gJE29fDVmmgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420344148","googleCitationCount":2,"googleAuthor":"E McGowan","doi":"10.1093/annonc/mdz448","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Pembrolizumab (pembro) plus mFOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC): KEYNOTE-651 cohorts B and D","googleId":"kEnW5m7b9aMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588287","googleCitationCount":2,"googleAuthor":"M Fakih","doi":"10.1093/annonc/mdz246.085","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Harmonization study of tumour mutational burden determination in non-small cell lung cancer (NSCLC)","googleId":"LWzbjhWKsyQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603625","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz394.002","elsevierCitationCount":0,"altmetricAuthors":["E.M. Garrido-Martin","J. Ramos-Paradas","S. Hernandez Prieto","E. Sanchez","A. Rosado","T. Caniego-Casas","N. Carrizo","A.B. Enguita","M.T. Muñoz-Jiménez","B. Rodriguez","U. Perez-Gonzalez","D. Gomez Sanchez","I. Ferrer","S. Ponce Aix","A. Nuñez Buiza","P. Garrido","J. Palacios","F. Lopez-Rios","L. Paz-Ares"],"twitterCount":0,"altmetricId":67768407},{"title":"Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial","googleId":"67N87ZRmiaIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459863","googleCitationCount":3,"googleAuthor":"EM Holmes","doi":"10.1093/annonc/mdz195","elsevierAuthor":"Holmes E.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"2","altmetricAuthors":["E.M. Holmes","I. Bradbury","L.S. Williams","L. Korde","E. de Azambuja","D. Fumagalli","A. Moreno-Aspitia","J. Baselga","M. Piccart-Gebhart","A.C. Dueck","R.D. Gelber"],"twitterCount":17,"altmetricId":62793928},{"title":"Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB …","googleId":"ZRds5-27lJUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50273-3/abstract","googleCitationCount":6,"googleAuthor":"A Puccini"},{"title":"Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial","googleId":"67N87ZRmiaIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419459863","googleCitationCount":3,"googleAuthor":"EM Holmes","doi":"10.1093/annonc/mdz195","elsevierAuthor":"Holmes E.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"2","altmetricAuthors":["E.M. Holmes","I. Bradbury","L.S. Williams","L. Korde","E. de Azambuja","D. Fumagalli","A. Moreno-Aspitia","J. Baselga","M. Piccart-Gebhart","A.C. Dueck","R.D. Gelber"],"twitterCount":17,"altmetricId":62793928},{"title":"Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB …","googleId":"ZRds5-27lJUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50273-3/abstract","googleCitationCount":6,"googleAuthor":"A Puccini"},{"title":"A Phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study)","googleId":"_qT-tXoBBbIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30957-3/abstract","googleCitationCount":4,"googleAuthor":""},{"title":"EMERGE: Epigenetic modulation of the immune response in gastrointestinal cancers","googleId":"LfnoKY2R69kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588901","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz246.147","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with post-platinum esophageal adenocarcinoma (EAC): Preliminary …","googleId":"CILzF8eBg4QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49105-9/abstract","googleCitationCount":5,"googleAuthor":"A Khattak"},{"title":"A Phase Ib study of oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy","googleId":"e7SVTZpTMk0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419590160","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz247.126","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in …","googleId":"pyKjmBDf3xgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420343969","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz447.015","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?","googleId":"NB8Hi1GuwtUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31250-5/abstract","googleCitationCount":3,"googleAuthor":""},{"title":"Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA","googleId":"ad5a_MrcssIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582217","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz446.016","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Phase i/ii study with cxcl12 inhibitor nox-a12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer","googleId":"f1NLCQtfecsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588330","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz246.090","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Kinase fusions in colorectal cancers: a unique biologic subset","googleId":"WUq5GpjCnUkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48923-0/abstract","googleCitationCount":6,"googleAuthor":"F Pietrantonio"},{"title":"Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)","googleId":"CqE-zjVeDAMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50464-1/abstract","googleCitationCount":6,"googleAuthor":"DS Tan"},{"title":"Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer …","googleId":"NtLBNKXgZ6UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30955-X/abstract","googleCitationCount":3,"googleAuthor":"P Hammel"},{"title":"Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 …","googleId":"2kUiw_nlLiYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419594327","googleCitationCount":2,"googleAuthor":"JJ Luke","doi":"10.1093/annonc/mdz253.046","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet","googleId":"GNc_h7abBzgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35001-X/abstract","googleCitationCount":6,"googleAuthor":"AJ Armstrong"},{"title":"Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients …","googleId":"jYGxuKR16nsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419603789","googleCitationCount":2,"googleAuthor":"P Bono","doi":"10.1093/annonc/mdz394.018","elsevierAuthor":"Chen Y.","publicationName":"Journal of Cellular Physiology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0},{"title":"Randomised efficacy and safety results for atezolizumab (Atezo)+ bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular …","googleId":"4xLbTARyipwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582114","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz446.006","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Impact of digital patient monitoring (DPM) on quality of clinical care of cancer immunotherapy (CIT)-treated patients (pts) with advanced/metastatic non-small …","googleId":"Lo2Empmm3LIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034463X","googleCitationCount":2,"googleAuthor":"C Jacob","doi":"10.1093/annonc/mdz449.039","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Analysis of efficacy outcomes based on programmed death ligand 1 (PD-L1) scoring techniques in patients with head and neck squamous cell carcinoma …","googleId":"jt_ciYIBIWcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593279","googleCitationCount":2,"googleAuthor":"E Cohen","doi":"10.1093/annonc/mdz252.007","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Cancer immunotherapy with STING agonist and PD-1 immune checkpoint inhibitor effectively suppresses peritoneal carcinomatosis of colon cancer","googleId":"e4WPTloFnGUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30650-7/abstract","googleCitationCount":4,"googleAuthor":"C Kim"},{"title":"Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen+/-gonadotropin …","googleId":"PB265SW4nzYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50398-2/abstract","googleCitationCount":4,"googleAuthor":"M Reinisch"},{"title":"A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell …","googleId":"7DB2nfYUFLcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419593528","googleCitationCount":2,"googleAuthor":"MC Merlano","doi":"10.1093/annonc/mdz252.032","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults: Epithelioid sarcoma cohort (NCT02601950)","googleId":"JXEhguGzaDsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50080-1/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L) 1 inhibitors (IO …","googleId":"miDYMwHljw8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49828-1/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Identification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444","googleId":"95qOOxbOaIAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49594-X/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumours","googleId":"NBUe0qPYAdoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419586781","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz244.018","elsevierCitationCount":0,"altmetricAuthors":["M. Yunokawa","S. Takahashi","D. Aoki","K. Yonemori","H. Hara","K. Hasegawa","K. Takehara","K. Harano","H. Nomura","E. Noguchi","K. Horie","A. Ogasawara","S. Okame","T. Doi"],"twitterCount":0,"altmetricId":100658799},{"title":"Phase II study of DHP107 oral paclitaxel in first-line, HER2 negative recurrent/metastatic breast cancer (OPTIMAL study, NCT03315364)","googleId":"v3vmDg4a2jQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419585684","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz242.041","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)","googleId":"Td8b0INfsyQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48879-0/abstract","googleCitationCount":7,"googleAuthor":"M Mau-Sorensen"},{"title":"PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC","googleId":"QY7AZBRV7b8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419582035","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz438.021","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Nab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a …","googleId":"4siBliACusoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419588925","googleCitationCount":2,"googleAuthor":"S Cascinu","doi":"10.1093/annonc/mdz247.001","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Comparison of patient populations identified by different PD-L1 assays in head and neck squamous cell carcinoma (HNSCC)","googleId":"P67rOlN-3LUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49508-2/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+ chemotherapy (CT) as neoadjuvant treatment (NAT) for triple …","googleId":"D2YnAkBP9dEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)30276-5/abstract","googleCitationCount":4,"googleAuthor":"S Loi"},{"title":"Phase II monotherapy efficacy of cancer metabolism targeting SM-88 in heavily pre-treated PDAC patients","googleId":"gm6dYt9myO4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419589360","googleCitationCount":3,"googleAuthor":"","doi":"10.1093/annonc/mdz247.046","elsevierCitationCount":0,"altmetricAuthors":["A. Ocean","M. Noel","A. Wang-Gillam","S. Chawla","V. Chung","S. Pant","R. Korn","G.l. De Priore","V. Picozzi"],"twitterCount":0,"altmetricId":97829025},{"title":"Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?","googleId":"QQz17_d7Vb0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350483","googleCitationCount":8,"googleAuthor":"ID Davis","doi":"10.1093/annonc/mdx715","elsevierAuthor":"Blinman P.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"6","altmetricAuthors":["P.L. Blinman","I.D. Davis","A. Martin","S. Troon","S. Sengupta","E. Hovey","X. Coskinas","R. Kaplan","A. Ritchie","A. Meade","T. Eisen","M.R. Stockler"],"twitterCount":33,"altmetricId":29208647},{"title":"Efficiency of controlled cryotherapy in prevention of chemotherapy induced peripheral neuropathy (CIPN)","googleId":"wTtQBxEakAgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419599343","googleCitationCount":2,"googleAuthor":"","doi":"10.1093/annonc/mdz265.048","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0},{"title":"Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort","googleId":"F8wS8Ce7ag0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49599-9/abstract","googleCitationCount":4,"googleAuthor":"J Mazieres"},{"title":"Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study","googleId":"tXHXunOKD9AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419621745","googleCitationCount":3,"googleAuthor":"J Mazieres","doi":"10.1093/annonc/mdz338.079","elsevierCitationCount":0,"altmetricAuthors":["Hiroshi Sakai","Remi Veillon","Alexis B. Cortot","Enriqueta Felip","Julien Mazieres","Masahiro Morise","Tomohiro Sakamoto","Takaaki Tokito","Shinji Atagi","Terufumi Kato","Toru Kumagai","Hiroshi Tanaka","Rolf Bruns","Josef Straub","Juergen Scheele","Xiuning Le","Paul K. Paik"],"twitterCount":0,"altmetricId":68314296},{"title":"Platelet Lymphocyte Ratio (PLR) Related with Clinicopathological Characteristics of Balinese Women Breast Cancer Patient","googleId":"cmSZPWL1sAkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419623732","googleCitationCount":4,"googleAuthor":"S Wiranata","doi":"10.1093/annonc/mdz343.124","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0}]